Safe Prescribing — MCQs

Q: A 28-year-old woman presents with a 3-day history of dysuria, urinary frequency, and suprapubic pain. She is otherwise well with no fever. Urine dipstick shows nitrites positive, leucocytes positive. What is the most appropriate first-line antibiotic treatment?

Trimethoprim 200mg BD for 3 days. ***Trimethoprim 200mg BD for 3 days***- This is a standard, highly effective **short course** regimen (3 days) recommended for community-acquired, uncomplicated **cystitis** in non-pregnant women, provided local **E. coli** resistance rates are acceptable (typically <20%).- Short courses improve adherence and minimize **collateral damage** (disruption of normal flora) and secondary resistance compared to longer courses.*Amoxicillin 500mg TDS for 7 days*- Amoxicillin monotherapy is unsuitable as first-line treatment for UTIs due to extremely high rates of **E. coli resistance** globally and poor efficacy in many regions.- The 7-day duration is unnecessarily long for uncomplicated **cystitis**, increasing antibiotic exposure and the risk of adverse effects.*Ciprofloxacin 500mg BD for 7 days*- **Fluoroquinolones** (like Ciprofloxacin) are generally reserved for complicated UTIs, **pyelonephritis**, or cases where first-line agents fail, due to resistance concerns and potential serious side effects.- A 7-day course is excessive. Uncomplicated cystitis usually requires only 3–5 days of effective therapy; 7 days is more appropriate for treating **pyelonephritis**.*Nitrofurantoin 50mg QDS for 3 days*- **Nitrofurantoin** is a preferred first-line agent, but the standard recommended regimen is typically 100mg BD for 5 days (or 50mg QDS for 5–7 days).- While highly effective against E. coli, a 3-day course of Nitrofurantoin is less established compared to the standard 3-day course used for **Trimethoprim** for uncomplicated cystitis.*Co-amoxiclav 625mg TDS for 7 days*- **Co-amoxiclav** (Amoxicillin/Clavulanate) is not a first-line agent for uncomplicated cystitis as it is a broad-spectrum antibiotic and increases the risk of **Clostridioides difficile infection** (CDI).- The 7-day duration is unnecessarily prolonged for treating simple **cystitis** in this patient, contributing to antibiotic selection pressure.

A 59-year-old man with type 1 diabetes for 25 years is admitted with acute pancreatitis. His usual insulin regimen is insulin glargine 32 units at bedtime and insulin lispro 8 units with meals. He is kept nil by mouth and started on intravenous fluids. His admission glucose is 16.2 mmol/L. According to best practice for managing insulin in acute illness with nil-by-mouth status, what is the most appropriate insulin management?

A 68-year-old woman with non-valvular atrial fibrillation (CHA₂DS₂-VASc score 4) is on apixaban 5mg twice daily. She is diagnosed with intermediate-risk myelodysplastic syndrome requiring treatment with azacitidine chemotherapy, which carries significant thrombocytopenia risk (expected platelet nadir 20-50 × 10⁹/L). What is the most appropriate anticoagulation strategy during chemotherapy?

A 55-year-old woman with type 2 diabetes is on insulin detemir 38 units at 22:00 and metformin 1g twice daily. Her blood glucose readings show: fasting 6-8 mmol/L, pre-lunch 12-15 mmol/L, pre-dinner 10-13 mmol/L, bedtime 8-10 mmol/L. HbA1c is 68 mmol/mol (8.4%). Understanding insulin pharmacodynamics, what is the most appropriate next step in optimizing her insulin regimen?

A 64-year-old man with atrial fibrillation is on rivaroxaban 20mg once daily. He requires emergency laparotomy for perforated diverticulitis within 2 hours. He took his last dose of rivaroxaban 8 hours ago. His renal function shows eGFR 58 ml/min/1.73m². Pre-operative blood tests show Hb 118 g/L. What is the most appropriate management of his anticoagulation?

A 46-year-old man with type 1 diabetes for 20 years presents with a 3-month history of unpredictable blood glucose control despite good insulin adherence. He reports that his hypoglycaemic episodes now occur without warning symptoms. Investigations show HbA1c 58 mmol/mol (7.5%) but frequent hypoglycaemia on continuous glucose monitoring. What is the most appropriate modification to his insulin regimen?

A 58-year-old woman with atrial fibrillation is on edoxaban 60mg once daily. She develops acute bacterial endocarditis affecting the mitral valve and requires valve replacement surgery in 48 hours. Current renal function shows eGFR 65 ml/min/1.73m². What is the most appropriate approach to managing her anticoagulation perioperatively?

A 52-year-old woman with type 2 diabetes is established on insulin glargine 42 units at bedtime and metformin 1g twice daily. She is about to commence treatment for latent tuberculosis with rifampicin 600mg daily for 3 months. What is the most important consideration regarding her diabetes management?

A 71-year-old man with mechanical mitral valve replacement is on warfarin (target INR 2.5-3.5). He requires urgent colonoscopy for suspected lower GI bleeding. His current INR is 3.2. The procedure is needed within 12 hours. What is the most appropriate management of his anticoagulation?

Q10

A 63-year-old man with type 1 diabetes is admitted with severe diabetic ketoacidosis (pH 7.08, ketones 5.2 mmol/L, glucose 28 mmol/L). He is commenced on a fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and receives fluid resuscitation. After 4 hours, his glucose has fallen to 14 mmol/L but ketones remain at 4.8 mmol/L and pH is 7.15. What is the most appropriate next step in his insulin management?

Safe Prescribing UK Medical PG Practice Questions and MCQs

Question 1: A 28-year-old woman presents with a 3-day history of dysuria, urinary frequency, and suprapubic pain. She is otherwise well with no fever. Urine dipstick shows nitrites positive, leucocytes positive. What is the most appropriate first-line antibiotic treatment?

A. Amoxicillin 500mg TDS for 7 days
B. Trimethoprim 200mg BD for 3 days (Correct Answer)
C. Ciprofloxacin 500mg BD for 7 days
D. Nitrofurantoin 50mg QDS for 3 days
E. Co-amoxiclav 625mg TDS for 7 days

Explanation: ***Trimethoprim 200mg BD for 3 days***- This is a standard, highly effective **short course** regimen (3 days) recommended for community-acquired, uncomplicated **cystitis** in non-pregnant women, provided local **E. coli** resistance rates are acceptable (typically <20%).- Short courses improve adherence and minimize **collateral damage** (disruption of normal flora) and secondary resistance compared to longer courses.*Amoxicillin 500mg TDS for 7 days*- Amoxicillin monotherapy is unsuitable as first-line treatment for UTIs due to extremely high rates of **E. coli resistance** globally and poor efficacy in many regions.- The 7-day duration is unnecessarily long for uncomplicated **cystitis**, increasing antibiotic exposure and the risk of adverse effects.*Ciprofloxacin 500mg BD for 7 days*- **Fluoroquinolones** (like Ciprofloxacin) are generally reserved for complicated UTIs, **pyelonephritis**, or cases where first-line agents fail, due to resistance concerns and potential serious side effects.- A 7-day course is excessive. Uncomplicated cystitis usually requires only 3–5 days of effective therapy; 7 days is more appropriate for treating **pyelonephritis**.*Nitrofurantoin 50mg QDS for 3 days*- **Nitrofurantoin** is a preferred first-line agent, but the standard recommended regimen is typically 100mg BD for 5 days (or 50mg QDS for 5–7 days).- While highly effective against E. coli, a 3-day course of Nitrofurantoin is less established compared to the standard 3-day course used for **Trimethoprim** for uncomplicated cystitis.*Co-amoxiclav 625mg TDS for 7 days*- **Co-amoxiclav** (Amoxicillin/Clavulanate) is not a first-line agent for uncomplicated cystitis as it is a broad-spectrum antibiotic and increases the risk of **Clostridioides difficile infection** (CDI).- The 7-day duration is unnecessarily prolonged for treating simple **cystitis** in this patient, contributing to antibiotic selection pressure.

Question 2: A 59-year-old man with type 1 diabetes for 25 years is admitted with acute pancreatitis. His usual insulin regimen is insulin glargine 32 units at bedtime and insulin lispro 8 units with meals. He is kept nil by mouth and started on intravenous fluids. His admission glucose is 16.2 mmol/L. According to best practice for managing insulin in acute illness with nil-by-mouth status, what is the most appropriate insulin management?

A. Continue insulin glargine at usual dose; omit insulin lispro while nil by mouth (Correct Answer)
B. Continue insulin glargine; give insulin lispro based on blood glucose readings every 4 hours
C. Stop all insulin until he is eating and drinking again
D. Convert to variable-rate intravenous insulin infusion at 0.05 units/kg/hour
E. Give half the usual total daily insulin dose as basal insulin only

Explanation: ***Continue insulin glargine at usual dose; omit insulin lispro while nil by mouth*** - Patients with **Type 1 diabetes** have an absolute insulin deficiency and require continuous **basal insulin** (glargine) to prevent the development of **diabetic ketoacidosis (DKA)**, even when not eating. - **Prandial insulin** (lispro) should be omitted while the patient is **nil by mouth** (NBM) to avoid hypoglycemia, as it is designed to cover carbohydrate intake. *Continue insulin glargine; give insulin lispro based on blood glucose readings every 4 hours* - While **glargine** must continue, scheduled **lispro** is for mealtime coverage; giving it every 4 hours without food intake significantly increases the risk of severe **hypoglycemia**. - High blood glucose readings in an NBM patient should be managed with specific **correction doses** or a variable-rate intravenous insulin infusion if clinically indicated, not routine prandial boluses. *Stop all insulin until he is eating and drinking again* - Stopping all insulin in a Type 1 diabetic is dangerous and will lead to **diabetic ketoacidosis (DKA)** within hours because basal insulin is essential to suppress hepatic glucose production and **ketogenesis**. - Total cessation of insulin is a common clinical error that must be avoided in **Type 1 diabetes** management during acute illness, regardless of nutritional status. *Convert to variable-rate intravenous insulin infusion at 0.05 units/kg/hour* - **Variable-rate intravenous insulin infusion (VRIII)** is typically reserved for metabolically unstable patients (e.g., DKA, severe hyperglycemia, major surgery, critical illness). - For a stable NBM patient with Type 1 diabetes, continuing their **usual subcutaneous basal insulin** is generally preferred as it is simpler and maintains a steady physiological insulin level. *Give half the usual total daily insulin dose as basal insulin only* - Arbitrarily reducing the **basal insulin dose** by half risks insufficient insulin coverage, potentially leading to **hyperglycemia** and metabolic decompensation, especially during acute stress. - The **standard dose of basal insulin** should generally be maintained in Type 1 diabetics to reflect their continuous physiological requirements and prevent DKA.

Question 3: A 68-year-old woman with non-valvular atrial fibrillation (CHA₂DS₂-VASc score 4) is on apixaban 5mg twice daily. She is diagnosed with intermediate-risk myelodysplastic syndrome requiring treatment with azacitidine chemotherapy, which carries significant thrombocytopenia risk (expected platelet nadir 20-50 × 10⁹/L). What is the most appropriate anticoagulation strategy during chemotherapy?

A. Continue apixaban 5mg twice daily throughout chemotherapy; monitor platelets weekly
B. Reduce apixaban to 2.5mg twice daily during chemotherapy cycles
C. Switch to prophylactic-dose LMWH during chemotherapy cycles
D. Switch to warfarin with target INR 2-3 as it can be more easily reversed
E. Temporarily stop all anticoagulation during chemotherapy cycles; restart when platelets >50 × 10⁹/L (Correct Answer)

Explanation: ***Temporarily stop all anticoagulation during chemotherapy cycles; restart when platelets >50 × 10⁹/L*** - For patients with **thrombocytopenia**, the bleeding risk from therapeutic anticoagulation significantly outweighs the stroke prevention benefit when the **platelet count drops below 50 × 10⁹/L**. - This strategy minimizes the risk of **life-threatening hemorrhage** during the anticipated chemotherapy-induced nadir while allowing for the resumption of protection once platelets recover. *Continue apixaban 5mg twice daily throughout chemotherapy; monitor platelets weekly* - Maintaining full-dose **DOAC therapy** with a platelet count between 20-50 × 10⁹/L carries an unacceptably high risk of **major bleeding**. - Weekly monitoring is insufficient to prevent acute bleeding events when severe **platelet suppression** is actively occurring due to cytotoxic agents. *Reduce apixaban to 2.5mg twice daily during chemotherapy cycles* - Dose reduction of **apixaban** is only indicated for specific criteria (age ≥80, weight ≤60kg, or creatinine ≥133 μmol/L); reducing it for **thrombocytopenia** is not evidence-based. - A reduced dose may still cause significant bleeding at low platelet levels while providing **sub-therapeutic stroke prevention**. *Switch to prophylactic-dose LMWH during chemotherapy cycles* - **Prophylactic-dose LMWH** is inadequate for stroke prevention in a patient with a high **CHA₂DS₂-VASc score** of 4. - In the setting of severe thrombocytopenia, even low-dose anticoagulation is often contraindicated until platelets reach a safer threshold. *Switch to warfarin with target INR 2-3 as it can be more easily reversed* - **Warfarin** is notoriously difficult to manage during chemotherapy due to **drug-nutrient interactions**, nausea, and fluctuating liver function. - The risk of **intracranial hemorrhage** is significantly higher with warfarin compared to DOACs, especially when **platelet counts** are unstable.

Question 4: A 55-year-old woman with type 2 diabetes is on insulin detemir 38 units at 22:00 and metformin 1g twice daily. Her blood glucose readings show: fasting 6-8 mmol/L, pre-lunch 12-15 mmol/L, pre-dinner 10-13 mmol/L, bedtime 8-10 mmol/L. HbA1c is 68 mmol/mol (8.4%). Understanding insulin pharmacodynamics, what is the most appropriate next step in optimizing her insulin regimen?

A. Split insulin detemir to twice-daily dosing (20 units morning, 20 units evening)
B. Increase insulin detemir to 44 units at 22:00
C. Add prandial rapid-acting insulin with main meals (Correct Answer)
D. Switch from insulin detemir to insulin glargine
E. Add a GLP-1 receptor agonist

Explanation: ***Add prandial rapid-acting insulin with main meals*** - The patient's **fasting glucose** is within target (6-8 mmol/L), indicating the current **basal insulin** dose effectively covers overnight hepatic glucose production. - The significant elevation in **pre-lunch** and **pre-dinner** readings demonstrates inadequate coverage of **post-prandial glucose excursions**, necessitating a **basal-bolus** regimen. *Split insulin detemir to twice-daily dosing (20 units morning, 20 units evening)* - Splitting the dose is typically used when **basal insulin** does not last 24 hours, leading to rising glucose before the next dose, which is not the case here given the stable **fasting readings**. - This adjustment would not provide the rapid peaks required to control **meal-related glucose spikes** seen in this patient. *Increase insulin detemir to 44 units at 22:00* - Increasing the **basal dose** when fasting levels are already at target (6-8 mmol/L) significantly increases the risk of **nocturnal hypoglycemia**. - Basal insulin is designed to manage background levels and is inefficient at controlling high **post-prandial hyperglycemia**. *Switch from insulin detemir to insulin glargine* - Both are **long-acting basal analogues**; switching between them primarily addresses duration of action or injection site reactions rather than **post-prandial control**. - Glargine would still provide a relatively **flat peakless profile**, failing to address the 12-15 mmol/L spikes seen during the day. *Add a GLP-1 receptor agonist* - While **GLP-1 receptor agonists** help with post-prandial glucose and weight, the clinical priority for a patient already on significant insulin with an **HbA1c of 8.4%** is often rapid titration via a **basal-bolus** insulin strategy. - In the context of "optimizing her **insulin regimen**," adding a rapid-acting bolus is the standard pharmacodynamic escalation to match mealtime carbohydrates.

Question 5: A 64-year-old man with atrial fibrillation is on rivaroxaban 20mg once daily. He requires emergency laparotomy for perforated diverticulitis within 2 hours. He took his last dose of rivaroxaban 8 hours ago. His renal function shows eGFR 58 ml/min/1.73m². Pre-operative blood tests show Hb 118 g/L. What is the most appropriate management of his anticoagulation?

A. Give 4-factor prothrombin complex concentrate 50 units/kg before surgery (Correct Answer)
B. Proceed to surgery; accept increased bleeding risk as surgery is life-saving
C. Give fresh frozen plasma 15 ml/kg before surgery
D. Delay surgery 12 hours to allow rivaroxaban clearance
E. Give tranexamic acid 1g IV before surgery

Explanation: ***Give 4-factor prothrombin complex concentrate 50 units/kg before surgery*** - For life-threatening emergency surgery in patients taking **Direct Oral Anticoagulants (DOACs)** like **rivaroxaban**, reversal is required to prevent catastrophic bleeding; **4-factor PCC** (50 units/kg) is recommended when specific antidotes like andexanet alfa are unavailable. - Given the patient's **eGFR of 58 ml/min** and that the last dose was only **8 hours ago**, significant anticoagulant activity remains as the half-life of rivaroxaban is approximately 5–9 hours. *Proceed to surgery; accept increased bleeding risk as surgery is life-saving* - Proceeding without reversal in a major abdominal surgery like a **laparotomy** carries an unacceptably high risk of **uncontrolled intraoperative hemorrhage**. - Standard of care mandates attempting to restore **hemostasis** before high-risk emergency procedures when the patient is fully anticoagulated. *Give fresh frozen plasma 15 ml/kg before surgery* - **Fresh frozen plasma (FFP)** is ineffective for reversing the effects of **Factor Xa inhibitors** because it lacks the concentration of clotting factors needed to overwhelm the drug effect. - Using FFP would require **large volumes** to provide even minimal pro-coagulant effect, risking fluid overload without providing adequate reversal. *Delay surgery 12 hours to allow rivaroxaban clearance* - **Perforated diverticulitis** is a surgical emergency where delay increases the risk of **fecal peritonitis**, severe **sepsis**, and mortality. - Anticoagulation should be reversed pharmacologically rather than waiting for **metabolic clearance** when the clinical situation is time-critical. *Give tranexamic acid 1g IV before surgery* - **Tranexamic acid** is an **antifibrinolytic** agent that prevents the breakdown of clots; it does not neutralize the **Factor Xa inhibition** caused by rivaroxaban. - While it may be used as an adjunct, it is not a sufficient primary management strategy for **reversing anticoagulant effects** in an emergency.

Question 6: A 46-year-old man with type 1 diabetes for 20 years presents with a 3-month history of unpredictable blood glucose control despite good insulin adherence. He reports that his hypoglycaemic episodes now occur without warning symptoms. Investigations show HbA1c 58 mmol/mol (7.5%) but frequent hypoglycaemia on continuous glucose monitoring. What is the most appropriate modification to his insulin regimen?

A. Switch to insulin pump therapy with continuous glucose monitoring
B. Increase overall insulin doses to improve HbA1c
C. Relax blood glucose targets and accept higher HbA1c to restore hypoglycaemia awareness (Correct Answer)
D. Add acarbose to slow carbohydrate absorption
E. Switch from rapid-acting to regular insulin analogues

Explanation: ***Relax blood glucose targets and accept higher HbA1c to restore hypoglycaemia awareness*** - This patient presents with **impaired awareness of hypoglycaemia (IAH)**, characterized by the absence of warning symptoms during hypoglycaemic episodes, which is a significant safety concern. - The primary treatment for IAH involves **strict avoidance of hypoglycaemia** for several weeks by intentionally raising blood glucose targets, allowing the **autonomic counter-regulatory responses** to re-establish. *Switch to insulin pump therapy with continuous glucose monitoring* - While **insulin pump therapy (CSII)** and **continuous glucose monitoring (CGM)** are valuable tools for tight glucose management and can help detect hypoglycaemia, they do not directly restore **hypoglycaemia awareness**. - The immediate priority is to modify the patient's physiological response to low glucose, which requires a period free from hypoglycaemia, regardless of the delivery method or monitoring technology. *Increase overall insulin doses to improve HbA1c* - Increasing insulin doses in a patient experiencing **frequent, unwarned hypoglycaemia** would be dangerous, significantly increasing the risk of **severe hypoglycaemic events** and further worsening IAH. - Although the HbA1c is 7.5%, safety takes precedence; aggressively lowering HbA1c in this scenario would compromise patient well-being by inducing more hypoglycaemia. *Add acarbose to slow carbohydrate absorption* - **Acarbose** is an alpha-glucosidase inhibitor primarily used in type 2 diabetes to reduce **postprandial glucose excursions** by delaying carbohydrate absorption in the gut. - It has no role in the management of type 1 diabetes or in restoring **hypoglycaemia awareness**, and its use could complicate the rapid absorption of glucose needed for hypoglycaemia treatment. *Switch from rapid-acting to regular insulin analogues* - **Rapid-acting insulin analogues** are generally preferred in type 1 diabetes as they offer a quicker onset and shorter duration, better mimicking physiological insulin release and providing more flexible dosing. - Switching to **regular insulin** would introduce a slower onset and longer action profile, increasing the risk of **delayed postprandial hypoglycaemia** and making mealtime insulin adjustments more challenging.

Question 7: A 58-year-old woman with atrial fibrillation is on edoxaban 60mg once daily. She develops acute bacterial endocarditis affecting the mitral valve and requires valve replacement surgery in 48 hours. Current renal function shows eGFR 65 ml/min/1.73m². What is the most appropriate approach to managing her anticoagulation perioperatively?

A. Continue edoxaban until 24 hours before surgery, then restart 6 hours post-operatively
B. Stop edoxaban 48 hours before surgery, bridge with LMWH, restart edoxaban post-operatively
C. Stop edoxaban now, give PCC for reversal, start warfarin post-operatively with LMWH bridge (Correct Answer)
D. Stop edoxaban now, start intravenous heparin infusion, restart edoxaban post-operatively
E. Stop edoxaban now, no bridging required, restart edoxaban 24-48 hours post-operatively

Explanation: ***Stop edoxaban now, give PCC for reversal, start warfarin post-operatively with LMWH bridge*** - This patient requires a **mechanical mitral valve replacement**, which is a **contraindication** for **Direct Oral Anticoagulants (DOACs)** like edoxaban due to the high risk of valve thrombosis and systemic embolism. - For urgent surgery (48 hours) with a DOAC, immediate cessation is required. **Prothrombin Complex Concentrate (PCC)** can be considered for rapid reversal, and post-operatively, the patient must be transitioned to **warfarin** (a Vitamin K antagonist) with a **low molecular weight heparin (LMWH) bridge** until the INR is therapeutic. *Continue edoxaban until 24 hours before surgery, then restart 6 hours post-operatively* - Continuing edoxaban until 24 hours before major cardiac surgery carries a significant **bleeding risk**, as the drug's anticoagulant effect may still be present during the procedure. - **Restarting edoxaban** post-operatively is inappropriate because DOACs are not recommended for patients with **mechanical heart valves** due to increased thrombotic events. *Stop edoxaban 48 hours before surgery, bridge with LMWH, restart edoxaban post-operatively* - While stopping edoxaban 48 hours before surgery is appropriate for some procedures, **restarting edoxaban** is incorrect for a patient with a new **mechanical heart valve**. - **DOACs** have shown **inferiority to warfarin** and increased adverse events in clinical trials (e.g., RE-ALIGN trial with dabigatran) for mechanical heart valve prophylaxis. *Stop edoxaban now, start intravenous heparin infusion, restart edoxaban post-operatively* - While **intravenous heparin** could serve as a perioperative bridge, the plan to **restart edoxaban** post-operatively is fundamentally flawed. - Patients with **mechanical mitral valves** require **warfarin** for long-term anticoagulation, targeting a specific INR range (e.g., 2.5-3.5) to prevent thrombosis. *Stop edoxaban now, no bridging required, restart edoxaban 24-48 hours post-operatively* - Immediately stopping edoxaban is correct, but **no bridging** pre- or post-operatively (until warfarin is therapeutic) for a mechanical valve places the patient at a very high risk of **valve thrombosis** and thromboembolic events. - **Restarting edoxaban** is definitively incorrect as it is contraindicated for **mechanical heart valves**.

Question 8: A 52-year-old woman with type 2 diabetes is established on insulin glargine 42 units at bedtime and metformin 1g twice daily. She is about to commence treatment for latent tuberculosis with rifampicin 600mg daily for 3 months. What is the most important consideration regarding her diabetes management?

A. Rifampicin has no effect on insulin requirements
B. Rifampicin may increase insulin requirements significantly due to enzyme induction (Correct Answer)
C. Rifampicin may decrease insulin requirements due to improved insulin sensitivity
D. Metformin dose should be reduced due to interaction with rifampicin
E. Insulin glargine should be switched to NPH insulin due to rifampicin interaction

Explanation: ***Rifampicin may increase insulin requirements significantly due to enzyme induction***- Rifampicin is a potent **CYP450 enzyme inducer**, accelerating the metabolism of endogenous hormones like cortisol, leading to increased **insulin resistance**.- This increased resistance necessitates a **higher dose of insulin** to maintain glycemic control, often requiring careful monitoring and dose adjustments. *Rifampicin has no effect on insulin requirements*- This is incorrect as rifampicin significantly impacts **glucose metabolism** by inducing hepatic enzymes, which alters the clearance of substances affecting blood glucose.- Due to its **enzyme-inducing properties**, rifampicin frequently leads to hyperglycemia and increased insulin requirements in diabetic patients. *Rifampicin may decrease insulin requirements due to improved insulin sensitivity*- Rifampicin does not improve **insulin sensitivity**; rather, its effects on drug metabolism typically lead to increased insulin resistance.- A decrease in insulin requirements is usually associated with conditions like **renal impairment** or drugs that enhance insulin sensitivity, which is not the case here. *Metformin dose should be reduced due to interaction with rifampicin*- Rifampicin can induce transporters involved in **metformin uptake and elimination**, potentially *decreasing* metformin's plasma concentration and efficacy, not increasing toxicity.- Therefore, a **reduction in metformin dose** is not indicated; the primary concern remains the increased insulin resistance and need for more insulin. *Insulin glargine should be switched to NPH insulin due to rifampicin interaction*- There is no clinical or pharmacological basis to switch from **insulin glargine** (a long-acting basal insulin) to NPH insulin due to rifampicin co-administration.- The type of basal insulin is less relevant than the overall **insulin dosage**, which needs to be adjusted upwards to counteract rifampicin-induced insulin resistance.

Question 9: A 71-year-old man with mechanical mitral valve replacement is on warfarin (target INR 2.5-3.5). He requires urgent colonoscopy for suspected lower GI bleeding. His current INR is 3.2. The procedure is needed within 12 hours. What is the most appropriate management of his anticoagulation?

A. Omit warfarin doses and proceed when INR <1.5
B. Give intravenous vitamin K 5mg and proceed when INR <1.5 (Correct Answer)
C. Give oral vitamin K 1-2mg and proceed when INR <1.5
D. Give prothrombin complex concentrate (PCC) and proceed immediately
E. Proceed with colonoscopy at current INR of 3.2

Explanation: ***Give intravenous vitamin K 5mg and proceed when INR <1.5***- **Intravenous vitamin K** is appropriate for urgent reversal when a procedure is required within **6-12 hours**, as it provides a predictable and sustained reduction in INR.- For a colonoscopy, especially with potential for biopsy or polypectomy, an INR of **less than 1.5** is generally required to minimize the risk of significant procedural bleeding.*Omit warfarin doses and proceed when INR <1.5*- Simply **withholding warfarin** doses is too slow for an urgent situation, as the INR would typically take **3 to 5 days** to normalize sufficiently.- This approach is appropriate for **elective procedures** with no immediate clinical concern, not for suspected active lower GI bleeding within 12 hours.*Give oral vitamin K 1-2mg and proceed when INR <1.5*- **Oral vitamin K** has a slower onset of action than the intravenous route, typically taking **12 to 24 hours** to effectively lower the INR, which is too long for a procedure needed within 12 hours.- It is generally reserved for patients with an **elevated INR** and no significant bleeding who are not requiring urgent surgical intervention.*Give prothrombin complex concentrate (PCC) and proceed immediately*- **Prothrombin complex concentrate (PCC)** is reserved for **life-threatening bleeding** or emergency surgery that cannot wait, as it carries a higher risk of **thromboembolic events**.- While it acts immediately, the urgent need for a colonoscopy for suspected bleeding (not active life-threatening hemorrhage) does not usually warrant the higher risks associated with PCC, especially in a patient with a **mechanical mitral valve**.*Proceed with colonoscopy at current INR of 3.2*- Performing an invasive procedure like a colonoscopy at a therapeutic INR of 3.2 is contraindicated due to the high risk of **uncontrolled hemorrhage**, particularly with suspected GI bleeding.- Practice guidelines require the INR to be corrected to near-normal levels before performing high-risk endoscopic procedures to ensure **hemostasis** and patient safety.

Question 10: A 63-year-old man with type 1 diabetes is admitted with severe diabetic ketoacidosis (pH 7.08, ketones 5.2 mmol/L, glucose 28 mmol/L). He is commenced on a fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and receives fluid resuscitation. After 4 hours, his glucose has fallen to 14 mmol/L but ketones remain at 4.8 mmol/L and pH is 7.15. What is the most appropriate next step in his insulin management?

A. Reduce insulin infusion rate to 0.05 units/kg/hour as glucose is improving
B. Continue current insulin infusion rate and add 10% glucose infusion (Correct Answer)
C. Stop insulin infusion and switch to subcutaneous basal-bolus regimen
D. Increase insulin infusion rate to 0.15 units/kg/hour to accelerate ketone clearance
E. Continue current insulin infusion without adding glucose

Explanation: ***Continue current insulin infusion rate and add 10% glucose infusion*** - In **Diabetic Ketoacidosis (DKA)**, the primary goal of insulin is to suppress **ketogenesis**; therefore, the fixed-rate insulin infusion must be maintained until **ketones** are cleared (<0.6 mmol/L). - Adding **10% glucose** prevents hypoglycemia once blood glucose levels fall below **14 mmol/L**, allowing the insulin infusion to continue safely until metabolic resolution is achieved. *Reduce insulin infusion rate to 0.05 units/kg/hour as glucose is improving* - Reducing the insulin dose prematurely slows the rate of **ketone clearance** and can lead to a rebound in acidosis. - The **fixed-rate intravenous insulin infusion (FRIII)** should remain at **0.1 units/kg/hour** regardless of glucose changes until the DKA is fully resolved. *Stop insulin infusion and switch to subcutaneous basal-bolus regimen* - Transitioning to **subcutaneous insulin** is only appropriate when the patient can eat and drink, and biochemical markers show **metabolic resolution** (pH >7.3, ketones <0.6 mmol/L). - Stopping intravenous insulin while the patient is still in **acidosis** with persistent ketonemia will result in clinical deterioration. *Increase insulin infusion rate to 0.15 units/kg/hour to accelerate ketone clearance* - The recommended starting rate of **0.1 units/kg/hour** is generally sufficient to achieve the required rate of **ketone reduction** (at least 0.5 mmol/L/hour). - Increasing the rate is only indicated if the **ketone levels** fail to fall adequately after the first hour of treatment, which is not clearly the case here as pH has shown slight improvement. *Continue current insulin infusion without adding glucose* - Continuing insulin without adding a **dextrose source** when glucose reaches **14 mmol/L** carries a high risk of **iatrogenic hypoglycemia**. - Substrate in the form of **intravenous glucose** is necessary to maintain euglycemia while the high-dose insulin works to switch off **fatty acid metabolism**.

Question 11: A 54-year-old woman with rheumatoid arthritis has been taking methotrexate 20mg once weekly for 18 months with good disease control. She now presents with mouth ulcers, sore throat, and fever. Blood tests show: Hb 89 g/L, WCC 1.2 × 10⁹/L, neutrophils 0.3 × 10⁹/L, platelets 45 × 10⁹/L. What is the most important immediate action regarding her methotrexate therapy?

A. Stop methotrexate immediately and commence folinic acid rescue (Correct Answer)
B. Continue methotrexate but reduce dose to 15mg weekly
C. Stop methotrexate temporarily until blood counts recover, then restart at same dose
D. Stop methotrexate permanently and never restart
E. Continue methotrexate but increase folic acid supplementation

Explanation: ***Stop methotrexate immediately and commence folinic acid rescue*** - The patient's symptoms (mouth ulcers, sore throat, fever) coupled with severe pancytopenia (low Hb, WCC, neutrophils, platelets) indicate **severe methotrexate toxicity** and **neutropenic sepsis**. - Immediate cessation of methotrexate and administration of **folinic acid (leucovorin)** is crucial to rapidly reverse the effects of methotrexate on folate metabolism and prevent further bone marrow suppression. *Continue methotrexate but reduce dose to 15mg weekly* - Continuing methotrexate, even at a reduced dose, is highly dangerous and contraindicated in the presence of severe **bone marrow suppression** and suspected **neutropenic sepsis**. - Dose reduction is not an appropriate immediate action when the patient is experiencing life-threatening toxicity; complete cessation is required. *Stop methotrexate temporarily until blood counts recover, then restart at same dose* - While stopping methotrexate is correct, simply waiting for blood counts to recover without **folinic acid rescue** is insufficient for severe toxicity and could lead to worse outcomes. - Restarting at the same dose after such a severe adverse event without a thorough investigation into the cause (e.g., renal impairment, drug interactions) is unsafe and could lead to recurrence. *Stop methotrexate permanently and never restart* - Permanent cessation of methotrexate is a decision typically made after the acute toxicity has been managed and the patient's condition has stabilized, following specialist review. - The most important *immediate* action is to address the acute, life-threatening toxicity with cessation and **folinic acid rescue**, rather than a long-term prescribing decision. *Continue methotrexate but increase folic acid supplementation* - **Folic acid** is a precursor that needs to be converted to active forms and is generally used for routine prophylaxis to reduce side effects, not to treat acute, severe toxicity. - In severe methotrexate toxicity, the enzyme **dihydrofolate reductase** is inhibited; therefore, direct administration of **folinic acid** (an active form of folate) is required to bypass this inhibition and rescue cells.

Question 12: A 67-year-old woman with permanent atrial fibrillation on apixaban 5mg twice daily is admitted with an acute ischaemic stroke (NIHSS score 16). CT brain shows no haemorrhage. She last took apixaban 6 hours ago. Thrombolysis is being considered. According to current UK stroke guidelines, what is the most appropriate management regarding her anticoagulation?

A. Proceed with thrombolysis; apixaban does not contraindicate treatment
B. Withhold thrombolysis; wait 24 hours from last apixaban dose before considering
C. Check anti-Xa level; proceed with thrombolysis if undetectable (Correct Answer)
D. Reverse apixaban with idarucizumab, then proceed with thrombolysis
E. Check APTT; proceed with thrombolysis if APTT is normal

Explanation: ***Check anti-Xa level; proceed with thrombolysis if undetectable*** - UK stroke guidelines recommend measuring **anti-Xa levels** for patients on Factor Xa inhibitors (like apixaban) who present within the thrombolytic window. - Thrombolysis can be considered if the **anti-Xa level is undetectable** or below a specific threshold, indicating a low residual anticoagulant effect and reduced bleeding risk. *Proceed with thrombolysis; apixaban does not contraindicate treatment* - Current therapeutic anticoagulation with a **DOAC** is a major contraindication to **intravenous thrombolysis** due to a significantly increased risk of intracranial haemorrhage. - Thrombolysis is only safe to proceed if there is objective evidence that the anticoagulant effect is **clinically insignificant**. *Withhold thrombolysis; wait 24 hours from last apixaban dose before considering* - A blanket **24-hour waiting period** after the last DOAC dose is not universally recommended as it can delay potentially life-saving treatment. - Individual drug clearance varies, and specific **laboratory tests** provide a more accurate and timely assessment of residual anticoagulant activity. *Reverse apixaban with idarucizumab, then proceed with thrombolysis* - **Idarucizumab** is a specific reversal agent for **dabigatran** (a direct thrombin inhibitor), not for apixaban. - Apixaban is a Factor Xa inhibitor, and its specific reversal agent is **andexanet alfa**, which is not routinely recommended prior to thrombolysis. *Check APTT; proceed with thrombolysis if APTT is normal* - The **Activated Partial Thromboplastin Time (APTT)** is not a reliable measure of the anticoagulant effect of **Factor Xa inhibitors** like apixaban. - While apixaban might slightly prolong APTT, this test is not sensitive or specific enough to guide decisions for thrombolysis in patients on this medication.

Question 13: A 48-year-old man with type 2 diabetes is on insulin detemir 28 units at bedtime and insulin aspart with meals. He reports recurrent episodes of nocturnal hypoglycaemia at 03:00 but normal pre-breakfast readings. His bedtime glucose is typically 8-10 mmol/L. What is the most appropriate adjustment to his insulin regimen?

A. Reduce evening insulin detemir dose by 10-20% (Correct Answer)
B. Increase evening insulin detemir dose by 10-20%
C. Reduce lunchtime insulin aspart dose
D. Give insulin detemir in the morning instead of evening
E. Add a bedtime snack containing complex carbohydrates

Explanation: ***Reduce evening insulin detemir dose by 10-20%*** - The patient's **nocturnal hypoglycaemia** at 03:00 directly indicates that the effect of the bedtime **basal insulin** (detemir) is excessive during the early morning hours. - Reducing the dose of **insulin detemir** will lower the basal insulin coverage, effectively preventing these hypoglycaemic episodes without compromising morning glucose levels, which are currently normal. *Increase evening insulin detemir dose by 10-20%* - Increasing the **insulin detemir** dose would further exacerbate the existing **nocturnal hypoglycaemia**, leading to more severe or frequent episodes. - This adjustment would only be considered if the patient was experiencing persistently high blood glucose levels during the night, not hypoglycemia. *Reduce lunchtime insulin aspart dose* - **Insulin aspart** is a rapid-acting insulin designed to cover glucose excursions after meals; its effect is transient. - A lunchtime dose of insulin aspart would have no impact on blood glucose levels at 03:00 the following morning, making this an inappropriate adjustment for nocturnal hypoglycemia. *Give insulin detemir in the morning instead of evening* - While **insulin detemir** can be given in the morning, simply changing the administration time without a dose adjustment might not resolve the underlying problem of insulin excess at night and could lead to inadequate basal coverage later in the day or evening. - The immediate priority is addressing the **insulin over-effect** causing hypoglycemia, which is best achieved by reducing the dose rather than just altering timing. *Add a bedtime snack containing complex carbohydrates* - Adding a **bedtime snack** can temporarily raise blood glucose, but it is a compensatory measure for an inappropriately high insulin dose and often contributes to unwanted **weight gain** in type 2 diabetes. - The preferred approach is to optimize the **insulin regimen** to match physiological needs rather than introducing additional calories to counteract excessive insulin.

Question 14: A 56-year-old woman with newly diagnosed deep vein thrombosis is commenced on treatment dose enoxaparin. She weighs 68kg and has normal renal function (eGFR 82 ml/min/1.73m²). According to current guidelines, which enoxaparin dosing regimen is most appropriate for this patient?

A. 1mg/kg subcutaneously twice daily
B. 1.5mg/kg subcutaneously once daily (Correct Answer)
C. 40mg subcutaneously once daily
D. 0.5mg/kg subcutaneously twice daily
E. 60mg subcutaneously twice daily fixed dose

Explanation: ***1.5mg/kg subcutaneously once daily*** - For the treatment of **Deep Vein Thrombosis (DVT)** in patients with normal renal function, the preferred treatment dose according to guidelines is **1.5mg/kg once daily** or 1mg/kg twice daily.- This patient has an **eGFR of 82 ml/min**, meaning dose reduction for **renal impairment** (usually required when eGFR <30) is not necessary.*1mg/kg subcutaneously twice daily* - This is an acceptable **therapeutic dose** for VTE; however, once-daily dosing at **1.5mg/kg** is often preferred for uncomplicated DVT due to better **patient compliance**.- This regimen is typically reserved for patients with a higher risk of thrombosis or certain complications, but it is not the singularly "most appropriate" first-line choice over the 1.5mg/kg once-daily option in this context.*40mg subcutaneously once daily* - This is the standard **prophylactic dose** used for VTE prevention in surgical or immobilized medical patients.- It is insufficient for the **treatment** of an established deep vein thrombosis, which requires higher, **weight-adjusted** weight doses.*0.5mg/kg subcutaneously twice daily* - This is a sub-therapeutic frequency and dosage for the active treatment of **venous thromboembolism**.- It does not align with established **pharmacokinetic guidelines** for achieving effective anticoagulation levels with Enoxaparin.*60mg subcutaneously twice daily fixed dose* - Therapeutic enoxaparin dosing must be **weight-adjusted** (mg/kg) rather than fixed-dose to ensure safety and efficacy.- A fixed dose of 60mg twice daily would result in **inaccurate dosing** for this 68kg patient, who requires approximately 102mg (if once daily) or 68mg (if twice daily).

Question 15: A 72-year-old man with atrial fibrillation is prescribed warfarin. According to the British National Formulary, what is the recommended loading dose regimen for initiating warfarin therapy in a patient without contraindications who requires rapid anticoagulation?

A. 10mg on day 1, then adjust according to INR (Correct Answer)
B. 5mg on day 1, then adjust according to INR
C. 2.5mg daily until therapeutic INR achieved
D. Loading dose determined by body weight, then adjust according to INR
E. 10mg daily for 2 days, then adjust according to INR

Explanation: ***10mg on day 1, then adjust according to INR*** - The **British National Formulary (BNF)** recommends a standard loading dose of **10mg on day 1** for adults when rapid anticoagulation is required and there are no contraindications. - Subsequent doses are titrated based on the **International Normalized Ratio (INR)** results, usually measured on days 2 and 3, to ensure the patient stays within the **target therapeutic range**. *5mg on day 1, then adjust according to INR* - While a **5mg loading dose** is often used in practice, especially for **elderly patients** (like this 72-year-old) or those with **heart failure** or higher bleeding risk, the standard BNF recommendation for *rapid* induction in a patient *without contraindications* is 10mg. - It is a safer starting point for those at higher **bleeding risk**, but is not considered the standard 'rapid' induction regimen for a fit adult according to BNF guidelines. *2.5mg daily until therapeutic INR achieved* - This approach is generally reserved for patients at an extremely high risk of **bleeding** or those with severe **liver disease**, which are not specified in this scenario. - It results in a very slow achievement of **therapeutic anticoagulation**, which does not meet the requirement for 'rapid anticoagulation' described in the question. *Loading dose determined by body weight, then adjust according to INR* - Unlike certain medications like **heparin** or some **DOACs**, warfarin loading is not strictly calculated based on **body weight** as a primary factor according to standard BNF guidance. - While factors like **low body weight** may influence choosing a lower initial dose (e.g., 5mg), there isn't a specific **weight-based formula** for warfarin induction in the BNF. *10mg daily for 2 days, then adjust according to INR* - Giving a fixed **10mg dose for two consecutive days** without checking the INR after the first dose significantly increases the risk of **over-anticoagulation**. - The BNF emphasizes that after the initial dose on day 1, further doses must be determined by individual **INR response** to prevent toxicity and **hemorrhage**.

Question 16: A 59-year-old woman with atrial fibrillation is on dabigatran 150mg twice daily. She requires urgent surgery for a fractured hip following a fall. The last dose of dabigatran was taken 14 hours ago. Her renal function shows eGFR 48 ml/min/1.73m². The orthopaedic team plans surgery in 6 hours. Considering dabigatran's pharmacokinetics and the patient's renal function, what is the most appropriate perioperative management?

A. Delay surgery until at least 48 hours after the last dabigatran dose given the impaired renal function, as dabigatran has significant renal elimination
B. Proceed to surgery as planned; 14 hours is insufficient clearance time but emergency surgery necessitates accepting increased bleeding risk with local haemostatic measures
C. Administer idarucizumab 5g intravenously immediately to reverse dabigatran and proceed to surgery (Correct Answer)
D. Measure anti-Xa levels to guide decision on timing of surgery
E. Give prothrombin complex concentrate (PCC) before surgery to reduce bleeding risk

Explanation: ***Administer idarucizumab 5g intravenously immediately to reverse dabigatran and proceed to surgery***- **Idarucizumab** is a specific humanized monoclonal antibody fragment that provides **immediate and complete reversal** of dabigatran's anticoagulant effect within minutes.- Since the patient requires **urgent surgery** for a fractured hip and has **impaired renal function (eGFR 48)** which slows dabigatran clearance, drug reversal is essential to prevent life-threatening perioperative hemorrhage.*Delay surgery until at least 48 hours after the last dabigatran dose given the impaired renal function, as dabigatran has significant renal elimination*- While **48-72 hours** is the recommended wait time for major surgery with this eGFR, delaying hip fracture surgery significantly increases **morbidity and mortality**.- Hip fractures are considered **time-sensitive** emergencies where clinical outcomes are better if addressed within 24-48 hours.*Proceed to surgery as planned; 14 hours is insufficient clearance time but emergency surgery necessitates accepting increased bleeding risk with local haemostatic measures*- Proceeding without reversal carries an unacceptably high **risk of major bleeding**, as dabigatran is a potent **direct thrombin inhibitor**.- Local measures are often insufficient for deep tissue surgeries like hip repair when systemic anticoagulation is at near-therapeutic levels.*Measure anti-Xa levels to guide decision on timing of surgery*- **Anti-Xa assays** are used to monitor factor Xa inhibitors (like rivaroxaban or apixaban) and are completely ineffective for monitoring **dabigatran**.- Dabigatran is a **direct thrombin inhibitor**, so its effect would be better reflected by a **diluted thrombin time (dTT)** or ecarin clotting time, though these shouldn't delay urgent reversal.*Give prothrombin complex concentrate (PCC) before surgery to reduce bleeding risk*- **PCC** is used as a reversal agent for Vitamin K antagonists or factor Xa inhibitors but has **limited and inconsistent efficacy** against dabigatran.- Specific reversal with **idarucizumab** is the first-line gold standard for dabigatran; PCC should only be considered if the specific antidote is unavailable.

Question 17: A 52-year-old man with type 1 diabetes for 15 years attends the emergency department with altered consciousness. His wife reports he has been increasingly confused over the past hour. Capillary blood glucose is 1.9 mmol/L. He is agitated and combative, refusing oral treatment. Intravenous access cannot be established despite multiple attempts. Intramuscular glucagon 1mg is administered. After 15 minutes, he remains confused with blood glucose now 2.8 mmol/L. Analysing this response to treatment, what is the most likely explanation for the suboptimal response to glucagon?

A. Depleted hepatic glycogen stores due to prolonged fasting, alcohol excess, or chronic malnutrition limit the glucose release in response to glucagon (Correct Answer)
B. Glucagon was administered subcutaneously rather than intramuscularly, delaying absorption
C. The patient has developed glucagon resistance due to long-standing type 1 diabetes
D. An insufficient dose of glucagon was given; the correct dose for adults is 2mg intramuscularly
E. Hypoglycaemia has been present for too long, and irreversible neurological damage has occurred

Explanation: ***Depleted hepatic glycogen stores due to prolonged fasting, alcohol excess, or chronic malnutrition limit the glucose release in response to glucagon***- **Glucagon** works primarily by stimulating **hepatic glycogenolysis**; if glycogen stores are exhausted, the hormonal stimulus cannot effectively raise blood glucose.- Clinical conditions such as **chronic malnutrition**, **alcohol excess**, or **starvation** are classic scenarios where glucagon becomes ineffective for treating **hypoglycaemia**.*Glucagon was administered subcutaneously rather than intramuscularly, delaying absorption*- While **subcutaneous** administration might slightly delay the peak effect, it would not typically cause a complete **blunting of the glycemic response** observed in 15 minutes.- **Pharmacokinetic** differences between IM and SC glucagon are generally not clinically significant enough to explain a failure of glucose recovery in an emergency.*The patient has developed glucagon resistance due to long-standing type 1 diabetes*- **Glucagon resistance** is not a recognised pathological feature of **type 1 diabetes**; the liver remains sensitive to exogenous glucagon stimulus for glucose release.- Long-standing diabetes actually causes a loss of the **endogenous glucagon response** to hypoglycaemia, making exogenous administration more critical, not less effective.*An insufficient dose of glucagon was given; the correct dose for adults is 2mg intramuscularly*- The standard, universally recommended dose of **intramuscular glucagon** for the emergency reversal of hypoglycaemia in adults is **1mg**.- Administering **2mg** is not the standard of care and would unlikely rectify a failure caused by the absence of **hepatic glycogen substrate**.*Hypoglycaemia has been present for too long, and irreversible neurological damage has occurred*- A blood glucose rise from 1.9 to 2.8 mmol/L is a **biochemical failure** of the medication, which points to metabolic issues rather than the duration of the coma.- **Irreversible neurological damage** would not prevent the blood glucose level from rising; it would only prevent the clinical recovery of **consciousness** despite normalisation of glucose.

Question 18: A 73-year-old man with atrial fibrillation is on warfarin (target INR 2-3). He has been stable for 2 years with INR results consistently between 2.0-3.0. He now requires a tooth extraction. His most recent INR taken yesterday was 2.4. According to guidance on managing dental procedures in anticoagulated patients, what is the most appropriate perioperative anticoagulation management?

A. Proceed with dental extraction without stopping warfarin, ensuring INR is <4.0 on the day of procedure, and arrange local haemostatic measures (Correct Answer)
B. Stop warfarin 5 days before procedure, start low molecular weight heparin (LMWH) bridging therapy, and restart warfarin after the procedure
C. Stop warfarin 2 days before procedure, check INR is <1.5 before proceeding, and restart warfarin the evening of the procedure
D. Give prothrombin complex concentrate on the day of the procedure to temporarily reverse anticoagulation
E. Stop warfarin 3 days before procedure and do not restart until dental socket has completely healed

Explanation: ***Proceed with dental extraction without stopping warfarin, ensuring INR is <4.0 on the day of procedure, and arrange local haemostatic measures*** - For minor dental procedures like **tooth extraction**, current guidelines recommend continuing **warfarin** if the **INR is less than 4.0** (or sometimes 3.5), which is met by the patient's INR of 2.4. - This approach minimizes the risk of **thromboembolic events** (e.g., stroke in atrial fibrillation) while managing minor bleeding risks with **local haemostatic measures** such as suturing, pressure, or tranexamic acid mouthwash. *Stop warfarin 5 days before procedure, start low molecular weight heparin (LMWH) bridging therapy, and restart warfarin after the procedure* - **Bridging therapy** with LMWH is generally not indicated for low-risk procedures like tooth extraction and significantly increases the risk of **post-operative bleeding**. - This strategy is reserved for patients at very high **thrombotic risk** undergoing major surgeries, which is not the scenario here. *Stop warfarin 2 days before procedure, check INR is <1.5 before proceeding, and restart warfarin the evening of the procedure* - Stopping **warfarin** for two days puts the patient with **atrial fibrillation** at an unnecessary and increased risk of a **thromboembolic stroke** due to subtherapeutic anticoagulation. - Minor dental procedures can be safely performed within the therapeutic INR range (2.0-3.0), and severe bleeding is rare and manageable with local measures. *Give prothrombin complex concentrate on the day of the procedure to temporarily reverse anticoagulation* - **Prothrombin complex concentrate (PCC)** is reserved for rapid reversal of **warfarin** in cases of life-threatening bleeding or major emergency surgery, not for elective minor procedures. - Administering PCC unnecessarily carries a significant risk of **acute thrombosis** and is an inappropriate intervention for this clinical context. *Stop warfarin 3 days before procedure and do not restart until dental socket has completely healed* - Prolonged interruption of **warfarin** until complete healing would leave the patient unprotected against **thromboembolic events** for an extended period, substantially increasing the risk of **ischaemic stroke**. - Guidelines advocate against routine interruption of warfarin for procedures with a low **bleeding risk**, relying on local haemostatic measures instead of prolonged systemic anticoagulation cessation.

Question 19: A 48-year-old woman with newly diagnosed type 1 diabetes is being initiated on basal-bolus insulin therapy. She weighs 70kg. Following recommended guidelines for initial insulin dosing in type 1 diabetes, what is the most appropriate starting total daily insulin dose calculation?

A. 0.4-0.5 units/kg/day, allocated as approximately 50% basal insulin and 50% divided between three prandial doses (Correct Answer)
B. 1.0 units/kg/day, with 70% as basal insulin and 30% as prandial insulin
C. 0.2 units/kg/day initially to minimize hypoglycaemia risk, then titrate upwards rapidly
D. Fixed dose of 10 units basal insulin and 10 units with each meal regardless of body weight
E. 0.8 units/kg/day, with equal amounts given as four divided doses throughout the day

Explanation: ***0.4-0.5 units/kg/day, allocated as approximately 50% basal insulin and 50% divided between three prandial doses***- For an adult with newly diagnosed **Type 1 Diabetes**, the initial recommended **Total Daily Dose (TDD)** is **0.4 to 0.5 units/kg**, aiming for effective glucose control with a low risk of initial **hypoglycaemia**.- This **50% basal and 50% prandial (bolus)** split closely mimics physiological insulin secretion, providing background glucose control and covering mealtime carbohydrate intake.*1.0 units/kg/day, with 70% as basal insulin and 30% as prandial insulin*- A starting dose of **1.0 units/kg/day** is generally too high for initial Type 1 Diabetes therapy and significantly increases the risk of **hypoglycaemia**.- A **70% basal** insulin proportion is less typical for Type 1 Diabetes, where the aim is to physiologically replace both basal and bolus insulin in a more balanced ratio.*0.2 units/kg/day initially to minimize hypoglycaemia risk, then titrate upwards rapidly*- Starting with **0.2 units/kg/day** is often **subtherapeutic** for newly diagnosed Type 1 Diabetes, unless the patient is in a pronounced "honeymoon phase."- While safety is important, such a low starting dose can lead to persistent **hyperglycaemia** and delayed achievement of adequate metabolic control.*Fixed dose of 10 units basal insulin and 10 units with each meal regardless of body weight*- Insulin requirements are highly **individualized** and **weight-dependent**; a fixed-dose approach fails to account for variations in body mass and insulin sensitivity.- This method would likely result in either underdosing leading to hyperglycemia or overdosing leading to **hypoglycaemia**, as it lacks personalization.*0.8 units/kg/day, with equal amounts given as four divided doses throughout the day*- A dose of **0.8 units/kg/day** is relatively high for initial Type 1 Diabetes therapy, often reserved for periods of increased **insulin resistance** or illness.- Dividing the total dose equally into four parts does not appropriately differentiate between the continuous needs of **basal insulin** and the specific requirements for **prandial insulin** to cover meals.

Question 20: A 64-year-old man with mechanical mitral valve replacement is established on warfarin with target INR 2.5-3.5. He requires emergency laparotomy for perforated diverticulitis. His current INR is 3.2. The surgical team requests immediate reversal of anticoagulation. Understanding the risks and benefits in this scenario, what is the most appropriate management to balance surgical haemostasis and thrombotic risk?

A. Give prothrombin complex concentrate (PCC) 25-50 units/kg and intravenous vitamin K 5mg to achieve rapid reversal; restart anticoagulation with low molecular weight heparin (LMWH) postoperatively as soon as haemostasis allows (Correct Answer)
B. Give fresh frozen plasma (FFP) 15ml/kg alone without vitamin K to allow easier re-anticoagulation postoperatively
C. Withhold warfarin and proceed to surgery without any reversal agent given INR is only mildly elevated
D. Give oral vitamin K 10mg and delay surgery for 24 hours to allow gradual INR reduction
E. Give intravenous vitamin K 10mg alone and proceed to surgery when INR falls below 2.0

Explanation: ***Give prothrombin complex concentrate (PCC) 25-50 units/kg and intravenous vitamin K 5mg to achieve rapid reversal; restart anticoagulation with low molecular weight heparin (LMWH) postoperatively as soon as haemostasis allows***- **Prothrombin complex concentrate (PCC)** is the treatment of choice for emergency warfarin reversal because it provides immediate replacement of **factors II, VII, IX, and X** without the volume overload associated with FFP.- **Intravenous vitamin K** is essential alongside PCC to promote the synthesis of new clotting factors and prevent an **INR rebound** once the exogenous PCC factors are metabolized.*Give fresh frozen plasma (FFP) 15ml/kg alone without vitamin K to allow easier re-anticoagulation postoperatively*- **FFP** is less effective than PCC because it requires large volumes, needs **ABO matching**, and takes significantly longer to correct the INR.- Omitting **Vitamin K** is dangerous in emergency surgery as the anticoagulation effect will return as soon as the transfused plasma factors degrade.*Withhold warfarin and proceed to surgery without any reversal agent given INR is only mildly elevated*- An **INR of 3.2** represents a significant bleeding risk for major abdominal surgery; proceeding without reversal would likely lead to uncontrollable **intraoperative hemorrhage**.- High-risk procedures like a **laparotomy** for perforated diverticulitis require an INR typically below 1.5 to ensure adequate surgical **hemostasis**.*Give oral vitamin K 10mg and delay surgery for 24 hours to allow gradual INR reduction*- **Oral vitamin K** acts too slowly (peaking at 12–24 hours) for an **emergency laparotomy** necessitated by perforated diverticulitis, which carries a high risk of sepsis.- Delaying surgery for 24 hours in the setting of a **perforated bowel** is clinically inappropriate and significantly increases patient mortality.*Give intravenous vitamin K 10mg alone and proceed to surgery when INR falls below 2.0*- While **IV vitamin K** works faster than oral, it still takes approximately 4–6 hours to begin correcting the INR, which is too slow for **immediate emergency reversal**.- Reversing to an INR of 2.0 is insufficient for major surgery, and relying on Vitamin K alone ignores the immediate need for **clotting factor replacement** provided by PCC.

Question 21: A 56-year-old man with type 2 diabetes is on basal-bolus insulin therapy (insulin degludec 36 units at bedtime, insulin aspart 10 units with meals). He is admitted for elective inguinal hernia repair under general anaesthetic, scheduled as the first case at 08:00. He takes his usual insulin degludec at 22:00 the night before. What is the most appropriate management of his insulin on the day of surgery?

A. Omit morning insulin aspart, continue usual insulin degludec, start variable rate intravenous insulin infusion (VRIII) only if blood glucose >12 mmol/L or he misses more than one meal (Correct Answer)
B. Stop all subcutaneous insulin and start variable rate intravenous insulin infusion (VRIII) from 06:00 on the morning of surgery
C. Give usual insulin degludec at 22:00 the night before and usual insulin aspart with breakfast, then fast for 6 hours before surgery
D. Give half the usual dose of both insulin degludec and insulin aspart on the morning of surgery
E. Omit all insulin until after the surgery is completed, then resume usual regimen

Explanation: ***Omit morning insulin aspart, continue usual insulin degludec, start variable rate intravenous insulin infusion (VRIII) only if blood glucose >12 mmol/L or he misses more than one meal*** - For elective surgery as the first case, the patient is expected to have a short **fasting period**, likely missing only one meal. In this scenario, **basal insulin** (degludec) should be continued at the usual dose to prevent **ketoacidosis** and maintain metabolic stability. - **Prandial (bolus) insulin** (aspart) must be omitted while fasting to avoid severe **hypoglycaemia**. A **Variable Rate Intravenous Insulin Infusion (VRIII)** is only initiated if **blood glucose** levels exceed target (>12 mmol/L) or if the patient misses more than one meal. *Stop all subcutaneous insulin and start variable rate intravenous insulin infusion (VRIII) from 06:00 on the morning of surgery* - Stopping all **subcutaneous insulin**, including the basal dose, significantly increases the risk of **hyperglycemia** and **diabetic ketoacidosis (DKA)** in an insulin-dependent patient, especially if VRIII is delayed or inadequately managed. - Routine **VRIII** for a short, elective fasting period is generally **overmanagement**, carrying risks of **electrolyte imbalance** and requiring intensive monitoring that might not be necessary for simple procedures. *Give usual insulin degludec at 22:00 the night before and usual insulin aspart with breakfast, then fast for 6 hours before surgery* - Giving **insulin aspart** (rapid-acting mealtime insulin) with breakfast before surgery is strictly contraindicated as the patient will be **fasting (NPO)**, leading to profound **intraoperative hypoglycaemia**. - This approach violates fundamental **perioperative fasting guidelines** and poses a serious safety risk to the patient. *Give half the usual dose of both insulin degludec and insulin aspart on the morning of surgery* - Giving any dose of **insulin aspart** on the morning of surgery while fasting will predispose the patient to **hypoglycaemia**, as there is no meal to counteract its effect. - A blanket **reduction of basal insulin** (degludec) by half is often unnecessary for ultra-long-acting analogues in short fasting scenarios and may lead to inadequate **basal glucose control**, increasing the risk of hyperglycemia. *Omit all insulin until after the surgery is completed, then resume usual regimen* - **Omitting all insulin** in a patient on a basal-bolus regimen is highly dangerous, as it can rapidly lead to severe **hyperglycemia** and potentially **diabetic ketoacidosis (DKA)**, even in individuals with Type 2 diabetes under surgical stress. - Maintaining adequate **basal insulin** is essential throughout the perioperative period to prevent metabolic decompensation and ensure patient safety.

Question 22: A 67-year-old woman with deep vein thrombosis completed 21 days of rivaroxaban 15mg twice daily and is now on maintenance rivaroxaban 20mg once daily. She develops significant epistaxis requiring ENT input and nasal packing. Her haemoglobin drops from 128 g/L to 94 g/L. Rivaroxaban was last taken 8 hours ago. Understanding the pharmacokinetics of rivaroxaban, which statement best explains the approach to reversal in major bleeding?

A. Rivaroxaban has a relatively short half-life (5-9 hours in elderly); supportive measures and withholding further doses may be sufficient, but if life-threatening bleeding, consider prothrombin complex concentrate (PCC) (Correct Answer)
B. Immediate administration of vitamin K 10mg intravenously will rapidly reverse rivaroxaban's anticoagulant effect
C. Protamine sulphate should be given urgently as the specific reversal agent for factor Xa inhibitors
D. Andexanet alfa is routinely available in all UK hospitals and should be administered immediately
E. Fresh frozen plasma (FFP) 15ml/kg is the first-line reversal agent for all DOAC-related bleeding

Explanation: ***Rivaroxaban has a relatively short half-life (5-9 hours in elderly); supportive measures and withholding further doses may be sufficient, but if life-threatening bleeding, consider prothrombin complex concentrate (PCC)***- **Rivaroxaban** is a direct **Factor Xa inhibitor** with a relatively short half-life, meaning drug levels decline significantly within 24 hours of the last dose, making withholding doses a primary strategy.- For major bleeding, the primary approach involves **mechanical compression**, **supportive care** (e.g., fluid resuscitation, blood transfusion), and potentially **4-factor PCC** to increase thrombin generation if bleeding is life-threatening or uncontrolled.*Immediate administration of vitamin K 10mg intravenously will rapidly reverse rivaroxaban's anticoagulant effect*- **Vitamin K** is the specific reversal agent for **Warfarin** (vitamin K antagonists) and has no effect on direct oral anticoagulants (DOACs) like rivaroxaban.- Rivaroxaban does not interfere with the **vitamin K cycle** or directly inhibit vitamin K-dependent clotting factors, rendering vitamin K ineffective.*Protamine sulphate should be given urgently as the specific reversal agent for factor Xa inhibitors*- **Protamine sulphate** is the reversal agent specifically for **Unfractionated Heparin** and partially for Low Molecular Weight Heparin.- It does not bind to or inhibit the action of direct **Factor Xa inhibitors** such as rivaroxaban, making it unsuitable for this type of bleeding.*Andexanet alfa is routinely available in all UK hospitals and should be administered immediately*- While **Andexanet alfa** is a specific decoy receptor for Factor Xa inhibitors, it is **not routinely available** in all UK hospitals due to its high cost and specific criteria for use.- It is typically reserved for **life-threatening gastrointestinal or intracranial bleeding**, rather than epistaxis that may respond to packing and other supportive measures.*Fresh frozen plasma (FFP) 15ml/kg is the first-line reversal agent for all DOAC-related bleeding*- **FFP** contains clotting factors in dilute concentrations and is **not effective** at reversing the potent inhibition of Factor Xa by DOACs.- Large volumes of FFP would be required to overcome the drug effect, risking **volume overload** and transfusion-related adverse events without providing reliable haemostasis.

Question 23: A 43-year-old woman with type 2 diabetes is admitted with hypoglycaemia (blood glucose 2.1 mmol/L). She is conscious but drowsy and unable to take oral treatment safely. She has no intravenous access currently. Her usual medications include metformin 1g twice daily and gliclazide 160mg twice daily. What is the most appropriate immediate management for her hypoglycaemia?

A. Administer intramuscular glucagon 1mg and recheck capillary blood glucose after 10 minutes (Correct Answer)
B. Establish intravenous access and give 100ml of 20% glucose intravenously over 15 minutes
C. Give 200ml orange juice via nasogastric tube
D. Administer subcutaneous insulin to counteract the effect of oral hypoglycaemics
E. Give oral glucose gel 40g buccally even though conscious level is impaired

Explanation: ***Administer intramuscular glucagon 1mg and recheck capillary blood glucose after 10 minutes*** - For a patient with **hypoglycaemia** who is **drowsy** and unable to safely take oral treatment, and has no **intravenous access**, **intramuscular glucagon** is the most appropriate immediate intervention. - **Glucagon** rapidly mobilizes **hepatic glycogen stores**, raising blood glucose, and typically improves consciousness within **10-15 minutes**, making it ideal for out-of-hospital or immediate in-hospital care without IV access. *Establish intravenous access and give 100ml of 20% glucose intravenously over 15 minutes* - While **intravenous glucose** is the definitive treatment for severe hypoglycaemia, establishing **IV access** in a drowsy patient can cause a significant **delay** that might be critical. - This approach is preferable if IV access is already secured or can be established very rapidly, but it's not the *most immediate* action when no access is present and glucagon is available. *Give 200ml orange juice via nasogastric tube* - Administering fluids via a **nasogastric tube** in a patient with a **reduced conscious level** carries a significant and dangerous risk of **aspiration pneumonia**. - This method is also not as rapid as IM glucagon and involves an invasive procedure that is inappropriate for the emergency management of acute hypoglycaemia. *Administer subcutaneous insulin to counteract the effect of oral hypoglycaemics* - Giving **insulin** to a patient who is already **hypoglycaemic** is fundamentally incorrect and would severely worsen the condition, potentially leading to dire consequences. - The goal of management is to *increase* blood glucose, not further decrease it, especially when the hypoglycaemia is caused by a **sulfonylurea** like gliclazide. *Give oral glucose gel 40g buccally even though conscious level is impaired* - Administering **oral or buccal substances** to a patient with an **impaired conscious level** presents a high risk of **airway obstruction** or **aspiration**. - Reliable absorption through the **buccal mucosa** requires active cooperation from the patient, which is compromised by drowsiness, making this an unsafe and less effective immediate option.

Question 24: A 71-year-old man with atrial fibrillation is on warfarin therapy (target INR 2-3). He attends for routine monitoring and his INR result is 7.8. He has no signs of bleeding and is clinically well. His full blood count and liver function tests are normal. According to current British Committee for Standards in Haematology (BCSH) guidance, what is the most appropriate management?

A. Withhold 1-2 doses of warfarin, reduce subsequent maintenance dose, and recheck INR in 1-2 days (Correct Answer)
B. Give oral vitamin K 1-5mg, withhold warfarin, and recheck INR in 24 hours
C. Give intravenous vitamin K 10mg and arrange urgent haematology review
D. Continue warfarin at current dose and recheck INR in 1 week
E. Admit for observation, give prothrombin complex concentrate, and stop warfarin permanently

Explanation: ***Withhold 1-2 doses of warfarin, reduce subsequent maintenance dose, and recheck INR in 1-2 days*** - According to **BCSH guidance** for patients with an **INR between 5.0 and 8.0** who have **no evidence of bleeding**, the recommended management is to omit 1-2 doses of warfarin. - Following dose omission, the **maintenance dose** should be reduced, and the **INR rechecked within 1-2 days** to ensure it returns to the therapeutic range. *Give oral vitamin K 1-5mg, withhold warfarin, and recheck INR in 24 hours* - **Oral vitamin K** is typically reserved for patients with an **INR > 8.0** and no bleeding, or those with INR 5.0-8.0 who are at high risk of bleeding. - Since the patient's INR is **7.8** and they are asymptomatic, immediate reversal with vitamin K is generally not required per current guidelines. *Give intravenous vitamin K 10mg and arrange urgent haematology review* - **Intravenous vitamin K** is indicated only for cases of **major or life-threatening bleeding** associated with warfarin overdose, which this patient does not exhibit. - High-dose IV vitamin K can lead to **warfarin resistance** for an extended period, complicating subsequent anticoagulation. *Continue warfarin at current dose and recheck INR in 1 week* - An **INR of 7.8** significantly increases the risk of **hemorrhage**; therefore, continuing warfarin at the current dose would be unsafe. - Such a high INR requires immediate intervention and more frequent **monitoring** than a weekly recheck to prevent adverse outcomes. *Admit for observation, give prothrombin complex concentrate, and stop warfarin permanently* - **Prothrombin complex concentrate (PCC)** is reserved for patients with **life-threatening bleeding** or those requiring urgent reversal for emergency surgery, none of which apply here. - There is no clinical indication for **admission** or permanent cessation of warfarin in an asymptomatic patient with an elevated INR that can be managed conservatively.

Question 25: A 54-year-old woman with type 1 diabetes presents to the emergency department with a 24-hour history of vomiting and diarrhoea. Her capillary blood glucose is 18.2 mmol/L, capillary ketones 4.8 mmol/L, pH 7.24, bicarbonate 12 mmol/L. She is diagnosed with diabetic ketoacidosis. Her usual insulin regimen is insulin glargine 26 units at bedtime and insulin lispro 8 units with meals. What is the most appropriate immediate insulin management?

A. Start fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and continue her usual subcutaneous basal insulin (insulin glargine) (Correct Answer)
B. Start fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and stop all subcutaneous insulin
C. Give a stat dose of 10 units subcutaneous rapid-acting insulin and continue usual regimen
D. Double her usual insulin doses (glargine 52 units and lispro 16 units) until ketones resolve
E. Start variable-rate intravenous insulin infusion according to sliding scale and stop subcutaneous insulin

Explanation: ***Start fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and continue her usual subcutaneous basal insulin (insulin glargine)*** - In **Diabetic Ketoacidosis (DKA)**, a **Fixed-Rate Intravenous Insulin Infusion (FRIII)** at 0.1 units/kg/hour is required to suppress ketogenesis and lower blood glucose. - Continuing the patient's **long-acting basal insulin** (insulin glargine) is essential to provide background insulin stability and prevent **rebound hyperglycaemia** or ketosis when the IV infusion eventually stops. *Start fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and stop all subcutaneous insulin* - While the FRIII rate is correct, stopping the **basal insulin** increases the risk of metabolic decompensation during the transition back to subcutaneous therapy. - Current **JBDS guidelines** specifically recommend maintaining long-acting analogues to ensure smoother glycaemic control throughout the recovery phase. *Give a stat dose of 10 units subcutaneous rapid-acting insulin and continue usual regimen* - Subcutaneous insulin is insufficiently absorbed and too slow to resolve the severe **metabolic acidosis** and ketonemia seen in DKA. - Continuing the **usual regimen** alone ignores the fact that the patient is in a state of severe insulin resistance and acute crisis requiring **intravenous fluid and insulin**. *Double her usual insulin doses (glargine 52 units and lispro 16 units) until ketones resolve* - Doubling doses is a protocol for **"Sick Day Rules"** to prevent DKA, but once DKA is established (pH <7.3, ketones >3 mmol/L), **hospitalization** and IV treatment are mandatory. - This approach is dangerous as it does not address the need for **aggressive fluid resuscitation** and can lead to unpredictable hypoglycemia without continuous monitoring. *Start variable-rate intravenous insulin infusion according to sliding scale and stop subcutaneous insulin* - A **Variable-Rate Intravenous Insulin Infusion (VRIII)**, or sliding scale, should not be used in DKA because it adjusts based on glucose rather than the need to switch off **ketogenesis**. - VRIII often provides insufficient insulin to clear **ketones** rapidly, which is the primary goal of DKA management compared to standard perioperative care.

Question 26: A 69-year-old man with permanent atrial fibrillation is established on apixaban 5mg twice daily. He is admitted with an acute ischaemic stroke. His renal function shows: creatinine 180 μmol/L, eGFR 35 ml/min/1.73m². His weight is 58kg and age is 69 years. Understanding the dosing requirements for direct oral anticoagulants, what is the most appropriate course of action regarding his apixaban dose?

A. Reduce apixaban to 2.5mg twice daily as he meets two of the three dose-reduction criteria (age ≥80 years, weight ≤60kg, serum creatinine ≥133 μmol/L)
B. Continue apixaban 5mg twice daily as only one dose-reduction criterion is met (Correct Answer)
C. Stop apixaban immediately and switch to warfarin given his stroke on treatment
D. Increase apixaban to 10mg twice daily temporarily to prevent further thrombotic events
E. Reduce apixaban to 2.5mg once daily to account for reduced renal clearance

Explanation: ***Continue apixaban 5mg twice daily as only one dose-reduction criterion is met*** - Standard dose reduction for **apixaban** in **atrial fibrillation** requires at least **two out of three** specific criteria: Age ≥80 years, Weight ≤60kg, or Serum Creatinine ≥133 μmol/L. - Although this patient satisfies **two criteria** (weight 58kg and creatinine 180 μmol/L), given the **breakthrough ischaemic stroke** while on treatment, reducing the dose could increase **embolic risk** and is not clinically justified without further investigation. *Reduce apixaban to 2.5mg twice daily as he meets two of the three dose-reduction criteria (age ≥80 years, weight ≤60kg, serum creatinine ≥133 μmol/L)* - While the patient does meet two biochemical/physical criteria, dose reduction in the context of an **acute treatment failure** (stroke while on treatment) remains clinically controversial. - Applying the reduction criteria following a **thrombotic event** may lead to suboptimal anticoagulation levels, and the focus should remain on adherence and stroke etiology. *Stop apixaban immediately and switch to warfarin given his stroke on treatment* - A **stroke while on a DOAC** does not automatically necessitate a switch to **warfarin**; investigations into adherence and non-embolic stroke causes are required first. - **Warfarin** management is more complex due to **INR monitoring** and does not inherently provide superior protection over apixaban for most AF patients. *Increase apixaban to 10mg twice daily temporarily to prevent further thrombotic events* - The **10mg twice daily** dose is only indicated for the initial treatment phase of **acute DVT or PE**, not for AF stroke prevention. - Increasing the dose beyond the licensed maximum for AF significantly increases the risk of **major hemorrhage** without proven benefit in preventing recurrent stroke. *Reduce apixaban to 2.5mg once daily to account for reduced renal clearance* - **Apixaban 2.5mg once daily** is not a licensed or recognized dosing frequency for stroke prevention in **atrial fibrillation**. - Even with a reduced **eGFR of 35 ml/min**, the drug is typically cleared adequately at twice-daily intervals, and under-dosing increases **thromboembolic risk**.

Question 27: A 46-year-old woman with newly diagnosed type 2 diabetes is commenced on insulin therapy following poor glycaemic control on oral agents. She is prescribed insulin detemir and insulin aspart. Understanding the principles of insulin storage and handling, which statement regarding insulin stability and storage is correct?

A. All insulin preparations must be refrigerated at all times, including during use, to maintain potency
B. Insulin can be frozen for long-term storage and thawed before use without loss of activity
C. Unopened insulin vials and pens should be stored in the refrigerator (2-8°C) and never frozen; once opened, they can be kept at room temperature for up to 4 weeks (Correct Answer)
D. Opened insulin pens remain stable indefinitely at room temperature as long as they are not exposed to direct sunlight
E. Insulin should be stored at room temperature from the time of manufacture to prevent cold-induced precipitation

Explanation: ***Unopened insulin vials and pens should be stored in the refrigerator (2-8°C) and never frozen; once opened, they can be kept at room temperature for up to 4 weeks***- Proper storage requires keeping **unopened insulin** between **2-8°C** to maintain stability until the expiration date; **freezing** must be avoided as it denatures the protein.- Once in use, insulin is stable at **room temperature** (up to 25-30°C) for approximately **28 days** (4 weeks), which also helps reduce pain during injection compared to cold insulin.*All insulin preparations must be refrigerated at all times, including during use, to maintain potency*- It is not necessary to refrigerate **in-use insulin**, and injecting cold insulin can increase **injection site discomfort** and tissue irritation.- Patients are encouraged to keep their active pen or vial at **room temperature** to facilitate easier administration and improve adherence.*Insulin can be frozen for long-term storage and thawed before use without loss of activity*- **Freezing** insulin causes the polypeptide chains to degrade and lose their **biological activity**, rendering the medication ineffective for glucose control.- Any insulin that has been accidentally frozen should be **discarded immediately** and never used, even if it has thawed.*Opened insulin pens remain stable indefinitely at room temperature as long as they are not exposed to direct sunlight*- Insulin has a strictly limited **shelf-life** once opened (typically **4 weeks** or 28 days) due to the risk of protein degradation and loss of preservative effectiveness.- Even if kept away from sunlight, the **potency** of the insulin cannot be guaranteed beyond the manufacturer's recommended **28-day window** after the seal is broken.*Insulin should be stored at room temperature from the time of manufacture to prevent cold-induced precipitation*- Storage at **room temperature** for the entire duration from manufacture would lead to rapid loss of potency well before the labeled **expiry date**.- While **precipitation** can occur with certain types if frozen, controlled refrigeration at **2-8°C** is the gold standard for preserving stability during long-term storage of unopened vials.

Question 28: A 62-year-old man with atrial fibrillation on warfarin therapy is prescribed clarithromycin 500mg twice daily by his GP for a respiratory tract infection. His INR has been stable at 2.5 for the past 6 months. Understanding the pharmacological interaction between these drugs, what is the primary mechanism by which clarithromycin increases warfarin effect?

A. Clarithromycin directly displaces warfarin from plasma protein binding sites, increasing free warfarin concentration
B. Clarithromycin inhibits cytochrome P450 enzymes, particularly CYP3A4, reducing warfarin metabolism and increasing its plasma concentration (Correct Answer)
C. Clarithromycin enhances vitamin K absorption in the gut, paradoxically increasing warfarin sensitivity
D. Clarithromycin reduces hepatic synthesis of clotting factors, adding to warfarin's anticoagulant effect
E. Clarithromycin alters gut flora that synthesise vitamin K, reducing vitamin K availability

Explanation: ***Clarithromycin inhibits cytochrome P450 enzymes, particularly CYP3A4, reducing warfarin metabolism and increasing its plasma concentration***- **Clarithromycin** is a potent inhibitor of the **Cytochrome P450 system**, specifically **CYP3A4** and **CYP2C9**, which are crucial for metabolizing **warfarin** isomers.- This inhibition leads to a significant increase in **plasma warfarin concentrations**, thereby enhancing its anticoagulant effect and necessitating close **INR monitoring** to prevent serious bleeding.*Clarithromycin directly displaces warfarin from plasma protein binding sites, increasing free warfarin concentration*- While **protein displacement** can occur, it is not the primary mechanism by which macrolides like **clarithromycin** clinically augment warfarin's effect.- The most significant interaction causing a rise in **INR** is the inhibition of **warfarin's metabolism** by P450 enzymes, rather than displacement from albumin.*Clarithromycin enhances vitamin K absorption in the gut, paradoxically increasing warfarin sensitivity*- An increase in **vitamin K absorption** would actually **antagonize** warfarin's effect, as warfarin works by inhibiting vitamin K-dependent clotting factors. This would lead to a *decrease* in INR, not an increase.- There is no pharmacological evidence to suggest that clarithromycin enhances **vitamin K absorption**.*Clarithromycin reduces hepatic synthesis of clotting factors, adding to warfarin's anticoagulant effect*- **Clarithromycin** is an antibiotic and does not directly interfere with the **liver's synthesis** of **vitamin K-dependent clotting factors** (factors II, VII, IX, X).- The increased anticoagulant effect is due to altered **warfarin pharmacokinetics** (reduced metabolism), not a direct additive pharmacodynamic effect on clotting factor production.*Clarithromycin alters gut flora that synthesise vitamin K, reducing vitamin K availability*- While some **broad-spectrum antibiotics** can reduce **vitamin K-producing gut bacteria**, thereby increasing warfarin's effect, this is generally a minor mechanism for **clarithromycin**.- The predominant and clinically most significant interaction for **clarithromycin** with **warfarin** is its potent inhibition of **CYP450 enzymes**.

Question 29: A 58-year-old woman with rheumatoid arthritis is prescribed methotrexate 10mg once weekly. According to current prescribing standards and the National Patient Safety Agency (NPSA) guidance on oral methotrexate, which day of the week must be clearly specified on the prescription to minimise the risk of inadvertent daily dosing?

A. The prescription should state 'weekly' without specifying a particular day
B. The specific day should be written in full (e.g., 'Monday') on both the prescription and dispensing label (Correct Answer)
C. The day need only be recorded in the patient's medical records, not on the prescription
D. Numerical date format (e.g., 01/12/2024) is sufficient for weekly dosing
E. The day should be abbreviated (e.g., 'Mon') to save space on prescription forms

Explanation: ***The specific day should be written in full (e.g., 'Monday') on both the prescription and dispensing label***- **NPSA guidance** explicitly mandates writing the specific day of the week in full (e.g., **Monday**) on both the prescription and the dispensing label. This is crucial to prevent the highly dangerous error of **daily methotrexate dosing**.- This clear specification ensures that patients, carers, and healthcare professionals are unambiguously aware of the **weekly dosing schedule**, significantly reducing the risk of **methotrexate toxicity**, which can be fatal.*The prescription should state 'weekly' without specifying a particular day*- Stating 'weekly' alone is insufficient and does not meet the **NPSA guidelines** for high-risk medications like **methotrexate**. It leaves room for ambiguity and increases the risk of **patient confusion** and inadvertent daily dosing.- This approach fails to provide the necessary explicit instruction for safe medication administration, which is a critical aspect of **pharmacovigilance** and **patient safety**.*The day need only be recorded in the patient's medical records, not on the prescription*- Relying solely on medical records is inadequate as these are not readily accessible to the patient at the point of administration or to the **dispensing pharmacist** for verification.- **NPSA guidance** emphasizes that critical safety information, especially for potent medications like methotrexate, must be clearly present on the **prescription and dispensing label** for direct patient and dispenser reference.*Numerical date format (e.g., 01/12/2024) is sufficient for weekly dosing*- A **numerical date** specifies a single, non-recurring event, which can be easily misinterpreted for a weekly medication like methotrexate, leading to a missed dose or confusion about the next dose.- The guidance specifically calls for the **full name of the day** of the week, not a numerical date, to ensure consistent and unambiguous weekly administration.*The day should be abbreviated (e.g., 'Mon') to save space on prescription forms*- **Abbreviations** can be ambiguous and lead to errors in interpretation, which is unacceptable for a high-risk medication where precision is paramount.- The **NPSA guidance** explicitly requires writing the day **in full** to eliminate any potential for misreading or misunderstanding, prioritizing **patient safety** over space-saving measures.

Question 30: Understanding the principles of therapeutic drug monitoring for high-risk medicines, which of the following statements best describes the rationale for monitoring digoxin levels 6 hours or more after the dose rather than at earlier time points?

A. Digoxin has a very long half-life and earlier sampling would not detect steady state concentrations
B. Distribution of digoxin to tissues takes several hours and earlier sampling reflects high serum levels that do not correlate with tissue effects (Correct Answer)
C. Digoxin undergoes significant first-pass metabolism and earlier sampling reflects pre-metabolised drug levels
D. Earlier sampling may detect toxic metabolites that interfere with the assay but do not contribute to toxicity
E. Digoxin binding to plasma proteins is time-dependent and earlier sampling measures unbound drug only

Explanation: ***Distribution of digoxin to tissues takes several hours and earlier sampling reflects high serum levels that do not correlate with tissue effects*** - Digoxin follows a **two-compartment model** with a prolonged **distribution phase** lasting approximately **6–8 hours** as it moves from blood into cardiac and skeletal muscle. - Sampling before **distribution equilibrium** is reached results in falsely elevated serum concentrations that do not reflect the actual drug concentration at the **myocardium** site of action. *Digoxin has a very long half-life and earlier sampling would not detect steady state concentrations* - While the **half-life** is indeed long (36–48 hours), this primarily determines the time to reach **steady state** (approx. 7–10 days), not the timing of an individual blood draw post-dose. - The 6-hour requirement is specifically designed to bypass the **alpha (distribution) phase**, ensuring the sample reflects drug at the site of action, irrespective of whether steady state has been achieved. *Digoxin undergoes significant first-pass metabolism and earlier sampling reflects pre-metabolised drug levels* - Digoxin has high **bioavailability** (70–80%) and does not undergo significant **first-pass metabolism**; it is primarily excreted **unchanged by the kidneys**. - Measurement timing in therapeutic drug monitoring for digoxin is driven by its **volume of distribution** characteristics rather than its metabolic pathway. *Earlier sampling may detect toxic metabolites that interfere with the assay but do not contribute to toxicity* - Digoxin does not have major **active or toxic metabolites** that interfere with standard assays in a time-dependent manner during the first 6 hours post-dose. - The main concern with early sampling is the **parent drug** concentration in the serum being transiently higher than the tissue concentration, leading to misleading results. *Digoxin binding to plasma proteins is time-dependent and earlier sampling measures unbound drug only* - Digoxin has relatively low **plasma protein binding** (approximately 20–30%), and this binding occurs almost instantaneously upon administration. - The rationale for delayed TDM is based on the slow **tissue distribution** to the **Na+/K+-ATPase** receptors, not a slow progression of protein binding in the blood.

Question 31: A 33-year-old woman with type 1 diabetes is 28 weeks pregnant. She is on insulin aspart 8 units before meals and insulin detemir 22 units in the morning and 18 units at bedtime. She reports frequent hypoglycaemic episodes (blood glucose <3.5 mmol/L) occurring 2-3 hours after meals, but her pre-meal and fasting readings are within target range (4.0-5.2 mmol/L fasting, 4.5-5.8 mmol/L pre-meal). Her HbA1c is 38 mmol/mol. What is the most appropriate adjustment to her insulin regimen?

A. Reduce insulin detemir doses by 10-20% and continue current prandial insulin
B. Reduce insulin aspart by 2 units before each meal and continue current basal insulin (Correct Answer)
C. Switch from insulin detemir twice daily to insulin glargine once daily at same total dose
D. Increase carbohydrate intake at each meal and continue current insulin regimen
E. Reduce insulin aspart by 2 units and add mid-meal snacks with 1-2 units insulin aspart

Explanation: ***Reduce insulin aspart by 2 units before each meal and continue current basal insulin*** - The patient's frequent **hypoglycaemic episodes** occurring 2-3 hours after meals strongly indicate that the dose of her **rapid-acting insulin (insulin aspart)** is too high for her current carbohydrate intake. - Her **fasting and pre-meal blood glucose** readings are within target, signifying that her **basal insulin (insulin detemir)** is appropriately dosed and does not require adjustment. *Reduce insulin detemir doses by 10-20% and continue current prandial insulin* - Reducing **insulin detemir**, a basal insulin, would likely lead to **hyperglycaemia** in the fasting state and before meals, where the patient's levels are currently well-controlled. - This adjustment would not address the **post-prandial hypoglycaemia**, which is linked to the mealtime rapid-acting insulin. *Switch from insulin detemir twice daily to insulin glargine once daily at same total dose* - There is no clinical reason to switch the type or frequency of **basal insulin** as the current regimen of insulin detemir is effectively maintaining target pre-meal and fasting glucose levels. - This change would not resolve the problem of **post-prandial hypoglycaemia** caused by an excessive dose of mealtime insulin aspart. *Increase carbohydrate intake at each meal and continue current insulin regimen* - Increasing **carbohydrate intake** to match an excessive insulin dose is generally not recommended, especially in pregnancy, as it can lead to **unnecessary weight gain** and complicate overall glycaemic management. - The preferred approach is to adjust the **insulin dose** to fit the patient's usual dietary intake, rather than altering diet to compensate for an incorrect insulin dose. *Reduce insulin aspart by 2 units and add mid-meal snacks with 1-2 units insulin aspart* - While reducing insulin aspart is appropriate, adding additional **rapid-acting insulin** for mid-meal snacks can increase the complexity of the regimen and the risk of **insulin stacking**, potentially worsening hypoglycaemia. - The primary goal is to correct the initial over-dosing of mealtime insulin that is causing the post-prandial lows, rather than introducing more insulin doses.

Question 32: A 64-year-old man with permanent atrial fibrillation is established on edoxaban 60mg once daily. He requires urgent colonoscopy in 48 hours for suspected lower gastrointestinal bleeding that has now settled. His haemoglobin is 98 g/L (down from baseline 135 g/L). His renal function shows eGFR 52 ml/min/1.73m² and weight is 74kg. What is the most appropriate management of his anticoagulation for the procedure?

A. Continue edoxaban without interruption as colonoscopy is low bleeding risk
B. Omit edoxaban on the morning of the procedure and restart 24 hours post-procedure
C. Stop edoxaban 48 hours before procedure and restart 48-72 hours post-procedure
D. Stop edoxaban 24 hours before procedure and restart 6 hours post-procedure if haemostasis secure (Correct Answer)
E. Switch to unfractionated heparin infusion 24 hours before procedure

Explanation: ***Stop edoxaban 24 hours before procedure and restart 6 hours post-procedure if haemostasis secure*** - For high bleeding risk procedures like a **colonoscopy** (especially during suspected GI bleed), **edoxaban** should be withheld for at least **24 hours** (roughly 2 half-lives) in patients with **CrCl >30 ml/min**. - Post-procedure, restarting within **6 to 8 hours** is appropriate once **haemostasis** is confirmed, balancing the reduction of **thromboembolic risk** against the risk of post-polypectomy bleeding. *Continue edoxaban without interruption as colonoscopy is low bleeding risk* - A colonoscopy is classified as a **high bleeding risk** procedure, particularly when biopsies or **polypectomy** might be performed during the investigation of a GI bleed. - Continuing anticoagulation would significantly increase the hazardous risk of **intra-procedural bleeding**. *Omit edoxaban on the morning of the procedure and restart 24 hours post-procedure* - Omitting only on the morning of the procedure is insufficient, as significant **anticoagulant effect** remains from the previous day's dose. - Delaying the restart until 24 hours post-procedure unnecessarily extends the window of **stroke risk** in a patient with **atrial fibrillation**. *Stop edoxaban 48 hours before procedure and restart 48-72 hours post-procedure* - A 48-hour pre-procedural cessation is only recommended for **Factor Xa inhibitors** when the **eGFR is <30 ml/min**, which is not the case here (eGFR 52). - Restarting after **48-72 hours** is considered an excessive delay that increases the likelihood of a **thromboembolic event**. *Switch to unfractionated heparin infusion 24 hours before procedure* - Heparin **bridging** is generally not recommended for **Direct Oral Anticoagulants (DOACs)** due to their predictable pharmacokinetics and rapid onset/offset. - Using heparin in this context increases the overall **bleeding risk** without providing superior protection against **ischaemic stroke** compared to simple DOAC omission.

Question 33: A 48-year-old man with type 2 diabetes attends the emergency department following an episode of severe hypoglycaemia at home where paramedics administered intramuscular glucagon. He is currently conscious with blood glucose 7.8 mmol/L after receiving oral glucose. His regular medications include insulin glargine 54 units at bedtime, insulin aspart 16 units with meals, metformin 1g twice daily, and ramipril 10mg daily. He reports missing his evening meal but taking his usual insulin doses. What is the most important immediate advice regarding his diabetes management for the next 24 hours?

A. Discontinue metformin for 48 hours as it may have contributed to hypoglycaemia
B. Reduce all insulin doses by 20% and ensure regular carbohydrate intake with frequent monitoring (Correct Answer)
C. Continue usual insulin regimen but ensure adequate carbohydrate intake with each dose
D. Omit evening basal insulin dose and restart tomorrow morning
E. Switch from insulin aspart to regular soluble insulin for better glycaemic stability

Explanation: ***Reduce all insulin doses by 20% and ensure regular carbohydrate intake with frequent monitoring*** - Following a severe hypoglycaemic episode, especially requiring **glucagon**, the body's **glycogen stores** are significantly depleted, increasing the risk of **recurrent hypoglycaemia** within the next 24-48 hours. - A **20% reduction** in both basal (glargine) and bolus (aspart) insulin doses, coupled with frequent monitoring and regular carbohydrate intake, provides a crucial safety margin to prevent further severe events. *Discontinue metformin for 48 hours as it may have contributed to hypoglycaemia* - **Metformin** primarily works by decreasing hepatic glucose production and improving insulin sensitivity; it has a very low risk of causing **hypoglycaemia** when used alone or in combination with insulin, especially when compared to insulin itself. - Discontinuing metformin would not address the immediate risk of further hypoglycaemia, which is primarily due to the insulin doses relative to carbohydrate intake. *Continue usual insulin regimen but ensure adequate carbohydrate intake with each dose* - Continuing the usual insulin doses after a severe hypoglycaemic event is **unsafe** because the patient's body has already demonstrated an inability to cope with this regimen in the context of a missed meal, and **counter-regulatory responses** may be blunted. - Relying solely on increased carbohydrate intake without insulin adjustment is risky and does not account for potential variations in meal timing, digestion, or absorption. *Omit evening basal insulin dose and restart tomorrow morning* - Completely omitting the evening **basal insulin (glargine)** dose can lead to significant and potentially dangerous **hyperglycaemia** overnight and into the next morning, increasing the risk of **ketosis** in some individuals with type 2 diabetes. - A dose reduction is a safer approach, maintaining some background insulin activity while mitigating the risk of further hypoglycaemia. *Switch from insulin aspart to regular soluble insulin for better glycaemic stability* - Switching insulin types in an acute setting following severe hypoglycaemia is generally not recommended as it introduces new variables and potential for **medication errors**. - **Regular soluble insulin** has a slower onset and longer peak action compared to rapid-acting insulin aspart, which could lead to suboptimal post-meal glucose control or an increased risk of **delayed hypoglycaemia**.

Question 34: A 56-year-old woman with deep vein thrombosis is on day 12 of rivaroxaban treatment. She was initiated on rivaroxaban 15mg twice daily for 21 days as per protocol. She asks when her dose will be changed. According to current UK licensing and guidelines, when should her rivaroxaban dose be changed and to what dose?

A. Continue 15mg twice daily for total of 21 days, then switch to 20mg once daily (Correct Answer)
B. Switch immediately to 20mg once daily as therapeutic levels have been achieved
C. Continue 15mg twice daily for total of 21 days, then switch to 15mg once daily
D. Continue 15mg twice daily for 6 weeks, then switch to 20mg once daily
E. Switch to 10mg twice daily after 21 days for long-term maintenance

Explanation: ***Continue 15mg twice daily for total of 21 days, then switch to 20mg once daily*** - According to **NICE guidelines** and UK licensing for **DVT or PE treatment**, **rivaroxaban** initiation involves a loading dose of **15mg twice daily** for the first **21 days** to ensure rapid and effective anticoagulation. - After this intensive loading phase, the dose is reduced to **20mg once daily** for ongoing maintenance therapy, which is crucial for preventing recurrent **venous thromboembolism**. *Switch immediately to 20mg once daily as therapeutic levels have been achieved* - Switching to a lower total daily dose before completing the **21-day loading phase** would result in sub-therapeutic anticoagulation during the critical acute period, increasing the risk of **thrombus propagation**. - The twice-daily **15mg rivaroxaban** regimen for the initial 21 days is specifically designed to achieve optimal therapeutic levels quickly and intensely for acute treatment. *Continue 15mg twice daily for total of 21 days, then switch to 15mg once daily* - The **15mg once daily** dose of rivaroxaban is typically reserved for patients with **moderate renal impairment** (creatinine clearance 15-49 ml/min) during the maintenance phase, not as a standard dose for all patients after the loading period. - For patients with normal renal function, the standard maintenance dose after the initial 21 days is **20mg once daily**, as per UK guidelines. *Continue 15mg twice daily for 6 weeks, then switch to 20mg once daily* - Extending the intensive **15mg twice daily** regimen beyond **21 days** (3 weeks) to 6 weeks is not in line with current UK licensing or **NICE guidelines** for the acute treatment of DVT/PE. - This prolonged high-dose therapy would unnecessarily increase the risk of **bleeding complications** without providing additional clinical benefit for most patients. *Switch to 10mg twice daily after 21 days for long-term maintenance* - A **10mg twice daily** regimen for rivaroxaban is not a recognized or licensed dose for the maintenance treatment of **DVT or PE** in the UK. - While a **10mg once daily** dose may be considered for extended prevention of recurrent VTE after at least 6 months of initial treatment, it is not the standard immediate maintenance dose after the 21-day loading phase.

Question 35: A 61-year-old man with type 1 diabetes for 28 years is admitted with a foot ulcer and cellulitis. He is commenced on intravenous antibiotics. His usual insulin regimen is insulin glargine 28 units at 22:00 and insulin lispro 10 units before each meal. He is eating normally. His blood glucose on admission is 16.8 mmol/L and ketones are 0.8 mmol/L. What is the most appropriate insulin management for this patient during his admission?

A. Continue subcutaneous basal-bolus insulin regimen and increase monitoring frequency (Correct Answer)
B. Discontinue subcutaneous insulin and commence variable rate intravenous insulin infusion
C. Continue insulin glargine and commence variable rate intravenous insulin infusion
D. Increase insulin glargine to 34 units and insulin lispro to 14 units for all meals
E. Switch to subcutaneous fixed-rate soluble insulin 6-hourly regimen

Explanation: ***Continue subcutaneous basal-bolus insulin regimen and increase monitoring frequency***- For patients with **type 1 diabetes** who are **eating and drinking normally**, the preferred management is to continue their established **basal-bolus regimen** and monitor closely for illness-related fluctuations.- While the blood glucose is elevated (16.8 mmol/L), the **ketones (0.8 mmol/L)** are below the threshold for **Diabetic Ketoacidosis (DKA)**, meaning a transition to intravenous insulin is not immediately required. *Discontinue subcutaneous insulin and commence variable rate intravenous insulin infusion*- **Variable Rate Intravenous Insulin Infusion (VRIII)** is generally reserved for patients who are **nil by mouth (NBM)**, those with **severe DKA/HHS**, or undergoing surgery.- The patient is **eating normally**, making VRIII inappropriate and increasing the risk of **iatrogenic hypoglycemia** and requiring intensive nursing supervision. *Continue insulin glargine and commence variable rate intravenous insulin infusion*- This combined approach (basal insulin plus VRIII) is typically used for NBM patients to provide basal coverage or during the transition from VRIII to subcutaneous insulin, but it is **not indicated** for a patient actively eating.- Since the patient is stable and consuming meals, **subcutaneous boluses** for meals are essential, and a continuous IV infusion is an **overkill** given the current ketone levels. *Increase insulin glargine to 34 units and insulin lispro to 14 units for all meals*- While infection and cellulitis increase **insulin resistance**, a large, **preemptive increase** in all doses carries a high risk of **hypoglycemia** once the infection begins to clear or the patient's condition improves.- Dose adjustments should be made **incrementally** based on **frequent blood glucose monitoring** (at least every 2-4 hours) and correctional scales, rather than a radical change at admission. *Switch to subcutaneous fixed-rate soluble insulin 6-hourly regimen*- Switching to a **fixed-rate soluble insulin** regimen is less physiological and flexible than the patient's existing **basal-bolus** routine, making glycemic control more difficult, especially in the context of fluctuating needs during illness.- Maintaining the patient's **insulin glargine** (long-acting basal insulin) provides better background stability compared to 6-hourly short-acting doses, which can lead to periods of **insulin stacking** or inadequate coverage.

Question 36: A 73-year-old woman with non-valvular atrial fibrillation has a CHA₂DS₂-VASc score of 5 and HAS-BLED score of 2. She has stage 4 chronic kidney disease with eGFR of 28 ml/min/1.73m². Her weight is 58kg. Which of the following represents the most appropriate anticoagulation regimen for stroke prevention in this patient?

A. Apixaban 5mg twice daily
B. Rivaroxaban 20mg once daily
C. Apixaban 2.5mg twice daily (Correct Answer)
D. Dabigatran 150mg twice daily
E. Edoxaban 60mg once daily

Explanation: ***Apixaban 2.5mg twice daily*** - Apixaban requires a dose reduction to 2.5mg twice daily if at least two of the following criteria are met: **age ≥80 years**, **weight ≤60 kg**, or **serum creatinine ≥1.5 mg/dL** (or CrCl <30 mL/min). - This patient meets two of these criteria: **weight 58kg** and an **eGFR of 28 mL/min/1.73m²** (indicating significant renal impairment), making the reduced dose the correct choice for safety and efficacy. *Apixaban 5mg twice daily* - The standard 5mg twice daily dose of Apixaban is inappropriate for this patient because she meets the criteria for **dose reduction** due to her low body weight and advanced kidney disease. - Prescribing the full dose would significantly increase her **risk of bleeding** (as indicated by a HAS-BLED score of 2) without providing additional benefit for stroke prevention. *Rivaroxaban 20mg once daily* - For patients with **non-valvular AF** and **CrCl 15-49 mL/min**, the recommended dose of Rivaroxaban is **15mg once daily**. - This patient's **eGFR of 28 mL/min/1.73m²** falls within this range, making the 20mg once daily dose inappropriate and unsafe due to increased bleeding risk. *Dabigatran 150mg twice daily* - Dabigatran is primarily excreted renally, and its use is **contraindicated** in patients with a **creatinine clearance (CrCl) less than 30 mL/min**. - With an **eGFR of 28 mL/min/1.73m²**, this patient has severe renal impairment where Dabigatran would accumulate to toxic levels, leading to a very high **risk of severe bleeding**. *Edoxaban 60mg once daily* - Edoxaban requires a dose reduction to **30mg once daily** if the patient's **CrCl is 15-50 mL/min** or if their **weight is ≤60 kg**. - This patient meets both of these criteria (**eGFR 28 mL/min** and **weight 58kg**), making the standard 60mg dose inappropriate and increasing the risk of bleeding.

Question 37: A 52-year-old man with type 2 diabetes is established on insulin glargine 42 units at bedtime and metformin 1g twice daily. He reports three episodes of nocturnal hypoglycaemia over the past week, with blood glucose readings of 2.8, 3.1, and 2.6 mmol/L at approximately 3am. His fasting glucose readings range from 9.2 to 11.4 mmol/L. What is the most appropriate next step in his insulin management?

A. Reduce insulin glargine dose by 10-20% and monitor blood glucose patterns
B. Switch insulin glargine from bedtime to morning administration (Correct Answer)
C. Add insulin aspart 4 units with evening meal and reduce glargine to 30 units
D. Increase insulin glargine to 48 units and advise bedtime snack
E. Continue current dose and ensure adequate carbohydrate intake before bed

Explanation: ***Switch insulin glargine from bedtime to morning administration*** - This patient exhibits a pattern of recurrent **nocturnal hypoglycemia** (2.6-3.1 mmol/L around 3 AM) followed by **rebound morning hyperglycemia** (9.2-11.4 mmol/L), characteristic of the **Somogyi effect**. - Moving the dose of **long-acting basal insulin (glargine)** to the morning helps shift its peak activity away from the vulnerable early morning hours, reducing the risk of hypoglycemia while maintaining overall 24-hour glycemic control. *Reduce insulin glargine dose by 10-20% and monitor blood glucose patterns* - While reducing the dose might mitigate nocturnal hypoglycemia, it would likely worsen the patient's already high **fasting glucose readings**, indicating insufficient basal insulin effect during the day. - This approach fails to address the underlying issue of **insulin timing** contributing to the Somogyi effect and could lead to poorer overall glycemic control. *Add insulin aspart 4 units with evening meal and reduce glargine to 30 units* - Adding **rapid-acting insulin (aspart)** with the evening meal could exacerbate early nocturnal hypoglycemia due to its peak action occurring within a few hours of injection. - This modification introduces unnecessary complexity and does not directly resolve the problem of inappropriately timed **basal insulin**, which is causing the 3 AM drops. *Increase insulin glargine to 48 units and advise bedtime snack* - Increasing the **insulin glargine dose** is contraindicated as it would significantly worsen the frequency and severity of the existing **nocturnal hypoglycaemia**. - Relying on a **bedtime snack** is a temporary measure and does not address the fundamental issue of the inappropriate timing of basal insulin, which is precipitating the recurrent lows. *Continue current dose and ensure adequate carbohydrate intake before bed* - Continuing the current regimen will perpetuate the cycle of **nocturnal hypoglycaemia** and subsequent **rebound hyperglycaemia**, leaving the patient at continued risk. - While ensuring adequate carbohydrate intake before bed can temporarily raise blood glucose, it is a reactive measure and does not resolve the fundamental problem with the **basal insulin's timing** that is causing the recurrent nocturnal drops.

Question 38: A 67-year-old man with mechanical aortic valve replacement is on warfarin with target INR 2.5-3.5. He presents to the emergency department with epistaxis that has been ongoing for 45 minutes and is haemodynamically stable. His INR is 8.2 and haemoglobin is 125 g/L. He is not actively bleeding at the time of assessment. What is the most appropriate immediate management of his elevated INR?

A. Administer vitamin K 5mg intravenously and withhold warfarin
B. Administer four-factor prothrombin complex concentrate and vitamin K 5mg intravenously
C. Administer vitamin K 1-3mg orally and withhold warfarin (Correct Answer)
D. Withhold warfarin and recheck INR in 24 hours without vitamin K administration
E. Administer fresh frozen plasma and vitamin K 10mg intravenously

Explanation: ***Administer vitamin K 1-3mg orally and withhold warfarin***- This patient presents with an **elevated INR (8.2)** and experienced **minor bleeding (epistaxis)**, but is now **haemodynamically stable** and not actively bleeding, making this the most appropriate approach.- For an INR between 4.5-10.0 with minor or no bleeding, guidelines recommend **withholding warfarin** and administering a **low dose of oral Vitamin K (1-2.5 mg)** to safely reduce the INR without causing over-reversal or warfarin resistance, which is vital for a patient with a **mechanical aortic valve**.*Administer vitamin K 5mg intravenously and withhold warfarin*- **Intravenous Vitamin K** is generally reserved for patients with **major bleeding** or those unable to take oral medication; neither applies here as his bleeding is minor and stopped.- A 5mg IV dose is relatively high for minor bleeding and risks rapid, excessive INR reduction, which can lead to **warfarin resistance** and increased **thromboembolic risk** for his prosthetic valve when warfarin is restarted.*Administer four-factor prothrombin complex concentrate and vitamin K 5mg intravenously*- **Four-factor prothrombin complex concentrate (PCC)** is indicated for urgent warfarin reversal in cases of **major or life-threatening bleeding** or before emergency surgery.- Since the patient is **haemodynamically stable** and not actively bleeding, aggressive reversal with PCC is unnecessary and carries a significant risk of **thrombosis**.*Withhold warfarin and recheck INR in 24 hours without vitamin K administration*- Simply withholding warfarin without Vitamin K is typically for **asymptomatic patients** with an INR between **5.0 and 8.0** without any bleeding.- Because this patient presented with **minor bleeding** and his INR is > 8.0, **Vitamin K administration** is necessary to more promptly and safely reduce the INR and mitigate further hemorrhage risk.*Administer fresh frozen plasma and vitamin K 10mg intravenously*- **Fresh frozen plasma (FFP)** is less effective than PCC for immediate warfarin reversal due to its volume and slower infusion time, and it is not indicated for stable patients with minor bleeding.- A **10mg IV dose of Vitamin K** is a high dose reserved for **severe, life-threatening hemorrhage**, which is not the clinical scenario here.

Question 39: A 38-year-old woman with type 2 diabetes is 8 weeks pregnant. She has been managed on metformin 1g twice daily and insulin detemir 18 units at bedtime for the past year with good glycaemic control (HbA1c 48 mmol/mol). She attends antenatal clinic for review. What is the most appropriate modification to her diabetes management in pregnancy?

A. Switch insulin detemir to insulin glargine as it has better pregnancy data
B. Switch insulin detemir to insulin aspart for better fetal safety profile
C. Continue insulin detemir and increase blood glucose monitoring frequency (Correct Answer)
D. Discontinue insulin detemir and increase metformin to 1.5g twice daily
E. Continue current regimen unchanged as glycaemic control is good

Explanation: ***Continue insulin detemir and increase blood glucose monitoring frequency***- **Insulin detemir** is a **long-acting insulin analog** considered safe and effective in pregnancy, with extensive data supporting its use. Continuing an established regimen is appropriate if control is good.- **Increased blood glucose monitoring** (e.g., fasting and 1-hour postprandial) is critical to meet **stricter glycaemic targets** during pregnancy, which are essential for minimizing maternal and fetal complications.*Continue current regimen unchanged as glycaemic control is good*- While pre-pregnancy control was good, **glycaemic targets become stricter** in pregnancy to prevent adverse outcomes, necessitating more intensive monitoring.- Physiological changes, including increasing **insulin resistance** in later trimesters, often require dose adjustments even if the initial regimen was effective.*Switch insulin detemir to insulin glargine as it has better pregnancy data*- Both **insulin detemir** and **insulin glargine** (U100) have robust safety profiles and are recommended basal insulins in pregnancy, so there is no clinical advantage in switching from one to the other.- Switching a well-controlled patient from one safe insulin to another without a clear indication can disrupt **stable glycaemic control**.*Switch insulin detemir to insulin aspart for better fetal safety profile*- **Insulin detemir** is a **basal (long-acting) insulin**, whereas **insulin aspart** is a **prandial (rapid-acting) insulin**; they serve different purposes and are not interchangeable.- Switching would eliminate **basal glucose control**, leading to hyperglycemia between meals and overnight, despite aspart being safe for prandial use in pregnancy.*Discontinue insulin detemir and increase metformin to 1.5g twice daily*- Discontinuing insulin in a patient who requires it for good control, especially in pregnancy when **insulin requirements increase**, would almost certainly lead to **hyperglycemia**.- While **metformin** can be continued, increasing its dose alone is unlikely to compensate for the complete withdrawal of basal insulin, risking poor glycaemic control and fetal complications like **macrosomia**.

Question 40: A 71-year-old man with atrial fibrillation is established on rivaroxaban 20mg once daily. He is admitted with acute limb ischaemia requiring emergency embolectomy within 2 hours. His most recent dose of rivaroxaban was taken 8 hours ago. He is haemodynamically stable. Which of the following is the most appropriate immediate management of his anticoagulation prior to surgery?

A. Administer protamine sulphate 50mg intravenously and proceed to surgery
B. Administer andexanet alfa and proceed to surgery
C. Administer vitamin K 10mg intravenously and delay surgery for 6 hours
D. Administer four-factor prothrombin complex concentrate and proceed to surgery
E. Proceed to surgery without reversal agent; use standard haemostatic measures (Correct Answer)

Explanation: ***Proceed to surgery without reversal agent; use standard haemostatic measures***- In **acute limb ischaemia**, time to revascularization is critical for limb viability, and the patient is currently **haemodynamically stable**, allowing for surgery with meticulous technique.- **Rivaroxaban** has a relatively short half-life (5-9 hours), and since the last dose was 8 hours ago, anticoagulant activity is already naturally declining.*Administer protamine sulphate 50mg intravenously and proceed to surgery*- **Protamine sulphate** is the specific reversal agent for **unfractionated heparin** and has no effect on Factor Xa inhibitors like rivaroxaban.- Using it in this context would be ineffective and provide a false sense of security regarding the patient's bleeding risk.*Administer andexanet alfa and proceed to surgery*- **Andexanet alfa** is typically reserved for **life-threatening or uncontrolled bleeding** (e.g., intracranial hemorrhage) rather than preoperative management in a stable patient.- Its use is limited by high cost and restricted availability in many surgical centers for non-hemorrhagic indications.*Administer vitamin K 10mg intravenously and delay surgery for 6 hours*- **Vitamin K** is used specifically to reverse the effects of **warfarin** by facilitating the synthesis of clotting factors; it does not affect DOACs like rivaroxaban.- Delaying surgery for 6 hours in a case of **acute limb ischaemia** unnecessarily increases the risk of irreversible tissue necrosis and limb loss.*Administer four-factor prothrombin complex concentrate and proceed to surgery*- **Four-factor PCC** is used off-label for Factor Xa inhibitor reversal primarily when **andexanet alfa** is unavailable or when there is active, severe bleeding.- In the absence of active bleeding or a high-risk life-threatening scenario, the **thrombotic risk** of PCC must be weighed against its questionable benefit for prophylactic surgical reversal.

Question 41: A 45-year-old woman with type 1 diabetes is admitted with suspected acute pancreatitis. Her current insulin regimen includes insulin glargine 24 units at bedtime and insulin aspart 8 units with meals. She is made nil by mouth and commenced on intravenous fluids. Her admission blood glucose is 14.2 mmol/L. What is the most appropriate insulin management strategy for this patient?

A. Continue subcutaneous basal-bolus insulin unchanged and monitor blood glucose 4-hourly
B. Switch to subcutaneous insulin detemir twice daily and discontinue prandial insulin
C. Discontinue all insulin and commence variable rate intravenous insulin infusion with glucose monitoring
D. Continue subcutaneous insulin glargine and commence variable rate intravenous insulin infusion (Correct Answer)
E. Discontinue all insulin temporarily and restart only when oral intake recommences

Explanation: ***Continue subcutaneous insulin glargine and commence variable rate intravenous insulin infusion***- In **Type 1 diabetes**, patients have an absolute insulin deficiency and always require a **basal insulin** (like glargine) to prevent the development of **diabetic ketoacidosis (DKA)**.- When a patient is **nil by mouth**, a **Variable Rate Intravenous Insulin Infusion (VRIII)** replaces mealtime boluses to maintain glycemic control while the background basal insulin provides stable metabolic coverage.*Continue subcutaneous basal-bolus insulin unchanged and monitor blood glucose 4-hourly*- Continuing **prandial (bolus) insulin** while the patient is not eating significantly increases the risk of severe **hypoglycemia**.- Monitoring every 4 hours is insufficient for a patient with an **acute illness** like pancreatitis who is not receiving oral nutrition.*Switch to subcutaneous insulin detemir twice daily and discontinue prandial insulin*- Switching basal insulin types during an acute admission is unnecessary and can cause **dosing errors** or metabolic instability.- Discontinuing prandial insulin without replacing it with a **VRIII** will result in poor glycemic control (hyperglycemia) due to the **stress response** of acute pancreatitis.*Discontinue all insulin and commence variable rate intravenous insulin infusion with glucose monitoring*- Discontinuing long-acting basal insulin makes the transition off the VRIII more difficult and increases the risk of **rebound hyperglycemia** or DKA if the infusion is interrupted.- Guidelines recommend continuing **basal subcutaneous insulin** alongside VRIII to provide a safety net and simplify the return to a standard regimen.*Discontinue all insulin temporarily and restart only when oral intake recommences*- This is a dangerous strategy in **Type 1 diabetes** as it will inevitably lead to **diabetic ketoacidosis** within hours due to the complete lack of circulating insulin.- Patients with Type 1 diabetes always require **endogenous or exogenous insulin** to suppress ketogenesis, regardless of their nutritional status.

Question 42: A 59-year-old man with atrial fibrillation is being initiated on warfarin therapy. His baseline INR is 1.1. He weighs 78kg and has normal liver and kidney function. Which of the following warfarin loading regimens is most appropriate according to current UK guidelines for initiating anticoagulation in this patient?

A. 10mg on day 1, 10mg on day 2, then dose according to INR on day 3 (Correct Answer)
B. 5mg on day 1, 5mg on day 2, then dose according to INR on day 3
C. 15mg on day 1, 10mg on day 2, then dose according to INR on day 3
D. 7.5mg on day 1, 7.5mg on day 2, then dose according to INR on day 3
E. 2.5mg on day 1, 5mg on day 2, then dose according to INR on day 3

Explanation: ***10mg on day 1, 10mg on day 2, then dose according to INR on day 3*** - According to **UK guidelines** (often following the Fennerty protocol), a loading dose of **10mg for the first two days** is standard for adults under 75 with normal liver function and average body weight. - This regimen ensures a rapid achievement of therapeutic **anticoagulation** while allowing the **INR on day 3** to guide subsequent maintenance dosing. *5mg on day 1, 5mg on day 2, then dose according to INR on day 3* - This lower loading dose is generally reserved for the **elderly (>75 years)**, those with **low body weight (<50kg)**, or patients with significant **liver disease**. - Using this dose for a relatively young, healthy-weight man might result in a delayed time to reach the **therapeutic range**. *15mg on day 1, 10mg on day 2, then dose according to INR on day 3* - High loading doses like **15mg** are no longer recommended due to the increased risk of causing a transient **hypercoagulable state** by rapidly depleting protein C. - Excessive loading also significantly increases the risk of over-anticoagulation and **bleeding complications** before the INR can be stabilized. *7.5mg on day 1, 7.5mg on day 2, then dose according to INR on day 3* - This is not a standard protocol dose for initial **warfarin induction** in the UK; standard practice favors either 10mg or 5mg based on risk profile. - While closer to the target than others, it lacks the evidence base of the **10mg induction protocol** for healthy patients. *2.5mg on day 1, 5mg on day 2, then dose according to INR on day 3* - This represents an **escalating dose strategy** which is inappropriate for initiating therapy in a patient requiring rapid anticoagulation for **atrial fibrillation**. - Such low doses are typically only considered in patients at an extreme **high risk of bleeding** or those with a very high baseline INR.

Question 43: A 54-year-old woman with rheumatoid arthritis is started on methotrexate 7.5mg weekly. She asks about important safety information regarding her new medication. According to current UK prescribing guidance, which of the following is the most appropriate advice regarding methotrexate administration?

A. Take the medication daily with food to reduce gastrointestinal side effects
B. Take the medication once weekly on the same day each week (Correct Answer)
C. Take the medication twice daily, morning and evening, for optimal efficacy
D. Take the medication every other day to maintain steady therapeutic levels
E. Take the medication three times weekly on alternate days

Explanation: ***Take the medication once weekly on the same day each week***- In the treatment of inflammatory conditions like **rheumatoid arthritis**, methotrexate must be taken as a **once-weekly dose** to prevent severe toxicity and potential fatality.- To enhance safety, patients should consistently choose the **same day each week** and clear "ONCE WEEKLY" instructions must be included on the prescription and packaging.*Take the medication daily with food to reduce gastrointestinal side effects*- Daily administration of methotrexate is typically reserved for **oncology protocols** and is inappropriate for rheumatological conditions.- Prescribing methotrexate daily instead of weekly is a high-risk **medication error** that can lead to life-threatening **bone marrow suppression** and mucositis.*Take the medication twice daily, morning and evening, for optimal efficacy*- Multi-dose daily regimens are not used for rheumatoid arthritis and significantly increase the risk of acute **methotrexate toxicity**.- Guidance emphasizes that **splitting doses** within a single day is generally discouraged in primary care to avoid confusion with daily dosing.*Take the medication every other day to maintain steady therapeutic levels*- **Alternate-day dosing** is not a recognized regimen for methotrexate in this clinical context and would result in an accumulated overdose.- Maintaining "steady levels" through frequent dosing leads to the inhibition of folate metabolism in healthy cells, causing **organ failure**.*Take the medication three times weekly on alternate days*- This frequency is incorrect and deviates from the **NICE and MHRA safety guidelines** which mandate strictly weekly administration.- Safety warnings often highlight that any frequency more often than **once weekly** in rheumatology is a major prescribing hazard.

Question 44: A 74-year-old woman with atrial fibrillation has been on apixaban 5mg twice daily for 2 years. She now requires long-term rifampicin therapy for Mycobacterium avium complex infection. Her renal function is normal (eGFR 68 ml/min/1.73m²), weight 72kg, and she has no other significant medications. What is the most appropriate anticoagulation management during rifampicin treatment?

A. Continue apixaban 5mg twice daily as rifampicin does not affect apixaban levels significantly
B. Increase apixaban to 7.5mg twice daily to compensate for increased metabolism
C. Switch to warfarin and monitor INR closely, adjusting dose to maintain therapeutic range (Correct Answer)
D. Switch to rivaroxaban 20mg once daily as it is less affected by rifampicin than apixaban
E. Increase apixaban to 10mg twice daily during rifampicin therapy

Explanation: ***Switch to warfarin and monitor INR closely, adjusting dose to maintain therapeutic range***- **Rifampicin** is a potent inducer of **CYP3A4** and **P-glycoprotein**, which significantly reduces the plasma concentration of **DOACs** like apixaban, increasing stroke risk.- Unlike DOACs, **warfarin** allows for titration through **INR monitoring**, ensuring that the increased metabolic clearance caused by rifampicin is compensated for by dose adjustments.*Continue apixaban 5mg twice daily as rifampicin does not affect apixaban levels significantly*- This approach is dangerous because rifampicin can reduce **apixaban levels** by more than 50%, leaving the patient inadequately protected against **thromboembolism**.- Co-administration of strong **CYP3A4 inducers** with DOACs is generally contraindicated in current clinical guidelines due to unpredictable efficacy.*Increase apixaban to 7.5mg twice daily to compensate for increased metabolism*- There is no clinical evidence or established safety data to support **off-label dose escalation** of apixaban to override drug interactions.- 7.5mg is not a standard manufactured dose, and standard dosing cannot be reliably monitored for efficacy in the same way as **warfarin**.*Switch to rivaroxaban 20mg once daily as it is less affected by rifampicin than apixaban*- **Rivaroxaban** is also a substrate of **CYP3A4** and **P-gp**, meaning its levels are similarly depleted by rifampicin induction.- Using another DOAC does not solve the underlying problem of **unquantifiable drug levels** and high risk of anticoagulant failure.*Increase apixaban to 10mg twice daily during rifampicin therapy*- Doubling the dose to **10mg twice daily** lacks pharmacokinetic validation and increases the risk of unpredictable toxicity once rifampicin is eventually discontinued.- Monitoring **Factor Xa levels** is not widely available or standardized enough to safely manage such a high-dose regimen in primary or secondary care.

Question 45: A 63-year-old man with type 2 diabetes on insulin therapy presents to his GP with a 3-week history of recurrent hypoglycaemic episodes (glucose readings 2.6-3.4 mmol/L) occurring 2-3 hours after meals. His current regimen is insulin glargine 40 units at bedtime and insulin lispro 14 units before each meal. His HbA1c 3 months ago was 58 mmol/mol. He has recently lost 8kg unintentionally and reports early satiety and occasional vomiting. Examination reveals a succussion splash. What is the most likely explanation for his hypoglycaemia?

A. Excessive insulin lispro dosing relative to carbohydrate intake
B. Delayed gastric emptying causing mismatch between insulin action and carbohydrate absorption (Correct Answer)
C. Improved insulin sensitivity due to weight loss requiring dose reduction
D. Development of Addison's disease causing increased insulin sensitivity
E. Surreptitious insulin administration (factitious hypoglycaemia)

Explanation: ***Delayed gastric emptying causing mismatch between insulin action and carbohydrate absorption*** - The patient's symptoms of **early satiety**, **occasional vomiting**, unintentional **weight loss**, and a positive **succussion splash** are highly indicative of **diabetic gastroparesis**. - This condition leads to a delay in food absorption, causing the fast-acting **insulin lispro** to peak before carbohydrates are available, resulting in **post-prandial hypoglycaemia** 2-3 hours after meals.*Excessive insulin lispro dosing relative to carbohydrate intake*- While excessive dosing of rapid-acting insulin can cause hypoglycaemia, it does not explain the presence of **gastrointestinal symptoms** like early satiety, vomiting, and a **succussion splash**.- If the dosing was simply excessive, hypoglycaemia would likely occur more consistently or earlier, without the specific signs of **gastric stasis**.*Improved insulin sensitivity due to weight loss requiring dose reduction*- Unintentional weight loss can improve insulin sensitivity and reduce insulin requirements, potentially leading to hypoglycaemia.- However, this mechanism would not explain the specific **gastrointestinal symptoms** and the finding of a **succussion splash**, which point to a problem with gastric emptying.*Development of Addison's disease causing increased insulin sensitivity*- **Addison's disease** can cause weight loss and hypoglycaemia due to cortisol deficiency, increasing insulin sensitivity.- However, it typically presents with **hyperpigmentation**, fatigue, and **postural hypotension**, and does not cause a **succussion splash** or other signs of gastric outlet obstruction/delayed emptying.*Surreptitious insulin administration (factitious hypoglycaemia)*- **Factitious hypoglycaemia** is a possibility in unexplained recurrent hypoglycaemia, but it rarely presents with clear physiological signs like **early satiety**, vomiting, and a **succussion splash**.- The constellation of gastrointestinal symptoms strongly suggests a genuine medical condition affecting digestion and nutrient absorption, rather than intentional self-harm.

Question 46: Understanding the mechanism of action of anticoagulants, which statement best explains why the anticoagulant effect of warfarin can be enhanced by concurrent administration of broad-spectrum antibiotics?

A. Antibiotics inhibit cytochrome P450 enzymes that metabolise warfarin, increasing warfarin plasma levels
B. Antibiotics reduce gut bacteria that synthesise vitamin K, decreasing the availability of vitamin K (Correct Answer)
C. Antibiotics increase warfarin absorption from the gastrointestinal tract by altering gut pH
D. Antibiotics compete with warfarin for plasma protein binding sites, increasing free warfarin concentration
E. Antibiotics enhance the sensitivity of vitamin K-dependent clotting factors to warfarin inhibition

Explanation: ***Antibiotics reduce gut bacteria that synthesise vitamin K, decreasing the availability of vitamin K*** - Broad-spectrum antibiotics deplete **intestinal microflora**, which are responsible for synthesizing approximately 50% of the body's **vitamin K** requirements. - Since **warfarin** works by inhibiting vitamin K-dependent clotting factors (**II, VII, IX, X**), a reduction in available vitamin K potentiates the drug's effect, leading to a higher **INR** and increased bleeding risk. *Antibiotics inhibit cytochrome P450 enzymes that metabolise warfarin, increasing warfarin plasma levels* - While specific antibiotics like **macrolides** or **metronidazole** inhibit **CYP2C9**, this is not a universal mechanism for all broad-spectrum antibiotics. - Gut flora depletion is the more characteristic general mechanism associated with the "broad-spectrum" class rather than specific **enzyme inhibition**. *Antibiotics increase warfarin absorption from the gastrointestinal tract by altering gut pH* - Warfarin absorption is largely completed in the **upper gastrointestinal tract** and is not significantly affected by changes in **gut pH** induced by antibiotics. - **Bioavailability** remains relatively constant regardless of the presence of antibiotics in the intestinal lumen. *Antibiotics compete with warfarin for plasma protein binding sites, increasing free warfarin concentration* - Although many drugs can displace warfarin from **albumin**, this mechanism is rarely clinically significant as the **free fraction** is rapidly metabolized. - Most broad-spectrum antibiotics do not have a high enough affinity for **protein binding sites** to cause a sustained increase in warfarin's anticoagulant effect. *Antibiotics enhance the sensitivity of vitamin K-dependent clotting factors to warfarin inhibition* - Warfarin's efficacy is determined by its inhibition of **vitamin K epoxide reductase**, not by altering the **intrinsic sensitivity** of the clotting factors themselves. - Antibiotics influence the **substrate availability** (vitamin K) rather than altering the biochemical interaction between the drug and its target enzyme.

Question 47: A 51-year-old man with type 2 diabetes is on insulin glargine 44 units at bedtime and metformin 1g twice daily. He works night shifts (22:00-06:00) three times per week and day shifts (07:00-15:00) the other four days. He reports frequent hypoglycaemic episodes (glucose 2.8-3.5 mmol/L) at around 04:00 during his night shifts. His HbA1c is 51 mmol/mol. What is the most appropriate management strategy to address his hypoglycaemia while maintaining glycaemic control?

A. Reduce insulin glargine to 35 units at bedtime on all days
B. Change insulin glargine to twice-daily dosing (22 units morning, 22 units evening)
C. Switch from insulin glargine to insulin detemir which can be given at variable times (Correct Answer)
D. Advise taking a 20g carbohydrate snack at 02:00 on night shift days
E. Reduce insulin glargine to 35 units on night shift days only, continue 44 units on day shift days

Explanation: ***Switch from insulin glargine to insulin detemir which can be given at variable times***- **Insulin detemir** is an intermediate-to-long acting analog that allows for more **flexible timing** compared to glargine because its action profile typically lasts 12-20 hours, making it ideal for variable shift schedules.- By switching to detemir, the patient can adjust the **injection timing** to better align with the specific activity and feeding windows of both night and day shifts, reducing the risk of nocturnal/early morning **hypoglycaemia**.*Reduce insulin glargine to 35 units at bedtime on all days*- This would likely cause a significant **deterioration in glycaemic control**, as the patient's current **HbA1c (51 mmol/mol)** is already at target.- A blanket reduction does not address the specific **temporal mismatch** between insulin peak and activity levels that occurs only during the night shift.*Change insulin glargine to twice-daily dosing (22 units morning, 22 units evening)*- **Insulin glargine** is designed as a peakless, basal insulin intended for once-daily use; splitting the dose is not a standard regimen and typically provides no benefit in managing **shift work variability**.- This approach increases the risk of **insulin stacking** and does not resolve the specific 04:00 hypoglycaemia episodes occurring on work nights.*Advise taking a 20g carbohydrate snack at 02:00 on night shift days*- Adding a mandated carbohydrate snack treats the **symptom** of the mismatch rather than the cause and can lead to **unwanted weight gain** or post-shift hyperglycaemia.- This strategy is often unsustainable for long-term management compared to adjusting the **pharmacokinetic profile** of the insulin regimen itself.*Reduce insulin glargine to 35 units on night shift days only, continue 44 units on day shift days*- Glargine has a duration of action up to **24 hours or longer**; varying the dose day-to-day results in unpredictable **overlap (stacking)** between doses.- Because of its long half-life, the effects of a dose change take **2-3 days** to reach a new steady state, making daily adjustments ineffective and potentially dangerous.

Question 48: A 68-year-old woman on warfarin for atrial fibrillation (target INR 2-3) requires bridging anticoagulation with low molecular weight heparin (LMWH) before elective colonoscopy and polypectomy. Her baseline INR has been stable at 2.6. When should LMWH be commenced in relation to stopping warfarin to provide adequate anticoagulation coverage while minimising bleeding risk during the procedure?

A. Start LMWH immediately when warfarin is stopped, continue until the day before procedure
B. Start LMWH when INR falls below 3.0, give last dose 24 hours before procedure
C. Start LMWH when INR falls below 2.0, give last dose 24 hours before procedure (Correct Answer)
D. Wait until INR is <1.5, then start LMWH, give last dose 12 hours before procedure
E. Start LMWH 48 hours after stopping warfarin regardless of INR, stop 24 hours before procedure

Explanation: ***Start LMWH when INR falls below 2.0, give last dose 24 hours before procedure*** - **Bridging anticoagulation** is initiated when the **INR drops below the therapeutic range** (typically <2.0) to minimize the period of subtherapeutic coverage. - The final dose of **LMWH** must be administered **24 hours prior** to the procedure to ensure the drug is sufficiently cleared, thereby reducing the risk of **perioperative bleeding**. *Start LMWH immediately when warfarin is stopped, continue until the day before procedure* - Initiating LMWH while the **INR is still therapeutic** (>2.0) results in an additive anticoagulant effect and significantly increases the **bleeding risk**. - There is no clinical benefit to "stacking" these medications until the effect of **Warfarin** has actually dissipated. *Start LMWH when INR falls below 3.0, give last dose 24 hours before procedure* - Starting LMWH at an **INR of 3.0** is inappropriate because the patient is still within or above the **target therapeutic range** (2.0-3.0). - This approach leads to **over-anticoagulation**, which poses a danger during the transition period before the elective surgery. *Wait until INR is <1.5, then start LMWH, give last dose 12 hours before procedure* - Waiting for an **INR <1.5** leaves the patient without adequate protection for too long, increasing the risk of **thromboembolic events** like stroke. - A **12-hour gap** before the procedure is often insufficient for proper **LMWH clearance**, especially in elderly patients or those with reduced renal function. *Start LMWH 48 hours after stopping warfarin regardless of INR, stop 24 hours before procedure* - A **fixed-time approach** is unsafe because **warfarin metabolism** and its offset vary significantly between individuals based on genetics and diet. - Management must be guided by **INR monitoring** rather than a set timeline to ensure the patient is neither under- nor over-anticoagulated.

Question 49: A 56-year-old woman with type 1 diabetes for 30 years has developed end-stage renal failure and is established on peritoneal dialysis. Her insulin requirements have changed significantly since starting dialysis. Which factor most significantly affects insulin requirements in patients on peritoneal dialysis compared to those with normal renal function?

A. Increased insulin degradation by the peritoneal membrane
B. Reduced renal insulin clearance partially offset by glucose absorption from dialysate (Correct Answer)
C. Enhanced peripheral insulin sensitivity due to uraemia reduction
D. Increased hepatic insulin extraction compensating for loss of renal clearance
E. Decreased insulin absorption from subcutaneous sites due to fluid shifts

Explanation: ***Reduced renal insulin clearance partially offset by glucose absorption from dialysate*** - In end-stage renal failure, the loss of **renal insulin clearance** (normally 40-80%) prolongs insulin half-life, which traditionally decreases the required dose to avoid hypoglycemia. - This is counteracted in **peritoneal dialysis** by the absorption of significant amounts of **glucose from the dialysate** (100-200g/day), which increases insulin demand and necessitates careful dose titration. *Increased insulin degradation by the peritoneal membrane* - The **peritoneal membrane** serves as a semi-permeable barrier for exchange but does not possess significant enzymatic pathways for **insulin degradation**. - Insulin can actually be administered **intraperitoneally** in some patients because the membrane allows absorption into the systemic circulation rather than destroying it. *Enhanced peripheral insulin sensitivity due to uraemia reduction* - While effective dialysis reduces **uremic toxins** which can improve insulin sensitivity, this effect is often outweighed by the **glucose load** inherent to the dialysis fluid. - Improving **uremia** typically would decrease insulin requirements, but the clinical reality in PD patients is often an increased need due to **hyperglycemia** from the dialysate. *Increased hepatic insulin extraction compensating for loss of renal clearance* - **Hepatic insulin extraction** remains relatively constant and does not increase to compensate for the pathological loss of **renal filtration and catabolism** of insulin. - The liver primarily clears **endogenous insulin** via the portal vein, whereas exogenous insulin is cleared predominantly by the **kidneys**. *Decreased insulin absorption from subcutaneous sites due to fluid shifts* - Although **local edema** or fluid shifts can theoretically alter absorption, they do not represent the **primary metabolic driver** for changing insulin requirements in PD patients. - Clinical management focuses on the **carbohydrate load** from the dialysate rather than significant alterations in **subcutaneous absorption** pharmacokinetics.

Question 50: A 72-year-old man with permanent atrial fibrillation on edoxaban 60mg once daily presents to the emergency department with melaena. His haemoglobin is 68 g/L (previous baseline 135 g/L), heart rate 110 bpm, blood pressure 98/62 mmHg. Upper GI endoscopy shows a bleeding duodenal ulcer. His renal function shows creatinine 142 μmol/L (eGFR 44 ml/min/1.73m²). He is haemodynamically unstable despite fluid resuscitation. What is the most appropriate approach to reverse the anticoagulant effect of edoxaban?

A. Administer prothrombin complex concentrate (PCC) 50 units/kg (Correct Answer)
B. Administer fresh frozen plasma 15 ml/kg
C. Give oral activated charcoal 50g if within 2 hours of last dose
D. Administer intravenous tranexamic acid 1g three times daily
E. Administer vitamin K 10mg intravenously

Explanation: ***Administer prothrombin complex concentrate (PCC) 50 units/kg*** - In cases of life-threatening bleeding associated with **Factor Xa inhibitors** like **edoxaban**, and where specific reversal agents like andexanet alfa are unavailable, **four-factor PCC** at a dose of **50 units/kg** is the recommended treatment to restore haemostasis. - PCC provides a high concentration of **clotting factors II, VII, IX, and X**, bypassing the inhibition and facilitating thrombin generation in the face of ongoing instability. *Administer fresh frozen plasma 15 ml/kg* - **FFP** is not recommended for the reversal of DOACs as it contains insufficient concentrations of clotting factors to effectively neutralise the anticoagulant effect. - The volume required for any potential benefit carries a high risk of **fluid overload** and is too slow to administer in an emergency with **haemodynamic instability**. *Give oral activated charcoal 50g if within 2 hours of last dose* - **Activated charcoal** only prevents the absorption of the drug and is only useful if the patient presents within **2 hours** of ingestion; this patient is likely far beyond that window. - While it may be a supportive measure early on, it does not provide the **acute reversal** required for a patient currently in **haemorrhagic shock**. *Administer intravenous tranexamic acid 1g three times daily* - **Tranexamic acid** is an **antifibrinolytic** that can be used as an adjunct to help stabilize clots, but it does not directly reverse the pharmacological effect of **Factor Xa inhibitors**. - Relying on this alone would be insufficient for a patient with a massive **haemoglobin drop** and **life-threatening duodenal bleeding**. *Administer vitamin K 10mg intravenously* - **Vitamin K** is only effective for reversing **Vitamin K antagonists** like **warfarin** by facilitating the synthesis of new clotting factors, a process that takes several hours. - It has no role in the reversal of **direct oral anticoagulants (DOACs)** like edoxaban, which work by direct enzyme inhibition rather than factor depletion.

Question 51: A 67-year-old woman attends anticoagulation clinic. She has been on warfarin for 3 years following a mechanical mitral valve replacement. Her target INR is 3.0 (range 2.5-3.5). Today her INR is 7.8 and she reports no bleeding. She has mild bruising on her arms but denies any other symptoms. What is the most appropriate immediate management?

A. Omit warfarin for 2 days and restart at reduced dose when INR <5.0, recheck INR in 2 days
B. Admit immediately for intravenous vitamin K 5mg and prothrombin complex concentrate
C. Give oral vitamin K 1-3mg and omit warfarin, recheck INR in 24 hours (Correct Answer)
D. Continue warfarin at reduced dose and recheck INR in 1 week
E. Omit warfarin and recheck INR daily until it falls below 5.0, then restart at previous dose

Explanation: ***Give oral vitamin K 1-3mg and omit warfarin, recheck INR in 24 hours*** - For an **INR between 5.0 and 9.0** with **minor bleeding** (such as bruising), consensus guidelines recommend **oral Vitamin K** (1-3mg) to gently lower the INR. - **Withholding warfarin doses** and repeating the INR in **24 hours** ensures the level returns to the therapeutic range while minimizing the risk of thrombosis in a patient with a **mechanical mitral valve**. *Omit warfarin for 2 days and restart at reduced dose when INR <5.0, recheck INR in 2 days* - Simply **withholding warfarin** without Vitamin K is only appropriate if the INR is 5.0–9.0 and there is **no bleeding** at all. - This patient presents with **minor bleeding** (bruising), which necessitates active reversal with low-dose **oral Vitamin K**. *Admit immediately for intravenous vitamin K 5mg and prothrombin complex concentrate* - This aggressive approach is reserved for **major or life-threatening hemorrhage**, regardless of the INR level, which is not present here. - Using **Prothrombin Complex Concentrate (PCC)** and high-dose **IV Vitamin K** would be excessive for mild bruising and could cause prolonged **warfarin resistance**, increasing the risk of valve thrombosis. *Continue warfarin at reduced dose and recheck INR in 1 week* - Continuing warfarin with an **INR of 7.8** is dangerous and substantially increases the risk of a major **hemorrhagic stroke** or internal bleed. - Rechecking in **one week** is too late, as immediate clinical intervention is required to bring the INR down to safe levels within 24-48 hours. *Omit warfarin and recheck INR daily until it falls below 5.0, then restart at previous dose* - While omitting doses is part of the management, failing to give **Vitamin K** when minor bleeding is present delays the correction of the coagulopathy. - Restarting at the **previous dose** is incorrect; the maintenance dose must be **adjusted downwards** to prevent a recurrence of supratherapeutic INR.

Question 52: A 64-year-old man with type 1 diabetes is admitted with severe sepsis secondary to pneumonia. He becomes confused and aggressive, refusing all oral intake including medications and food. His capillary blood glucose is 18.2 mmol/L and ketones are 1.2 mmol/L. His regular insulin regimen is insulin glargine 36 units at night and insulin lispro 14 units with meals. What is the most appropriate immediate insulin management?

A. Administer intramuscular insulin glargine 36 units as he is refusing subcutaneous injections
B. Continue subcutaneous insulin injections and consider restraint if necessary as diabetes control is critical
C. Commence a variable rate intravenous insulin infusion (VRIII) with concurrent intravenous dextrose and monitoring (Correct Answer)
D. Withhold all insulin until the patient is cooperative to avoid risk of hypoglycaemia while confused
E. Administer insulin lispro 20 units subcutaneously every 6 hours to cover the elevated glucose

Explanation: ***Commence a variable rate intravenous insulin infusion (VRIII) with concurrent intravenous dextrose and monitoring*** - A **VRIII** is the most appropriate management for a **type 1 diabetic** patient who is acutely unwell (severe sepsis, pneumonia), confused, refusing oral intake, and has elevated glucose and ketones (indicating impending DKA). - It provides **precise and adjustable insulin delivery**, preventing **DKA** while allowing concurrent **intravenous dextrose** to prevent hypoglycemia, especially when the patient is nil by mouth. *Administer intramuscular insulin glargine 36 units as he is refusing subcutaneous injections* - **Insulin glargine** is a long-acting insulin analog designed for **subcutaneous administration**; intramuscular injection can lead to unpredictable absorption and erratic glucose control. - Administering a fixed dose of **basal insulin intramuscularly** does not provide the flexibility needed for acute illness, severe sepsis, or fluctuating insulin requirements. *Continue subcutaneous insulin injections and consider restraint if necessary as diabetes control is critical* - Using **physical restraint** for routine medical procedures like insulin administration in a confused patient raises serious **ethical and legal concerns** and is generally not an acceptable practice. - Continuing **subcutaneous mealtime insulin (lispro)** when a patient is refusing all food and fluids carries a very high risk of severe **hypoglycaemia**, which would worsen the patient's confusion and overall condition. *Withhold all insulin until the patient is cooperative to avoid risk of hypoglycaemia while confused* - **Withholding all insulin** in a patient with **type 1 diabetes** is critically dangerous as they have **absolute insulin deficiency** and will rapidly progress to severe **diabetic ketoacidosis (DKA)**, which is life-threatening. - Even if the patient is not eating, **basal insulin** or an intravenous substitute is essential to prevent unchecked ketogenesis and glucose elevation. *Administer insulin lispro 20 units subcutaneously every 6 hours to cover the elevated glucose* - Administering fixed doses of **short-acting insulin (lispro)** every 6 hours without considering nutritional intake and in the context of sepsis is prone to causing **hypoglycaemia** and does not provide adequate **basal insulin coverage**. - This regimen lacks the **dynamic titration** and continuous delivery offered by a **VRIII**, which is necessary for stable and safe glucose management in this acute setting.

Question 53: A 53-year-old woman with newly diagnosed pulmonary embolism is commenced on apixaban. She weighs 58kg and her serum creatinine is 118 μmol/L (eGFR 48 ml/min/1.73m²). She is also taking diltiazem 120mg twice daily for hypertension. What is the most appropriate apixaban dosing regimen?

A. Apixaban 10mg twice daily for 7 days, then 5mg twice daily
B. Apixaban 10mg twice daily for 7 days, then 2.5mg twice daily (Correct Answer)
C. Apixaban 5mg twice daily continuously
D. Apixaban 2.5mg twice daily continuously
E. Apixaban is contraindicated; use warfarin instead

Explanation: ***Apixaban 10mg twice daily for 7 days, then 2.5mg twice daily***- For treatment of **pulmonary embolism**, the standard loading dose of **apixaban** is **10mg twice daily for 7 days**.- The maintenance dose is reduced to **2.5mg twice daily** because the patient meets two criteria for dose reduction: **body weight ≤60kg** (58kg) and concomitant use of **diltiazem**, a **moderate CYP3A4 inhibitor**.*Apixaban 10mg twice daily for 7 days, then 5mg twice daily*- While the initial **loading dose** is correct, the maintenance dose of **5mg twice daily** is inappropriate for this patient.- The patient's **low body weight (58kg)** and use of **diltiazem** (a moderate CYP3A4 inhibitor) increase apixaban exposure, necessitating a lower maintenance dose to reduce **bleeding risk**.*Apixaban 5mg twice daily continuously*- This regimen is incorrect as it lacks the essential **initial 10mg twice daily loading dose for 7 days** required for acute **pulmonary embolism** treatment.- It also fails to account for the patient's specific characteristics (low weight, diltiazem use) that warrant a **2.5mg twice daily maintenance dose** if a loading dose were properly administered.*Apixaban 2.5mg twice daily continuously*- Administering **2.5mg twice daily continuously** is insufficient for the acute management of a **pulmonary embolism** as it omits the critical **10mg twice daily loading phase for 7 days**.- While 2.5mg twice daily is the appropriate *maintenance* dose for this patient, starting with it would lead to **inadequate anticoagulation** during the acute phase.*Apixaban is contraindicated; use warfarin instead*- Apixaban is not contraindicated here; the patient's **eGFR (48 ml/min/1.73m²)** is above the usual threshold (typically <15 ml/min/1.73m²) for avoiding direct oral anticoagulants (**DOACs**).- **DOACs** like apixaban are generally preferred over **warfarin** for **pulmonary embolism** treatment due to their more favorable **safety profile** and ease of use.

Question 54: According to the National Patient Safety Agency (NPSA) guidance, which abbreviation is considered unsafe and must NOT be used when prescribing insulin?

A. BD (twice daily)
B. SC (subcutaneous)
C. U (units) (Correct Answer)
D. OD (once daily)
E. TDS (three times daily)

Explanation: ***U (units)*** - The abbreviation **'U'** is strictly prohibited by the **National Patient Safety Agency (NPSA)** because it can be easily misread as a zero (**0**), four (**4**), or **'cc'**, leading to a potentially fatal **10-fold dosing error**. - To ensure patient safety, the word **'units'** must always be written in full when prescribing **insulin** or other narrow therapeutic index drugs. *BD (twice daily)* - **BD** is a standard abbreviation for **bis in die** and is generally considered acceptable in conventional prescribing to denote a frequency of twice a day. - While hospital guidelines increasingly favor plain English, **BD** is not specifically prohibited as a dangerous abbreviation in the same high-risk category as **'U'**. *SC (subcutaneous)* - **SC** is a commonly used abbreviation for the **subcutaneous** route of administration and is familiar to healthcare professionals across most clinical settings. - Although writing the route in full is always safer, the **NPSA** does not classify **'SC'** as an inherently unsafe abbreviation compared to unit-based indicators. *OD (once daily)* - **OD** stands for **omne in die** and is used to signify a **once-daily** regimen; it is a standard prescription term that does not carry the same misinterpretation risk as insulin units. - Safety concerns for **OD** are minimal compared to **'U'**, as misreading the frequency is less likely to cause the immediate, severe metabolic crisis seen with tenfold insulin errors. *TDS (three times daily)* - **TDS (ter die sumendum)** is widely recognized for medications taken **three times a day** and is standard practice in many medical records and drug charts. - While clear communication is encouraged, there is no high-risk safety alert from the **NPSA** specifically banning **TDS** in the context of insulin therapy.

Question 55: A 70-year-old man with atrial fibrillation on rivaroxaban 20mg once daily develops infective endocarditis. Blood cultures grow Streptococcus viridans and transoesophageal echocardiography confirms a 12mm vegetation on the mitral valve. What is the most appropriate anticoagulation management?

A. Switch to warfarin with target INR 2-3
B. Continue rivaroxaban 20mg once daily throughout treatment
C. Stop all anticoagulation until endocarditis is treated (Correct Answer)
D. Switch to therapeutic dose low molecular weight heparin
E. Reduce rivaroxaban to 15mg once daily

Explanation: ***Stop all anticoagulation until endocarditis is treated*** - In native valve **infective endocarditis (IE)**, the risk of **intracranial hemorrhage** from septic emboli or ruptured **mycotic aneurysms** outweighs the benefits of stroke prevention from atrial fibrillation. - Major guidelines recommend **discontinuing anticoagulation** in the acute phase of native valve IE because the vegetation remains friable and the risk of **hemorrhagic transformation** of an embolic stroke is high (up to 60%). *Switch to warfarin with target INR 2-3* - **Warfarin** is contraindicated in acute native valve endocarditis as it carries a high risk of **intramuscular or intracranial bleeding** during the unstable infectious period. - While warfarin is used for mechanical valves, this patient has **atrial fibrillation**, which does not justify the hemorrhagic risks during acute IE. *Continue rivaroxaban 20mg once daily throughout treatment* - **Rivaroxaban** (a DOAC) should not be continued because its anticoagulant effect is fixed and difficult to reverse quickly if a **haemorrhagic stroke** occurs. - **Direct Oral Anticoagulants** have no established safety profile in the setting of acute infective endocarditis and increase the risk of severe **embolic complications**. *Switch to therapeutic dose low molecular weight heparin* - Even though **LMWH** has a shorter half-life than some agents, **therapeutic doses** still significantly increase the risk of bleeding into septic brain infarcts. - LMWH or **unfractionated heparin** might only be considered in very specific scenarios involving mechanical valves, but it is not recommended for native valve IE in this patient. *Reduce rivaroxaban to 15mg once daily* - Reducing the dose of rivaroxaban does not mitigate the high risk of **septic embolism-induced bleeding** and remains clinically unsafe. - There is no evidence supporting **dose reduction** of DOACs as a strategy to manage the bleeding risks associated with **mitral valve vegetations**.

Question 56: A 61-year-old woman with type 2 diabetes is admitted with acute kidney injury secondary to dehydration. Her creatinine has risen from 95 μmol/L to 284 μmol/L. She is on insulin glargine 40 units at night and insulin aspart 12 units three times daily with meals. What is the most appropriate insulin adjustment during her acute illness?

A. Continue current insulin doses unchanged as diabetes management remains a priority
B. Reduce all insulin doses by 25% due to decreased renal clearance of insulin (Correct Answer)
C. Switch to a variable rate intravenous insulin infusion (VRIII) until renal function improves
D. Stop basal insulin but continue mealtime insulin at reduced doses
E. Increase insulin doses by 20% to account for stress hyperglycaemia

Explanation: ***Reduce all insulin doses by 25% due to decreased renal clearance of insulin*** - In **acute kidney injury (AKI)**, the kidneys' ability to degrade and clear insulin is significantly impaired, leading to a prolonged **half-life** and high risk of **hypoglycemia**. - Guidelines suggest a **dose reduction of 25-50%** when the eGFR or creatinine clearance drops significantly to ensure patient safety while maintaining glycemic control. *Continue current insulin doses unchanged as diabetes management remains a priority* - Maintaining the same dose in the setting of a **tripled creatinine** (95 to 284 μmol/L) would likely result in severe, life-threatening **hypoglycemia**. - While diabetes management is a priority, the **pharmacokinetics** of insulin are altered by renal failure, necessitating an immediate adjustment. *Switch to a variable rate intravenous insulin infusion (VRIII) until renal function improves* - A **VRIII** is typically reserved for patients who are **nil by mouth**, vomiting, or undergoing surgery, rather than for AKI alone. - If the patient is still eating and drinking, a **subcutaneous basal-bolus regimen** with dose adjustments is the preferred and safer management strategy. *Stop basal insulin but continue mealtime insulin at reduced doses* - Stopping **basal insulin** (Glargine) completely puts the patient at risk for **hyperglycemia** and potentially **diabetic ketoacidosis (DKA)** or ketosis, even in Type 2 diabetes. - A **basal-bolus** approach should be maintained to provide a steady physiological level of insulin, but at lower quantities. *Increase insulin doses by 20% to account for stress hyperglycaemia* - Although **stress hyperglycemia** occurs during acute illness, the effect of **reduced renal clearance** in AKI far outweighs the increase in insulin resistance. - Increasing the dose would dangerously exacerbate the risk of **hypoglycemic episodes** in a patient with reduced renal function.

Question 57: A 58-year-old man with chronic atrial fibrillation on warfarin therapy requires antibiotic treatment for a lower respiratory tract infection. His INR has been stable at 2.4 for the past 6 months. Which antibiotic is most likely to significantly increase his INR and require closer monitoring?

A. Amoxicillin
B. Clarithromycin (Correct Answer)
C. Doxycycline
D. Nitrofurantoin
E. Trimethoprim

Explanation: ***Clarithromycin***- **Clarithromycin** is a potent inhibitor of the **CYP450 system**, specifically **CYP3A4**, which reduces the metabolism of **warfarin** and leads to a significant increase in **INR**.- Co-prescribing this macrolide requires intensive **INR monitoring** and potential dose reduction to prevent life-threatening **bleeding complications**.*Amoxicillin*- **Amoxicillin** is generally considered safe with **warfarin** as it has minimal direct effect on **hepatic enzyme metabolism**.- While any broad-spectrum antibiotic can theoretically alter **gut flora** and reduce **Vitamin K synthesis**, the risk of significant INR elevation with this agent is very low.*Doxycycline*- **Doxycycline** can occasionally cause a mild increase in the anticoagulant effect of **warfarin**, but the interaction is usually less clinically significant than with macrolides.- It does not inhibit the primary **CYP enzymes** responsible for **warfarin metabolism** as strongly as clarithromycin does.*Nitrofurantoin*- **Nitrofurantoin** has no documented significant interaction with **warfarin** and is not associated with an increase in **INR**.- It is primarily used for **urinary tract infections** and is unsuitable for treating the lower respiratory tract infection described.*Trimethoprim*- **Trimethoprim** (and Co-trimoxazole) can increase the **INR** by inhibiting **CYP2C9**, the main enzyme for **S-warfarin**.- While it requires monitoring, the metabolic inhibition by **macrolides** like **clarithromycin** is a frequently tested high-risk interaction in safe prescribing.

Question 58: A 65-year-old woman with atrial fibrillation is on warfarin with target INR 2-3. She has been stable for 2 years with INR checks every 10 weeks. She is prescribed a 7-day course of ciprofloxacin 500mg twice daily for a urinary tract infection. Her current INR is 2.4 measured 3 days ago. What is the most appropriate monitoring and management strategy?

A. Continue warfarin at current dose, recheck INR in 10 weeks as scheduled
B. Reduce warfarin dose by 20% for the duration of antibiotic therapy, recheck INR in 1 week
C. Continue warfarin at current dose, check INR 3-5 days after starting ciprofloxacin (Correct Answer)
D. Temporarily switch from warfarin to low molecular weight heparin for the duration of antibiotic therapy
E. Increase frequency of INR monitoring to twice weekly but continue warfarin at current dose

Explanation: ***Continue warfarin at current dose, check INR 3-5 days after starting ciprofloxacin*** - **Ciprofloxacin** inhibits **CYP450 enzymes** (primarily CYP1A2 and CYP3A4) and reduces gut bacterial **Vitamin K** production, both of which potentiate the anticoagulant effect of **warfarin** and increase bleeding risk. - Maintaining the current warfarin dose while performing early **INR monitoring** (within 3-5 days of starting ciprofloxacin) is the most appropriate strategy to detect an elevated INR and adjust the dose if necessary. *Continue warfarin at current dose, recheck INR in 10 weeks as scheduled* - Waiting 10 weeks for an INR check is unsafe as **ciprofloxacin** can cause a rapid and significant increase in **INR** within the first week of therapy. - This approach fails to address a known **drug-drug interaction** and places the patient at high risk of **hemorrhagic complications**. *Reduce warfarin dose by 20% for the duration of antibiotic therapy, recheck INR in 1 week* - **Empirical dose reduction** is generally not recommended as the individual response to warfarin-antibiotic interactions is highly variable. - Reducing the dose without evidence of supratherapeutic INR could lead to an **under-therapeutic INR**, increasing the risk of **thromboembolism**. *Temporarily switch from warfarin to low molecular weight heparin for the duration of antibiotic therapy* - **Bridging therapy** with **LMWH** is typically reserved for procedures or conditions where oral anticoagulation is interrupted or contraindicated, not for managing a common **drug interaction** for a **UTI**. - This strategy is unnecessarily complex, more expensive, and less convenient than adjusting warfarin based on monitored INR. *Increase frequency of INR monitoring to twice weekly but continue warfarin at current dose* - Monitoring **INR twice weekly** for a short 7-day course of antibiotics is usually excessive and creates an unnecessary burden on the patient. - A single, well-timed INR check 3-5 days after starting the antibiotic is generally sufficient to assess the peak interaction effect and guide dose adjustments.

Question 59: A 73-year-old man with non-valvular atrial fibrillation (CHA₂DS₂-VASc score 5) is established on dabigatran 150mg twice daily. He requires urgent surgery for acute appendicitis within the next 6 hours. His last dose of dabigatran was 3 hours ago. His creatinine is 118 μmol/L (eGFR 52 ml/min/1.73m²). Laboratory tests show: APTT 46 seconds (normal 26-36), thrombin time >200 seconds (normal 15-19). What is the most appropriate management of his anticoagulation before proceeding to surgery?

A. Proceed to surgery without delay as the bleeding risk is acceptable with urgent surgery
B. Delay surgery for 12 hours to allow dabigatran clearance, then proceed without reversal
C. Administer prothrombin complex concentrate 50 units/kg immediately before surgery
D. Administer idarucizumab 5g intravenously as a specific reversal agent before surgery (Correct Answer)
E. Give activated charcoal 50g orally to reduce dabigatran absorption and delay surgery by 4 hours

Explanation: ***Administer idarucizumab 5g intravenously as a specific reversal agent before surgery*** - **Idarucizumab** is a specific monoclonal antibody fragment that provides immediate and complete reversal of **dabigatran** by binding to it with high affinity. - It is indicated for patients requiring **urgent surgery** or procedures where the bleeding risk is high, especially when lab tests like **thrombin time** are significantly prolonged. *Proceed to surgery without delay as the bleeding risk is acceptable with urgent surgery* - Proceeding without reversal is unsafe given the **thrombin time >200 seconds**, which indicates a high concentration of dabigatran in the system. - The **eGFR of 52 ml/min** and the recent dose (3 hours ago) mean the drug is likely at peak levels, posing a severe **haemorrhagic risk**. *Delay surgery for 12 hours to allow dabigatran clearance, then proceed without reversal* - With an **eGFR of 52 ml/min**, the half-life of dabigatran is approximately **15-18 hours**, meaning 12 hours is insufficient for complete clearance. - Clinical delay in **acute appendicitis** management increases the risk of **perforation** and peritonitis. *Administer prothrombin complex concentrate 50 units/kg immediately before surgery* - **Prothrombin complex concentrate (PCC)** is primarily used for the reversal of **Warfarin** or **Factor Xa inhibitors** (like Apixaban or Rivaroxaban). - PCC is not a specific reversal agent for **direct thrombin inhibitors** like dabigatran and is much less effective than **idarucizumab**. *Give activated charcoal 50g orally to reduce dabigatran absorption and delay surgery by 4 hours* - **Activated charcoal** is only effective if administered within **2 hours** of dabigatran ingestion; this patient took his dose 3 hours ago. - This intervention would not address the drug already absorbed into the **systemic circulation** or the immediate need for surgery.

Question 60: A 44-year-old man with type 2 diabetes is on insulin glargine 48 units at bedtime and insulin lispro 12 units with each meal. Over the past month he has gained 6kg in weight and reports frequent hypoglycaemic episodes, particularly nocturnal. His home blood glucose diary shows: pre-breakfast 3.2-4.8 mmol/L, pre-lunch 8.2-11.4 mmol/L, pre-dinner 9.8-13.2 mmol/L, bedtime 6.8-8.4 mmol/L. His HbA1c is 64 mmol/mol (8.0%). Which insulin adjustment represents the best management approach?

A. Reduce insulin glargine to 38 units at bedtime and increase insulin lispro to 16 units with each meal
B. Continue insulin glargine at 48 units, reduce breakfast insulin lispro to 8 units, increase lunch and dinner insulin lispro to 16 units each
C. Reduce insulin glargine to 40 units and split the dose to twice daily administration to reduce nocturnal hypoglycaemia (Correct Answer)
D. Switch insulin glargine to morning administration and reduce dose to 40 units, increase all insulin lispro doses to 14 units
E. Reduce insulin glargine to 42 units at bedtime, maintain breakfast insulin lispro at 12 units, increase lunch and dinner insulin lispro to 14 units each

Explanation: ***Reduce insulin glargine to 40 units and split the dose to twice daily administration to reduce nocturnal hypoglycaemia*** - The current **insulin glargine** dose of 48 units at bedtime is causing **nocturnal hypoglycaemia** and very low **pre-breakfast glucose** levels (3.2-4.8 mmol/L), indicating an excessive basal effect during the night. - Reducing the total daily dose to 40 units and splitting it into **twice-daily administration** provides a more stable and consistent **basal insulin** profile, effectively reducing nocturnal lows and improving overall control without severe peaks. *Reduce insulin glargine to 38 units at bedtime and increase insulin lispro to 16 units with each meal* - While reducing the **basal insulin** dose is appropriate, a single large reduction to 38 units at bedtime may still leave the patient vulnerable to nocturnal lows or create a gap in **basal coverage** later in the 24-hour cycle. - Increasing all **insulin lispro** doses significantly, without addressing the timing of basal delivery, could lead to **daytime hypoglycaemia** and does not optimize the **basal insulin** profile to prevent nocturnal lows. *Continue insulin glargine at 48 units, reduce breakfast insulin lispro to 8 units, increase lunch and dinner insulin lispro to 16 units each* - Continuing **insulin glargine** at 48 units fails to address the core problem of **nocturnal hypoglycaemia** and low **pre-breakfast glucose** readings. - Although mealtime **lispro** adjustments are considered, the underlying excessive **basal insulin** dose will likely perpetuate the unsafe nocturnal pattern and contribute to the patient's weight gain. *Switch insulin glargine to morning administration and reduce dose to 40 units, increase all insulin lispro doses to 14 units* - Switching the entire **basal insulin** dose to morning administration may not provide adequate **basal coverage** during the later night and early morning hours, potentially leading to increased glucose levels before breakfast despite current lows. - While reducing the **glargine** dose is appropriate, increasing all **insulin lispro** doses without fine-tuning the **basal** timing could lead to inconsistent blood glucose control and further weight gain. *Reduce insulin glargine to 42 units at bedtime, maintain breakfast insulin lispro at 12 units, increase lunch and dinner insulin lispro to 14 units each* - A modest reduction of **insulin glargine** to 42 units may not be sufficient to completely eliminate the **frequent nocturnal hypoglycaemia** and significantly low **pre-breakfast glucose** readings (3.2 mmol/L). - While increasing lunch and dinner **insulin lispro** addresses daytime hyperglycemia, this option does not optimize the **basal insulin** profile for stable 24-hour coverage as effectively as splitting the dose to manage nocturnal risk.

Question 61: A 58-year-old woman is commenced on enoxaparin 1.5mg/kg once daily for treatment of confirmed pulmonary embolism. Her weight is 112kg and her renal function shows: creatinine 102 μmol/L, eGFR 56 ml/min/1.73m². On day 3 of treatment, she develops new thrombocytopenia with platelet count dropping from 298×10⁹/L to 92×10⁹/L. She has no bleeding and is haemodynamically stable. What is the most appropriate immediate management?

A. Continue enoxaparin and monitor platelets daily as this represents typical thrombocytopenia secondary to acute thrombosis
B. Discontinue enoxaparin immediately, send blood for heparin-induced thrombocytopenia antibodies, commence fondaparinux (Correct Answer)
C. Reduce enoxaparin dose by 50% and add aspirin 75mg once daily to maintain anticoagulation while investigating
D. Switch to unfractionated heparin infusion as this has lower risk of thrombocytopenia than LMWH
E. Discontinue enoxaparin, commence warfarin with target INR 2-3, give platelet transfusion if count falls below 50×10⁹/L

Explanation: ***Discontinue enoxaparin immediately, send blood for heparin-induced thrombocytopenia antibodies, commence fondaparinux*** - The patient's **platelet count drop of >50%** (from 298 to 92 × 10⁹/L) within 3 days of starting enoxaparin is highly suggestive of **Heparin-Induced Thrombocytopenia (HIT)**, especially given the timing. - Immediate management for suspected HIT involves stopping all heparin products (including LMWH) and initiating a **non-heparin anticoagulant** like **fondaparinux** to prevent **paradoxical thrombosis**, which is the primary danger. *Continue enoxaparin and monitor platelets daily as this represents typical thrombocytopenia secondary to acute thrombosis* - A **>50% drop in platelet count** is not a typical manifestation of acute thrombosis; it strongly indicates an **immune-mediated process** like HIT. - Continuing heparin in the setting of suspected HIT significantly increases the risk of **life-threatening thrombotic complications** (HIT with thrombosis, HITT). *Reduce enoxaparin dose by 50% and add aspirin 75mg once daily to maintain anticoagulation while investigating* - Dose reduction of enoxaparin is ineffective for HIT as even small amounts of heparin perpetuate the **antibody-mediated platelet activation** and immune response. - **Aspirin** is an antiplatelet agent and does not provide adequate anticoagulation for a confirmed pulmonary embolism, nor does it address the underlying pathophysiology of HIT. *Switch to unfractionated heparin infusion as this has lower risk of thrombocytopenia than LMWH* - This statement is incorrect; **Unfractionated Heparin (UFH)** actually carries a significantly **higher risk of HIT** compared to LMWH. - Antibodies in HIT (anti-PF4/heparin) generally **cross-react** with both LMWH and UFH, making switching to UFH ineffective and potentially harmful. *Discontinue enoxaparin, commence warfarin with target INR 2-3, give platelet transfusion if count falls below 50×10⁹/L* - Initiating **warfarin** as monotherapy in acute HIT is contraindicated due to the risk of precipitating **venous limb gangrene** and skin necrosis from rapid protein C depletion in an already prothrombotic state. - **Platelet transfusions** are generally *avoided* in HIT because they can exacerbate the prothrombotic state by providing more platelets for activation by the circulating antibodies, unless there is severe, life-threatening bleeding.

Question 62: A 69-year-old woman with mechanical mitral valve replacement (St Jude prosthesis) is established on warfarin with target INR 3.0-4.0. She is admitted with major gastrointestinal bleeding presenting with haematemesis and melaena. Her observations show: BP 88/52 mmHg, HR 118 bpm, temperature 36.8°C. Blood tests reveal: Hb 72 g/L, INR 3.6, creatinine 178 μmol/L. What is the most appropriate immediate management of her anticoagulation?

A. Withhold warfarin and give oral vitamin K 5mg, transfuse blood products as needed, restart warfarin when INR <2.0
B. Administer prothrombin complex concentrate 50 units/kg and intravenous vitamin K 5mg immediately (Correct Answer)
C. Give fresh frozen plasma 4 units and vitamin K 10mg intravenously, arrange urgent upper GI endoscopy
D. Withhold warfarin, give vitamin K 10mg orally, commence therapeutic dose low molecular weight heparin once haemodynamically stable
E. Administer tranexamic acid 1g intravenously and withhold warfarin for 48 hours until INR normalises

Explanation: ***Administer prothrombin complex concentrate 50 units/kg and intravenous vitamin K 5mg immediately*** - In the presence of **major/life-threatening bleeding** (haematemesis with tachycardia and hypotension), **Prothrombin Complex Concentrate (PCC)** is the gold standard for immediate reversal of warfarin-induced coagulopathy. - **Intravenous Vitamin K** is required alongside PCC to sustain the reversal once the exogenous clotting factors are metabolised. *Withhold warfarin and give oral vitamin K 5mg, transfuse blood products as needed, restart warfarin when INR <2.0* - **Oral vitamin K** has a slow onset of action (6–24 hours), which is clinically inappropriate and dangerous in the context of **haemodynamic instability**. - While blood products like RBCs are needed for her **Hb of 72 g/L**, they do not address the underlying coagulopathy required to stop the active bleeding. *Give fresh frozen plasma 4 units and vitamin K 10mg intravenously, arrange urgent upper GI endoscopy* - **Fresh Frozen Plasma (FFP)** is no longer first-line because it requires large volumes (risk of **fluid overload**), needs time to thaw, and provides less reliable factor concentration than PCC. - Management must prioritize **haemostatic correction** with PCC before invasive procedures like endoscopy are performed in an unstable patient. *Withhold warfarin, give vitamin K 10mg orally, commence therapeutic dose low molecular weight heparin once haemodynamically stable* - **Low Molecular Weight Heparin (LMWH)** is contraindicated during active, major bleeding and could worsen the patient's prognosis. - Switching to LMWH is a strategy for long-term management of **mechanical valves**, but the immediate priority here is emergency **reversal of anticoagulation**. *Administer tranexamic acid 1g intravenously and withhold warfarin for 48 hours until INR normalises* - **Tranexamic acid** is an antifibrinolytic and does not directly reverse the **Vitamin K antagonist** effect of warfarin. - Simply withholding warfarin and waiting 48 hours is insufficient, as the patient is currently in **haemorrhagic shock** and requires replacement of factors II, VII, IX, and X.

Question 63: A 51-year-old man with type 1 diabetes for 25 years attends diabetes clinic. He has recurrent hypoglycaemia unawareness and experiences 3-4 episodes weekly of blood glucose <3.0 mmol/L, often without warning symptoms. He is on insulin degludec 32 units once daily and insulin aspart with meals. His HbA1c is 48 mmol/mol (6.5%). What is the most appropriate adjustment to his insulin regimen?

A. Reduce insulin degludec to 26 units and accept higher HbA1c target of 53-58 mmol/mol (7-7.5%) to minimise hypoglycaemia (Correct Answer)
B. Switch from insulin degludec to insulin glargine which has lower risk of nocturnal hypoglycaemia
C. Add acarbose to slow carbohydrate absorption and reduce post-prandial insulin requirements
D. Increase insulin degludec to 38 units to reduce counter-regulatory hormone surges causing rebound hypoglycaemia
E. Switch to insulin pump therapy (continuous subcutaneous insulin infusion) as this is contraindicated with impaired awareness

Explanation: ***Reduce insulin degludec to 26 units and accept higher HbA1c target of 53-58 mmol/mol (7-7.5%) to minimise hypoglycaemia*** - The patient has **hypoglycaemia unawareness** and frequent episodes, indicating that the current HbA1c of 6.5% is achieved at the cost of dangerous **iatrogenic hypoglycaemia**. - Scrupulous avoidance of low blood glucose for several weeks can help **restore warning symptoms**; therefore, reducing the basal dose and relaxing targets is the first-line management. *Switch from insulin degludec to insulin glargine which has lower risk of nocturnal hypoglycaemia* - **Insulin degludec** is an ultra-long-acting analogue that generally has a **lower or similar risk** of nocturnal hypoglycaemia compared to standard glargine (U100). - Switching to glargine would not address the primary issue of **over-insulinisation** and the need for a higher glycaemic target. *Add acarbose to slow carbohydrate absorption and reduce post-prandial insulin requirements* - **Acarbose** is an alpha-glucosidase inhibitor primarily used in Type 2 Diabetes and is not a standard treatment for **hypoglycaemia unawareness** in Type 1 Diabetes. - If a patient on acarbose develops hypoglycaemia, they must be treated with **pure glucose (dextrose)** because the drug prevents the breakdown of complex sugars. *Increase insulin degludec to 38 units to reduce counter-regulatory hormone surges causing rebound hypoglycaemia* - Increasing the insulin dose in a patient already experiencing 3-4 hypoglycaemic episodes per week is **dangerous** and will exacerbate the risk of a fatal event. - "Rebound" effects (like the **Somogyi phenomenon**) are managed by reducing the preceding insulin dose, not increasing it. *Switch to insulin pump therapy (continuous subcutaneous insulin infusion) as this is contraindicated with impaired awareness* - **Insulin pump therapy** is actually **indicated** (not contraindicated) by NICE for patients with disabling hypoglycaemia or impaired awareness despite optimized MDIs. - While a pump may be a future step, the statement incorrectly claims it is contraindicated, and the immediate priority is **dose adjustment**.

Question 64: A 74-year-old man with permanent atrial fibrillation on apixaban 5mg twice daily is admitted with acute hip fracture requiring surgical fixation. His renal function shows: creatinine 156 μmol/L, eGFR 42 ml/min/1.73m². He weighs 58kg and is 168cm tall. Surgery is planned for the next morning. On admission his APTT is 38 seconds (normal 26-36 seconds). What is the most appropriate perioperative anticoagulation management?

A. Continue apixaban 5mg twice daily throughout as it is needed for stroke prevention
B. Omit apixaban on the day of surgery, restart 5mg twice daily 48 hours post-operatively if haemostasis achieved (Correct Answer)
C. Stop apixaban now, give low molecular weight heparin bridging at treatment dose until 12 hours before surgery
D. Reduce apixaban to 2.5mg twice daily perioperatively due to renal impairment and bleeding risk
E. Discontinue apixaban, give prothrombin complex concentrate pre-operatively, restart apixaban 7 days post-surgery

Explanation: ***Omit apixaban on the day of surgery, restart 5mg twice daily 48 hours post-operatively if haemostasis achieved*** - For **urgent surgery** with a **high bleeding risk** like hip fixation, the DOAC should be held to ensure at least a 24-hour gap from the last dose to minimize perioperative bleeding. - The 5mg dose is correct because the patient only meets two criteria for dose reduction (**weight ≤60kg** and **creatinine ≥133 μmol/L**) but not the necessary two out of three (age ≥80, weight ≤60kg, creatinine ≥133 μmol/L) as he is 74 (under 80). *Continue apixaban 5mg twice daily throughout as it is needed for stroke prevention* - Continuing a **direct oral anticoagulant (DOAC)** during major surgery poses an unacceptable **bleeding risk**, especially for procedures involving bone. - **Periprocedural management** of DOACs requires a temporary interruption to ensure safe surgical hemostasis. *Stop apixaban now, give low molecular weight heparin bridging at treatment dose until 12 hours before surgery* - **Heparin bridging** is generally not recommended for DOACs due to their predictable and rapid onset and offset of action. - Bridging significantly increases the **risk of bleeding** without providing a clear benefit in preventing thromboembolism compared to simple interruption. *Reduce apixaban to 2.5mg twice daily perioperatively due to renal impairment and bleeding risk* - Dose reduction to 2.5mg twice daily is indicated for long-term therapy only if **two of three** criteria are met: **age ≥80**, **weight ≤60kg**, or **creatinine ≥133 μmol/L**; perioperative management focuses on interruption rather than reduction. - Reducing the dose does not provide sufficient **hemostatic safety** for major surgery compared to omitting the dose entirely. *Discontinue apixaban, give prothrombin complex concentrate pre-operatively, restart apixaban 7 days post-surgery* - **Prothrombin complex concentrate (PCC)** or specific reversal agents are reserved for **emergency surgery** (within 6 hours) or life-threatening bleeds, not scheduled semi-urgent cases. - Restarting anticoagulation as late as 7 days post-surgery would excessively increase the risk of **venous thromboembolism (VTE)** and stroke in a patient with **atrial fibrillation**.

Question 65: A 56-year-old woman with type 2 diabetes is admitted with severe community-acquired pneumonia requiring ICU admission. She is on insulin glargine 40 units at bedtime and metformin 1g twice daily at home. She is intubated and ventilated, receiving vasopressor support. Her capillary blood glucose is 18.4 mmol/L. What is the most appropriate diabetes management strategy?

A. Continue insulin glargine 40 units daily via nasogastric tube and start intravenous insulin infusion to target glucose 6-10 mmol/L
B. Commence variable rate intravenous insulin infusion targeting glucose 6-10 mmol/L, discontinue all other glucose-lowering medications (Correct Answer)
C. Increase insulin glargine to 50 units daily, add rapid-acting insulin correction doses every 4 hours as needed
D. Start sliding scale subcutaneous insulin four times daily, withhold insulin glargine and metformin until extubated
E. Continue insulin glargine at current dose, restart metformin via nasogastric tube, add intravenous insulin as needed

Explanation: ***Commence variable rate intravenous insulin infusion targeting glucose 6-10 mmol/L, discontinue all other glucose-lowering medications*** - For **critically ill patients** (intubated and on vasopressors), a **variable rate intravenous insulin infusion (VRIII)** is the gold standard as it allows for rapid titration against fluctuating insulin resistance. - The recommended target blood glucose in the ICU is **6.0–10.0 mmol/L** to balance glycemic control while minimizing the significant risk of **hypoglycemia** associated with tighter targets. *Continue insulin glargine 40 units daily via nasogastric tube and start intravenous insulin infusion to target glucose 6-10 mmol/L* - **Insulin glargine** is a basal insulin intended for subcutaneous injection; it is not administered via a **nasogastric tube** because it is a protein that would be digested in the stomach. - When starting a **VRIII** in the acute ICU setting for Type 2 Diabetes, overlapping with subcutaneous basal insulin is generally avoided to prevent **unpredictable hypoglycemia** during hemodynamic instability. *Increase insulin glargine to 50 units daily, add rapid-acting insulin correction doses every 4 hours as needed* - Subcutaneous insulin absorption is highly **unreliable** in patients on **vasopressors** due to peripheral vasoconstriction and poor tissue perfusion. - Relying on intermittent correction doses (reactive management) leads to poor glycemic stability compared to the proactive, continuous titration provided by **intravenous infusion**. *Start sliding scale subcutaneous insulin four times daily, withhold insulin glargine and metformin until extubated* - **Sliding scale insulin (SSI)** alone is widely discouraged in clinical practice as it treats hyperglycemia after it occurs rather than preventing it, leading to poor control. - In the context of **shock and multiorgan failure**, intravenous delivery is mandatory to ensure the medication reaches the systemic circulation effectively. *Continue insulin glargine at current dose, restart metformin via nasogastric tube, add intravenous insulin as needed* - **Metformin** must be discontinued in critically ill patients due to the high risk of **lactic acidosis**, especially in those with potential renal impairment or tissue hypoxia. - Continuing **subcutaneous glargine** while simultaneously adding an IV infusion complicates the management and increases the risk of **dose stacking** and hypoglycemia.

Question 66: A 67-year-old man with deep vein thrombosis is on day 18 of rivaroxaban treatment. He was initially prescribed 15mg twice daily for the first 21 days. He attends for review and asks when his dose will change. What is the correct next step in his anticoagulation management?

A. Continue rivaroxaban 15mg twice daily for a total of 3 months, then stop if provoked DVT
B. Change to rivaroxaban 20mg once daily after completing 21 days of 15mg twice daily dosing (Correct Answer)
C. Continue rivaroxaban 15mg twice daily for 6 weeks, then reduce to 15mg once daily
D. Switch to warfarin after 21 days as DOACs are only licensed for initial DVT treatment
E. Reduce to rivaroxaban 10mg once daily now for long-term prophylaxis against recurrence

Explanation: ***Change to rivaroxaban 20mg once daily after completing 21 days of 15mg twice daily dosing*** - For the treatment of **DVT or PE**, the standard licensing for **rivaroxaban** requires an initial high-intensity phase of **15mg twice daily** for exactly **21 days**. - Following this 21-day loading period, the dose must transition to a maintenance dose of **20mg once daily** to ensure continued efficacy and safety during the treatment window. *Continue rivaroxaban 15mg twice daily for a total of 3 months, then stop if provoked DVT* - Continuing the high-dose **twice daily** regimen for 3 months significantly increases the **bleeding risk** without providing additional therapeutic benefit over maintenance dosing. - While the total duration for a **provoked DVT** is typically 3 months, the dosage must still transition to **once daily** after the first 3 weeks. *Continue rivaroxaban 15mg twice daily for 6 weeks, then reduce to 15mg once daily* - There is no clinical indication or licensed guideline for extending the **initial loading phase** to 6 weeks for standard DVT treatment. - A **15mg once daily** dose is not the standard maintenance dose for DVT treatment; the correct maintenance dose is **20mg**. *Switch to warfarin after 21 days as DOACs are only licensed for initial DVT treatment* - **DOACs** like rivaroxaban are licensed and often preferred for both the **initial and long-term treatment** of VTE due to no requirement for INR monitoring. - Switching to **warfarin** is not mandatory and would require a complex transition period involving **heparin overlap** or strict bridging protocols. *Reduce to rivaroxaban 10mg once daily now for long-term prophylaxis against recurrence* - The **10mg once daily** dose is reserved for **extended prevention** of recurrent VTE after a patient has already completed at least **6 months** of therapeutic anticoagulation. - This patient is still in the **acute treatment phase** (day 18), and reducing the dose this early would lead to **under-treatment** and high risk of clot extension.

Question 67: A 42-year-old woman with type 1 diabetes is admitted for elective cholecystectomy. She is on insulin aspart three times daily with meals and insulin glargine 24 units at bedtime. Surgery is scheduled for 09:00. Her capillary blood glucose at 06:00 is 8.2 mmol/L. What is the most appropriate perioperative insulin management?

A. Omit morning insulin aspart, give usual insulin glargine dose, commence variable rate intravenous insulin infusion (Correct Answer)
B. Give half the usual insulin glargine dose at 06:00, omit insulin aspart, start 5% dextrose with potassium
C. Omit both insulin glargine and insulin aspart, commence variable rate intravenous insulin infusion with glucose-potassium-insulin solution
D. Give usual insulin glargine dose at bedtime the night before, omit morning insulin aspart, start intravenous insulin infusion once nil by mouth
E. Continue usual insulin regimen until immediately before surgery, then commence subcutaneous sliding scale insulin

Explanation: ***Omit morning insulin aspart, give usual insulin glargine dose, commence variable rate intravenous insulin infusion*** - In **Type 1 Diabetes**, patients should always continue their **basal insulin** (e.g., glargine) during surgery to prevent **diabetic ketoacidosis (DKA)**, as they have an absolute insulin deficiency. - **Prandial insulin** (aspart) is omitted as the patient is **nil by mouth**, and a **variable rate intravenous insulin infusion (VRIII)** is commenced for precise glucose control during the surgical period. *Give half the usual insulin glargine dose at 06:00, omit insulin aspart, start 5% dextrose with potassium* - Reducing the **basal insulin** dose to half in **Type 1 diabetes** carries a significant risk of **DKA** due to absolute insulin deficiency, especially during the physiological stress of surgery. - Starting **5% dextrose** without concomitant titrated insulin (like a VRIII) can lead to **hyperglycemia**, and dextrose alone is insufficient for safe glycemic control in Type 1 diabetics perioperatively. *Omit both insulin glargine and insulin aspart, commence variable rate intravenous insulin infusion with glucose-potassium-insulin solution* - **Omitting basal insulin** (glargine) in a Type 1 diabetic is highly dangerous and can lead to **DKA**, as the VRIII is a temporary measure and does not replace long-term basal coverage. - **Glucose-Potassium-Insulin (GKI) solutions** are less flexible and precise than a modern **VRIII** and separate fluid infusion, making dynamic glucose management more challenging. *Give usual insulin glargine dose at bedtime the night before, omit morning insulin aspart, start intravenous insulin infusion once nil by mouth* - While the bedtime glargine is appropriate, this option does not explicitly state the continuation of **basal insulin** on the morning of surgery, which is crucial for DKA prevention. - The term "intravenous insulin infusion" is too general; **Variable Rate Intravenous Insulin Infusion (VRIII)** is the specific standard of care, implying dynamic titration and careful monitoring, not just a fixed infusion. *Continue usual insulin regimen until immediately before surgery, then commence subcutaneous sliding scale insulin* - Continuing **mealtime insulin aspart** while the patient is **nil by mouth** (fasting) poses a significant and dangerous risk of **hypoglycemia** immediately before surgery. - **Subcutaneous sliding scale insulin** is generally considered inadequate for optimal perioperative glucose control in **Type 1 diabetes** due to unpredictable absorption and delayed action, especially compared to the **VRIII**.

Question 68: A 70-year-old man with atrial fibrillation on warfarin therapy (target INR 2-3) presents with an INR of 7.8 measured at routine monitoring. He has no signs of bleeding and is haemodynamically stable. His full blood count and coagulation screen show: Hb 132 g/L, platelets 245×10⁹/L, PT 78 seconds. What is the most appropriate immediate management according to current UK guidelines?

A. Administer vitamin K 5mg intravenously and withhold warfarin for 2 doses
B. Give oral vitamin K 1-5mg and withhold warfarin, recheck INR in 24 hours (Correct Answer)
C. Withhold warfarin for 1-2 doses and recheck INR daily until it falls to therapeutic range
D. Administer prothrombin complex concentrate and vitamin K 5mg intravenously
E. Continue warfarin at reduced dose and arrange repeat INR in 1 week

Explanation: ***Give oral vitamin K 1-5mg and withhold warfarin, recheck INR in 24 hours*** - For a **stable patient** with an **INR between 5.0 and 8.0** and **no evidence of bleeding**, UK guidelines (e.g., BNF, NICE) recommend withholding warfarin and administering **oral vitamin K 1-2mg** (some guidelines allow up to 5mg for higher INRs within this range). - An INR of **7.8** is significantly elevated, making **oral vitamin K** prudent to expedite INR reduction and prevent bleeding, with a recheck in **24 hours** to confirm the response. *Administer vitamin K 5mg intravenously and withhold warfarin for 2 doses* - **Intravenous vitamin K** is typically reserved for patients with **major bleeding**, an **INR > 8.0** with *some* bleeding, or those requiring very rapid reversal for emergency surgery. - Since the patient is **haemodynamically stable** and has **no signs of bleeding**, the oral route is preferred as it is effective and avoids the small risk of **anaphylaxis** associated with IV administration. *Withhold warfarin for 1-2 doses and recheck INR daily until it falls to therapeutic range* - Simply **withholding warfarin** is appropriate for an **INR between 5.0 and 8.0** when the INR is not critically high (e.g., 5.0-6.0) or if the patient is considered at low risk of bleeding. - With an INR as high as **7.8**, administering **oral vitamin K** is recommended to more rapidly and reliably reduce the INR and mitigate the significant risk of **spontaneous hemorrhage**. *Administer prothrombin complex concentrate and vitamin K 5mg intravenously* - **Prothrombin complex concentrate (PCC)** is indicated only for **major or life-threatening bleeding** (e.g., intracranial hemorrhage) or for urgent reversal prior to emergency surgery, regardless of INR level. - This patient is **haemodynamically stable** with **no signs of bleeding**, making such aggressive reversal unnecessary and potentially increasing the risk of **thromboembolism**. *Continue warfarin at reduced dose and arrange repeat INR in 1 week* - Continuing **warfarin** when the INR is significantly supra-therapeutic at **7.8** is highly dangerous and poses an immediate, critical risk of **major bleeding**. - Management for such a high INR must involve immediate **cessation of dosing** and active reversal measures, such as **oral vitamin K**, rather than a mere dose reduction and delayed monitoring.

Question 69: A 48-year-old woman with severe psoriasis is started on methotrexate 15mg once weekly. She is counselled about the importance of folic acid supplementation. Which explanation best describes the rationale for folic acid co-prescription with methotrexate?

A. Folic acid enhances the immunosuppressive effects of methotrexate by potentiating dihydrofolate reductase inhibition
B. Folic acid reduces methotrexate-related toxicity without significantly compromising its therapeutic efficacy (Correct Answer)
C. Folic acid is required to prevent megaloblastic anaemia caused by methotrexate-induced vitamin B12 deficiency
D. Folic acid increases methotrexate absorption from the gastrointestinal tract, improving bioavailability
E. Folic acid accelerates methotrexate metabolism and renal excretion, reducing plasma drug levels

Explanation: ***Folic acid reduces methotrexate-related toxicity without significantly compromising its therapeutic efficacy*** - **Methotrexate** is a folate antagonist that inhibits **dihydrofolate reductase (DHFR)**, impairing DNA synthesis in rapidly dividing cells, which is the basis of its therapeutic effect but also causes significant side effects. - **Folic acid supplementation** provides a substrate for normal folate pathways in non-target cells, thereby mitigating common toxicities like **mucositis**, **bone marrow suppression**, and **hepatotoxicity**, without negating the anti-inflammatory or anti-proliferative effects against psoriasis. *Folic acid enhances the immunosuppressive effects of methotrexate by potentiating dihydrofolate reductase inhibition* - Folic acid acts as a **substrate** in the folate pathway and does not enhance or potentiate the inhibitory effect of methotrexate on DHFR. - The purpose of co-prescription is to **counteract**, not augment, methotrexate's mechanism, specifically in healthy cells. *Folic acid is required to prevent megaloblastic anaemia caused by methotrexate-induced vitamin B12 deficiency* - Methotrexate primarily interferes with **folate metabolism**, leading to functional folate deficiency and potentially **macrocytic anemia** (which resembles megaloblastic anemia). - It does not directly cause or address a deficiency in **vitamin B12**, which is involved in a separate but interconnected metabolic pathway. *Folic acid increases methotrexate absorption from the gastrointestinal tract, improving bioavailability* - There is no evidence that folic acid improves the **gastrointestinal absorption** or **bioavailability** of methotrexate. - In fact, patients are often advised to take folic acid at least **24 hours after** their weekly methotrexate dose to avoid potential competitive absorption or interaction at the cellular level. *Folic acid accelerates methotrexate metabolism and renal excretion, reducing plasma drug levels* - Folic acid does not significantly alter the **pharmacokinetics** of methotrexate, including its metabolism or **renal excretion**. - Its role is to provide a competitive substrate to protect healthy cells from the **antifolate effects** of methotrexate, not to directly reduce systemic drug levels.

Question 70: A 63-year-old woman with atrial fibrillation is established on rivaroxaban 20mg once daily. She develops cellulitis requiring hospital admission and intravenous antibiotics. Her renal function shows: creatinine 145 μmol/L, eGFR 38 ml/min/1.73m². Which statement best describes the appropriate management of her anticoagulation?

A. Continue rivaroxaban 20mg once daily as the eGFR is above 30 ml/min/1.73m²
B. Reduce rivaroxaban dose to 15mg once daily due to moderate renal impairment (Correct Answer)
C. Switch to warfarin as DOACs are contraindicated in renal impairment
D. Temporarily discontinue rivaroxaban until the acute infection resolves
E. Increase monitoring but continue current dose as dosing is primarily based on indication

Explanation: ***Reduce rivaroxaban dose to 15mg once daily due to moderate renal impairment*** - For stroke prevention in **atrial fibrillation**, the standard dose of **rivaroxaban** is reduced from 20mg to **15mg once daily** when the **eGFR** falls between **15-49 ml/min/1.73m²**. - This patient's **eGFR of 38 ml/min/1.73m²** falls directly into this range, necessitating a dose adjustment to prevent drug accumulation and mitigate the **risk of bleeding**. *Continue rivaroxaban 20mg once daily as the eGFR is above 30 ml/min/1.73m²* - The dose reduction threshold for rivaroxaban in **atrial fibrillation** is an **eGFR below 50 ml/min/1.73m²**, not 30 for continuation. - Continuing the full 20mg dose with an **eGFR of 38 ml/min/1.73m²** would lead to increased drug exposure and a higher **bleeding risk**. *Switch to warfarin as DOACs are contraindicated in renal impairment* - **Direct Oral Anticoagulants (DOACs)** like rivaroxaban are not contraindicated in all degrees of renal impairment; specific dose adjustments are made, and they are generally contraindicated only when **eGFR falls below 15 ml/min/1.73m²**. - Switching to **warfarin** would introduce additional complexities, such as the need for frequent **INR monitoring** and potential drug interactions, without clear clinical benefit over a dose-adjusted DOAC. *Temporarily discontinue rivaroxaban until the acute infection resolves* - While acute illness can transiently affect renal function, **cellulitis** itself is not an indication to discontinue anticoagulation for **atrial fibrillation**. - Discontinuing rivaroxaban would place the patient at a significantly increased risk of **thromboembolic events**, such as **stroke**, given their underlying condition. *Increase monitoring but continue current dose as dosing is primarily based on indication* - While the indication (**atrial fibrillation**) dictates the need for anticoagulation, **renal function** is a critical parameter that determines the appropriate dose for many drugs, including **rivaroxaban**. - Simply increasing monitoring without adjusting the dose, when guidelines clearly indicate a need for dose reduction based on **eGFR**, is insufficient and would not adequately address the increased **bleeding risk**.

Question 71: A 55-year-old man with type 2 diabetes is prescribed insulin detemir. According to the British National Formulary, what is the typical time to onset of action for insulin detemir after subcutaneous injection?

A. 15 minutes
B. 30 minutes
C. 1-2 hours (Correct Answer)
D. 4-6 hours
E. 8-10 hours

Explanation: ***1-2 hours*** - **Insulin detemir** is a **long-acting basal insulin** analogue, designed to provide steady glucose control with a typical **onset of action** of **1 to 2 hours** after subcutaneous injection. - Its prolonged action is due to **reversible albumin binding** and **hexamer formation**, which delays absorption from the injection site. *15 minutes* - This onset time is characteristic of **rapid-acting insulin analogues** (e.g., **insulin aspart**, **lispro**, **glulisine**). - These insulins are typically administered immediately before or after meals to manage **postprandial glucose** excursions. *30 minutes* - This onset time is associated with **short-acting (soluble) insulins** (e.g., **Actrapid**, **Humulin S**). - They require administration approximately 20-30 minutes before a meal to allow their **peak effect** to coincide with food absorption. *4-6 hours* - An onset of **4-6 hours** is much slower than expected for **insulin detemir** and most basal insulins, which aim to provide earlier glucose lowering. - This timeframe is more reflective of the **duration of action** or peak for some **intermediate-acting insulins** rather than the onset for a basal insulin. *8-10 hours* - An onset of **8-10 hours** would be clinically inappropriate and dangerous, as it would leave a significant period of **uncontrolled hyperglycemia** after injection. - This timeframe far exceeds the typical onset of any commonly used insulin and is more aligned with the **duration** of some **long-acting insulins** rather than their initiation of effect.

Question 72: A 81-year-old woman with atrial fibrillation (CHA₂DS₂-VASc score 6) has been on apixaban 2.5mg twice daily for 2 years. She now develops stage 4 chronic kidney disease with eGFR declining from 48 ml/min/1.73m² to 24 ml/min/1.73m² over 6 months. She weighs 64kg and is aged 81 years. Her serum creatinine is 198 μmol/L. She has no recent bleeding and takes no interacting medications. What is the most appropriate management of her anticoagulation?

A. Continue apixaban 2.5mg twice daily as she meets dose reduction criteria (Correct Answer)
B. Increase apixaban to 5mg twice daily as eGFR >15 ml/min/1.73m²
C. Switch to warfarin as DOACs are contraindicated with eGFR <30 ml/min/1.73m²
D. Stop apixaban as risks outweigh benefits with severe renal impairment
E. Reduce apixaban to 2.5mg once daily due to significant renal impairment

Explanation: ***Continue apixaban 2.5mg twice daily as she meets dose reduction criteria*** - Apixaban dose reduction from 5mg to **2.5mg twice daily** is indicated if a patient meets two out of three criteria: **age ≥80 years**, body **weight ≤60 kg**, or **serum creatinine ≥133 μmol/L**. - This patient, at 81 years and with a serum creatinine of 198 μmol/L, meets two criteria, confirming that her current dose of 2.5mg twice daily is the **correct renally-adjusted dose** for stroke prevention in atrial fibrillation. *Increase apixaban to 5mg twice daily as eGFR >15 ml/min/1.73m²* - Increasing the dose to 5mg twice daily would be inappropriate because the patient **meets criteria for dose reduction** based on age and serum creatinine, irrespective of her eGFR being >15 ml/min/1.73m². - The standard 5mg dose would significantly elevate the **risk of major bleeding** in this elderly patient with established stage 4 CKD. *Switch to warfarin as DOACs are contraindicated with eGFR <30 ml/min/1.73m²* - This statement is incorrect as apixaban is **not contraindicated** for eGFR between 15-29 ml/min/1.73m², and its use is supported down to an eGFR of 15 ml/min/1.73m². - While some DOACs, like **dabigatran**, have a stricter contraindication below 30 ml/min/1.73m², apixaban has a more favorable profile in patients with moderate to severe CKD compared to warfarin. *Stop apixaban as risks outweigh benefits with severe renal impairment* - With a **CHA₂DS₂-VASc score of 6**, the patient has a very high risk of **thromboembolic stroke**, meaning the benefits of appropriate anticoagulation generally outweigh the bleeding risk. - Anticoagulation with apixaban is typically continued until the **eGFR drops below 15 ml/min/1.73m²** or the patient progresses to end-stage renal disease, which is not the case here. *Reduce apixaban to 2.5mg once daily due to significant renal impairment* - Apixaban is only licensed for **twice-daily (BD) administration** for stroke prevention in atrial fibrillation; a once-daily regimen is not an approved dosing schedule. - Reducing to once-daily dosing would result in **sub-therapeutic drug levels**, significantly increasing the patient's risk of **ischemic stroke** due to inadequate anticoagulation.

Question 73: A 49-year-old woman with type 2 diabetes is established on insulin detemir 26 units twice daily (morning and bedtime) and metformin 1g twice daily. Her home blood glucose monitoring shows: fasting 6-8 mmol/L, pre-lunch 5-7 mmol/L, pre-dinner 12-15 mmol/L, bedtime 8-10 mmol/L. Her HbA1c is 64 mmol/mol. She is keen to optimize her diabetes control. What is the most appropriate modification to her treatment regimen?

A. Increase both morning and evening insulin detemir doses by 10%
B. Increase evening insulin detemir dose only by 4 units
C. Add rapid-acting insulin before lunch (Correct Answer)
D. Increase metformin to 1g three times daily
E. Switch to basal-bolus regimen with once-daily basal insulin and rapid-acting insulin before each meal

Explanation: ***Add rapid-acting insulin before lunch*** - The patient's blood glucose is significantly elevated **pre-dinner (12-15 mmol/L)**, indicating **postprandial hyperglycemia** following the lunch meal that is not adequately covered by the current basal regimen. - Fasting and pre-lunch readings are within target (5-8 mmol/L), suggesting that the **twice-daily insulin detemir** provides adequate basal coverage, making a targeted **prandial insulin** addition the most appropriate next step. *Increase both morning and evening insulin detemir doses by 10%* - Increasing the morning detemir dose is unlikely to correct the **pre-dinner hyperglycemia** and could lead to **hypoglycemia** before lunch, as current pre-lunch levels are good. - Increasing the evening detemir dose would primarily lower **fasting glucose**, which is already near target, and risks **nocturnal hypoglycemia** without directly addressing the post-lunch spike. *Increase evening insulin detemir dose only by 4 units* - An increase in the evening basal insulin primarily affects **fasting glucose levels**, which are currently well-controlled (6-8 mmol/L). - This modification risks **hypoglycemia** during the night or early morning without correcting the significant **post-lunch/pre-dinner hyperglycemia**. *Increase metformin to 1g three times daily* - The patient is already on metformin 2g daily, which is often the **maximum effective dose**; increasing to 3g offers marginal additional benefit and significantly increases the risk of **gastrointestinal side effects**. - Metformin alone is generally insufficient to manage the significant **postprandial glucose excursion** observed in a patient already on basal insulin therapy. *Switch to basal-bolus regimen with once-daily basal insulin and rapid-acting insulin before each meal* - While a **full basal-bolus regimen** is a potential long-term goal for type 2 diabetes, it represents a more complex and intensive treatment step. - The current problem is a specific **post-lunch hyperglycemia**, which can be effectively managed with a **step-wise intensification** (adding one mealtime insulin dose) before escalating to a full regimen.

Question 74: A 67-year-old man with non-valvular atrial fibrillation (CHA₂DS₂-VASc score 4) has been on rivaroxaban 20mg once daily for 18 months. He now presents with biopsy-proven hepatocellular carcinoma and is being considered for transarterial chemoembolization (TACE). His baseline liver function shows: bilirubin 42 μmol/L, ALT 128 U/L, ALP 245 U/L, albumin 32 g/L, INR 1.4. His renal function is normal (eGFR 74 ml/min/1.73m²). What is the most appropriate anticoagulation strategy for this patient?

A. Continue rivaroxaban 20mg once daily as hepatocellular carcinoma is not a contraindication to DOACs
B. Reduce rivaroxaban to 15mg once daily due to hepatic impairment
C. Switch to apixaban 2.5mg twice daily which is safer in liver disease
D. Stop rivaroxaban and avoid anticoagulation due to high bleeding risk from liver disease and planned TACE (Correct Answer)
E. Stop rivaroxaban and switch to warfarin with careful INR monitoring

Explanation: ***Stop rivaroxaban and avoid anticoagulation due to high bleeding risk from liver disease and planned TACE*** - The patient presents with significant **hepatic impairment**, characterized by elevated bilirubin (42 μmol/L), low albumin (32 g/L), and an elevated INR (1.4). These features indicate at least **Child-Pugh Class B** liver disease, which contraindicates the use of DOACs like rivaroxaban due to increased risk of bleeding. - The combination of **severe liver disease-associated coagulopathy** and the planned invasive procedure of **Transarterial Chemoembolization (TACE)** significantly elevates the risk of hemorrhage, making continued anticoagulation unsafe and outweighing its benefits for stroke prevention. *Continue rivaroxaban 20mg once daily as hepatocellular carcinoma is not a contraindication to DOACs* - While hepatocellular carcinoma itself isn't a direct contraindication for DOACs, the patient's **hepatic synthetic dysfunction** and resultant **coagulopathy** (INR 1.4) are critical contraindications for rivaroxaban. - **Rivaroxaban** relies significantly on hepatic metabolism, and its use is contraindicated in patients with **Child-Pugh Class B or C** liver disease due to unpredictable drug accumulation and heightened bleeding risk. *Reduce rivaroxaban to 15mg once daily due to hepatic impairment* - The dose adjustment of **rivaroxaban to 15mg** is primarily indicated for patients with moderate **renal impairment** (eGFR 15-49 ml/min), not for liver impairment. - There is no established evidence or guideline to support the safe and effective use of a reduced rivaroxaban dose in patients with **Child-Pugh B or C** liver disease, where it remains generally contraindicated. *Switch to apixaban 2.5mg twice daily which is safer in liver disease* - Although **apixaban** has a lesser degree of hepatic metabolism compared to rivaroxaban, all **DOACs** are contraindicated in severe liver disease (Child-Pugh C) and in **Child-Pugh B** patients with associated coagulopathy. - The 2.5mg twice daily dose of apixaban is typically reserved for specific criteria related to age, weight, or renal function, and is not a generalized strategy to manage significant **liver-induced bleeding risk** in cases where DOACs are otherwise contraindicated. *Stop rivaroxaban and switch to warfarin with careful INR monitoring* - Managing **warfarin** in patients with advanced liver disease is extremely challenging and often unsafe, as the underlying condition causes an **elevated baseline INR** due to impaired synthesis of clotting factors. - This makes **INR monitoring** unreliable for warfarin titration, leading to a high risk of both **thrombosis and hemorrhage** and making it an inappropriate choice in this patient's condition.

Question 75: A 54-year-old woman with type 1 diabetes for 32 years presents with a 6-month history of frequent hypoglycaemic episodes without warning symptoms. She is on insulin degludec 28 units once daily and insulin aspart using carbohydrate counting. Her HbA1c is 48 mmol/mol. Continuous glucose monitoring reveals multiple episodes of glucose <3.0 mmol/L, including nocturnal episodes. She has normal renal function and no evidence of gastroparesis. What is the most important factor contributing to her impaired hypoglycaemia awareness?

A. The use of long-acting insulin analogue rather than intermediate-acting insulin
B. Autonomic neuropathy resulting from long-standing diabetes
C. Recurrent hypoglycaemia causing reduced counter-regulatory hormone responses (Correct Answer)
D. Overly strict glycaemic control with HbA1c target that is too low
E. Defective glucagon secretion specific to insulin degludec use

Explanation: ***Recurrent hypoglycaemia causing reduced counter-regulatory hormone responses***- Recurrent low glucose episodes lead to **hypoglycaemia-associated autonomic failure (HAAF)**, where the brain adapts by lowering the threshold for triggering a **sympathoadrenal response**.- This creates a vicious cycle where frequent lows diminish the **warning symptoms** and the hormonal counter-regulation (especially **epinephrine**) needed to raise blood sugar naturally.*The use of long-acting insulin analogue rather than intermediate-acting insulin*- **Long-acting insulin analogues** like degludec generally have a lower risk of nocturnal hypoglycaemia compared to **NPH (intermediate-acting) insulin** due to their flatter profiles.- Switching to an analogue is often an intervention to **reduce hypoglycaemia risk**, not the primary cause of impaired awareness.*Autonomic neuropathy resulting from long-standing diabetes*- While **autonomic neuropathy** can impair the heart rate response to low glucose, it is less commonly considered the primary cause of **impaired hypoglycaemia awareness** itself.- The patient's loss of **neuroglycopenic awareness** (warning symptoms) is primarily due to central nervous system adaptation, not directly peripheral nerve damage.*Overly strict glycaemic control with HbA1c target that is too low*- An **HbA1c of 48 mmol/mol** (6.5%) is a standard and often recommended target for many Type 1 diabetics and is not inherently considered **'too low'** in general guidelines.- While aggressive control *can* increase hypoglycaemia risk, this HbA1c alone doesn't suggest an overly strict target as the *most important* factor for *impaired awareness* in a patient with frequent documented lows.*Defective glucagon secretion specific to insulin degludec use*- **Defective glucagon secretion** is a common feature of long-standing Type 1 diabetes itself, regardless of the specific insulin used.- There is no evidence suggesting that **insulin degludec** specifically causes or exacerbates defective glucagon secretion compared to other insulins.

Question 76: A 72-year-old man with mechanical mitral valve replacement is established on warfarin with target INR 2.5-3.5. He is diagnosed with a new deep vein thrombosis and his current INR is 2.2. He has eGFR of 58 ml/min/1.73m² and weighs 82kg. What is the most appropriate management of his anticoagulation for the acute DVT?

A. Switch from warfarin to apixaban 10mg twice daily for 7 days then 5mg twice daily
B. Start low molecular weight heparin at treatment dose and increase warfarin dose targeting INR 3.0-4.0 (Correct Answer)
C. Continue current warfarin dose and add low molecular weight heparin until INR >3.0 for 2 consecutive days
D. Double the warfarin dose immediately and check INR daily until therapeutic
E. Start intravenous unfractionated heparin and continue current warfarin dose

Explanation: ***Start low molecular weight heparin at treatment dose and increase warfarin dose targeting INR 3.0-4.0***- This patient experienced a new **deep vein thrombosis (DVT)** despite being on warfarin for a **mechanical mitral valve**, indicating that the current anticoagulation (INR 2.2, target 2.5-3.5) is insufficient.- For recurrent or breakthrough thrombosis on warfarin, especially with a **mechanical valve**, guidelines recommend **intensifying anticoagulation** by increasing the target **INR range (e.g., to 3.0-4.0)** and initiating **low molecular weight heparin (LMWH)** as a bridge until the new, higher target INR is achieved.*Switch from warfarin to apixaban 10mg twice daily for 7 days then 5mg twice daily*- **Direct Oral Anticoagulants (DOACs)** like apixaban are **contraindicated** in patients with **mechanical heart valves** due to an increased risk of stroke and valve thrombosis.- Clinical trials, such as the **RE-ALIGN trial**, have demonstrated significantly worse outcomes (increased thrombotic events and bleeding) when DOACs are used in this specific patient population.*Continue current warfarin dose and add low molecular weight heparin until INR >3.0 for 2 consecutive days*- Continuing the **current warfarin dose** is inappropriate because the patient developed a DVT, signifying **treatment failure** at the existing therapeutic level and target range.- The appropriate strategy for breakthrough thrombosis on warfarin is to **escalate the INR target** to a higher, more intense range, not simply to achieve a target within the previously failed range.*Double the warfarin dose immediately and check INR daily until therapeutic*- **Doubling the warfarin dose** immediately carries a high risk of significant **over-anticoagulation** and **bleeding** once the drug reaches a steady state, due to its variable patient response and delayed action.- This approach does not provide the **immediate anticoagulation** needed for an acute DVT; bridging with a rapid-acting anticoagulant like LMWH is crucial for acute management.*Start intravenous unfractionated heparin and continue current warfarin dose*- While **unfractionated heparin (UFH)** is an effective acute anticoagulant, **low molecular weight heparin (LMWH)** is generally preferred for DVT management in patients with stable renal function (eGFR 58 ml/min/1.73m²) due to its easier administration and predictable pharmacokinetics.- Similar to other incorrect options, continuing the **current warfarin dose** is inadequate as the patient's DVT indicates the need for a **higher INR target range** to prevent further thrombotic events.

Question 77: A 59-year-old man with type 2 diabetes is on basal-bolus insulin therapy (insulin glargine 36 units at bedtime and insulin aspart 12 units three times daily before meals). He reports recurrent hypoglycaemic episodes between 3-4 AM, with blood glucose readings of 2.8-3.2 mmol/L on multiple occasions. His bedtime glucose readings are typically 8-10 mmol/L and his pre-lunch and pre-dinner readings are well controlled at 5-7 mmol/L. What is the most appropriate modification to his insulin regimen?

A. Switch from once-daily to twice-daily insulin glargine dosing
B. Reduce his bedtime insulin glargine dose by 10-20% (Correct Answer)
C. Reduce his evening mealtime insulin aspart dose by 2-4 units
D. Increase his bedtime insulin glargine dose and advise a bedtime snack
E. Add a bedtime dose of rapid-acting insulin

Explanation: ***Reduce his bedtime insulin glargine dose by 10-20%***- The patient is experiencing recurrent **nocturnal hypoglycaemia** (3-4 AM) with low blood glucose readings, which directly indicates that the **basal insulin** (insulin glargine) dose administered at bedtime is excessive.- A dose reduction of **10-20%** is the most appropriate and safest initial step to prevent further hypoglycaemic episodes without significantly compromising overall glycemic control, especially since other readings are well-managed.*Switch from once-daily to twice-daily insulin glargine dosing*- While **splitting basal insulin** can sometimes improve glycemic control by providing more even coverage, it does not directly address the underlying issue of an **absolute excess** of basal insulin causing nocturnal hypoglycemia.- The primary goal here is to reduce the total effective basal insulin overnight, which is best achieved through a **dose reduction** rather than a dosing schedule change that might still lead to excess.*Reduce his evening mealtime insulin aspart dose by 2-4 units*- **Insulin aspart** is a **rapid-acting insulin** with a duration of action of typically 2-5 hours; therefore, its effect would have largely worn off by 3-4 AM.- Reducing the evening mealtime dose would primarily impact **post-dinner glucose levels** and would not prevent the early morning nocturnal hypoglycemia caused by the long-acting glargine.*Increase his bedtime insulin glargine dose and advise a bedtime snack*- Increasing the **insulin glargine dose** would exacerbate the already problematic **nocturnal hypoglycaemia** and significantly heighten the risk of severe adverse events.- Advising a **bedtime snack** is a compensatory measure for excessive insulin and can lead to unwanted **weight gain** and suboptimal long-term glycemic management rather than fixing the insulin imbalance.*Add a bedtime dose of rapid-acting insulin*- Adding a **rapid-acting insulin** dose at bedtime when glucose levels are already 8-10 mmol/L would likely cause immediate and dangerous **hypoglycaemia** much earlier in the night (e.g., within 1-3 hours of injection).- Bedtime rapid-acting insulin is typically used for specific correction doses when blood glucose is significantly elevated, which is not the case for this patient's bedtime readings.

Question 78: A 76-year-old woman with atrial fibrillation is on dabigatran 150mg twice daily. She is admitted with a large retroperitoneal haemorrhage. Her haemoglobin is 72 g/L (baseline 135 g/L), blood pressure 88/52 mmHg, and heart rate 118 bpm. She last took dabigatran 6 hours ago. Her renal function shows eGFR 42 ml/min/1.73m². What is the most appropriate specific reversal strategy for her anticoagulation?

A. Administer prothrombin complex concentrate (PCC) 50 units/kg
B. Administer intravenous vitamin K 10mg
C. Administer idarucizumab 5g intravenously (Correct Answer)
D. Arrange urgent haemodialysis to remove dabigatran
E. Administer tranexamic acid 1g intravenously

Explanation: ***Administer idarucizumab 5g intravenously***- **Idarucizumab** is a specific monoclonal antibody fragment that binds directly to **dabigatran**, rapidly and completely reversing its anticoagulant effect.- This immediate reversal is critical for patients with **life-threatening bleeding**, such as a **retroperitoneal haemorrhage** causing hemodynamic instability. *Administer prothrombin complex concentrate (PCC) 50 units/kg*- **PCC** is primarily used to reverse the effects of **vitamin K antagonists** (e.g., warfarin) or, less effectively, Factor Xa inhibitors.- It is not the specific or most effective reversal agent for **dabigatran**, as its mechanism does not directly counteract dabigatran's action. *Administer intravenous vitamin K 10mg*- **Vitamin K** is administered to reverse the effects of **warfarin** by promoting the synthesis of vitamin K-dependent clotting factors.- It has no role in reversing **dabigatran**, which is a **direct thrombin inhibitor** and does not interact with the vitamin K pathway. *Arrange urgent haemodialysis to remove dabigatran*- While **dabigatran** is partially dialyzable due to its low protein binding, **haemodialysis** is a slow process.- It is not an appropriate immediate strategy for an **acute, life-threatening bleed** requiring rapid reversal of anticoagulation. *Administer tranexamic acid 1g intravenously*- **Tranexamic acid** is an **antifibrinolytic** agent that inhibits fibrinolysis, helping to stabilize clots.- It does not reverse the underlying **anticoagulant effect** of dabigatran and is therefore not a specific reversal strategy, although it may be used as adjunctive therapy.

Question 79: A 43-year-old woman with newly diagnosed type 1 diabetes is being discharged on basal-bolus insulin therapy. She will use insulin degludec 22 units once daily and insulin aspart before each meal using a carbohydrate counting ratio of 1 unit per 10g carbohydrate. She asks about alcohol consumption. Which of the following represents the most appropriate advice regarding alcohol and insulin management?

A. Avoid alcohol completely as it unpredictably affects blood glucose levels
B. Alcohol increases blood glucose, so increase mealtime insulin dose by 20% when drinking
C. Alcohol can cause delayed hypoglycaemia, so reduce basal insulin dose on days when drinking
D. Alcohol inhibits gluconeogenesis and can cause delayed hypoglycaemia for up to 24 hours; have carbohydrate snack before bed (Correct Answer)
E. Alcohol has no effect on insulin requirements if consumed with food

Explanation: ***Alcohol inhibits gluconeogenesis and can cause delayed hypoglycaemia for up to 24 hours; have carbohydrate snack before bed*** - Alcohol consumption inhibits **hepatic gluconeogenesis**, which significantly increases the risk of **delayed hypoglycemia** long after the acute effects of the drink have worn off. - Patients on insulin should be advised to consume a **carbohydrate snack** before bed and never drink on an empty stomach to prevent nocturnal or next-day hypoglycemic episodes. *Avoid alcohol completely as it unpredictably affects blood glucose levels* - While alcohol does affect glucose levels, it is not necessary to **avoid it completely**; patients can drink in moderation if they follow safety precautions. - Complete avoidance is generally unrealistic for many patients and prevents them from learning how to manage **real-world scenarios** safely. *Alcohol increases blood glucose, so increase mealtime insulin dose by 20% when drinking* - Increasing insulin doses while drinking is dangerous because the predominant risk of alcohol in insulin-treated patients is **hypoglycemia**, not hyperglycemia. - Although sugary mixers may cause a transient rise, the metabolic effect of alcohol suppresses **liver glucose output**, making extra insulin a risk for severe reactions. *Alcohol can cause delayed hypoglycaemia, so reduce basal insulin dose on days when drinking* - Reducing the **basal insulin** (like degludec) is discouraged because it can lead to poor glycemic control and a risk of **diabetic ketoacidosis (DKA)**. - Management should focus on supplemental **carbohydrate intake** rather than adjusting the long-acting insulin dose which lasts for many hours beyond the metabolic window of the alcohol. *Alcohol has no effect on insulin requirements if consumed with food* - Even when consumed with food, alcohol still impairs the liver's ability to release glucose, potentially necessitating **less bolus insulin** or extra snacks. - Claiming it has **no effect** is medically inaccurate and dangerous, as it ignores the 24-hour window of increased **hypoglycemia risk**.

Question 80: A 68-year-old man with atrial fibrillation is established on apixaban 5mg twice daily. He develops cellulitis of his right leg and is prescribed flucloxacillin by his general practitioner. After 5 days of antibiotics, he presents with frank haematuria and bruising. His renal function shows eGFR has dropped from 65 ml/min/1.73m² to 38 ml/min/1.73m². What is the most appropriate immediate management of his anticoagulation?

A. Continue apixaban 5mg twice daily and monitor renal function in 1 week
B. Reduce apixaban to 2.5mg twice daily and recheck renal function in 48 hours
C. Stop apixaban immediately, give prothrombin complex concentrate
D. Stop apixaban temporarily until bleeding resolves and renal function stabilizes (Correct Answer)
E. Switch to warfarin with target INR 2-3

Explanation: ***Stop apixaban temporarily until bleeding resolves and renal function stabilizes*** - The patient presents with **frank haematuria** and **bruising**, indicating **active bleeding** while on an anticoagulant. This, combined with a significant **acute kidney injury (AKI)** (eGFR dropped from 65 to 38), means apixaban clearance is impaired, increasing drug accumulation and bleeding risk. - Temporarily stopping **apixaban** is crucial to allow the drug to be cleared (half-life ~12 hours) and to allow time for the **bleeding** to resolve and **renal function** to recover and stabilize, at which point the need for anticoagulation can be reassessed. *Continue apixaban 5mg twice daily and monitor renal function in 1 week* - Continuing a full dose of **apixaban** in the presence of **frank haematuria** and an acute drop in **renal function** is unsafe and will exacerbate the bleeding risk and renal impairment due to drug accumulation. - Waiting one week to monitor renal function is too long given the acute nature of the **AKI** and active bleeding; immediate action and closer monitoring are required. *Reduce apixaban to 2.5mg twice daily and recheck renal function in 48 hours* - While apixaban dose reduction is indicated for certain renal impairment criteria (e.g., eGFR 15-50 ml/min with other factors), this is for stable conditions, not for managing **active bleeding** and **acute kidney injury**. - In the setting of ongoing bleeding and impaired drug clearance, a temporary **cessation of apixaban** is necessary rather than a mere dose reduction, as reduction may still allow for further accumulation and bleeding. *Stop apixaban immediately, give prothrombin complex concentrate* - Stopping apixaban immediately is correct, but administering **prothrombin complex concentrate (PCC)** or specific reversal agents (like Andexanet alfa for apixaban) is typically reserved for **severe or life-threatening bleeding** (e.g., intracranial hemorrhage, hemodynamic instability). - While haematuria is significant, the scenario doesn't describe a life-threatening bleed requiring immediate full reversal. The primary step for non-life-threatening but active bleeding is to stop the anticoagulant and support the patient. *Switch to warfarin with target INR 2-3* - Switching to **warfarin** is inappropriate in this acute setting, as warfarin has a slow onset of action and would not address the immediate issues of **active bleeding** and **acute kidney injury**. - Furthermore, managing **warfarin** in a patient with fluctuating **renal function** and potential drug-drug interactions (e.g., with antibiotics affecting gut flora) would be complex and delay resolution of the acute problem.

Question 81: A 55-year-old woman with type 2 diabetes is admitted with acute coronary syndrome. She is normally managed on metformin 1g twice daily, sitagliptin 100mg once daily, and insulin glargine 40 units at bedtime. Her admission glucose is 14.2 mmol/L and HbA1c is 68 mmol/mol. She is scheduled for coronary angiography with possible percutaneous coronary intervention later today. Which modification to her diabetes medications is most appropriate prior to the procedure?

A. Continue all medications as normal and check glucose 2 hours post-procedure
B. Omit metformin on the day of procedure and for 48 hours afterwards, continue other medications (Correct Answer)
C. Stop insulin and metformin, continue sitagliptin only
D. Stop all oral medications, convert to variable rate intravenous insulin infusion
E. Continue metformin and insulin, omit sitagliptin on day of procedure

Explanation: ***Omit metformin on the day of procedure and for 48 hours afterwards, continue other medications***- **Metformin** should be withheld during procedures involving **iodinated contrast media** to prevent the risk of **lactic acidosis** if contrast-induced nephropathy occurs.- **Insulin glargine** (basal insulin) and **sitagliptin** (DPP-4 inhibitor) are typically continued to maintain glycemic control with a low risk of hypoglycemia.*Continue all medications as normal and check glucose 2 hours post-procedure*- Continuing **metformin** during **coronary angiography** is unsafe due to the potential for acute kidney injury and associated toxic accumulation of the drug.- Monitoring glucose alone does not address the physiological risks associated with **contrast media** and metformin interaction.*Stop insulin and metformin, continue sitagliptin only*- Stopping **basal insulin** (glargine) in a patient with type 2 diabetes managed on insulin can lead to severe **hyperglycemia** or ketoacidosis during the stress of a procedure.- **Metformin** must be stopped, but the omission of insulin is clinically inappropriate for maintaining stable peri-operative glucose levels.*Stop all oral medications, convert to variable rate intravenous insulin infusion*- A **variable rate intravenous insulin infusion (VRIII)** is generally reserved for patients with poor glycemic control who are fasting for long periods or are hemodynamically unstable.- This patient is undergoing a discrete procedure and can be managed by omitting **metformin** while continuing other medications to maintain safety.*Continue metformin and insulin, omit sitagliptin on day of procedure*- This approach is incorrect as it fails to address the high-risk medication, **metformin**, which is the priority for omission before **contrast exposure**.- Omission of **sitagliptin** is unnecessary as it does not carry the same systemic risks as metformin in the context of **angiography**.

Question 82: A 71-year-old man with atrial fibrillation on warfarin (target INR 2-3) attends for routine monitoring. His INR today is 4.8. He has no signs of bleeding. He had an INR of 2.6 two weeks ago and reports no changes to his diet or medications. According to British Society for Haematology guidelines, what is the most appropriate immediate management?

A. Withhold 1 dose of warfarin, reduce maintenance dose, repeat INR in 1 week
B. Withhold 2 doses of warfarin, give oral vitamin K 1-5mg, repeat INR the following day
C. Continue warfarin at same dose, repeat INR in 3 days
D. Withhold 1-2 doses of warfarin, repeat INR the following day, restart when INR <5.0 (Correct Answer)
E. Give intravenous vitamin K 10mg and withhold warfarin until INR <2.0

Explanation: ***Withhold 1-2 doses of warfarin, repeat INR the following day, restart when INR <5.0***- For an **INR between 4.5 and 8.0** without bleeding, British Society for Haematology (BSH) guidelines recommend **withholding 1-2 doses** of warfarin.- **Close monitoring** with a repeat INR the following day is crucial to ensure the INR is declining appropriately and to guide re-initiation when it is safely below 5.0.*Withhold 1 dose of warfarin, reduce maintenance dose, repeat INR in 1 week*- Waiting **1 week** for a repeat INR is too long and unsafe for an INR of 4.8, which is significantly elevated and requires more immediate follow-up.- While a **maintenance dose reduction** might be considered after the INR has normalized, the immediate priority is managing the acute elevation.*Withhold 2 doses of warfarin, give oral vitamin K 1-5mg, repeat INR the following day*- **Oral vitamin K** is generally reserved for INRs >8.0 without bleeding, or for an INR of 5.0-8.0 with minor bleeding.- Giving vitamin K unnecessarily can cause **warfarin resistance**, making subsequent anticoagulation management more challenging.*Continue warfarin at same dose, repeat INR in 3 days*- Continuing warfarin at the same dose is **contraindicated** as it would further increase the INR and significantly elevate the patient's risk of bleeding.- An INR of 4.8 necessitates immediate intervention, not just continued therapy, and requires closer monitoring than a **3-day interval**.*Give intravenous vitamin K 10mg and withhold warfarin until INR <2.0*- **Intravenous vitamin K 10mg** is reserved for cases of **major or life-threatening bleeding** or very high INRs (e.g., >8.0 with high bleeding risk).- Withholding warfarin until the INR is **<2.0** for a patient with atrial fibrillation leaves them at a high risk of **thromboembolic events**, as they would be sub-therapeutic for too long.

Question 83: A 47-year-old man with type 1 diabetes presents to the emergency department with a 2-day history of vomiting and diarrhoea. He has continued taking his usual insulin doses (insulin detemir 32 units twice daily and insulin aspart 10 units before meals) but has been unable to eat. His capillary blood glucose is 3.2 mmol/L and ketones are 0.4 mmol/L. What is the most appropriate immediate insulin management?

A. Continue basal insulin at current dose but omit all bolus insulin until eating normally
B. Reduce both basal and bolus insulin by 50% until symptoms resolve
C. Stop all insulin until the patient can tolerate oral intake
D. Continue basal insulin and give small doses of rapid-acting insulin with glucose drinks (Correct Answer)
E. Switch to variable rate intravenous insulin infusion

Explanation: ***Continue basal insulin and give small doses of rapid-acting insulin with glucose drinks*** - In **Type 1 Diabetes**, **basal insulin** must **never be stopped** during illness to prevent the rapid development of **diabetic ketoacidosis (DKA)**. - This approach aligns with "sick day rules" for managing illness: treating **hypoglycemia** with **glucose-containing drinks** while providing sufficient insulin to prevent **ketone production** and cover consumed carbohydrates. *Continue basal insulin at current dose but omit all bolus insulin until eating normally* - While **basal insulin** is crucial, omitting all **bolus insulin** when consuming glucose-containing fluids to manage hypoglycemia can lead to **hyperglycemia** and risk of **ketosis**. - Patients should be advised to take **small, adjusted bolus doses** of rapid-acting insulin to cover the carbohydrates from **liquid intake**. *Reduce both basal and bolus insulin by 50% until symptoms resolve* - A fixed **50% reduction** is an arbitrary and potentially insufficient adjustment, as illness can increase **insulin resistance** due to **stress hormones**, thus increasing insulin requirements. - Insulin adjustments during illness should be **dynamic** and guided by frequent **blood glucose** and **ketone monitoring**, rather than a blanket reduction. *Stop all insulin until the patient can tolerate oral intake* - Stopping all insulin is extremely dangerous for **Type 1 diabetics** and will rapidly lead to severe **diabetic ketoacidosis (DKA)** within hours, as the body cannot produce its own insulin. - Even without solid food intake, **basal insulin** is essential to regulate endogenous glucose production and prevent severe **lipolysis** and **ketogenesis**. *Switch to variable rate intravenous insulin infusion* - **Variable rate intravenous insulin infusion (VRIII)** is typically reserved for more severe conditions, such as persistent or uncontrollable vomiting, severe **DKA**, surgical procedures, or prolonged inability to tolerate oral intake. - For a patient who can potentially manage oral intake of glucose drinks and whose ketones are only slightly elevated, initial management typically involves **sick day rules** and close monitoring rather than immediate intravenous therapy.

Question 84: A 64-year-old woman with newly diagnosed atrial fibrillation and CHA₂DS₂-VASc score of 4 is being considered for anticoagulation. She has normal renal function (eGFR 78 ml/min/1.73m²) and no valvular heart disease. She expresses concern about the need for regular blood monitoring. Which of the following statements regarding direct oral anticoagulants (DOACs) versus warfarin is most accurate in this context?

A. DOACs require monthly INR monitoring but have fewer dietary restrictions than warfarin
B. DOACs do not require routine coagulation monitoring and have predictable pharmacokinetics (Correct Answer)
C. DOACs require weekly monitoring of anti-Xa levels for the first 3 months
D. DOACs have similar monitoring requirements to warfarin but shorter half-lives
E. DOACs require monthly renal function testing but no coagulation monitoring

Explanation: ***DOACs do not require routine coagulation monitoring and have predictable pharmacokinetics*** - **DOACs** provide a consistent anticoagulant response due to their **predictable pharmacokinetics**, which eliminates the need for routine **INR** or coagulation monitoring. - They are often preferred for patients with **non-valvular atrial fibrillation** who desire convenience and lack of **dietary restrictions** compared to warfarin. *DOACs require monthly INR monitoring but have fewer dietary restrictions than warfarin* - **INR monitoring** is specific to **Warfarin** (Vitamin K Antagonist) therapy to ensure the patient remains within the **therapeutic range**. - While DOACs do have fewer **dietary restrictions**, they do not use INR as a measurement of their therapeutic effect. *DOACs require weekly monitoring of anti-Xa levels for the first 3 months* - Routine monitoring of **anti-Xa levels** is not recommended for patients on DOACs such as **Apixaban** or **Rivaroxaban**. - Measurement of drug levels is only typically considered in **emergency situations**, such as major bleeding or prior to urgent surgery. *DOACs have similar monitoring requirements to warfarin but shorter half-lives* - The primary advantage of DOACs is that they have **significantly fewer monitoring requirements** compared to the frequent blood tests needed for warfarin. - While they do generally have **shorter half-lives**, their monitoring protocols are entirely distinct from the **INR-based** approach used for warfarin. *DOACs require monthly renal function testing but no coagulation monitoring* - While DOACs do require **renal function monitoring** because they are renally excreted, **monthly testing** is unnecessary for a patient with an **eGFR of 78**. - Guidelines generally recommend checking renal function at **initiation** and then **annually**, unless the patient is elderly or has known **chronic kidney disease**.

Question 85: A 52-year-old man with type 2 diabetes is established on a basal-bolus insulin regimen. He uses insulin glargine 24 units at bedtime and insulin lispro before meals. Which of the following statements best describes the pharmacokinetic profile of insulin lispro compared to regular human insulin?

A. Insulin lispro has a delayed onset of action of 60 minutes and duration of 6-8 hours
B. Insulin lispro has an onset of action within 15 minutes and duration of 2-5 hours (Correct Answer)
C. Insulin lispro has an onset of action of 30 minutes and duration of 8-10 hours
D. Insulin lispro has an onset of action within 15 minutes and duration of 12-24 hours
E. Insulin lispro has an onset of action of 45 minutes and duration of 4-6 hours

Explanation: ***Insulin lispro has an onset of action within 15 minutes and duration of 2-5 hours***- **Insulin lispro** is a **rapid-acting insulin analogue** designed to mimic the physiological postprandial insulin spike, starting to work within **15 minutes**.- Its shorter duration of **2-5 hours** reduces the risk of **late postprandial hypoglycemia** compared to regular human insulin.*Insulin lispro has a delayed onset of action of 60 minutes and duration of 6-8 hours*- This profile more closely resembles **regular (short-acting) human insulin**, which requires administration 30-60 minutes before meals.- **Insulin lispro** is specifically engineered to avoid this delay by preventing the formation of **hexamers**, allowing for faster absorption.*Insulin lispro has an onset of action of 30 minutes and duration of 8-10 hours*- An onset of 30 minutes is characteristic of **regular insulin**, but a duration of 8-10 hours is unusually long for any bolus insulin.- **Rapid-acting analogues** like lispro are cleared more quickly from the circulation, typically lasting no more than **5 hours**.*Insulin lispro has an onset of action within 15 minutes and duration of 12-24 hours*- While the onset matches lispro, a **12-24 hour duration** is characteristic of **long-acting basal insulins** like **glargine** or **detemir**.- Using a bolus insulin with such a long duration would lead to cumulative and dangerous **hypoglycemia** if dosed with every meal.*Insulin lispro has an onset of action of 45 minutes and duration of 4-6 hours*- An onset of 45 minutes is too slow for **lispro** and would not provide adequate coverage for immediate **postprandial glucose excursions**.- **Lispro** is intended for injection immediately before or even just after a meal due to its much faster **15-minute onset**.

Question 86: A 66-year-old man with atrial fibrillation on warfarin therapy presents for routine INR monitoring. His target INR is 2-3. Today's INR is 2.4. He reports starting a course of antibiotics from his general practitioner 3 days ago for a chest infection. Which antibiotic is most likely to require increased frequency of INR monitoring due to significant interaction with warfarin?

A. Amoxicillin
B. Doxycycline
C. Clarithromycin (Correct Answer)
D. Penicillin V
E. Azithromycin

Explanation: ***Clarithromycin*** - **Clarithromycin** is a potent inhibitor of the **CYP3A4** enzyme, which significantly reduces the metabolism of **warfarin**, leading to a dangerous rise in **INR** levels. - Due to this high-risk interaction, clinical guidelines mandate **increased frequency of INR monitoring** (typically within 3-5 days) to prevent spontaneous bleeding. *Amoxicillin* - While broad-spectrum antibiotics can theoretically alter **gut flora** and reduce vitamin K synthesis, **Amoxicillin** has a relatively low risk of significant warfarin interaction. - It does not inhibit the **cytochrome P450** system, making it a safer profile compared to macrolides, though routine caution is still advised. *Doxycycline* - **Doxycycline** can occasionally enhance the effect of warfarin by interfering with **prothrombin activity**, but the effect is generally less predictable and potent than enzyme inhibitors. - It is not considered a primary **CYP450 inhibitor**, so it rarely necessitates the same level of urgent monitoring as clarithromycin. *Penicillin V* - **Penicillin V** has no major pharmacokinetic interaction with warfarin as it does not interfere with its metabolic pathways in the **liver**. - It is frequently chosen for infections in anticoagulated patients because it is unlikely to cause a clinically significant **INR deviation**. *Azithromycin* - Although a macrolide, **Azithromycin** is unique because it does not significantly inhibit **CYP3A4**, resulting in a much lower risk of interaction than clarithromycin or erythromycin. - While caution is still recommended, it is generally preferred over other macrolides for patients on **warfarin therapy**.

Question 87: A 58-year-old woman with rheumatoid arthritis is started on methotrexate 15mg weekly. According to the British National Formulary guidance, which of the following represents the most appropriate monitoring schedule for this patient during the first 3 months of treatment?

A. Full blood count, renal function and liver function tests every 4 weeks
B. Full blood count and liver function tests every 2 weeks
C. Full blood count, renal function and liver function tests every 1-2 weeks (Correct Answer)
D. Full blood count every week and liver function tests every 2 weeks
E. Full blood count and renal function tests every 2 weeks, liver function tests every 4 weeks

Explanation: ***Full blood count, renal function and liver function tests every 1-2 weeks***- According to **BNF guidance**, patients starting **methotrexate** require monitoring of FBC, U&Es (renal function), and LFTs every **1–2 weeks** until the dose is stabilized.- This frequent monitoring during the first **3 months** is critical to detect early-onset side effects like **bone marrow suppression**, **hepatotoxicity**, and **renal impairment**.*Full blood count, renal function and liver function tests every 4 weeks*- This frequency is insufficient for the **initial stabilization phase** and does not meet the safety standards for high-risk drug initiation.- Monthly monitoring is typically reserved for patients who have already been on a **stable dose** for several months.*Full blood count and liver function tests every 2 weeks*- This option incorrectly omits **renal function tests (U&Es)**, which are vital as methotrexate is **renally excreted**.- **Renal impairment** can lead to toxic accumulation of methotrexate, making U&E monitoring mandatory alongside FBC and LFTs.*Full blood count every week and liver function tests every 2 weeks*- While frequent, the **BNF protocol** groups FBC, LFT, and renal function into the same monitoring interval rather than splitting them.- It also fails to explicitly emphasize the necessity of **renal function monitoring** at every check during the initiation period.*Full blood count and renal function tests every 2 weeks, liver function tests every 4 weeks*- Staggering the tests in this manner is inconsistent with clinical guidelines which require **simultaneous assessment** of all three parameters.- Delaying **LFT monitoring** to every 4 weeks during the first 3 months increases the risk of missing early signs of **drug-induced liver injury**.

Question 88: A 67-year-old woman with atrial fibrillation has been stable on warfarin for 18 months with target INR 2-3. She requires antibiotic treatment for a urinary tract infection. Her recent INR was 2.6. Which of the following antibiotics poses the highest risk of significantly increasing her INR through pharmacokinetic interaction with warfarin?

A. Nitrofurantoin 100mg twice daily for 7 days
B. Trimethoprim 200mg twice daily for 7 days (Correct Answer)
C. Cefalexin 500mg three times daily for 7 days
D. Fosfomycin 3g single dose
E. Pivmecillinam 400mg three times daily for 7 days

Explanation: ***Trimethoprim 200mg twice daily for 7 days*** - **Trimethoprim** is a potent inhibitor of the **CYP2C9** enzyme, which is the primary metabolic pathway for the more active **S-warfarin** isomer. - This pharmacokinetic interaction significantly elevates plasma warfarin levels and the **INR**, posing a high risk of clinically significant bleeding. *Nitrofurantoin 100mg twice daily for 7 days* - **Nitrofurantoin** has no significant clinical interaction with the **cytochrome P450** system and does not typically affect warfarin metabolism. - It is generally considered a **safe choice** for treating or preventing UTIs in patients stabilized on warfarin. *Cefalexin 500mg three times daily for 7 days* - **Cefalexin**, like many broad-spectrum cephalosporins, may cause a slight increase in INR by reducing **Vitamin K-producing gut flora**, but this effect is usually mild. - Unlike trimethoprim, it does not involve a direct **pharmacokinetic inhibition** of warfarin metabolism, making it a lower risk option. *Fosfomycin 3g single dose* - **Fosfomycin** is a phosphonic acid derivative that lacks significant **enzyme inhibition** or induction properties regarding the CYP450 system. - The **single-dose administration** further minimizes the potential for any sustained or significant change in the patient's steady-state INR. *Pivmecillinam 400mg three times daily for 7 days* - **Pivmecillinam** is a penicillin derivative with highly targeted activity and has **not been associated** with major pharmacokinetic interactions involving warfarin. - While minor changes in Vitamin K synthesis are theoretically possible with any penicillin, the risk is clinically **negligible** compared to trimethoprim.

Question 89: A 49-year-old man with type 2 diabetes for 12 years is admitted with hypoglycaemia (blood glucose 2.1 mmol/L). He is conscious and able to swallow. His medications include insulin detemir 38 units at bedtime, insulin aspart 12 units with each meal, metformin 1g twice daily, and gliclazide 80mg twice daily. After initial treatment with oral glucose, his blood glucose stabilizes at 6.8 mmol/L. What is the most appropriate medication review to prevent recurrence?

A. Reduce insulin detemir dose by 20% as basal insulin is likely cause of overnight hypoglycaemia
B. Discontinue gliclazide as sulfonylureas add limited benefit to insulin therapy and increase hypoglycaemia risk substantially (Correct Answer)
C. Reduce all insulin doses by 10% and continue all oral medications
D. Discontinue metformin as it can potentiate insulin action and cause hypoglycaemia
E. Switch gliclazide to a DPP-4 inhibitor as they have lower hypoglycaemia risk

Explanation: ***Discontinue gliclazide as sulfonylureas add limited benefit to insulin therapy and increase hypoglycaemia risk substantially***- **Sulfonylureas** stimulate endogenous insulin secretion, which offers minimal cumulative benefit once a patient is established on a full **basal-bolus insulin** regimen.- Discontinuing this class significantly reduces the risk of **recurrent hypoglycaemia** and rationalizes treatment by removing unnecessary polypharmacy.*Reduce insulin detemir dose by 20% as basal insulin is likely cause of overnight hypoglycaemia*- While adjusting basal insulin may be necessary later, the **priority** is removing a drug class (Sulfonylurea) that is generally redundant once insulin is optimized.- The question does not specify the timing of the event; solely reducing insulin without addressing **gliclazide** leaves the patient at continued risk.*Reduce all insulin doses by 10% and continue all oral medications*- Simply reducing insulin doses is a reactive measure that fails to address the underlying **安全 risk** posed by combining secretagogues with exogenous insulin.- Continuing **sulfonylureas** alongside intensive insulin therapy is generally discouraged due to the high risk/low benefit ratio.*Discontinue metformin as it can potentiate insulin action and cause hypoglycaemia*- **Metformin** works by improving insulin sensitivity and inhibiting gluconeogenesis; it does not typically cause hypoglycaemia as single therapy.- Metformin should be **continued** in most type 2 diabetics on insulin because it provides cardiovascular benefits and helps limit weight gain.*Switch gliclazide to a DPP-4 inhibitor as they have lower hypoglycaemia risk*- While **DPP-4 inhibitors** have a lower hypoglycaemia profile, most patients on a basal-bolus regimen do not require additional agents beyond metformin.- Adding another agent instead of **rationalizing therapy** adds unnecessary cost and complexity without clear clinical benefit for this patient.

Question 90: A 58-year-old woman with rheumatoid arthritis has been taking methotrexate 20mg once weekly for 3 years with good disease control. She develops a severe chest infection and her GP prescribes co-amoxiclav. Three days later she is admitted with mouth ulcers, sore throat, fever, and lethargy. Blood tests show: WBC 1.8 × 10⁹/L (neutrophils 0.4 × 10⁹/L), Hb 102 g/L, platelets 98 × 10⁹/L. What is the most likely explanation for her presentation?

A. Coincidental viral infection causing transient bone marrow suppression
B. Co-amoxiclav has displaced methotrexate from protein binding sites, increasing free drug concentration and toxicity
C. The patient has inadvertently taken methotrexate daily instead of weekly during her illness (Correct Answer)
D. Co-amoxiclav has reduced renal excretion of methotrexate, leading to accumulation and toxicity
E. Rheumatoid arthritis disease flare has caused reactive bone marrow suppression

Explanation: ***The patient has inadvertently taken methotrexate daily instead of weekly during her illness***- Inadvertent **daily administration** of methotrexate is a major cause of severe **pancytopenia** and **mucositis** (mouth ulcers, sore throat), as it inhibits dihydrofolate reductase and prevents DNA synthesis in rapidly dividing cells.- High-risk prescribing errors often occur during acute illnesses when patients become confused about **weekly dosing schedules**, leading to life-threatening **bone marrow suppression**.*Coincidental viral infection causing transient bone marrow suppression*- While some viruses (like Parvovirus B19) can cause marrow suppression, they typically cause a **pure red cell aplasia** rather than global pancytopenia with severe mucositis as seen here.- The temporal relationship with an acute illness and long-term **methotrexate** use makes drug toxicity a much more probable cause for these symptoms.*Co-amoxiclav has displaced methotrexate from protein binding sites, increasing free drug concentration and toxicity*- Methotrexate is significantly bound to **albumin**, but protein displacement by co-amoxiclav is not a clinically significant mechanism for acute, severe **methotrexate toxicity** at this dosage.- Drug interactions based on protein binding are generally less dangerous than those affecting **renal excretion** or metabolic pathways for methotrexate.*Co-amoxiclav has reduced renal excretion of methotrexate, leading to accumulation and toxicity*- While some antibiotics like **Trimethoprim** or **Penicillins** can compete for **renal tubular secretion** of methotrexate, this interaction is rarely severe enough to cause rapid-onset, profound pancytopenia and mucositis at low rheumatological doses of methotrexate.- Clinical guidelines suggest this interaction is more relevant with **high-dose methotrexate** used in oncology or in patients with underlying **renal impairment**.*Rheumatoid arthritis disease flare has caused reactive bone marrow suppression*- A rheumatoid flare usually causes **anemia of chronic disease** (normocytic/microcytic) and sometimes **thrombocytosis**, rather than profound **neutropenia** and **thrombocytopenia**.- Systemic features like severe **mouth ulcers** and **pancytopenia** are highly characteristic of methotrexate toxicity, not typically a direct manifestation of an RA flare itself.

Question 91: A 66-year-old man with non-valvular atrial fibrillation (CHA₂DS₂-VASc score 4) is on edoxaban 60mg once daily. He develops progressive chronic kidney disease, and his most recent eGFR is 28 ml/min/1.73m². His weight is 72kg and he has no other comorbidities. What is the most appropriate adjustment to his anticoagulation?

A. Continue edoxaban 60mg once daily as dose reduction is only needed below eGFR 15 ml/min/1.73m²
B. Reduce edoxaban dose to 30mg once daily (Correct Answer)
C. Switch to apixaban 2.5mg twice daily as it is safer in renal impairment
D. Switch to warfarin as DOACs should be avoided in CKD stage 4
E. Stop anticoagulation as bleeding risk outweighs stroke risk at this level of renal function

Explanation: ***Reduce edoxaban dose to 30mg once daily*** - For patients with **non-valvular atrial fibrillation**, the standard dose of **edoxaban** (60mg) must be reduced to **30mg once daily** if the **creatinine clearance (or eGFR)** is between **15-50 ml/min**. - This patient's **eGFR of 28 ml/min/1.73m²** falls within this range, necessitating a dose reduction to maintain therapeutic levels and minimize **bleeding risk**. *Continue edoxaban 60mg once daily as dose reduction is only needed below eGFR 15 ml/min/1.73m²* - Maintaining the full **60mg dose** in the presence of **moderate renal impairment** (eGFR 28 ml/min) significantly increases the risk of **drug accumulation** and **major bleeding**. - **Edoxaban** dose reduction is required for an eGFR of **15-50 ml/min**, not just below 15 ml/min, where it is contraindicated. *Switch to apixaban 2.5mg twice daily as it is safer in renal impairment* - **Apixaban** dose reduction to 2.5mg twice daily is indicated only if the patient meets at least two of the following: **age ≥80 years**, **weight ≤60 kg**, or **serum creatinine ≥1.5 mg/dL**. - This patient (age 66, weight 72kg, eGFR 28 ml/min) does not meet these specific criteria, making a switch unnecessary when **edoxaban** can be appropriately adjusted. *Switch to warfarin as DOACs should be avoided in CKD stage 4* - **DOACs** are generally preferred over **warfarin** for non-valvular AF, even in **CKD stage 4** (eGFR 15-29 ml/min), provided accurate **dose adjustments** are made. - **Warfarin** is typically reserved for patients with specific conditions like **mechanical heart valves** or when eGFR is below 15 ml/min (End-Stage Renal Disease). *Stop anticoagulation as bleeding risk outweighs stroke risk at this level of renal function* - A **CHA₂DS₂-VASc score of 4** indicates a **high annual stroke risk** (~4%) that generally outweighs the bleeding risk in patients with stable CKD, making continued anticoagulation crucial. - **Chronic kidney disease** is an independent risk factor for both **stroke and bleeding**, necessitating careful **anticoagulation dose management** rather than cessation.

Question 92: A 41-year-old woman with type 1 diabetes on insulin pump therapy (continuous subcutaneous insulin infusion) is admitted with acute pyelonephritis. She is alert, tolerating oral fluids, and maintaining her oral intake. Her blood glucose is 14.2 mmol/L and capillary ketones are 0.8 mmol/L. What is the most appropriate insulin management during her admission?

A. Continue insulin pump therapy with increased basal and bolus rates to account for infection (Correct Answer)
B. Discontinue pump and convert to variable rate intravenous insulin infusion
C. Discontinue pump and convert to basal-bolus subcutaneous insulin regimen
D. Continue pump but add supplementary subcutaneous rapid-acting insulin for correction
E. Continue pump unchanged as ketones are not significantly elevated

Explanation: ***Continue insulin pump therapy with increased basal and bolus rates to account for infection***- Patients on **continuous subcutaneous insulin infusion (CSII)** should continue their therapy during illness if they are **alert**, tolerating oral intake, and able to **self-manage** the device.- Acute infection increases **insulin resistance** and counter-regulatory hormones, necessitating an **increase in basal and bolus rates** to maintain glycemic control and prevent ketoacidosis.*Discontinue pump and convert to variable rate intravenous insulin infusion*- **Variable rate intravenous insulin infusion (VRIII)** is only indicated if the patient is **vomiting**, unable to eat, has a reduced level of consciousness, or is undergoing **major surgery**.- This patient is alert and tolerating fluids, so transitioning to intravenous therapy unnecessarily complicates management and increases the risk of **glycemic instability**.*Discontinue pump and convert to basal-bolus subcutaneous insulin regimen*- Switching to a **basal-bolus regimen** is unnecessary when the patient's existing pump therapy is effective and they are capable of managing it.- Disrupting established **pump therapy** can be distressing for the patient and often leads to poorer control during the transition period.*Continue pump but add supplementary subcutaneous rapid-acting insulin for correction*- Giving separate injections while the pump is running increases the risk of **insulin stacking**, which can lead to severe **hypoglycemia**.- Dose adjustments for hyperglycemia should be managed through the **pump's bolus calculator** or by temporary basal rate increases rather than supplementary injections.*Continue pump unchanged as ketones are not significantly elevated*- Leaving the pump rates unchanged during an infection is inappropriate because **pro-inflammatory cytokines** elevate blood glucose regardless of ketone levels.- A **blood glucose of 14.2 mmol/L** and the presence of ketones (0.8 mmol/L) indicate that current insulin delivery is insufficient to meet the body's **increased metabolic demands**.

Question 93: A 73-year-old man with mechanical aortic valve replacement on warfarin (target INR 2.5-3.5) presents with melaena. His INR is 7.2 and haemoglobin is 74 g/L (baseline 135 g/L). He is haemodynamically stable (BP 128/76 mmHg, HR 88 bpm). Upper GI endoscopy is planned. What is the most appropriate immediate management of his anticoagulation?

A. Stop warfarin and give oral vitamin K 1-3mg; repeat INR in 24 hours
B. Stop warfarin, give intravenous vitamin K 5mg, and arrange urgent endoscopy once INR normalises (Correct Answer)
C. Stop warfarin, give prothrombin complex concentrate and intravenous vitamin K 5mg for immediate reversal
D. Stop warfarin and arrange urgent endoscopy without reversal as he is haemodynamically stable
E. Continue warfarin at reduced dose as cessation risks valve thrombosis

Explanation: ***Stop warfarin, give intravenous vitamin K 5mg, and arrange urgent endoscopy once INR normalises*** - The patient has **major bleeding** (melaena with significant haemoglobin drop) but is **haemodynamically stable**, making intravenous vitamin K the appropriate choice for rapid reversal (within 6-12 hours). - Reversing the INR to a safer level before endoscopy is crucial to minimize the risk of **procedural bleeding**, while avoiding the immediate and complete reversal of PCC which carries a higher **thromboembolic risk** for mechanical valves. *Stop warfarin and give oral vitamin K 1-3mg; repeat INR in 24 hours* - **Oral vitamin K** has a slower onset of action and is typically used for **non-bleeding** or **minor bleeding** scenarios with elevated INR, not active melaena with a significant Hb drop. - Waiting 24 hours to recheck INR is too long for a patient with **active gastrointestinal bleeding** and an INR of 7.2, as this delays necessary intervention and increases bleeding risk. *Stop warfarin, give prothrombin complex concentrate and intravenous vitamin K 5mg for immediate reversal* - **Prothrombin complex concentrate (PCC)** provides immediate reversal but carries a higher risk of **thromboembolic events**, particularly with mechanical heart valves. - PCC is generally reserved for **life-threatening bleeding** or intracranial hemorrhage. Since the patient is **haemodynamically stable**, the immediate thrombotic risks of PCC outweigh its benefit in this specific context. *Stop warfarin and arrange urgent endoscopy without reversal as he is haemodynamically stable* - Performing an **endoscopy** with an INR of 7.2 carries an unacceptably high risk of **uncontrolled bleeding**, especially if therapeutic interventions like biopsy or cautery are required. - While currently stable, the significant **haemoglobin drop** indicates serious bleeding that necessitates correction of the coagulopathy before any invasive procedure. *Continue warfarin at reduced dose as cessation risks valve thrombosis* - Continuing **warfarin** in a patient with an INR of 7.2 and active **melaena** is contraindicated, as it will exacerbate bleeding and could lead to a life-threatening hemorrhage. - The immediate risk of severe bleeding from over-anticoagulation far outweighs the theoretical risk of **valve thrombosis** from temporary warfarin cessation in this acute situation.

Question 94: A 55-year-old woman with type 2 diabetes is on a basal-bolus insulin regimen (insulin glargine 32 units at bedtime, insulin lispro 8 units with each meal). She is scheduled for elective laparoscopic cholecystectomy as the first case in the morning. What is the most appropriate perioperative insulin management?

A. Omit morning rapid-acting insulin, give usual basal insulin, convert to variable rate intravenous insulin infusion perioperatively (Correct Answer)
B. Omit all insulin on the day of surgery and commence sliding scale when blood glucose exceeds 12 mmol/L
C. Give 50% of usual basal insulin on morning of surgery, omit rapid-acting insulin, start variable rate insulin infusion
D. Continue all usual insulin doses and schedule surgery after lunch
E. Give usual basal insulin the night before but omit morning dose, commence intravenous insulin at induction

Explanation: ***Omit morning rapid-acting insulin, give usual basal insulin, convert to variable rate intravenous insulin infusion perioperatively***- For a patient on a **basal-bolus** regimen, the **basal insulin** (glargine) should be continued to provide background coverage and prevent **ketoacidosis** while nil by mouth.- **Rapid-acting insulin** (lispro) is omitted because the patient will not be consuming a meal, and a **Variable Rate Intravenous Insulin Infusion (VRIII)** ensures precise glucose control during the surgical stress response.*Omit all insulin on the day of surgery and commence sliding scale when blood glucose exceeds 12 mmol/L*- Omitting all insulin is dangerous as it can lead to **hyperglycemia** and life-threatening **diabetic ketoacidosis (DKA)**, even in Type 2 diabetics under stress.- Waiting for glucose to exceed 12 mmol/L before acting is reactive rather than **proactive management**, leading to poor glycemic control during surgery.*Give 50% of usual basal insulin on morning of surgery, omit rapid-acting insulin, start variable rate insulin infusion*- Cutting the **basal dose by 50%** is generally unnecessary for patients with stable Type 2 diabetes and may result in inadequate background insulin levels.- Current guidelines recommend continuing the **full dose** of long-acting analogues like glargine to maintain metabolic stability and prevent hyperglycemia.*Continue all usual insulin doses and schedule surgery after lunch*- Continuing **bolus insulin** doses while the patient is fasting for surgery would cause severe **hypoglycemia** due to lack of carbohydrate intake.- Delaying surgery until after lunch is inappropriate for **pre-operative fasting protocols** and disrupts efficient theatre scheduling for elective cases.*Give usual basal insulin the night before but omit morning dose, commence intravenous insulin at induction*- The **morning dose** of basal insulin should not be omitted if it is usually taken then, as continuous basal coverage is essential to prevent metabolic decompensation, especially during surgical stress.- Waiting until **anaesthetic induction** to start insulin management may be too late to control the elevation in blood glucose caused by the **surgical stress response**, leading to hyperglycemia before surgery even begins.

Question 95: A 68-year-old man with atrial fibrillation on apixaban 5mg twice daily requires emergency surgery for a perforated duodenal ulcer. His last dose of apixaban was 8 hours ago. His renal function is normal (eGFR 68 ml/min/1.73m²). What is the most appropriate approach to managing his anticoagulation perioperatively?

A. Proceed to surgery immediately; apixaban effect is minimal at 8 hours
B. Delay surgery for 24 hours after last apixaban dose to minimise bleeding risk
C. Administer idarucizumab to reverse anticoagulation before surgery
D. Proceed to surgery and consider prothrombin complex concentrate (PCC) if significant bleeding occurs (Correct Answer)
E. Give vitamin K 10mg intravenously before proceeding to surgery

Explanation: ***Proceed to surgery and consider prothrombin complex concentrate (PCC) if significant bleeding occurs*** - A **perforated duodenal ulcer** is a life-threatening emergency requiring immediate surgical intervention; delaying surgery to allow for apixaban washout is not an option. - Although **andexanet alfa** is the specific reversal agent for Factor Xa inhibitors, **four-factor Prothrombin Complex Concentrate (PCC)** is a widely available and recommended option to manage severe or life-threatening bleeding in patients on apixaban when specific agents are unavailable or in an emergency setting. *Proceed to surgery immediately; apixaban effect is minimal at 8 hours* - Apixaban has a half-life of approximately **12 hours**, meaning a substantial anticoagulant effect is still present 8 hours after the last dose, not a minimal one. - While surgery must proceed immediately due to the emergency, the surgical team must be prepared for **increased bleeding risk** and have strategies in place to manage it. *Delay surgery for 24 hours after last apixaban dose to minimise bleeding risk* - Delaying surgery for a **perforated viscus** will significantly increase the risk of **peritonitis, sepsis, and mortality**. - The recommended 24-48 hour interruption for apixaban before surgery is appropriate for **elective procedures**, not for urgent or emergent interventions. *Administer idarucizumab to reverse anticoagulation before surgery* - **Idarucizumab** is the specific reversal agent for **dabigatran**, a direct thrombin inhibitor. - It is completely ineffective against **apixaban**, which is a direct Factor Xa inhibitor, and thus would provide no benefit. *Give vitamin K 10mg intravenously before proceeding to surgery* - **Vitamin K** is used to reverse the anticoagulant effects of **warfarin** by increasing the synthesis of Vitamin K-dependent clotting factors. - It has no mechanism of action or effect on **Direct Oral Anticoagulants (DOACs)** like apixaban, which directly inhibit specific clotting factors.

Question 96: A 37-year-old woman with type 1 diabetes for 18 years is admitted with severe vomiting and abdominal pain. Her capillary blood glucose is 22.4 mmol/L and capillary ketones are 4.8 mmol/L. Arterial blood gas shows pH 7.24, bicarbonate 12 mmol/L. She is diagnosed with diabetic ketoacidosis. Her usual insulin is insulin aspart three times daily with meals and insulin glargine at bedtime. What is the most appropriate initial insulin management?

A. Continue her usual basal-bolus regimen and add intravenous insulin infusion
B. Stop all subcutaneous insulin and commence fixed-rate intravenous insulin infusion at 0.1 units/kg/hour
C. Stop rapid-acting insulin, continue basal insulin, and start fixed-rate intravenous insulin infusion (Correct Answer)
D. Double her usual insulin doses and administer subcutaneously
E. Give stat dose of 10 units rapid-acting insulin subcutaneously then reassess

Explanation: ***Stop rapid-acting insulin, continue basal insulin, and start fixed-rate intravenous insulin infusion***- Current guidelines recommend commencing a **fixed-rate intravenous insulin infusion (FRIII)** at 0.1 units/kg/hour to manage acute DKA effectively, allowing precise titration.- **Basal insulin** (e.g., glargine) should be continued to provide a background level of insulin, preventing **rebound hyperglycemia** and ketosis when the IV infusion is eventually discontinued or transitioning to subcutaneous insulin.*Continue her usual basal-bolus regimen and add intravenous insulin infusion*- Continuing **rapid-acting mealtime insulin** (aspart) is inappropriate as the patient is symptomatic with vomiting and likely **nil by mouth (NBM)**.- Using both IV insulin and subcutaneous bolus insulin simultaneously increases the risk of unpredictable and dangerous **hypoglycemia** and makes insulin titration challenging.*Stop all subcutaneous insulin and commence fixed-rate intravenous insulin infusion at 0.1 units/kg/hour*- While FRIII is the standard of care for DKA, stopping **basal insulin** is an outdated practice that can lead to a gap in insulin coverage and complicate the transition back to subcutaneous therapy.- Maintaining the long-acting insulin during the acute phase ensures better **glycemic stability** and prevents a sudden drop in insulin levels once the IV infusion is tapered.*Double her usual insulin doses and administer subcutaneously*- **Subcutaneous insulin** is unreliable for treating severe DKA due to poor peripheral perfusion, especially in dehydrated patients, and does not allow for the rapid and precise titration provided by the **intravenous route**.- Simply doubling the dose does not address the underlying pathophysiology of DKA, which requires a controlled **fixed-rate infusion** to suppress ketogenesis and manage hyperglycemia.*Give stat dose of 10 units rapid-acting insulin subcutaneously then reassess*- A stat dose of subcutaneous insulin is insufficient and delays the initiation of the necessary **weight-based IV insulin infusion**, which is critical for rapid correction of DKA.- This approach fails to address the systemic emergency of DKA, including the severe **metabolic acidosis** and electrolyte disturbances that require continuous and controlled insulin administration.

Question 97: A 52-year-old woman with newly diagnosed deep vein thrombosis is commenced on rivaroxaban. She weighs 58kg and has normal renal function (eGFR 78 ml/min/1.73m²). She is also taking carbamazepine 400mg twice daily for epilepsy. What is the most appropriate anticoagulation regimen?

A. Rivaroxaban 15mg twice daily for 21 days, then 20mg once daily
B. Rivaroxaban 15mg twice daily for 21 days, then 15mg once daily due to weight <60kg
C. Switch to apixaban as it has less drug interaction with carbamazepine
D. Continue rivaroxaban but avoid concurrent use; seek alternative anticoagulation (Correct Answer)
E. Rivaroxaban 20mg twice daily for 21 days to compensate for enzyme induction

Explanation: ***Continue rivaroxaban but avoid concurrent use; seek alternative anticoagulation***- **Carbamazepine** is a potent **CYP3A4** and **P-glycoprotein inducer**, which significantly reduces the plasma concentration of **Direct Oral Anticoagulants (DOACs)** like rivaroxaban.- Because the reduction in efficacy increases the risk of **thromboembolism** and cannot be reliably monitored, DOACs should be avoided in favor of agents like **warfarin** (where the interaction can be managed via **INR monitoring**) or LMWH.*Rivaroxaban 15mg twice daily for 21 days, then 20mg once daily*- While this is the standard loading and maintenance dose for acute **DVT**, it is inappropriate here due to the severe drug-drug interaction with **carbamazepine**.- Using standard dosing in the presence of a strong inducer leads to **subtherapeutic levels** and potential treatment failure.*Rivaroxaban 15mg twice daily for 21 days, then 15mg once daily due to weight <60kg*- Dose reduction for **weight <60kg** is specifically indicated for **apixaban** (if other criteria are met) or **edoxaban**, but is not the standard protocol for rivaroxaban in DVT treatment.- Reducing the dose further in a patient taking an **enzyme inducer** would dangerously exacerbate the risk of recurrent thrombosis.*Switch to apixaban as it has less drug interaction with carbamazepine*- All currently available DOACs, including **apixaban**, are substrates of **P-gp** and **CYP3A4**, meaning they are all significantly affected by carbamazepine.- Switching from one DOAC to another does not resolve the interaction; an alternative class like **VKA (warfarin)** is required.*Rivaroxaban 20mg twice daily for 21 days to compensate for enzyme induction*- Increasing the DOAC dose to compensate for induction is not clinically validated, as the degree of **metabolic induction** varies widely between individuals.- There is no routine way to monitor the **anticoagulant effect** of rivaroxaban to ensure a higher dose is safe or sufficient.

Question 98: A 64-year-old man with atrial fibrillation is on rivaroxaban 20mg once daily. He develops acute bacterial meningitis and requires treatment with rifampicin. Understanding drug interactions with DOACs, what is the most appropriate management of his anticoagulation?

A. Continue rivaroxaban at current dose as no significant interaction exists
B. Increase rivaroxaban dose to 30mg once daily to compensate for reduced levels
C. Switch to warfarin and monitor INR closely during rifampicin treatment (Correct Answer)
D. Stop anticoagulation temporarily until rifampicin course is completed
E. Switch to dabigatran as it is not affected by rifampicin

Explanation: ***Switch to warfarin and monitor INR closely during rifampicin treatment*** - **Rifampicin** is a potent inducer of **P-glycoprotein (P-gp)** and **CYP3A4**, which significantly reduces the plasma concentration of **rivaroxaban**, leading to a sub-therapeutic effect and increased **stroke risk**. - Unlike DOACs, the effect of rifampicin on **warfarin** metabolism can be safely managed because the anticoagulant effect is easily measurable via **INR monitoring**, allowing for precise dose adjustments. *Continue rivaroxaban at current dose as no significant interaction exists* - A major interaction exists; **rifampicin** can reduce **rivaroxaban** levels by up to 50% by inducing **P-gp** and **CYP3A4**, making it highly likely the patient will be under-anticoagulated. - Modern guidelines explicitly recommend avoiding the co-administration of **DOACs** with potent **enzyme inducers** like rifampicin due to the risk of **thromboembolism**. *Increase rivaroxaban dose to 30mg once daily to compensate for reduced levels* - There is no clinical evidence or licensed protocol for **dose-escalation** of rivaroxaban to overcome drug-drug interactions with potent inducers. - Increasing the dose without the ability to monitor **therapeutic drug levels** (unlike **INR** for **warfarin**) puts the patient at an unquantified risk of either **thrombosis** due to inadequate levels or **bleeding** from unpredictable high levels. *Stop anticoagulation temporarily until rifampicin course is completed* - This patient has **atrial fibrillation** and is at significant risk of a **thromboembolic stroke** if anticoagulation is discontinued, especially during an acute illness like **meningitis** which can increase hypercoagulability. - Temporary cessation is only appropriate for high-risk surgical procedures and is not a valid strategy for managing long-term **drug interactions** where anticoagulation is still required. *Switch to dabigatran as it is not affected by rifampicin* - This is incorrect as **dabigatran** is a major substrate of the **P-glycoprotein** efflux transporter, which is strongly induced by **rifampicin**. - Concurrent use of **rifampicin** and **dabigatran** results in a marked decrease in **dabigatran exposure**, similar to the effect seen with factor Xa inhibitors like rivaroxaban, leading to a loss of anticoagulation.

Question 99: A 71-year-old woman with type 2 diabetes on insulin glargine 26 units at bedtime and metformin 1g twice daily presents with a painful diabetic foot ulcer. She is started on oral antibiotics but reports poor oral intake due to nausea. Her capillary blood glucose readings over the past 24 hours range from 4.2 to 6.8 mmol/L. What is the most appropriate approach to her insulin management?

A. Continue current insulin dose unchanged as infection increases insulin requirements
B. Reduce insulin glargine to 50% of usual dose due to reduced oral intake and risk of hypoglycaemia (Correct Answer)
C. Stop insulin temporarily until oral intake improves
D. Switch to sliding scale insulin until the acute illness resolves
E. Increase insulin dose by 20% to account for infection-related insulin resistance

Explanation: ***Reduce insulin glargine to 50% of usual dose due to reduced oral intake and risk of hypoglycaemia***- Although infection usually increases insulin resistance, the patient's **poor oral intake** and current glucose levels (4.2-6.8 mmol/L) create a significant risk of **hypoglycaemia**.- A **50% dose reduction** of basal insulin is a safe strategy to prevent low blood sugar while maintaining a baseline metabolic requirement during acute illness.*Continue current insulin dose unchanged as infection increases insulin requirements*- While **systemic infection** increases metabolic demands, this patient is already at the lower end of the target range (**4.2 mmol/L**) while eating poorly.- Continuing the full dose of **26 units** without adequate carbohydrate intake would likely result in symptomatic hypoglycemia.*Stop insulin temporarily until oral intake improves*- Basal insulin should **never be stopped** in patients who require it, as a complete lack of insulin can lead to **metabolic decompensation** or ketoacidosis.- Even during fasting, the body requires **basal insulin** to suppress hepatic glucose production and ketogenesis.*Switch to sliding scale insulin until the acute illness resolves*- **Sliding scale insulin** as a monotherapy is generally discouraged because it is reactive rather than proactive, leading to **glycaemic variability**.- It is typically reserved for specialized inpatient settings or **perioperative care**, not as a substitute for appropriate basal insulin adjustment in this scenario.*Increase insulin dose by 20% to account for infection-related insulin resistance*- Increasing the dose is dangerous here because the patient's blood glucose is already **near-normal**, indicating that her current intake cannot sustain more insulin.- While **sick day rules** often suggest increasing doses for hyperglycemia during infection, they mandate a **dose reduction** if blood glucose levels are low or if intake is severely restricted.

Question 100: A 46-year-old man with epilepsy is established on phenytoin 300mg daily. He attends for routine monitoring. His recent phenytoin level is 18 mg/L (therapeutic range 10-20 mg/L), but he reports mild ataxia and diplopia. What is the most appropriate explanation for these symptoms?

A. These symptoms are unrelated to phenytoin as the level is therapeutic
B. Phenytoin exhibits zero-order kinetics, so small dose increases can cause disproportionate rises in plasma concentration
C. The symptoms suggest phenytoin resistance requiring dose escalation
D. A drug interaction has reduced phenytoin protein binding, increasing free fraction despite therapeutic total level (Correct Answer)
E. The laboratory reference range is incorrect for this patient

Explanation: ***A drug interaction has reduced phenytoin protein binding, increasing free fraction despite therapeutic total level*** - Phenytoin is highly **protein-bound** (approx. 90%), and standard lab assays measure the **total phenytoin** (bound + unbound) rather than the active free fraction. - Clinical toxicity (e.g., **ataxia**, **diplopia**) can occur within the therapeutic total range if the **unbound (free) fraction** increases due to hypoalbuminemia or displacement by other drugs like **valproate**. *These symptoms are unrelated to phenytoin as the level is therapeutic* - Symptoms like **nystagmus**, **ataxia**, and **diplopia** are hallmark signs of phenytoin toxicity regardless of the reported total plasma level. - Relying solely on **total drug levels** is dangerous when clinical signs of toxicity are present, as individual patient physiology varies. *Phenytoin exhibits zero-order kinetics, so small dose increases can cause disproportionate rises in plasma concentration* - While it is true that phenytoin follows **zero-order (saturation) kinetics**, this would typically result in a high **total level** on the lab report. - In this scenario, the total level is still **within the normal range**, making protein displacement a more likely explanation for current toxicity. *The symptoms suggest phenytoin resistance requiring dose escalation* - These symptoms represent neurological **toxicity**, not treatment failure or resistance to the antiepileptics drugs. - Increasing the dose in a patient already experiencing **ataxia** would exacerbate the toxicity and risk severe **cerebellar dysfunction**. *The laboratory reference range is incorrect for this patient* - The standard therapeutic range (10-20 mg/L) is generally valid for most patients, but lab values must always be interpreted in a **clinical context**. - The issue is not the reference range itself, but the failure to account for the **biologically active free drug fraction** which is not routinely measured.

Question 101: According to the Medicines and Healthcare products Regulatory Agency (MHRA) guidance on direct oral anticoagulants (DOACs), which parameter must be assessed before prescribing and monitored regularly during treatment?

A. Liver function tests only
B. International normalised ratio (INR)
C. Renal function (creatinine clearance or eGFR) (Correct Answer)
D. Activated partial thromboplastin time (APTT)
E. Anti-Xa levels

Explanation: ***Renal function (creatinine clearance or eGFR)*** - **MHRA guidance** mandates that **renal function** must be assessed before starting **DOACs** and monitored at least **annually** because these drugs are renally cleared. - Dose adjustments are essential based on **creatinine clearance (CrCl)** to prevent drug accumulation and reduce the risk of **major bleeding** events. *Liver function tests only* - While **liver function** should be checked periodically for some agents, it is not the primary parameter used for **dose titrations** or mandatory routine monitoring under MHRA safety guidance. - **Renal function** is the more critical parameter as it directly dictates the safety threshold for continuing medication or reducing the dose. *International normalised ratio (INR)* - **INR** is used to monitor **warfarin** therapy but is not a reliable or required measure for monitoring the anticoagulant effect of **DOACs**. - One of the primary clinical advantages of **DOACs** is that they offer stable anticoagulation without the need for **routine coagulation monitoring**. *Activated partial thromboplastin time (APTT)* - **APTT** may be prolonged by some **DOACs** (particularly **dabigatran**), but it does not provide a linear or accurate measurement of the drug's therapeutic level. - This test is primarily used for monitoring **unfractionated heparin** and is not recommended for routine monitoring of **direct oral anticoagulants**. *Anti-Xa levels* - **Anti-Xa assays** can be used to measure the activity of Factor Xa inhibitors (like **rivaroxaban** or **apixaban**) in emergencies, but they are not used for **regular monitoring**. - MHRA focuses on **organ function** (renal) for routine safety monitoring rather than the drug's direct biochemical effect on the clotting cascade.

Question 102: A 59-year-old woman with ulcerative colitis is started on azathioprine 150mg once daily. According to current UK prescribing guidance, what is the recommended frequency for monitoring full blood count in the first 8 weeks of treatment?

A. Daily for the first week, then weekly
B. Weekly for the first 8 weeks (Correct Answer)
C. Fortnightly for the first 8 weeks
D. At baseline, 2 weeks, 4 weeks, then 8 weeks
E. At baseline, then monthly

Explanation: ***Weekly for the first 8 weeks***- According to current **UK prescribing guidance** and the **BNF**, patients starting **azathioprine** must have their **Full Blood Count (FBC)** monitored weekly for at least the first **8 weeks**.- This intensive monitoring is essential to detect early **myelosuppression** (bone marrow suppression), a common and serious dose-related side effect.*Daily for the first week, then weekly*- **Daily blood tests** are overly frequent and not required for routine initiation of azathioprine in an outpatient setting.- This level of monitoring is usually reserved for acute inpatient **haematological emergencies** or highly experimental protocols.*Fortnightly for the first 8 weeks*- **Fortnightly** (every 2 weeks) monitoring is insufficient during the high-risk initiation phase where **neutropenia** or **thrombocytopenia** can develop rapidly.- Guidelines only transition to less frequent intervals (e.g., every 3 months) after the initial stable period of **8 to 12 weeks**.*At baseline, 2 weeks, 4 weeks, then 8 weeks*- While it captures some early data points, this schedule misses the crucial **weekly requirement** mandated for safety during the first two months.- Adhering to this schedule would increase the clinical risk of missing a significant drop in **white cell count** between scheduled tests.*At baseline, then monthly*- **Monthly monitoring** is too infrequent for the initiation phase of **thiopurines** like azathioprine.- Monthly or three-monthly checks are only appropriate for patients who have already established a **stable dose** and demonstrated a consistent haematological profile.

Question 103: A 51-year-old woman with type 1 diabetes is admitted with hyperemesis gravidarum at 8 weeks gestation. She is unable to tolerate oral intake. Her usual insulin regimen is insulin glargine 26 units at bedtime and insulin aspart 8 units before meals. Her admission blood glucose is 7.2 mmol/L, and ketones are 1.8 mmol/L. She is commenced on intravenous fluids. What is the most appropriate insulin management to prevent starvation ketosis while avoiding hypoglycaemia?

A. Omit all insulin until she resumes oral intake, monitor ketones 4-hourly
B. Continue insulin glargine at usual dose, omit insulin aspart, add 10% glucose to intravenous fluids (Correct Answer)
C. Reduce insulin glargine to 13 units daily, omit insulin aspart, give correction doses for glucose >12 mmol/L
D. Commence variable rate intravenous insulin infusion with 5% glucose infusion
E. Continue insulin glargine 26 units, give insulin aspart 4 units every 6 hours regardless of oral intake

Explanation: ***Continue insulin glargine at usual dose, omit insulin aspart, add 10% glucose to intravenous fluids*** - In **Type 1 Diabetes**, basal insulin must never be omitted to prevent **diabetic ketoacidosis (DKA)**; adding **intravenous glucose** allows the basal insulin to suppress ketogenesis without causing hypoglycemia. - **Hyperemesis gravidarum** causes a starvation state; maintaining the usual **basal insulin** dose while providing carbohydrate substrate is the standard strategy for patients who are **nil by mouth**. *Omit all insulin until she resumes oral intake, monitor ketones 4-hourly* - Omitting insulin in a patient with **Type 1 Diabetes** will rapidly lead to **absolute insulin deficiency**, causing uncontrolled lipolysis and life-threatening **DKA**. - Safe management requires at least **basal insulin** cover regardless of oral intake to maintain metabolic stability. *Reduce insulin glargine to 13 units daily, omit insulin aspart, give correction doses for glucose >12 mmol/L* - Reducing the **basal insulin** dose significantly increases the risk of **ketosis** and development of DKA, especially as insulin requirements often rise in pregnancy. - Relying on **correction doses** is a reactive rather than proactive approach and fails to prevent the metabolic shift toward **ketone production**. *Commence variable rate intravenous insulin infusion with 5% glucose infusion* - While effective, a **Variable Rate Intravenous Insulin Infusion (VRIII)** is more invasive and complex than necessary if the patient's glucose is currently stable and they are not in established DKA. - This approach is typically reserved for prolonged periods of being **nil by mouth** or during active labor and delivery, rather than initial hyperemesis management. *Continue insulin glargine 26 units, give insulin aspart 4 units every 6 hours regardless of oral intake* - Administering **insulin aspart** (a rapid-acting analog) without concurrent carbohydrate intake significantly increases the risk of severe **iatrogenic hypoglycemia**. - **Prandial or bolus insulin** should generally only be given when there is a corresponding nutritional intake to cover.

Question 104: A 63-year-old man with chronic kidney disease stage 4 (eGFR 24 ml/min/1.73m²) develops acute deep vein thrombosis. He weighs 82kg. Low molecular weight heparin is prescribed. According to BNF guidance for patients with significant renal impairment requiring therapeutic anticoagulation with LMWH, what is the most appropriate monitoring strategy?

A. No monitoring required; use standard weight-based dosing throughout treatment
B. Monitor anti-Xa levels 3-4 hours post-dose, aiming for peak level 0.5-1.0 IU/ml (Correct Answer)
C. Monitor APTT daily, aiming for ratio 1.5-2.5 times control
D. Measure trough anti-Xa levels before next dose, aiming for level <0.2 IU/ml
E. Monitor anti-Xa levels 3-4 hours post-dose, aiming for peak level 1.0-2.0 IU/ml

Explanation: ***Monitor anti-Xa levels 3-4 hours post-dose, aiming for peak level 0.5-1.0 IU/ml*** - In patients with **renal impairment (eGFR <30)**, LMWH can accumulate; therefore, **anti-Xa levels** must be monitored to ensure safety and efficacy. - The **peak level** should be measured **3-4 hours post-dose**, with a target range of **0.5-1.0 IU/ml** for standard twice-daily therapeutic dosing. *No monitoring required; use standard weight-based dosing throughout treatment* - Standard dosing without monitoring is risky in **CKD stage 4** because LMWH is **renally cleared**, leading to an increased risk of **hemorrhage**. - Most guidelines and the **BNF** recommend either dose reduction or intense monitoring of **anti-Xa levels** in severe renal failure. *Monitor APTT daily, aiming for ratio 1.5-2.5 times control* - **APTT** is used to monitor **unfractionated heparin (UFH)**, not low molecular weight heparin (LMWH). - LMWH has a more predictable response but does not significantly prolong the **Activated Partial Thromboplastin Time**. *Measure trough anti-Xa levels before next dose, aiming for level <0.2 IU/ml* - Monitoring for LMWH is primarily based on **peak levels** to assess therapeutic efficacy and risk of toxicity. - **Trough levels** are not standard practice for routine LMWH monitoring, although they may occasionally be used to assess **accumulation** in complex cases. *Monitor anti-Xa levels 3-4 hours post-dose, aiming for peak level 1.0-2.0 IU/ml* - A peak range of **1.0-2.0 IU/ml** is generally the target for **once-daily** high-dose regimens, which are often avoided in renal impairment. - In significant renal impairment, **twice-daily** divided doses with a lower target peak (0.5-1.0 IU/ml) are preferred to minimize **bleeding risk**.

Question 105: A 54-year-old woman with type 2 diabetes is on a basal-bolus insulin regimen consisting of insulin detemir 28 units twice daily and insulin aspart 10 units with meals. She is admitted with community-acquired pneumonia and started on clarithromycin. Over 48 hours, her blood glucose readings increase from typical range of 6-9 mmol/L to consistent readings of 14-18 mmol/L despite good oral intake. Which mechanism best explains this deterioration in glycaemic control?

A. Clarithromycin-induced reduction in insulin absorption from subcutaneous sites
B. Increased insulin resistance secondary to acute infection and inflammatory response (Correct Answer)
C. Drug interaction between clarithromycin and insulin causing enhanced insulin clearance
D. Clarithromycin-induced pancreatitis reducing endogenous insulin secretion
E. Impaired glucose renal excretion due to clarithromycin nephrotoxicity

Explanation: ***Increased insulin resistance secondary to acute infection and inflammatory response*** - Acute illness, such as **pneumonia**, triggers the release of **counter-regulatory hormones** (e.g., cortisol, catecholamines, glucagon) and **pro-inflammatory cytokines** (e.g., TNF-α, IL-6). - These substances significantly increase **insulin resistance** in peripheral tissues and stimulate **hepatic glucose production**, leading to marked hyperglycaemia despite the usual insulin doses. *Clarithromycin-induced reduction in insulin absorption from subcutaneous sites* - Macrolide antibiotics like **clarithromycin** have no known pharmacological effect on the **subcutaneous absorption** kinetics of insulin analogues. - The deterioration in glycaemic control is primarily driven by the systemic **inflammatory state** of pneumonia, not a drug-delivery failure. *Drug interaction between clarithromycin and insulin causing enhanced insulin clearance* - There is no direct **pharmacokinetic interaction** between clarithromycin and insulin; insulin is primarily cleared by **proteolysis** in the liver and kidneys. - While clarithromycin inhibits **CYP3A4**, this enzyme system is not involved in the metabolism or clearance of exogenous insulin. *Clarithromycin-induced pancreatitis reducing endogenous insulin secretion* - While some drugs can cause **acute pancreatitis**, clarithromycin is not a classic causative agent, and the patient presents with **pneumonia**, not symptoms like epigastric pain. - In Type 2 diabetes patients on a **basal-bolus regimen**, the primary driver of acute hyperglycaemia during infection is **peripheral insulin resistance**, not a sudden loss of residual beta-cell function. *Impaired glucose renal excretion due to clarithromycin nephrotoxicity* - **Clarithromycin** is not typically associated with significant **nephrotoxicity** or alterations in the renal threshold for glucose. - Renal glucose excretion is a compensatory mechanism; impairing it would not be the primary driver of such a marked **glycaemic rise** during an acute infection.

Question 106: A 77-year-old man with mechanical aortic valve replacement is established on warfarin with target INR 2.5-3.5. He develops epistaxis that is controlled with anterior nasal packing in the emergency department. His INR on arrival is 7.8 and haemoglobin is 118 g/L (baseline 135 g/L). He has no other sites of bleeding. What is the most appropriate management of his anticoagulation?

A. Give oral vitamin K 5mg, withhold warfarin, and recheck INR in 24 hours
B. Give intravenous vitamin K 1mg, withhold warfarin, and recheck INR in 6-12 hours (Correct Answer)
C. Give prothrombin complex concentrate and intravenous vitamin K 5mg immediately
D. Withhold warfarin only and recheck INR daily until <5.0
E. Give fresh frozen plasma 15 ml/kg and oral vitamin K 10mg

Explanation: ***Give intravenous vitamin K 1mg, withhold warfarin, and recheck INR in 6-12 hours***- For an **INR between 5.0 and 8.0 with minor bleeding** (like controlled epistaxis), guidelines recommend **intravenous vitamin K** due to its more predictable and rapid onset compared to the oral route.- A low dose of **1mg** is preferred in patients with **mechanical heart valves** to avoid complete reversal of anticoagulation, which would increase the risk of **valve thrombosis**.*Give oral vitamin K 5mg, withhold warfarin, and recheck INR in 24 hours*- **Oral vitamin K** has a slower onset of action than the intravenous route, making it less suitable when there is active, albeit minor, bleeding.- A **5mg dose** is excessively high for this clinical scenario and risks making the patient resistant to warfarin for several days.*Give prothrombin complex concentrate and intravenous vitamin K 5mg immediately*- **Prothrombin complex concentrate (PCC)** is reserved for **major bleeding** (life-threatening or into critical organs) or an INR > 8.0 with specific risk factors.- This patient's bleeding is **clinically controlled** with packing and his hemoglobin drop is modest, so high-dose reversal is not indicated.*Withhold warfarin only and recheck INR daily until <5.0*- Simply **withholding warfarin** is insufficient management for a patient with an **INR > 5.0 who is experiencing active bleeding**.- Active bleeding requires pharmacological intervention with **Vitamin K** to speed up the synthesis of clotting factors and ensure patient safety.*Give fresh frozen plasma 15 ml/kg and oral vitamin K 10mg*- **Fresh frozen plasma (FFP)** is inferior to PCC for warfarin reversal; it requires large volumes and takes longer to administer and work.- A **10mg dose of vitamin K** would cause prolonged resistance to warfarin, which is dangerous for a patient requiring lifelong anticoagulation for a **mechanical aortic valve**.

Question 107: A 69-year-old woman with atrial fibrillation on edoxaban 60mg once daily is scheduled for colonoscopy with polypectomy in 5 days. She has normal renal function (eGFR 72 ml/min/1.73m²) and no other significant comorbidities. What is the most appropriate perioperative management of her anticoagulation according to current UK guidance?

A. Omit edoxaban on the morning of the procedure, resume normal dose 6 hours post-procedure if haemostasis achieved (Correct Answer)
B. Stop edoxaban 48 hours before procedure, resume 24 hours post-procedure
C. Stop edoxaban 24 hours before procedure, bridge with LMWH, resume edoxaban 48 hours post-procedure
D. Continue edoxaban without interruption as colonoscopy is low bleeding risk
E. Stop edoxaban 72 hours before procedure, resume normal dose 12 hours post-procedure

Explanation: ***Omit edoxaban on the morning of the procedure, resume normal dose 6 hours post-procedure if haemostasis achieved***- For DOACs like **edoxaban** in patients with a normal **eGFR**, omitting the dose on the day of a **moderate bleeding risk** procedure (such as polypectomy) is generally sufficient due to its short half-life.- Post-procedure resumption at **6 hours** is appropriate once **primary haemostasis** is confirmed, balancing the risk of stroke against the risk of post-polypectomy bleeding.*Stop edoxaban 48 hours before procedure, resume 24 hours post-procedure*- A **48-hour cessation** is typically reserved for patients with **impaired renal function** or those undergoing very **high-risk surgery**, which does not apply here.- Resuming at 24 hours is unnecessarily cautious if **haemostasis** is achieved earlier, potentially increasing the **thromboembolic risk** for a patient with atrial fibrillation.*Stop edoxaban 24 hours before procedure, bridge with LMWH, resume edoxaban 48 hours post-procedure*- **Bridging with LMWH** is not recommended for **DOACs** because of their rapid onset and offset of action; it increases **bleeding risk** without benefit.- Resuming at **48 hours** is a delayed reintroduction for a standard colonoscopy with polypectomy, leaving the patient under-anticoagulated and at risk for **atrial fibrillation-related stroke**.*Continue edoxaban without interruption as colonoscopy is low bleeding risk*- While a diagnostic colonoscopy is low risk, a **polypectomy** is classified as a **moderate bleeding risk** procedure requiring temporary cessation of anticoagulants.- Continuing anticoagulation during an invasive procedure with a moderate bleeding risk significantly increases the risk of **uncontrolled gastrointestinal bleeding**.*Stop edoxaban 72 hours before procedure, resume normal dose 12 hours post-procedure*- A **72-hour cessation** is excessive for edoxaban in a patient with an **eGFR of 72**, as the drug is mostly cleared within 24-48 hours.- This prolonged interruption creates an unnecessary and extended **prothrombotic window** for a patient already categorized as needing anticoagulation for atrial fibrillation.

Question 108: A 48-year-old man with type 1 diabetes for 22 years presents to the emergency department with a 2-day history of vomiting and abdominal pain. His capillary blood glucose is 24.8 mmol/L, ketones 4.2 mmol/L, and arterial blood gas shows pH 7.21, bicarbonate 12 mmol/L. He is diagnosed with diabetic ketoacidosis. His usual insulin is insulin degludec 35 units once daily and insulin aspart with meals. What is the most appropriate initial insulin management?

A. Continue insulin degludec at usual dose and commence fixed-rate intravenous insulin infusion at 0.1 units/kg/hour (Correct Answer)
B. Omit insulin degludec and commence variable rate intravenous insulin infusion based on hourly blood glucose
C. Double the dose of insulin degludec and give boluses of insulin aspart every 2 hours
D. Continue insulin degludec and give boluses of intravenous insulin 10 units hourly
E. Omit all subcutaneous insulin and commence fixed-rate intravenous insulin infusion at 0.05 units/kg/hour

Explanation: ***Continue insulin degludec at usual dose and commence fixed-rate intravenous insulin infusion at 0.1 units/kg/hour*** - Guidelines recommend continuing **long-acting basal insulin** (like degludec) alongside iv insulin to prevent **rebound ketosis** and facilitate the transition back to subcutaneous insulin. - A **fixed-rate intravenous insulin infusion (FRIII)** at **0.1 units/kg/hour** is the standard protocol to reliably suppress **ketogenesis** and clear ketones. *Omit insulin degludec and commence variable rate intravenous insulin infusion based on hourly blood glucose* - **Variable rate intravenous insulin infusion (VRIII)** is used for glycaemic control in stable patients, not for the acute management of **ketosis** in DKA. - Omitting the basal insulin analogue can lead to a baseline insulin deficit, increasing the risk of **hyperglycaemia** when the infusion is eventually discontinued. *Double the dose of insulin degludec and give boluses of insulin aspart every 2 hours* - DKA is a medical emergency that requires **intravenous insulin** for rapid onset and precise titration; subcutaneous boluses are too slow and unpredictable. - Doubling the **basal dose** is inappropriate and increases the risk of delayed **hypoglycaemia** once the acute metabolic storm has resolved. *Continue insulin degludec and give boluses of intravenous insulin 10 units hourly* - **Hourly intravenous boluses** provide fluctuating insulin levels rather than the steady-state concentration needed to effectively suppress **lipolysis**. - Modern protocols have replaced bolus therapy with **continuous infusion (FRIII)** to ensure a more stable and safe reduction in ketones. *Omit all subcutaneous insulin and commence fixed-rate intravenous insulin infusion at 0.05 units/kg/hour* - Omitting the **basal analogue** is contrary to current best practice for patients already established on long-acting insulin regimens. - A rate of **0.05 units/kg/hour** is generally insufficient for adult DKA management and is typically reserved for specialized cases like **pregnancy** or extreme sensitivity.

Question 109: A 56-year-old woman is commenced on dabigatran 150mg twice daily for stroke prevention in atrial fibrillation. She has a CHA₂DS₂-VASc score of 3. Her baseline renal function shows eGFR 68 ml/min/1.73m². According to MHRA and NICE guidance, what is the recommended frequency for monitoring renal function in this patient?

A. Monthly for the first 3 months, then 3-monthly thereafter
B. Annually, or more frequently if clinically indicated (Correct Answer)
C. At baseline only, then if clinical deterioration occurs
D. 3-monthly for the first year, then 6-monthly thereafter
E. 6-monthly indefinitely

Explanation: ***Annually, or more frequently if clinically indicated*** - For patients on **DOACs** with an **eGFR >60 ml/min/1.73m²**, MHRA and NICE guidelines recommend **renal function monitoring** at least once every 12 months. - This frequency ensures the **dosage** remains appropriate as renal function naturally declines with age or due to **intercurrent illness**. *Monthly for the first 3 months, then 3-monthly thereafter* - This intensive monitoring schedule is not required by standard guidelines for a patient with relatively **preserved renal function** (eGFR 68). - Such frequent testing is excessive and typically reserved for clinical trials or patients with **unstable renal status**. *At baseline only, then if clinical deterioration occurs* - Relying only on **baseline results** is unsafe, as **dabigatran** is highly dependent on **renal excretion** (approximately 80%). - Undetected declines in renal function can lead to **drug accumulation** and a significantly increased **risk of major bleeding**. *3-monthly for the first year, then 6-monthly thereafter* - This schedule is more aligned with patients who have **moderate renal impairment** (CrCl <60 ml/min). - For a patient with an **eGFR of 68**, this represents unnecessary healthcare utilization according to current **NICE guidance**. *6-monthly indefinitely* - While safer than annual monitoring, this is not the **standard minimum recommendation** for someone with an **eGFR above 60**. - A **6-monthly** frequency (or the "eGFR divided by 10" rule) is generally applied strictly when the eGFR falls below **60 ml/min/1.73m²**.

Question 110: A 61-year-old man with type 2 diabetes on basal-bolus insulin therapy (insulin glargine 40 units at bedtime, insulin lispro 12 units with meals) is admitted with suspected stroke. His admission blood glucose is 3.8 mmol/L. CT brain confirms acute ischaemic stroke with no indication for thrombolysis. He is kept nil by mouth pending swallow assessment. What is the most appropriate immediate insulin management?

A. Continue insulin glargine 40 units, omit insulin lispro, commence 10% glucose infusion, and monitor blood glucose 4-6 hourly (Correct Answer)
B. Omit all insulin, commence variable rate intravenous insulin infusion with glucose-potassium-insulin regime
C. Reduce insulin glargine to 20 units, omit insulin lispro, and monitor blood glucose 2-hourly
D. Continue insulin glargine 40 units, omit insulin lispro, and give correction doses of rapid-acting insulin for glucose >12 mmol/L
E. Omit insulin glargine, commence variable rate intravenous insulin infusion only, without glucose supplementation

Explanation: ***Continue insulin glargine 40 units, omit insulin lispro, commence 10% glucose infusion, and monitor blood glucose 4-6 hourly*** - In patients with **Type 2 Diabetes** who are **nil by mouth**, the **basal insulin** (glargine) should be continued at the full dose to prevent rebound hyperglycaemia. - Because the patient is not eating and has a baseline low glucose (3.8 mmol/L), **10% glucose infusion** is necessary to prevent further **hypoglycaemia** while omitting meal-time boluses. *Omit all insulin, commence variable rate intravenous insulin infusion with glucose-potassium-insulin regime* - A **Variable Rate Intravenous Insulin Infusion (VRIII)** is generally reserved for patients where subcutaneous management is unsafe or in **Type 1 Diabetes** with prolonged fasting. - It is unnecessarily complex and carries a higher risk of **iatrogenic delivery errors** for a Type 2 diabetic patient awaiting a simple swallow assessment. *Reduce insulin glargine to 20 units, omit insulin lispro, and monitor blood glucose 2-hourly* - Reducing the **basal insulin dose** by half is likely to lead to significant **rebound hyperglycaemia**, which is detrimental to neural recovery post-stroke. - Maintaining established basal insulin provides more stable glycaemic control than arbitrary dose reduction when used alongside **dextrose support**. *Continue insulin glargine 40 units, omit insulin lispro, and give correction doses of rapid-acting insulin for glucose >12 mmol/L* - This approach fails to address the patient's current **hypoglycaemia (3.8 mmol/L)** and the lack of carbohydrate intake while **nil by mouth**. - Relying solely on **sliding scale/correction doses** leads to erratic blood glucose fluctuations rather than the steady state required in **acute ischaemic stroke**. *Omit insulin glargine, commence variable rate intravenous insulin infusion only, without glucose supplementation* - Stopping **basal insulin** without providing an alternative source of insulin or glucose is dangerous and can lead to **ketosis** or severe hyperglycaemia. - Providing an **insulin infusion without glucose** in a patient with a blood sugar of 3.8 mmol/L would cause life-threatening **severe hypoglycaemia**.

Question 111: According to NICE guidance on anticoagulation for atrial fibrillation, which clinical scenario would require dose reduction of apixaban from the standard 5mg twice daily to 2.5mg twice daily?

A. Age ≥75 years with body weight 65kg and serum creatinine 110 µmol/L
B. Age 68 years with body weight 58kg and serum creatinine 145 µmol/L (Correct Answer)
C. Age 82 years alone, regardless of other parameters
D. Body weight 55kg alone, regardless of other parameters
E. Serum creatinine 150 µmol/L alone, regardless of other parameters

Explanation: ***Age 68 years with body weight 58kg and serum creatinine 145 µmol/L*** - Apixaban dose reduction (2.5mg twice daily) is required if a patient meets at least **two of the following three criteria**: age ≥80 years, body weight ≤60kg, or serum creatinine ≥133 µmol/L. - This scenario satisfies **two criteria** (body weight 58kg and serum creatinine 145 µmol/L), necessitating the lower dose to prevent excessive bleeding risk. *Age ≥75 years with body weight 65kg and serum creatinine 110 µmol/L* - This patient satisfies **zero criteria** for dose reduction; the age is below 80, weight is above 60kg, and creatinine is below the 133 µmol/L threshold. - Standard dosing of **5mg twice daily** is appropriate here to ensure adequate stroke prophylaxis while minimizing bleeding risk. *Age 82 years alone, regardless of other parameters* - Advanced **age ≥80 years** is only one of the three required criteria and does not trigger a dose reduction on its own. - Dosing remains at **5mg twice daily** unless either body weight or serum creatinine also meet their respective thresholds. *Body weight 55kg alone, regardless of other parameters* - While **body weight ≤60kg** is a risk factor, it must be accompanied by another qualifying criterion to adjust the dose. - Using the lower dose based solely on weight can lead to **under-anticoagulation** and an increased risk of ischemic stroke. *Serum creatinine 150 µmol/L alone, regardless of other parameters* - Elevated **serum creatinine ≥133 µmol/L** represents impaired renal clearance but requires a second clinical factor for dose adjustment in atrial fibrillation according to NICE. - Always calculate the **Cockcroft-Gault** clearance for renal function, but for apixaban, these specific threshold-based criteria are the primary guide for this dose reduction.

Question 112: A 39-year-old woman with newly diagnosed type 2 diabetes is being considered for basal-bolus insulin therapy after failing to achieve glycaemic control with metformin and gliclazide. She works as a long-distance lorry driver. Which factor represents an absolute contraindication to her continuing this occupation while on insulin therapy?

A. HbA1c above 58 mmol/mol despite treatment optimization
B. History of one episode of severe hypoglycaemia requiring third-party assistance
C. Presence of mild background diabetic retinopathy on screening
D. Taking insulin for less than 12 months duration
E. Impaired awareness of hypoglycaemia (Correct Answer)

Explanation: ***Impaired awareness of hypoglycaemia*** - For **Group 2 drivers** (lorry and bus), **impaired awareness of hypoglycaemia** is an absolute contraindication to driving while on insulin therapy due to the high risk of sudden incapacitation. - Safety regulations, such as those from the **DVLA**, require these drivers to demonstrate **full awareness** of hypoglycaemic symptoms and consistently monitor blood glucose levels to prevent dangerous episodes. *HbA1c above 58 mmol/mol despite treatment optimization* - While an **HbA1c** above target indicates suboptimal glycaemic control, it is not a direct legal disqualifier for heavy vehicle driving on its own. - The primary safety concern for the **DVLA** regarding insulin and driving is the **risk of hypoglycaemia**, not a specific ceiling on hyperglycemia levels, unless it's associated with acute complications affecting driving ability. *History of one episode of severe hypoglycaemia requiring third-party assistance* - For Group 2 drivers, the regulation specifies that **more than one episode** of severe hypoglycaemia in the preceding 12 months is a disqualification. - A **single episode** requires a temporary suspension and a review of control, but it is not an absolute, permanent contraindication if awareness remains intact and other conditions are met. *Presence of mild background diabetic retinopathy on screening* - **Mild background retinopathy** typically does not affect visual acuity or the visual field, which are the primary determinants for fitness to drive a heavy vehicle. - Only **advanced retinopathy** (e.g., proliferative) or laser treatment causing significant **visual field defects** would necessitate a license review or disqualification for a lorry driver. *Taking insulin for less than 12 months duration* - There is no specific **minimum duration** of insulin use (like 12 months) required before a person is allowed to drive a lorry. - Drivers can hold a **Group 2 license** while on insulin as long as they satisfy specific criteria regarding **hypoglycaemic awareness**, frequency of monitoring, and absence of recent severe episodes.

Question 113: A 73-year-old man with atrial fibrillation has been on warfarin for 18 months with consistently stable INR values between 2.2-2.8 (target 2-3). He attends for routine monitoring and his INR is 4.6. He denies any bleeding, dietary changes, or new medications. His only other medication is amlodipine 5mg daily. What is the most appropriate immediate management?

A. Give oral vitamin K 1-3mg and omit warfarin for 1-2 doses, recheck INR in 24 hours
B. Omit 1 dose of warfarin, reduce maintenance dose, and recheck INR in 3-5 days (Correct Answer)
C. Continue current warfarin dose and recheck INR in 1 week
D. Give intravenous vitamin K 10mg and admit for observation
E. Withhold warfarin until INR <2.5, then restart at reduced dose

Explanation: ***Omit 1 dose of warfarin, reduce maintenance dose, and recheck INR in 3-5 days***- For an INR of 4.6 with no bleeding, a temporary reduction in warfarin's effect is needed, which is best achieved by **omitting a dose** and then **reducing the maintenance dose**.- This approach carefully brings the INR back into the therapeutic range (2.0-3.0) without causing **over-correction** or leaving the patient unprotected for too long, with re-evaluation in 3-5 days being appropriate. *Give oral vitamin K 1-3mg and omit warfarin for 1-2 doses, recheck INR in 24 hours*- Oral **Vitamin K** is generally reserved for INRs of **5.0-8.0 with minor or no bleeding**, or greater than 8.0 without bleeding, to rapidly reduce the INR.- Administering Vitamin K unnecessarily for an INR of 4.6 can cause **warfarin resistance**, making it difficult to re-establish therapeutic anticoagulation for several days. *Continue current warfarin dose and recheck INR in 1 week*- An INR of 4.6 is significantly **supra-therapeutic** for a target range of 2-3 and carries an increased risk of **hemorrhage**.- Continuing the current dose would leave the patient at an elevated bleeding risk without intervention, and waiting a full week for recheck is too long. *Give intravenous vitamin K 10mg and admit for observation*- **Intravenous Vitamin K** (especially 10mg) is reserved for **major life-threatening bleeding** or extremely high INRs (typically >10-20) requiring rapid and complete reversal.- This patient is **asymptomatic** and has no bleeding, making such an aggressive and potentially risky intervention entirely inappropriate. *Withhold warfarin until INR <2.5, then restart at reduced dose*- Completely withholding warfarin until the INR drops below 2.5 might take several days, leaving the patient **unprotected** against **thromboembolic events** (e.g., stroke) due to atrial fibrillation.- A more controlled adjustment and earlier reintroduction at a reduced dose is preferred to maintain some level of anticoagulation and prevent rebound hypercoagulability.

Question 114: A 44-year-old man with type 1 diabetes is admitted with acute appendicitis requiring emergency surgery. His usual insulin regimen is insulin detemir 24 units at bedtime and insulin aspart 8 units before each meal. He last ate 8 hours ago and has been nil by mouth since. His current blood glucose is 11.2 mmol/L. Surgery is planned in 2 hours. What is the most appropriate insulin management?

A. Continue basal insulin, omit meal-time insulin, and start variable rate intravenous insulin infusion (Correct Answer)
B. Omit all subcutaneous insulin and commence variable rate intravenous insulin infusion immediately
C. Give half the usual basal insulin dose, omit meal-time insulin, and monitor blood glucose hourly
D. Continue basal insulin at usual dose, give correction doses of rapid-acting insulin as needed
E. Switch to intravenous insulin boluses of 4 units hourly until surgery

Explanation: ***Continue basal insulin, omit meal-time insulin, and start variable rate intravenous insulin infusion*** - In **Type 1 Diabetes**, **basal insulin** must never be omitted to prevent **ketogenesis** and progression to **Diabetic Ketoacidosis (DKA)**. - For emergency surgery and fasting patients, a **Variable Rate Intravenous Insulin Infusion (VRIII)** is the gold standard to provide precise glycemic control during the perioperative stress response. *Omit all subcutaneous insulin and commence variable rate intravenous insulin infusion immediately* - Stopping **basal insulin** increases the risk of **rebound hyperglycemia** and ketosis if the VRIII is briefly interrupted or when the patient transitions back to subcutaneous injections. - Current guidelines recommend continuing **long-acting analogues** (like **insulin detemir**) at their usual dose to maintain a background level of insulin. *Give half the usual basal insulin dose, omit meal-time insulin, and monitor blood glucose hourly* - Reducing the **basal dose** by half is often recommended for elective surgery if the patient is expected to miss only one meal, but it is insufficient for **emergency surgery** with high metabolic stress. - This approach does not offer the same level of flexibility or safety as a **VRIII** for managing blood glucose fluctuations during general anesthesia. *Continue basal insulin at usual dose, give correction doses of rapid-acting insulin as needed* - Correction doses of **subcutaneous rapid-acting insulin** have a slow onset and long duration, making them unpredictable for a patient who is **nil by mouth (NBM)** and undergoing surgery. - The **VRIII** is preferred because it allows for immediate adjustments based on real-time blood glucose monitoring, ensuring a tighter target range of **6–10 mmol/L**. *Switch to intravenous insulin boluses of 4 units hourly until surgery* - **Intravenous boluses** have a very short half-life and cause significant fluctuations in blood glucose levels, leading to unstable control. - A **continuous infusion** (VRIII) is the only appropriate intravenous method to ensure a steady state and prevent **iatrogenic hypoglycemia** or hyperglycemia.

Question 115: A 67-year-old woman with atrial fibrillation on rivaroxaban 20mg once daily is admitted with acute cholecystitis requiring emergency laparoscopic cholecystectomy. Surgery is scheduled for the following morning. She took her last dose of rivaroxaban 6 hours ago. What is the most appropriate perioperative management of her anticoagulation?

A. Proceed with surgery and omit rivaroxaban for 48 hours postoperatively
B. Delay surgery for 24 hours, omit next rivaroxaban dose, then proceed (Correct Answer)
C. Administer prothrombin complex concentrate and proceed immediately
D. Switch to unfractionated heparin infusion and proceed when APTT normalizes
E. Bridge with therapeutic dose LMWH and proceed when anti-Xa level is <0.4 IU/ml

Explanation: ***Delay surgery for 24 hours, omit next rivaroxaban dose, then proceed*** - **Rivaroxaban** has a half-life of 5–9 hours in healthy individuals but can be longer in the elderly; delaying surgery for **24 hours** after the last dose allows sufficient drug clearance for intermediate-risk procedures like laparoscopic cholecystectomy. - Monitoring is generally not required, and **omitting the next dose** provides a safe window for the emergency procedure while balancing the risk of thrombosis and surgical hemorrhage. *Proceed with surgery and omit rivaroxaban for 48 hours postoperatively* - Since the patient took her last dose only **6 hours ago**, the anticoagulant effect is near **peak levels**, making immediate surgery unsafe due to high intraoperative bleeding risk. - Omission postoperatively is necessary for recovery, but the primary concern is the **active anticoagulation** present at the time of the proposed incision. *Administer prothrombin complex concentrate and proceed immediately* - **Prothrombin complex concentrate (PCC)** or andexanet alfa is indicated for **life-threatening bleeding** or truly emergent surgery that cannot wait even a few hours. - Acute cholecystitis is urgent but typically allows for a **24-hour stabilization period**, making the use of expensive/risky reversal agents unnecessary. *Switch to unfractionated heparin infusion and proceed when APTT normalizes* - **Bridging** with unfractionated heparin (UFH) is not indicated for patients on **DOACs** and would inappropriately maintain a high level of anticoagulation when the goal is to clear the drug. - Rivaroxaban does not have a reliable relationship with **APTT**, so using this marker to guide surgical timing would be clinically inaccurate. *Bridge with therapeutic dose LMWH and proceed when anti-Xa level is <0.4 IU/ml* - **LMWH bridging** is generally contraindicated in DOAC patients as it increases **bleeding complications** without clear benefit in the perioperative period. - While rivaroxaban does affect **anti-Xa levels**, delaying the surgery is a more standard and practical approach than serial laboratory monitoring for an urgent case.

Question 116: A 52-year-old woman with rheumatoid arthritis is commenced on methotrexate 15mg weekly. She asks about when she should take her folic acid supplement. According to current UK prescribing guidance, when should folic acid be administered in patients taking weekly methotrexate?

A. On the same day as methotrexate to enhance absorption
B. At least 24 hours after the methotrexate dose (Correct Answer)
C. Daily including on the day of methotrexate administration
D. Only on the three days immediately following methotrexate
E. On alternate days throughout the week

Explanation: ***At least 24 hours after the methotrexate dose*** - According to **BNF and BSR guidelines**, folic acid is administered at least **24 hours after** methotrexate to reduce side effects like **mucosal and hematological toxicity**. - Typically, a 5mg dose is given **once weekly** on a specific day that does not coincide with the methotrexate dose to maintain its **therapeutic efficacy**. *On the same day as methotrexate to enhance absorption* - Taking folic acid on the **same day** as methotrexate is avoided because it may competitively inhibit the **dihydrofolate reductase** enzyme, potentially reducing the drug's effectiveness. - It does not enhance absorption; rather, it interferes with the **antifolate mechanism** of methotrexate. *Daily including on the day of methotrexate administration* - While some localized protocols allow daily use, standard UK guidance advises against administration on the **day of the methotrexate dose**. - Consistent daily use including the methotrexate day increases the risk of **diminishing the clinical response** of the arthritis treatment. *Only on the three days immediately following methotrexate* - This regimen is not supported by standard **UK prescribing guidance** and adds unnecessary **complexity** for the patient. - Most clinical outcomes are better managed with a **single weekly dose** or a consistent strategy that avoids the 24-hour window around methotrexate. *On alternate days throughout the week* - **Alternate day dosing** is not a recommended or conventional approach in rheumatology for folic acid supplementation. - Following a **simple weekly schedule** improves patient **compliance** and ensures the safest pharmacodynamic interaction between the two medications.

Question 117: A 58-year-old man with bipolar disorder is established on lithium carbonate 800mg twice daily. He presents to his GP feeling generally unwell with reduced appetite. Blood tests reveal serum lithium level of 0.9 mmol/L (therapeutic range 0.4-1.0 mmol/L), sodium 129 mmol/L, potassium 4.2 mmol/L, urea 8.2 mmol/L, and creatinine 115 µmol/L. Which monitoring parameter change would warrant immediate lithium dose reduction?

A. Development of fine hand tremor
B. Serum sodium falling to 125 mmol/L
C. Thyroid-stimulating hormone rising from 2.5 to 4.8 mU/L
D. eGFR declining from 65 to 58 ml/min/1.73m²
E. Serum lithium level rising to 1.15 mmol/L (Correct Answer)

Explanation: ***Serum lithium level rising to 1.15 mmol/L***- **Lithium** has a very **narrow therapeutic index** (typically 0.4–1.0 mmol/L), and a level of 1.15 mmol/L exceeds the safe range, significantly increasing the risk of **toxicity**.- Urgent dose adjustment is required as toxicity can lead to severe **neurological symptoms**, renal impairment, and cardiac arrhythmias.*Development of fine hand tremor*- A **fine hand tremor** is a common **side effect** of lithium therapy that can occur even when serum levels are within the therapeutic range.- While bothersome, it is not an immediate indication for dose reduction unless it progresses to a **coarse tremor**, which is a sign of more severe toxicity.*Serum sodium falling to 125 mmol/L*- **Hyponatremia** increases the risk of lithium toxicity because the kidneys conserve lithium in an attempt to reabsorb sodium.- While significant and requiring attention, the priority for immediate dose reduction is the **actual serum lithium level** exceeding the therapeutic range.*Thyroid-stimulating hormone rising from 2.5 to 4.8 mU/L*- Lithium can cause **hypothyroidism** or a rise in **TSH**, but this is typically managed by adding **levothyroxine** rather than immediately reducing the lithium dose.- A mild rise in TSH, even into the subclinical hypothyroid range, does not indicate acute lithium toxicity and does not warrant an immediate reduction in psychiatric maintenance therapy.*eGFR declining from 65 to 58 ml/min/1.73m²*- A mild decline in **eGFR** warrants close monitoring of renal function, as lithium is **renally excreted**, but this specific drop is relatively minor.- Immediate action for a dose reduction is usually triggered by a more significant drop or if the eGFR falls below 45 ml/min/1.73m².

Question 118: A 63-year-old man with type 2 diabetes is admitted with acute pancreatitis. He is nil by mouth with nasogastric aspiration. His usual diabetes medications are metformin 1g twice daily, gliclazide 80mg twice daily, and insulin detemir 38 units at bedtime. A variable rate intravenous insulin infusion (VRIII) is commenced. On day 3, he is improving and planning to restart oral intake. Which medication should be restarted first and when should the VRIII be discontinued?

A. Restart all oral diabetes medications together, then stop VRIII 30 minutes later
B. Restart subcutaneous insulin first, continue VRIII for 30-60 minutes, then restart oral medications once eating normally (Correct Answer)
C. Stop VRIII when oral intake commences, then restart all medications immediately
D. Restart metformin and gliclazide with first meal, then stop VRIII 2 hours later
E. Continue VRIII until full diet established, then restart all medications and stop VRIII 6 hours later

Explanation: ***Restart subcutaneous insulin first, continue VRIII for 30-60 minutes, then restart oral medications once eating normally***- For patients already on **subcutaneous basal insulin**, it should be continued or restarted first to provide a stable background level before transitioning off the **VRIII**.- A **30-60 minute overlap** between the subcutaneous dose and stopping the VRIII is essential to prevent **rebound hyperglycemia**, as intravenous insulin has an extremely short half-life.*Restart all oral diabetes medications together, then stop VRIII 30 minutes later*- **Metformin** should be withheld until **renal function** (eGFR) and clinical stability are confirmed, especially after an acute episode like pancreatitis and nil-by-mouth status.- Oral medications do not provide the immediate basal glycemic control needed to safely discontinue an insulin infusion in a patient who requires insulin.*Stop VRIII when oral intake commences, then restart all medications immediately*- Stopping VRIII immediately upon caloric intake without a **priming dose** of subcutaneous insulin leads to a rapid drop in circulating insulin levels.- This approach carries a high risk of **ketosis** or severe hyperglycemia because oral medications have a slower onset than the rapidly cleared IV insulin.*Restart metformin and gliclazide with first meal, then stop VRIII 2 hours later*- **Gliclazide** (a sulfonylurea) increases the risk of **hypoglycemia** if the patient's oral intake remains inconsistent or low during the recovery phase.- Reintroducing oral agents without first establishing the **basal insulin** requirement ignores the patient's pre-existing need for insulin detemir.*Continue VRIII until full diet established, then restart all medications and stop VRIII 6 hours later*- A **6-hour overlap** is unnecessarily long and significantly increases the risk of **iatrogenic hypoglycemia** due to excessive insulin stacking.- Standard clinical guidelines recommend a much shorter transition period (typically **30-60 minutes**) once the subcutaneous insulin has been administered.

Question 119: A 72-year-old woman with non-valvular atrial fibrillation and CHA₂DS₂-VASc score of 4 has been taking apixaban 5mg twice daily for 2 years. She now requires long-term treatment with rifampicin and isoniazid for pulmonary tuberculosis. Her eGFR is 72 ml/min/1.73m², weight 68kg, and she has no other relevant medical history. What is the most appropriate management of her anticoagulation?

A. Continue apixaban 5mg twice daily as rifampicin does not significantly interact
B. Increase apixaban dose to 7.5mg twice daily to compensate for enzyme induction
C. Switch to rivaroxaban 20mg once daily as it has fewer interactions with rifampicin
D. Switch to warfarin with target INR 2-3 and monitor INR more frequently (Correct Answer)
E. Discontinue anticoagulation during tuberculosis treatment and restart afterwards

Explanation: ***Switch to warfarin with target INR 2-3 and monitor INR more frequently*** - **Rifampicin** is a potent inducer of **P-glycoprotein (P-gp)** and **CYP3A4**, which significantly reduces the plasma concentration of **apixaban**, increasing the risk of **thromboembolic stroke**. - Unlike DOACs, the anticoagulant effect of **warfarin** can be reliably monitored and adjusted using the **International Normalized Ratio (INR)**, making it suitable for co-administration with **enzyme inducers** like rifampicin. *Continue apixaban 5mg twice daily as rifampicin does not significantly interact* - This is incorrect because **rifampicin** is a strong **CYP3A4** and **P-gp inducer**, leading to a significant **reduction in apixaban plasma concentrations** (up to 50% decrease in AUC). - Maintaining the same dose would result in **subtherapeutic anticoagulation**, leaving a high-risk patient (**CHA₂DS₂-VASc of 4**) vulnerable to **stroke** and other thromboembolic events. *Increase apixaban dose to 7.5mg twice daily to compensate for enzyme induction* - There are **no established clinical guidelines** or evidence to support increasing the apixaban dose beyond its standard therapeutic range (2.5mg or 5mg twice daily) to counteract **enzyme induction** by rifampicin. - **Non-standard dosing** strategies for DOACs are not validated and carry unknown risks regarding both efficacy and safety, making this an inappropriate management strategy. *Switch to rivaroxaban 20mg once daily as it has fewer interactions with rifampicin* - **Rivaroxaban** is also a substrate of **CYP3A4** and **P-gp**, meaning its plasma levels would similarly be significantly reduced by co-administration with **rifampicin**. - Current guidelines generally recommend **avoiding all Direct Oral Anticoagulants (DOACs)** when a patient requires concomitant treatment with potent **CYP3A4 and P-gp inducers**. *Discontinue anticoagulation during tuberculosis treatment and restart afterwards* - With a high **CHA₂DS₂-VASc score of 4**, this patient has a significantly elevated annual risk of **stroke**, making discontinuation of **anticoagulation** medically unsafe. - **Tuberculosis treatment** typically lasts for many months (e.g., 6 months), and discontinuing **thromboprophylaxis** for such a prolonged period would expose the patient to an unacceptably high risk of **thromboembolic events**.

Question 120: A 51-year-old woman with type 1 diabetes for 28 years presents to the emergency department with abdominal pain and vomiting for 12 hours. Her capillary blood glucose is 24.8 mmol/L and ketones are 4.2 mmol/L. Venous blood gas shows pH 7.28, bicarbonate 14 mmol/L. She is being treated for diabetic ketoacidosis with fixed rate intravenous insulin infusion (FRIII) at 0.1 units/kg/hour and fluid resuscitation. After 4 hours, her glucose has fallen to 13.2 mmol/L but ketones remain 3.8 mmol/L and pH is 7.31. What is the most appropriate adjustment to her management?

A. Stop the insulin infusion as glucose is adequately controlled
B. Reduce the insulin infusion rate to 0.05 units/kg/hour to prevent hypoglycaemia
C. Continue the same insulin infusion rate and commence 10% glucose infusion (Correct Answer)
D. Increase the insulin infusion rate to 0.15 units/kg/hour
E. Switch from intravenous insulin to subcutaneous rapid-acting insulin

Explanation: ***Continue the same insulin infusion rate and commence 10% glucose infusion*** - In **Diabetic Ketoacidosis (DKA)**, the primary goal is to suppress **ketogenesis** and resolve acidosis; therefore, the weight-based **Fixed Rate Intravenous Insulin Infusion (FRIII)** must be maintained at 0.1 units/kg/h. - When blood glucose drops below **14 mmol/L** but ketones remain high (>0.6 mmol/L), **10% glucose** must be started as a substrate to prevent hypoglycemia while allowing the insulin to continue clearing the ketones. *Stop the insulin infusion as glucose is adequately controlled* - Stopping insulin before the **anion gap** closes and ketones are cleared will lead to a rebound of **ketoacidosis** and clinical deterioration. - Insulin should only be discontinued once the patient is eating/drinking and has transitioned to **subcutaneous insulin**. *Reduce the insulin infusion rate to 0.05 units/kg/hour to prevent hypoglycaemia* - Reducing the insulin rate is inappropriate because lower doses may not be sufficient to switch off **ketone production** at the required rate. - The correct approach to avoid hypoglycemia is to supplement with **intravenous glucose** rather than compromising the insulin infusion. *Increase the insulin infusion rate to 0.15 units/kg/hour* - Increasing the rate is unnecessary as the blood glucose has already shown a significant drop from **24.8 to 13.2 mmol/L**, indicating an adequate response to the current dose. - Adjusting the insulin rate upwards is usually reserved for cases where the **ketone level** fails to fall by at least 0.5 mmol/L per hour. *Switch from intravenous insulin to subcutaneous rapid-acting insulin* - Switching to **subcutaneous insulin** is premature because the patient still has significant **ketonemia (3.8 mmol/L)** and the acidosis has not fully resolved (bicarbonate is still low at 14 mmol/L). - Criteria for resolution usually include **ketones < 0.6 mmol/L**, pH > 7.3, and the patient being able to tolerate oral intake.

Question 121: A 68-year-old man with atrial fibrillation is on dabigatran 150mg twice daily. He is admitted with a large intracranial haemorrhage with midline shift on CT scan. He is deteriorating neurologically and neurosurgery is considering emergency evacuation. His last dose of dabigatran was 4 hours ago. His eGFR is 58 ml/min/1.73m². Which is the most appropriate immediate management?

A. Administer idarucizumab 5g intravenously and proceed to emergency surgery (Correct Answer)
B. Administer andexanet alfa and proceed to emergency surgery
C. Administer prothrombin complex concentrate 50 units/kg and proceed to surgery
D. Wait 12 hours since last dabigatran dose before considering surgery
E. Administer tranexamic acid 1g intravenously and proceed to emergency surgery

Explanation: ***Administer idarucizumab 5g intravenously and proceed to emergency surgery***- **Idarucizumab** is a specific and immediate reversal agent for **dabigatran**, directly neutralizing its anticoagulant effect.- This immediate administration is crucial for **life-threatening bleeding**, such as an intracranial haemorrhage with midline shift, requiring urgent surgical intervention.*Administer andexanet alfa and proceed to emergency surgery*- **Andexanet alfa** is specifically indicated for the reversal of **Factor Xa inhibitors** (e.g., rivaroxaban, apixaban), not for dabigatran.- Administering this agent for dabigatran-induced bleeding would be ineffective and inappropriate, delaying the correct treatment.*Administer prothrombin complex concentrate 50 units/kg and proceed to surgery*- **Prothrombin complex concentrate (PCC)** is primarily used for **warfarin reversal** or in cases of Factor Xa inhibitor overdose when specific agents are unavailable.- PCC has **limited or unproven efficacy** in reversing dabigatran and is not recommended when a specific reversal agent like idarucizumab is accessible.*Wait 12 hours since last dabigatran dose before considering surgery*- Delaying emergency surgery in a patient with **neurological deterioration** and **midline shift** would significantly increase the risk of irreversible brain damage and mortality.- Although dabigatran has a half-life of 12-17 hours (potentially longer with mild renal impairment), active reversal is mandatory for **emergent procedures**.*Administer tranexamic acid 1g intravenously and proceed to emergency surgery*- **Tranexamic acid** is an antifibrinolytic agent that helps stabilize clots by inhibiting fibrinolysis but does not reverse the **anticoagulant effect** of dabigatran.- It is insufficient as a standalone therapy for significant bleeding caused by a direct thrombin inhibitor and would not be the primary immediate management.

Question 122: A 45-year-old man with newly diagnosed type 1 diabetes is being initiated on basal-bolus insulin. His HbA1c is 98 mmol/mol (11.2%). He weighs 76kg. He is nervous about starting insulin and asks for the lowest possible starting doses. What total daily insulin dose would you recommend initially?

A. 0.2-0.3 units/kg/day (15-23 units total daily dose)
B. 0.4-0.6 units/kg/day (30-46 units total daily dose) (Correct Answer)
C. 0.8-1.0 units/kg/day (61-76 units total daily dose)
D. 1.2-1.5 units/kg/day (91-114 units total daily dose)
E. The starting dose should be determined by the fasting glucose level only

Explanation: ***0.4-0.6 units/kg/day (30-46 units total daily dose)***- For a newly diagnosed patient with **Type 1 Diabetes**, the standard recommended starting **Total Daily Dose (TDD)** is **0.4 to 0.6 units/kg/day**.- This dose provides a safe balance between achieving glycemic control (given his high **HbA1c of 11.2%**) and minimizing the risk of severe **hypoglycemia** during the initiation phase.*0.2-0.3 units/kg/day (15-23 units total daily dose)*- This lower range is usually reserved for the "**honeymoon period**" where there is significant residual beta-cell function, which is less likely given the patient's high presentation HbA1c.- Starting at this dose would likely lead to persistent **hyperglycemia** and fail to meet the metabolic demands of a 76kg adult.*0.8-1.0 units/kg/day (61-76 units total daily dose)*- Such high doses are typically required only in cases of significant **insulin resistance**, severe **obesity**, or during acute **intercurrent illness** (e.g., sepsis).- Using this as a starting dose for a newly diagnosed patient would carry a very high risk of **treatment-induced hypoglycemia**.*1.2-1.5 units/kg/day (91-114 units total daily dose)*- This range is far beyond typical initiation protocols and is generally only seen in **adolescents during growth spurts** or patients with extreme insulin resistance.- Initiating at this level in a nervous patient would be unsafe and could lead to life-threatening **hypoglycemic episodes**.*The starting dose should be determined by the fasting glucose level only*- Relying solely on **fasting glucose** ignores the insulin requirements for meals and the overall metabolic state reflected by the weight and **HbA1c**.- A **weight-based calculation** (basal-bolus split) is the established standard for safely initiating therapy in Type 1 Diabetes to cover both **basal** and **prandial** needs.

Question 123: A 59-year-old woman with mechanical mitral valve replacement is on warfarin with target INR 3.0-4.0. She presents to the emergency department with epistaxis for 3 hours that has not stopped with local measures. Her INR is 7.2. Her haemoglobin is 118 g/L (baseline 135 g/L). She is haemodynamically stable. What is the most appropriate immediate management of her elevated INR?

A. Withhold warfarin and administer oral vitamin K 1-3mg
B. Withhold warfarin and administer intravenous vitamin K 5mg (Correct Answer)
C. Withhold warfarin, administer intravenous vitamin K 5mg, and give prothrombin complex concentrate
D. Withhold warfarin only and recheck INR in 24 hours
E. Continue warfarin at reduced dose and give fresh frozen plasma

Explanation: ***Withhold warfarin and administer intravenous vitamin K 5mg***- In patients with **major bleeding** (such as persistent epistaxis causing a drop in haemoglobin) and a significantly elevated **INR**, the immediate goal is rapid reversal of anticoagulation.- **Intravenous vitamin K** acts faster than oral vitamin K, typically beginning to reduce the INR within 6-8 hours by promoting the synthesis of **vitamin K-dependent clotting factors**.*Withhold warfarin and administer oral vitamin K 1-3mg*- **Oral vitamin K** is generally reserved for patients with an INR > 8.0 who have **no bleeding** or only minor bleeding.- In the presence of **active major bleeding**, pharmacological reversal must be more rapid, making the oral route insufficient compared to the **intravenous route**.*Withhold warfarin, administer intravenous vitamin K 5mg, and give prothrombin complex concentrate*- While **Prothrombin Complex Concentrate (PCC)** is the gold standard for **life-threatening bleeding** or intracranial hemorrhage, it is often reserved for patients who are **haemodynamically unstable**.- Since this patient is **haemodynamically stable**, intravenous vitamin K is the most appropriate first-line active intervention to manage the risk while monitoring for clinical deterioration.*Withhold warfarin only and recheck INR in 24 hours*- Simply **withholding warfarin** is only appropriate for patients with a mildly elevated INR (usually < 5.0) and **no bleeding**.- Because the INR is 7.2 and there is **clinically significant bleeding**, passive monitoring alone puts the patient at high risk for further blood loss or complications.*Continue warfarin at reduced dose and give fresh frozen plasma*- **Fresh frozen plasma (FFP)** is no longer the preferred agent for warfarin reversal as it is less effective than PCC and carries risks of **volume overload** and transfusion-related lung injury.- **Continuing warfarin** at any dose is contraindicated when a patient presents with an **supratherapeutic INR** and active bleeding.

Question 124: A 56-year-old woman with type 2 diabetes is on insulin glargine 34 units at bedtime and metformin 1g twice daily. She is scheduled for colonoscopy with sedation at 2pm. She has been nil by mouth since midnight. What is the most appropriate insulin management on the day of the procedure?

A. Omit morning metformin and reduce insulin glargine to 50% of usual dose given at usual time (Correct Answer)
B. Omit metformin and give insulin glargine at usual dose at usual time
C. Omit all diabetes medications until after the procedure
D. Give insulin glargine at 50% dose in the morning rather than at usual bedtime
E. Switch to variable rate intravenous insulin infusion from midnight

Explanation: ***Omit morning metformin and reduce insulin glargine to 50% of usual dose given at usual time*** - For patients undergoing procedures requiring fasting, **basal insulin** (glargine) should be reduced (typically by 20-50%) to account for reduced caloric intake while preventing **hyperglycemia** and ketosis. - **Metformin** is generally omitted on the day of the procedure to minimize the risk of **lactic acidosis** and gastrointestinal side effects during fasting and sedation. *Omit metformin and give insulin glargine at usual dose at usual time* - Maintaining the full dose of **insulin glargine** during a prolonged fast significantly increases the risk of **hypoglycemia** during the procedure. - While metformin should be omitted, the basal insulin dose must be adjusted downwards to maintain safety while **Nil by Mouth (NBM)**. *Omit all diabetes medications until after the procedure* - Omitting all insulin in a patient with Type 2 Diabetes on a significant insulin dose can lead to severe **uncontrolled hyperglycemia** or potential **ketosis**. - Basal insulin provides the necessary **background insulin** required for metabolic processes unrelated to meals. *Give insulin glargine at 50% dose in the morning rather than at usual bedtime* - Changing the **timing of administration** for a long-acting analogue like glargine is unnecessary and can complicate the insulin profile for the following 24 hours. - The dose reduction should ideally occur at the **usual administration time** to maintain a steady state of insulin delivery. *Switch to variable rate intravenous insulin infusion from midnight* - A **Variable Rate Intravenous Insulin Infusion (VRIII)** is usually reserved for prolonged fasting (missing more than one meal) or for patients with **Type 1 Diabetes** undergoing major surgery. - For a routine day-case procedure like a colonoscopy in a **Type 2 diabetic**, VRIII is overly invasive and carries its own risks like fluid overload or electrolyte disturbances.

Question 125: A 74-year-old man with atrial fibrillation on apixaban 5mg twice daily is admitted with acute cholecystitis requiring emergency cholecystectomy. His last dose of apixaban was 14 hours ago. His renal function is normal (eGFR 68 ml/min/1.73m²). When is it safe to proceed with surgery?

A. Surgery can proceed immediately as 14 hours is sufficient (Correct Answer)
B. Wait until 24 hours after the last dose before proceeding
C. Wait until 48 hours after the last dose before proceeding
D. Wait until 72 hours after the last dose before proceeding
E. Administer idarucizumab to reverse the anticoagulation before emergency surgery

Explanation: ***Surgery can proceed immediately as 14 hours is sufficient*** - In an **emergency surgical** context, a time interval of >12 hours since the last dose of **apixaban** is generally considered acceptable for proceeding, as the peak effect occurs at 3-4 hours and levels have significantly declined. - With a **half-life** of approximately 12 hours and preserved **renal function** (eGFR >60), the anticoagulant effect at 14 hours is reduced enough to balance the risks of surgical bleeding against the risks of delaying emergency treatment for cholecystitis. *Wait until 24 hours after the last dose before proceeding* - While 24 hours provides a larger safety margin, it is not strictly required for an **emergency procedure** when more than 12 hours have already elapsed. - Delaying emergency surgery for an extra 10 hours may increase the risk of **gallbladder perforation** or sepsis in the setting of acute cholecystitis. *Wait until 48 hours after the last dose before proceeding* - This protocol is typically reserved for **elective surgeries** with a **high bleeding risk** where complete clearance of the drug (approximately 4-5 half-lives) is desired. - Following this timeline in an **emergency setting** would represent an unnecessary and potentially dangerous delay in surgical intervention. *Wait until 72 hours after the last dose before proceeding* - A 72-hour delay is generally only considered for patients with **severe renal impairment** (CrCl <30 mL/min) undergoing very high-risk procedures. - The patient's **eGFR of 68 ml/min** indicates sufficient renal clearance, making such a long wait clinically inappropriate. *Administer idarucizumab to reverse the anticoagulation before emergency surgery* - **Idarucizumab** is a specific reversal agent for **dabigatran** (a direct thrombin inhibitor) and has no efficacy against **apixaban**, which is a **Factor Xa inhibitor**. - The specific reversal agent for apixaban is **andexanet alfa**, but it is generally reserved for life-threatening or uncontrolled bleeding rather than preparing for surgery at 14 hours post-dose.

Question 126: A 67-year-old man with deep vein thrombosis is established on rivaroxaban 15mg twice daily (day 18 of treatment). He has normal renal function. What is the most appropriate next step in his anticoagulation management?

A. Continue rivaroxaban 15mg twice daily for a total of 3 weeks, then switch to 20mg once daily (Correct Answer)
B. Continue rivaroxaban 15mg twice daily for a total of 6 weeks, then switch to 20mg once daily
C. Switch immediately to rivaroxaban 20mg once daily as he is beyond the initial treatment phase
D. Continue rivaroxaban 15mg twice daily for the entire treatment duration
E. Switch to warfarin with target INR 2-3 after completing 3 weeks of rivaroxaban

Explanation: ***Continue rivaroxaban 15mg twice daily for a total of 3 weeks, then switch to 20mg once daily***- For acute **deep vein thrombosis (DVT)**, the standard initiation dose of **rivaroxaban** is **15mg twice daily** for the first **21 days (3 weeks)**.- This initial aggressive dosing ensures effective anticoagulation during the period of highest risk for clot propagation and is followed by a **maintenance dose of 20mg once daily**.*Continue rivaroxaban 15mg twice daily for a total of 6 weeks, then switch to 20mg once daily*- Extending the **15mg twice-daily** dosing to 6 weeks is not aligned with established guidelines for **rivaroxaban** in **DVT** treatment.- This prolonged higher dose increases the **risk of bleeding** without offering additional benefit over the standard 3-week initial phase.*Switch immediately to rivaroxaban 20mg once daily as he is beyond the initial treatment phase*- The patient is on **day 18** of treatment; the initial intense phase of **rivaroxaban 15mg twice daily** is for **21 days**.- Switching prematurely would mean the patient receives a sub-therapeutic dose during the critical final days of the **acute treatment phase**, increasing the risk of recurrent thrombosis.*Continue rivaroxaban 15mg twice daily for the entire treatment duration*- Maintaining the **15mg twice-daily** dose for the entire treatment duration (typically 3-6 months or longer) is an incorrect and excessive regimen.- Long-term use of this higher dose substantially increases the cumulative **risk of major bleeding** and is not standard practice.*Switch to warfarin with target INR 2-3 after completing 3 weeks of rivaroxaban*- **Rivaroxaban** is a **direct oral anticoagulant (DOAC)**, often preferred for DVT due to its predictable pharmacokinetics and no need for routine **INR monitoring**.- There is no indication to switch to **warfarin** in a patient tolerating rivaroxaban with normal renal function, as DOACs are equally or more effective and often safer.

Question 127: A 53-year-old woman with newly diagnosed type 1 diabetes is being discharged on basal-bolus insulin therapy. She will be taking insulin glargine 22 units at bedtime and insulin aspart before meals. When should she administer the insulin aspart in relation to eating?

A. 30-45 minutes before meals
B. Immediately before or with the first mouthful of food (Correct Answer)
C. Midway through the meal
D. Immediately after finishing the meal
E. 30 minutes after completing the meal

Explanation: ***Immediately before or with the first mouthful of food*** - **Insulin aspart** is a **rapid-acting insulin analogue** with a very quick onset of action (10–20 minutes), designed to cover the rapid postprandial glucose surge. - Administering it right as the meal begins ensures its peak action coincides with the digestion and absorption of carbohydrates, optimizing **postprandial glucose control** and preventing early **hyperglycemia**. *30-45 minutes before meals* - This timing is typically appropriate for **soluble (regular) insulin**, which has a slower onset of action (30-60 minutes) and requires a longer lead time before food. - Giving **rapid-acting insulin aspart** this early would significantly increase the risk of **pre-meal hypoglycemia** before the consumed carbohydrates can raise blood glucose levels. *Midway through the meal* - Administering insulin aspart midway through the meal would delay its action relative to the initial carbohydrate absorption, potentially leading to **early postprandial hyperglycemia**. - While occasionally considered in specific clinical scenarios (e.g., severe gastroparesis), it is not the standard or optimal recommendation for general postprandial glucose management. *Immediately after finishing the meal* - Taking **insulin aspart** after completing the meal means its peak action will occur too late to effectively cover the initial and rapid **postprandial glucose rise**, resulting in undesirable hyperglycemia. - This delayed timing can lead to a mismatch between insulin action and carbohydrate absorption, making it harder to achieve stable glucose control. *30 minutes after completing the meal* - This significantly delayed administration would result in a prolonged period of **hyperglycemia** following the meal, as the insulin's peak effect would be far behind the carbohydrate absorption. - Such a substantial delay leads to poor glucose management, with potential for high blood glucose levels post-meal and an increased risk of **delayed hypoglycemia** hours later.

Question 128: A 62-year-old man on warfarin for atrial fibrillation attends for INR check. His INR is 1.8 (target 2-3). He reports he has been taking co-trimoxazole for a urinary tract infection prescribed by his GP 5 days ago. What is the most likely explanation for his subtherapeutic INR despite the drug interaction?

A. Co-trimoxazole typically causes INR elevation; the low INR suggests non-compliance with warfarin (Correct Answer)
B. The timing is too early; co-trimoxazole takes 7-10 days to affect INR
C. Co-trimoxazole reduces warfarin absorption from the gastrointestinal tract
D. The patient has likely increased his vitamin K intake during the infection
E. Co-trimoxazole is a weak enzyme inducer causing increased warfarin metabolism

Explanation: ***Co-trimoxazole typically causes INR elevation; the low INR suggests non-compliance with warfarin*** - **Co-trimoxazole** (trimethoprim/sulfamethoxazole) is a potent **CYP2C9 inhibitor**, which significantly reduces the metabolism of **warfarin's S-isomer**, leading to a **marked increase in INR**. - Given that the expected outcome of co-trimoxazole use in a patient on warfarin is a **supratherapeutic INR**, a subtherapeutic INR of 1.8 strongly suggests **non-compliance** or omission of warfarin doses by the patient. *The timing is too early; co-trimoxazole takes 7-10 days to affect INR* - The **pharmacokinetic interaction** between co-trimoxazole and warfarin typically manifests quite rapidly, with a significant **INR elevation** often observed within **3 to 5 days** of starting co-trimoxazole. - Therefore, after 5 days, the effect should already be apparent, making the claim that it's "too early" incorrect. *Co-trimoxazole reduces warfarin absorption from the gastrointestinal tract* - There is **no clinical evidence** to support that co-trimoxazole interferes with the **gastrointestinal absorption** of warfarin. - The primary and significant interaction occurs at the **metabolic level** in the liver, not at the absorption site. *The patient has likely increased his vitamin K intake during the infection* - While an increase in **dietary vitamin K** can indeed lower INR, it is generally **unlikely** for a patient with an acute urinary tract infection to suddenly and significantly increase their vitamin K intake. - This explanation is less probable compared to the direct and potent drug-drug interaction expected or the possibility of **non-compliance**. *Co-trimoxazole is a weak enzyme inducer causing increased warfarin metabolism* - **Co-trimoxazole** is a well-known **enzyme inhibitor** (specifically of CYP2C9), not an enzyme inducer. - As an inhibitor, it would **decrease warfarin metabolism**, leading to **increased warfarin levels** and a higher INR, which is the opposite effect of enzyme induction.

Question 129: A 70-year-old man with type 2 diabetes on basal-bolus insulin therapy is admitted with community-acquired pneumonia. His inflammatory markers are significantly elevated. He is alert and eating normally. Which aspect of his insulin management requires particular attention during acute illness?

A. Insulin should be temporarily discontinued until the acute illness resolves
B. Only basal insulin should be continued; bolus insulin should be stopped
C. Insulin requirements typically increase during acute illness and infection (Correct Answer)
D. Insulin dose should be halved to prevent hypoglycaemia during reduced oral intake
E. Insulin should be switched to twice-daily premixed insulin for simplicity

Explanation: ***Insulin requirements typically increase during acute illness and infection*** - Acute illness, particularly infection like pneumonia, activates a **stress response** leading to the release of **counter-regulatory hormones** (e.g., cortisol, glucagon). These hormones significantly increase **insulin resistance** and glucose production. - Even with normal oral intake, this heightened physiological stress means that patients with diabetes usually require **higher insulin doses** to maintain adequate glycemic control and prevent hyperglycemia. *Insulin should be temporarily discontinued until the acute illness resolves* - Discontinuing insulin therapy in a patient with type 2 diabetes on basal-bolus insulin is extremely dangerous during acute illness, potentially precipitating **diabetic ketoacidosis (DKA)** or **hyperosmolar hyperglycemic state (HHS)**. - **Basal insulin** is continuously needed to suppress hepatic glucose output and ketogenesis, regardless of whether the patient is eating. *Only basal insulin should be continued; bolus insulin should be stopped* - Since the patient is reported to be **alert and eating normally**, **bolus insulin** is crucial to cover the carbohydrate intake and manage **postprandial glucose excursions**. - Stopping bolus insulin while eating would inevitably lead to severe **postprandial hyperglycemia**, worsening overall glycemic control during the illness. *Insulin dose should be halved to prevent hypoglycaemia during reduced oral intake* - The patient is explicitly stated to be **eating normally**, contradicting the premise of reduced oral intake. Therefore, arbitrarily halving the insulin dose is inappropriate. - Given the typical **increase in insulin requirements** during acute illness, such a drastic reduction would likely result in significant **hyperglycemia** rather than preventing hypoglycemia. *Insulin should be switched to twice-daily premixed insulin for simplicity* - During an acute illness in a hospital setting, a **basal-bolus insulin regimen** offers superior flexibility, allowing for precise adjustments to both basal and bolus doses based on frequent blood glucose monitoring and varying nutritional needs. - Switching to a **premixed insulin regimen** would limit this flexibility, making it more challenging to achieve optimal glycemic control in a rapidly changing clinical situation.

Question 130: A 65-year-old woman with atrial fibrillation is commenced on edoxaban 60mg once daily. She weighs 58kg and has normal renal function. After 3 months, her weight has decreased to 55kg. What is the most appropriate action regarding her anticoagulation?

A. Continue edoxaban 60mg once daily unchanged
B. Reduce edoxaban dose to 30mg once daily (Correct Answer)
C. Switch to apixaban 5mg twice daily
D. Switch to warfarin with target INR 2-3
E. Stop anticoagulation and prescribe aspirin 75mg daily

Explanation: ***Reduce edoxaban dose to 30mg once daily*** - **Edoxaban** requires a dose reduction to 30mg once daily if the patient's **body weight is ≤ 60kg** to minimize the risk of bleeding while maintaining efficacy. - Since the patient's weight has decreased to **55kg**, she now meets the mandatory criterion for this dose adjustment. *Continue edoxaban 60mg once daily unchanged* - Continuing the standard 60mg dose in a patient weighing **less than 60kg** significantly increases the **bleeding risk**. - Dose adjustments for **DOACs** must be reviewed when a patient's clinical parameters, such as **weight or renal function**, change. *Switch to apixaban 5mg twice daily* - Switching to another DOAC is unnecessary as **edoxaban** remains appropriate, provided the dose is adjusted for the patient's current **weight**. - While **apixaban** is also an effective anticoagulant, its dosing also depends on criteria like age, weight, and creatinine, but simple dose adjustment of the current drug is the standard first step. *Switch to warfarin with target INR 2-3* - **Warfarin** is generally less preferred than **DOACs** for non-valvular atrial fibrillation due to the need for frequent **INR monitoring** and dietary restrictions. - There is no clinical indication to switch from a DOAC to a **Vitamin K Antagonist** solely due to a weight change, especially when the DOAC can be dose-adjusted. *Stop anticoagulation and prescribe aspirin 75mg daily* - **Aspirin** is no longer recommended for stroke prevention in **atrial fibrillation** as it is significantly less effective than anticoagulants and still carries bleeding risks. - Stopping anticoagulation entirely would leave the patient at a high risk for **cardioembolic stroke** given her history of atrial fibrillation.

Question 131: What is the recommended monitoring frequency for full blood count in a patient who has been stable on methotrexate for rheumatoid arthritis for 18 months?

A. Every 2-4 weeks
B. Every 1-2 months
C. Every 2-3 months (Correct Answer)
D. Every 6 months
E. Annually

Explanation: ***Every 2-3 months*** - For patients on a **stable dose** of methotrexate for more than 12 months, the standard monitoring interval for **full blood count (FBC)** and LFTs is every 2-3 months. - This frequency balances the need to detect late-onset **myelosuppression** or **hepatotoxicity** while reducing the burden of frequent testing on stable patients. *Every 2-4 weeks* - This intensive monitoring is typically reserved for the **initiation phase** or during **dose escalation** until the dose and bloods have been stable for 6 weeks. - It is not required for a patient who has been stable for 18 months, as the risk of acute adverse reactions is lower. *Every 1-2 months* - While safer than longer intervals, this is generally the transitional frequency once a dose is stable but before moving to **long-term maintenance monitoring**. - Current guidelines specifically recommend extending the interval to **12-weekly (3 months)** once clinical stability is established. *Every 6 months* - Monitoring every 6 months is considered unsafe for methotrexate because **bone marrow suppression** can occur unpredictably at any time during treatment. - Most guidelines mandate that the monitoring interval should **never exceed 3 months** for this high-risk DMARD. *Annually* - Annual monitoring is insufficient for detecting **cytopenias** or **liver enzyme elevations** associated with chronic methotrexate use. - Failure to monitor more frequently increases the risk of serious complications like **pancytopenia** or progressive **pulmonary toxicity** going unnoticed.

Question 132: A 58-year-old woman with inflammatory bowel disease is started on azathioprine 150mg daily. Which baseline investigation is essential before commencing this high-risk medication to identify patients at increased risk of myelosuppression?

A. Thiopurine methyltransferase (TPMT) activity (Correct Answer)
B. Glucose-6-phosphate dehydrogenase (G6PD) level
C. Serum immunoglobulin levels
D. HLA-B*5801 genotyping
E. Serum complement C3 and C4 levels

Explanation: ***Thiopurine methyltransferase (TPMT) activity*** - **TPMT** is the primary enzyme responsible for metabolizing thiopurine drugs; patients with low or absent activity are at a high risk of **life-threatening myelosuppression**. - Testing is essential to guide **dosage adjustments**, as those with intermediate activity require significant reduction, while those with deficiency should avoid the drug entirely. *Glucose-6-phosphate dehydrogenase (G6PD) level* - This test identifies risks for **hemolysis** when prescribing oxidative drugs such as **dapsone** or **primaquine**. - It does not relate to the metabolism of thiopurines or the risk of **bone marrow suppression** with azathioprine. *Serum immunoglobulin levels* - These are checked to identify **immunodeficiencies** but are not useful for predicting specific metabolic reactions to azathioprine. - Azathioprine may reduce levels over time, but baseline levels do not screen for **azathioprine toxicity**. *HLA-B*5801 genotyping* - This genetic screening is performed prior to starting **allopurinol** to identify patients at high risk for **Stevens-Johnson syndrome**. - While both drugs involve the purine pathway, this specific allele is not a marker for **azathioprine-induced leukopenia**. *Serum complement C3 and C4 levels* - Complement levels are used to monitor **disease activity** in autoimmune conditions like SLE, rather than drug metabolism. - They have no predictive value for **myelosuppression** or adverse reactions associated with thiopurine therapy.

Question 133: A 76-year-old man with non-valvular atrial fibrillation has a CHA₂DS₂-VASc score of 5 and HAS-BLED score of 4. He has a history of previous ischaemic stroke, chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²), hypertension, and previous gastrointestinal bleeding from gastric ulcer (successfully treated 2 years ago with no recurrence). He declines warfarin due to monitoring burden. Which direct oral anticoagulant (DOAC) regimen represents the most appropriate choice considering his risk factors?

A. Apixaban 5mg twice daily
B. Apixaban 2.5mg twice daily (Correct Answer)
C. Rivaroxaban 20mg once daily
D. Edoxaban 60mg once daily
E. Dabigatran 150mg twice daily

Explanation: ***Apixaban 2.5mg twice daily***- Dose reduction to **2.5mg twice daily** is indicated if the patient meets at least two of the three criteria: **age ≥80**, **weight ≤60kg**, or **serum creatinine ≥133 µmol/L**; in clinical practice, patients with high bleeding risk (**HAS-BLED 4**) and low **eGFR** often benefit from this reduced dose.- Apixaban is frequently the preferred **DOAC** in patients with a history of **gastrointestinal bleeding**, as it has demonstrated a superior safety profile regarding major bleeding compared to other agents.*Apixaban 5mg twice daily*- This is the standard dose for **non-valvular atrial fibrillation**, but it may be inappropriate for a patient with a high **HAS-BLED score** and impaired renal function.- Using the full dose in a patient with a significantly elevated stroke and bleeding risk requires careful balancing, and reduction is often prioritized when **renal impairment** (eGFR 38) is present.*Rivaroxaban 20mg once daily*- The standard 20mg dose is inappropriate here because **Rivaroxaban** requires dose reduction to **15mg once daily** when the **eGFR** falls between 15-49 ml/min.- **Rivaroxaban** has been associated with a higher risk of **GI bleeding** compared to apixaban, making it less suitable for this specific patient history.*Edoxaban 60mg once daily*- Similar to rivaroxaban, **Edoxaban** requires a dose reduction to **30mg once daily** for patients with a **CrCl** between 15-50 ml/min or a body weight ≤60kg.- The 60mg dose would pose an unacceptably high risk of bleeding in a patient with **Stage 3b Chronic Kidney Disease**.*Dabigatran 150mg twice daily*- **Dabigatran** is heavily dependent on **renal excretion**, and the 150mg dose is generally avoided or used with extreme caution in moderate renal impairment.- It is specifically noted for causing a higher incidence of **gastrointestinal side effects** and bleeding, which is contraindicated by this patient's history of a **gastric ulcer**.

Question 134: A 41-year-old woman with type 1 diabetes is 16 weeks pregnant. She has been experiencing recurrent nocturnal hypoglycaemia (2-3 episodes per week with glucose <3.5 mmol/L at 03:00) despite adjusting her evening meal bolus. Her current regimen is insulin detemir 18 units at 22:00 and insulin aspart with meals (6-8 units per meal). Her fasting glucose is 4.2-5.1 mmol/L and HbA1c is 42 mmol/mol. What is the most appropriate adjustment to minimize nocturnal hypoglycaemia?

A. Reduce insulin detemir dose to 14 units at 22:00
B. Split insulin detemir to 10 units at 08:00 and 10 units at 22:00 (Correct Answer)
C. Change the timing of insulin detemir from 22:00 to 08:00
D. Switch from insulin detemir to insulin glargine U300 for longer duration of action
E. Add a complex carbohydrate snack at bedtime without adjusting insulin

Explanation: ***Split insulin detemir to 10 units at 08:00 and 10 units at 22:00*** - **Insulin detemir** often has a duration of action of 12–20 hours; splitting the dose provides more **physiological basal coverage** and reduces the peak effect that occurs when a large single dose is given at night. - This approach addresses **nocturnal hypoglycaemia** (at 03:00) while ensuring adequate daytime basal insulin, which is critical for maintaining the tight **glycaemic control** required in pregnancy. *Reduce insulin detemir dose to 14 units at 22:00* - Simply reducing the dose may resolve the hypoglycemia but will likely lead to **fasting hyperglycaemia**, as the current fasting levels (4.2–5.1 mmol/L) are already at the lower end of the target range. - In **pregnancy**, avoiding both hypoglycemia and hyperglycemia is essential; a simple reduction lacks the necessary **basal coverage** for the rest of the 24-hour cycle. *Change the timing of insulin detemir from 22:00 to 08:00* - Moving detemir to the morning only would leave the patient with no **basal insulin cover** overnight, significantly increasing the risk of **nocturnal hyperglycaemia** and ketosis. - Due to the shorter duration of action of detemir compared to other analogues, **once-daily morning dosing** is generally insufficient for Type 1 Diabetes management. *Switch from insulin detemir to insulin glargine U300 for longer duration of action* - **Insulin glargine U300** (Toujeo) is currently not licensed for use during **pregnancy**, and there is limited safety data compared to detemir or glargine U100. - Detemir and **glargine U100** are the preferred long-acting analogues in pregnancy due to extensive evidence supporting their **safety and efficacy**. *Add a complex carbohydrate snack at bedtime without adjusting insulin* - Adding a snack without adjusting insulin is an outdated strategy that can lead to unnecessary **weight gain** and suboptimal control of **morning glucose levels**. - This does not address the underlying **pharmacokinetic issue** of the insulin detemir peak causing the 03:00 hypoglycaemic episodes.

Question 135: A 68-year-old man with mechanical aortic valve replacement on warfarin (target INR 2.5-3.5) is admitted with a large retroperitoneal haematoma. His INR is 7.8, haemoglobin 72 g/L (from 135 g/L two weeks ago), BP 95/60 mmHg, heart rate 108 bpm. He is not actively bleeding externally. What is the most appropriate immediate management of his anticoagulation?

A. Withhold warfarin and give oral vitamin K 5mg, repeat INR in 24 hours
B. Withhold warfarin and give intravenous vitamin K 5mg by slow infusion, repeat INR in 6 hours
C. Give intravenous vitamin K 5-10mg by slow infusion and four-factor prothrombin complex concentrate (PCC) 25-50 units/kg immediately (Correct Answer)
D. Give fresh frozen plasma 4 units and intravenous vitamin K 10mg immediately
E. Withhold warfarin only and monitor, as INR will normalize within 48 hours

Explanation: ***Give intravenous vitamin K 5-10mg by slow infusion and four-factor prothrombin complex concentrate (PCC) 25-50 units/kg immediately*** - This patient has **major, life-threatening bleeding** (retroperitoneal haematoma with significant blood loss and **hemodynamic instability** due to a critically high INR of 7.8). - **Four-factor PCC** provides immediate replacement of **vitamin K-dependent clotting factors (II, VII, IX, X)**, rapidly normalizing INR, while **intravenous vitamin K** ensures sustained new factor synthesis, preventing recurrence. *Withhold warfarin and give oral vitamin K 5mg, repeat INR in 24 hours* - **Oral vitamin K** has a delayed onset of action (12-24 hours) and is unsuitable for **major, life-threatening bleeding** requiring immediate reversal. - Simply withholding warfarin and waiting 24 hours would allow the patient to continue bleeding internally, leading to further **hemodynamic deterioration** and potential death. *Withhold warfarin and give intravenous vitamin K 5mg by slow infusion, repeat INR in 6 hours* - While **intravenous vitamin K** acts faster than oral (onset 4-6 hours), it still takes too long for a patient with **active, life-threatening bleeding** and **hemodynamic instability**. - **Immediate factor replacement** with agents like PCC is crucial for rapid hemostasis in such critical situations. *Give fresh frozen plasma 4 units and intravenous vitamin K 10mg immediately* - **Fresh Frozen Plasma (FFP)** is considered second-line to PCC because it requires **large volumes**, carries a risk of **fluid overload**, and needs thawing and cross-matching, causing delays. - **PCC** is superior for rapid warfarin reversal as it provides a concentrated, small-volume source of **vitamin K-dependent factors** with a faster administration time. *Withhold warfarin only and monitor, as INR will normalize within 48 hours* - Withholding warfarin alone is appropriate for **supratherapeutic INR without bleeding** or minor bleeding, but entirely inadequate for **major hemorrhage**. - The patient's **hemodynamic instability** and severe drop in **haemoglobin** indicate a critical need for immediate and aggressive reversal to prevent further blood loss and stabilize their condition.

Question 136: A 73-year-old woman with type 2 diabetes is admitted with hospital-acquired pneumonia. She is on insulin detemir 36 units at bedtime and metformin 1g twice daily at home. On day 3 of admission, she is on a variable rate insulin infusion (VRIII) requiring 4 units/hour to maintain glucose 6-10 mmol/L. Her oral intake has improved. You plan to transition to subcutaneous insulin. What total daily insulin dose should be prescribed?

A. 36 units total daily dose (same as her home insulin)
B. 50 units total daily dose (based on average requirement over 12 hours)
C. 72 units total daily dose (based on 24-hour VRIII requirement) (Correct Answer)
D. 96 units total daily dose (24-hour requirement plus 30% for stress)
E. 90 units total daily dose (24-hour requirement plus 25% safety margin)

Explanation: ***72 units total daily dose (based on 24-hour VRIII requirement)***- When transitioning from a **Variable Rate Insulin Infusion (VRIII)** to subcutaneous insulin, the total daily dose is typically estimated at 75-80% of the previous **24-hour VRIII requirement**.- In this case, 4 units/hour over 24 hours equals 96 units; 75% of this is **72 units**, which prudently accounts for the anticipated decrease in **insulin resistance** as the patient recovers from pneumonia and her acute illness. *36 units total daily dose (same as her home insulin)*- The patient's **home insulin dose** is insufficient during acute illness, as stress from hospital-acquired pneumonia significantly increases **insulin requirements** and resistance.- Her current need for 4 units/hour on VRIII (96 units/day) clearly indicates that her insulin demand is substantially higher than her usual **basal insulin** dose. *50 units total daily dose (based on average requirement over 12 hours)*- Calculating the total daily insulin dose based on only a **12-hour average** is inaccurate and can lead to significant under- or over-dosing, as insulin needs fluctuate over a full 24-hour period.- A **24-hour profile** is essential to accurately capture both **basal and prandial insulin** requirements for a safe and effective transition. *96 units total daily dose (24-hour requirement plus 30% for stress)*- Prescribing 100% of the VRIII dose (96 units) plus an additional 30% is dangerous and inappropriate when a patient is recovering from **acute illness**.- As the patient's condition improves and her oral intake is better, her **stress-induced insulin resistance** will decrease, making this dose highly likely to cause **hypoglycemia**. *90 units total daily dose (24-hour requirement plus 25% safety margin)*- Adding a

Question 137: A 55-year-old man with atrial fibrillation on dabigatran 150mg twice daily requires emergency surgery for perforated diverticulitis within 2 hours. His last dose of dabigatran was 6 hours ago. His renal function is normal (eGFR 78 ml/min/1.73m²). Laboratory testing shows an elevated activated partial thromboplastin time (APTT). What is the most appropriate management of his anticoagulation?

A. Proceed with surgery immediately without reversal agent as 6 hours have elapsed
B. Administer vitamin K 10mg intravenously and proceed with surgery in 30 minutes
C. Administer prothrombin complex concentrate (PCC) and proceed with surgery
D. Administer idarucizumab 5g intravenously and proceed with surgery when haemostasis is confirmed (Correct Answer)
E. Wait for another 6 hours (12 hours total) before proceeding with surgery to allow natural clearance

Explanation: ***Administer idarucizumab 5g intravenously and proceed with surgery when haemostasis is confirmed*** - **Idarucizumab** is a specific monoclonal antibody fragment used for the **rapid reversal** of the direct thrombin inhibitor **dabigatran** in cases of life-threatening bleeding or emergency surgery. - The standard dose is **5g IV** (two 2.5g vials), which provides immediate and sustained reversal, necessary here as the patient has significant anticoagulant activity (**elevated APTT**) and requires surgery within 2 hours. *Proceed with surgery immediately without reversal agent as 6 hours have elapsed* - **Dabigatran** has a half-life of **12–14 hours** in patients with normal renal function; therefore, significant levels remain in the system 6 hours after the last dose. - Moving forward without reversal in the setting of **perforated diverticulitis** carries a high risk of life-threatening **intraoperative hemorrhage**. *Administer vitamin K 10mg intravenously and proceed with surgery in 30 minutes* - **Vitamin K** is used specifically to reverse the effects of **warfarin** by facilitating the synthesis of clotting factors II, VII, IX, and X. - It has no effect on **dabigatran**, which works by directly inhibiting **thrombin** (Factor IIa), making this treatment ineffective in this scenario. *Administer prothrombin complex concentrate (PCC) and proceed with surgery* - **PCC** is a non-specific reversal agent primarily used for factor-depleting anticoagulants and can be considered for **Factor Xa inhibitors** if specific agents are unavailable. - Because **idarucizumab** is the specific, high-affinity antidote for **dabigatran**, it is the gold standard and preferred over non-specific PCC. *Wait for another 6 hours (12 hours total) before proceeding with surgery to allow natural clearance* - Waiting for natural clearance would delay the treatment of **perforated diverticulitis**, a surgical emergency that can lead to **sepsis** and death if not treated urgently. - Even at 12 hours post-dose, **therapeutic drug levels** may still be present, especially given the seriousness of the planned abdominal procedure.

Question 138: A 67-year-old woman with type 1 diabetes for 35 years is admitted with pneumonia. Her blood glucose is managed with a variable rate insulin infusion (VRIII). She is now eating and drinking and ready to transition back to subcutaneous insulin. Her pre-admission regimen was insulin detemir 28 units twice daily and insulin aspart 8-10 units with meals. When should her VRIII be discontinued?

A. Immediately after giving the first dose of subcutaneous rapid-acting insulin
B. 30 minutes after giving subcutaneous rapid-acting insulin
C. At least 30-60 minutes after giving long-acting insulin and with the first meal and rapid-acting insulin (Correct Answer)
D. 2 hours after giving the first dose of long-acting insulin
E. Once blood glucose is stable below 10 mmol/L for 4 hours

Explanation: ***At least 30-60 minutes after giving long-acting insulin and with the first meal and rapid-acting insulin***- To prevent **rebound hyperglycemia** or **ketosis**, a **variable rate insulin infusion (VRIII)** must overlap with subcutaneous insulin until the latter has reached therapeutic systemic levels.- Disconnecting the infusion 30-60 minutes after **basal insulin** (detemir) and concurrently with a **mealtime bolus** (aspart) ensures a safe transition without a gap in insulin coverage, which is critical in Type 1 diabetes.*Immediately after giving the first dose of subcutaneous rapid-acting insulin*- Subcutaneous **rapid-acting insulin** takes approximately 15-20 minutes to start working and longer to peak, leaving a dangerous window of inadequate insulin if the VRIII is stopped immediately.- This approach fails to account for the necessary **basal insulin** overlap required to maintain stable background glucose levels, which is vital for preventing **ketoacidosis** in Type 1 diabetes.*30 minutes after giving subcutaneous rapid-acting insulin*- While this provides a short overlap for the bolus, it does not ensure that the **long-acting basal insulin** (detemir) has reached sufficient plasma concentrations.- Without adequate **basal insulin overlap**, patients with **Type 1 diabetes** are at significant risk of developing ketosis or **diabetic ketoacidosis** due to the very short half-life of intravenous insulin.*2 hours after giving the first dose of long-acting insulin*- While 2 hours ensures the **basal insulin** is active, VRIII transition should ideally be timed with a **meal** to allow the patient to resume their normal subcutaneous bolus regimen.- Keeping the VRIII running for 2 hours after basal insulin without coordinating with a meal and **rapid-acting insulin** increases the risk of **hypoglycemia** if the patient is not eating or if the basal dose is excessive.*Once blood glucose is stable below 10 mmol/L for 4 hours*- Metabolic stability (blood glucose below 10 mmol/L) is a prerequisite for initiating the transition, but it does not dictate the physical timing of **discontinuing the infusion** pump.- The transition must always be managed by ensuring **pharmacokinetic overlap** between IV and SC routes, ensuring continuous insulin supply regardless of how long the glucose has been stable.

Question 139: A 63-year-old man with deep vein thrombosis is on rivaroxaban 15mg twice daily for initial treatment. He has completed 21 days of therapy. His renal function shows creatinine clearance of 48 ml/min, weight 82kg. What is the most appropriate ongoing anticoagulation management?

A. Continue rivaroxaban 15mg twice daily for another 21 days then switch to 20mg once daily
B. Switch to rivaroxaban 20mg once daily for ongoing therapy (Correct Answer)
C. Switch to rivaroxaban 15mg once daily for ongoing therapy due to renal impairment
D. Switch to apixaban 2.5mg twice daily for ongoing therapy
E. Continue rivaroxaban 15mg twice daily indefinitely

Explanation: ***Switch to rivaroxaban 20mg once daily for ongoing therapy***- For the treatment of **DVT/PE**, the standard **rivaroxaban** regimen is **15mg twice daily** for the first **21 days**, followed by a transition to **20mg once daily** for maintenance phase.- Since the patient has completed his 21-day initial treatment and his **CrCl is 48 ml/min** (which is >30 ml/min), the full maintenance dose of **20mg once daily** is appropriate.*Continue rivaroxaban 15mg twice daily for another 21 days then switch to 20mg once daily*- The **initial treatment phase** with twice-daily dosing specifically lasts only **21 days**; extending this phase increases the **bleeding risk** unnecessarily.- There is no clinical indication for a 42-day loading period for **Deep Vein Thrombosis** management.*Switch to rivaroxaban 15mg once daily for ongoing therapy due to renal impairment*- **Rivaroxaban dose reduction** to 15mg once daily for maintenance is typically only indicated if the **Creatinine Clearance (CrCl)** is between **15-29 ml/min**.- With a **CrCl of 48 ml/min**, this patient does not meet the threshold for renal dose adjustment and should receive the standard **20mg dose**.*Switch to apixaban 2.5mg twice daily for ongoing therapy*- **Apixaban 2.5mg twice daily** is a secondary prevention (prophylactic) dose used only after **6 months** of full-dose anticoagulant treatment.- This patient requires ongoing **treatment-dose anticoagulation**; switching to a low-dose prophylactic regimen at 3 weeks would be **sub-therapeutic** for an acute DVT.*Continue rivaroxaban 15mg twice daily indefinitely*- Continuing a **twice-daily loading regimen** indefinitely is not the licensed protocol and significantly increases the risk of **major hemorrhage**.- Stable maintenance therapy for DVT requires transitioning to **once-daily dosing** to ensure patient compliance and safety profile.

Question 140: A 49-year-old woman with type 2 diabetes is admitted for elective total knee replacement. She is on insulin glargine 40 units at bedtime and metformin 1g twice daily. Her HbA1c is 58 mmol/mol. Surgery is scheduled for 08:00. What is the most appropriate perioperative insulin management?

A. Omit morning metformin, give 80% of usual glargine dose on morning of surgery, start variable rate insulin infusion (Correct Answer)
B. Omit morning metformin, omit glargine, start variable rate insulin infusion on morning of surgery
C. Continue metformin and glargine as normal, start variable rate insulin infusion in addition
D. Omit morning metformin, give 100% of usual glargine dose on morning of surgery, no variable rate insulin infusion needed
E. Omit morning metformin, give 80% of usual glargine dose on morning of surgery, no variable rate insulin infusion needed

Explanation: ***Omit morning metformin, give 80% of usual glargine dose on morning of surgery, start variable rate insulin infusion*** - For elective surgery, **metformin** is omitted on the morning of surgery to minimize risks associated with fasting and potential renal impairment. - Administering **80% of basal insulin** (glargine) provides essential background coverage to prevent **ketosis**, while a **Variable Rate Intravenous Insulin Infusion (VRIII)** ensures precise glucose control during the perioperative fasting period. *Omit morning metformin, omit glargine, start variable rate insulin infusion on morning of surgery* - Completely omitting **glargine** is inappropriate as it can lead to **hyperglycemia** and a lack of baseline insulin coverage, increasing the risk of metabolic instability. - Even with a **VRIII**, maintaining a portion of the **basal insulin** helps stabilize blood glucose levels during the transition back to subcutaneous regimens. *Continue metformin and glargine as normal, start variable rate insulin infusion in addition* - Continuing **metformin** while fasting for surgery is avoided due to the potential risk of **lactic acidosis** if renal perfusion is compromised. - Giving **100% of the glargine dose** while the patient is nil-by-mouth (NBM) significantly increases the risk of **hypoglycemia**. *Omit morning metformin, give 100% of usual glargine dose on morning of surgery, no variable rate insulin infusion needed* - A full dose of **glargine** without oral intake is unsafe and likely to cause **hypoglycemia** during or after the procedure. - In major surgery (like a knee replacement), a **VRIII** is typically required to manage the metabolic stress response and maintain strict **glycaemic control**. *Omit morning metformin, give 80% of usual glargine dose on morning of surgery, no variable rate insulin infusion needed* - While the reduction in **glargine** is correct, omitting the **VRIII** for a major procedure where the patient is NBM ignores the need for active glucose management. - **VRIII** is the standard tier of care for insulin-dependent patients undergoing major surgery to prevent intraoperative **hyperglycemic** fluctuations.

Question 141: A 71-year-old man with atrial fibrillation has been on warfarin for 4 years with stable INR control. He is admitted with an acute ischaemic stroke. CT head shows no haemorrhage. His INR on admission is 2.4 (target 2-3) and his NIHSS score is 16. He is outside the thrombolysis window. What is the most appropriate management of his anticoagulation?

A. Continue warfarin unchanged and monitor INR daily
B. Withhold warfarin for 7 days then restart when neurologically stable
C. Immediately reverse anticoagulation with vitamin K and prothrombin complex concentrate
D. Switch immediately to low molecular weight heparin for 14 days
E. Withhold warfarin for 14 days then restart after repeat CT excludes haemorrhagic transformation (Correct Answer)

Explanation: ***Withhold warfarin for 14 days then restart after repeat CT excludes haemorrhagic transformation***- For patients with **severe ischaemic stroke** (indicated by an **NIHSS score of 16**), current guidelines generally recommend delaying anticoagulation for **14 days** to minimize the risk of haemorrhagic transformation.- Repeat imaging is essential before restarting to ensure there is no **haemorrhagic transformation**, which is a high risk in large infarcts regardless of the therapeutic INR.*Continue warfarin unchanged and monitor INR daily*- Continuing full anticoagulation in the acute phase of a **large ischaemic stroke** significantly increases the risk of symptomatic **intracranial haemorrhage** into the infarcted tissue.- Current clinical guidelines recommend a temporary interruption of therapy even if the patient was previously stable and within the **therapeutic range**.*Withhold warfarin for 7 days then restart when neurologically stable*- While some guidelines suggest a 3 to 7-day delay for **minor strokes** or TIAs, a 7-day window is considered too short for a **severe stroke** (NIHSS > 15).- Severity of the stroke, as measured by the **NIHSS score**, dictates the length of the delay; a longer period is required for larger areas of brain tissue damage.*Immediately reverse anticoagulation with vitamin K and prothrombin complex concentrate*- Acute reversal with **PCC and Vitamin K** is indicated for **haemorrhagic strokes** or life-threatening bleeding, not for an acute ischaemic stroke.- Reversing anticoagulation unnecessarily in a patient with **atrial fibrillation** may increase the risk of further **thromboembolic events** unnecessarily.*Switch immediately to low molecular weight heparin for 14 days*- Starting **LMWH** would still provide full systemic anticoagulation, which carries the same high risk of **haemorrhagic transformation** as warfarin in the acute setting.- Heparin is not recommended as a bridge or acute treatment for **ischaemic stroke** prevention immediately following the event due to the bleeding risk.

Question 142: A 34-year-old woman with type 1 diabetes on insulin pump therapy presents to the emergency department with nausea, vomiting, and abdominal pain. Her capillary blood glucose is 24.5 mmol/L and blood ketones are 4.8 mmol/L. Her insulin pump is functioning normally. She is diagnosed with diabetic ketoacidosis. What is the most appropriate initial insulin management?

A. Continue the insulin pump at current basal rate and add intravenous variable rate insulin infusion
B. Discontinue the insulin pump completely and start intravenous variable rate insulin infusion (Correct Answer)
C. Increase the pump basal rate by 20% and add correction boluses
D. Continue the pump and administer intramuscular insulin instead of intravenous
E. Continue the pump unchanged and give subcutaneous rapid-acting insulin boluses

Explanation: ***Discontinue the insulin pump completely and start intravenous variable rate insulin infusion*** - In the management of **Diabetic Ketoacidosis (DKA)**, standard protocols require the transition to **Fixed Rate Intravenous Insulin Infusion (FRIII)** or Variable Rate (VRIII) to ensure reliable insulin delivery and rapid titration. - Continuing the pump during severe DKA is avoided because **subcutaneous absorption** can be unpredictable due to dehydration and poor peripheral perfusion, making IV the preferred route. *Continue the insulin pump at current basal rate and add intravenous variable rate insulin infusion* - Running both systems simultaneously increases the risk of **insulin stacking**, which can lead to severe **hypoglycemia** as the ketoacidosis resolves. - Standard guidelines recommend that all **subcutaneous insulin** (except long-acting analogs in some protocols) be stopped while an IV insulin infusion is active. *Increase the pump basal rate by 20% and add correction boluses* - This approach is inappropriate for established **DKA** as it relies on subcutaneous delivery which is too slow and unreliable for metabolic emergency stabilization. - Pump failure (e.g., infusion set blockage) is a common cause of DKA in pump users, so relying on the same device for rescue therapy is **clinically unsafe**. *Continue the pump and administer intramuscular insulin instead of intravenous* - **Intramuscular insulin** is not the standard of care for DKA management in a hospital setting when **intravenous access** is available. - **Intravenous insulin** has a much shorter half-life and allows for the immediate adjustment of rates needed to suppress **ketogenesis** and stabilize blood glucose. *Continue the pump unchanged and give subcutaneous rapid-acting insulin boluses* - Subcutaneous boluses are insufficient to clear **ketonemia** and correct the severe metabolic acidosis associated with a blood ketone level of **4.8 mmol/L**. - Management must focus on systemic volume expansion and **IV insulin** to halt the production of fatty acids and ketones at the liver.

Question 143: A 52-year-old man with rheumatoid arthritis has been stable on methotrexate 20mg weekly for 18 months. He develops an acute chest infection with productive cough and fever. His blood tests show: WCC 3.2 × 10⁹/L, neutrophils 1.1 × 10⁹/L, platelets 145 × 10⁹/L. What is the most appropriate immediate management of his methotrexate therapy?

A. Continue methotrexate at the same dose and monitor weekly
B. Reduce methotrexate dose to 10mg weekly until infection resolves
C. Withhold methotrexate temporarily until infection resolves and blood counts recover (Correct Answer)
D. Switch to subcutaneous methotrexate to improve bioavailability
E. Add folinic acid rescue therapy while continuing methotrexate

Explanation: ***Withhold methotrexate temporarily until infection resolves and blood counts recover***- Immediate cessation of **methotrexate** is required due to the presence of both **neutropenia** (neutrophils 1.1 × 10⁹/L, below the < 1.5 × 10⁹/L threshold) and an **active infection**, which significantly increases the risk of **sepsis**.- **Methotrexate** is a folate antagonist that can cause **bone marrow suppression**; withholding it allows the marrow to recover and the immune system to effectively combat the bacterial load.*Continue methotrexate at the same dose and monitor weekly*- Continuing methotrexate therapy in the face of **neutropenia** and infection presents an unacceptable risk for **life-threatening sepsis** and worsening infection.- Weekly monitoring is insufficient for an acute drop in **white cell counts** coupled with symptomatic clinical deterioration and infection.*Reduce methotrexate dose to 10mg weekly until infection resolves*- Dose reduction is inappropriate when **cytopenia** is already present; the drug must be stopped entirely to permit rapid **neutrophil recovery**.- Even a lower dose maintains **immunosuppression**, which would interfere with the body's ability to clear the **acute chest infection**.*Switch to subcutaneous methotrexate to improve bioavailability*- Increasing bioavailability by switching to subcutaneous administration would likely worsen **methotrexate toxicity** and potentially exacerbate the suppression of the **haematopoietic system**.- Subcutaneous administration is primarily used to bypass **gastrointestinal side effects** or improve absorption, not to manage **hematologic complications** or infections.*Add folinic acid rescue therapy while continuing methotrexate*- **Folinic acid (leucovorin)** rescue is typically reserved for high-dose oncology regimens, specific toxicity, or acute **methotrexate overdose**, rather than managing infection-related neutropenia.- Adding folinic acid while continuing the drug does not adequately address the immediate danger posed by the patient's **low neutrophil count** and active infection.

Question 144: A 66-year-old woman with atrial fibrillation is established on apixaban 5mg twice daily. She develops acute pyelonephritis and requires antibiotic therapy. Her renal function shows eGFR of 42 ml/min/1.73m². Which antibiotic should be prescribed with particular caution due to potential interaction increasing apixaban levels?

A. Amoxicillin
B. Nitrofurantoin
C. Trimethoprim
D. Clarithromycin (Correct Answer)
E. Cefalexin

Explanation: ***Clarithromycin***- **Clarithromycin** is a potent inhibitor of both **CYP3A4** and **P-glycoprotein (P-gp)**, which are the primary pathways responsible for the metabolism and transport of apixaban.- Concurrent use significantly increases **apixaban plasma concentrations**, raising the risk of major **bleeding**, especially in patients with existing **renal impairment** (eGFR < 50 ml/min).*Amoxicillin*- **Amoxicillin** is a penicillin-based antibiotic that does not inhibit **CYP3A4** or **P-gp** enzymes.- It has no clinically significant **pharmacokinetic interaction** with apixaban and is generally safe to prescribe for susceptible infections.*Nitrofurantoin*- **Nitrofurantoin** is primarily excreted renally and acts locally in the bladder; it does not interfere with the **metabolic pathways** of DOACs like apixaban.- Notably, it is often avoided in **pyelonephritis** due to poor tissue penetration and should be used with caution when **eGFR** is low, but not due to drug interactions.*Trimethoprim*- **Trimethoprim** does not have a major affect on the **CYP450 system**, specifically the 3A4 isoform relevant to apixaban.- While it can increase levels of drugs like **methotrexate** or **phenytoin**, it does not increase the risk of bleeding when combined with **apixaban**.*Cefalexin*- **Cefalexin** is a first-generation cephalosporin that lacks the **enzyme inhibition** properties required to alter apixaban levels.- It is considered a relatively safe alternative for **urinary tract infections** in patients taking oral anticoagulants.

Question 145: A 58-year-old man with type 2 diabetes is prescribed insulin aspart. He asks about the appropriate timing of administration relative to meals. What is the recommended timing for administering rapid-acting insulin analogues such as insulin aspart?

A. 15-30 minutes before meals
B. 30-45 minutes before meals
C. Immediately before meals or within 5-15 minutes of starting a meal (Correct Answer)
D. Immediately after completing the meal
E. At bedtime, regardless of meal timing

Explanation: ***Immediately before meals or within 5-15 minutes of starting a meal*** - **Rapid-acting insulin analogues** like **aspart**, **lispro**, and **glulisine** have a very fast onset of action (10-20 minutes), making them ideal for managing **postprandial glucose** peaks. - Administering them just before or at the start of eating ensures that the insulin's **peak effect** (1-3 hours) aligns precisely with the absorption of carbohydrates from the meal. *30-45 minutes before meals* - This timing is specific to **Regular (Short-acting) human insulin**, which requires more time to dissociate from hexamers into monomers for absorption. - Giving **aspart** this early would significantly increase the risk of **pre-meal hypoglycemia** because its action begins much faster than regular insulin. *15-30 minutes before meals* - While closer to the correct window, this is generally too early for **rapid-acting analogues** and may lead to a mismatch between glucose entry and insulin action. - Standardization for these medications emphasizes **immediate administration** to optimize safety and patient compliance with meal routines. *Immediately after completing the meal* - Post-meal dosing is generally reserved for patients with **gastroparesis** or unpredictable intake, such as **young children** or the elderly. - For most adults, waiting until after the meal leads to **postprandial hyperglycemia** because the blood glucose rises faster than the insulin can take effect. *At bedtime, regardless of meal timing* - **Intermediate-acting (NPH)** or **long-acting (glargine, detemir)** insulins are administered at bedtime to provide **basal coverage** throughout the night. - **Rapid-acting insulin** is strictly for **bolus (mealtime) coverage** or correction; using it at bedtime without food would cause severe **nocturnal hypoglycemia**.

Question 146: According to the Medicines and Healthcare products Regulatory Agency (MHRA) guidance, what is the recommended minimum interval between switching from warfarin to a direct oral anticoagulant (DOAC) such as apixaban in a patient with atrial fibrillation?

A. Start DOAC when INR falls below 3.0
B. Start DOAC when INR falls below 2.5
C. Start DOAC when INR falls below 2.0 (Correct Answer)
D. Start DOAC when INR falls below 1.5
E. Start DOAC immediately and stop warfarin

Explanation: ***Start DOAC when INR falls below 2.0***- According to **MHRA guidance**, warfarin should be discontinued and the **DOAC** initiated once the **INR** is less than **2.0** to ensure a safe transition.- This threshold minimizes the **bleeding risk** that would occur from the overlapping pharmacological effects of both **anticoagulants**.*Start DOAC when INR falls below 3.0*- An **INR of 3.0** indicates that the patient is still significantly anticoagulated by **warfarin**, leading to an unsafe overlap.- Initiating a **DOAC** at this level markedly increases the risk of **major hemorrhage** due to supra-therapeutic anticoagulation.*Start DOAC when INR falls below 2.5*- While the target range for many conditions is 2.0–3.0, 2.5 is still high enough to cause **excessive anticoagulation** when combined with a new agent.- Most clinical guidelines and the **MHRA** specifically mandate waiting for the **INR** to drop further to prioritize **patient safety**.*Start DOAC when INR falls below 1.5*- Waiting for the **INR** to fall below **1.5** is unnecessary and may leave the patient at an increased risk of **thromboembolic events** (like stroke in AF).- The pharmacological transition is considered safe and effective at the **2.0 threshold**, making a lower target inefficient.*Start DOAC immediately and stop warfarin*- Immediate initiation without monitoring the **washout of warfarin** is dangerous because warfarin has a **long half-life**.- This approach results in a period of **dual anticoagulation**, significantly raising the risk of **life-threatening bleeding**.

Question 147: A 45-year-old woman with newly diagnosed psoriatic arthritis is prescribed methotrexate 15mg once weekly. According to the British National Formulary, which day of the week should folic acid supplementation be avoided to ensure optimal efficacy of methotrexate therapy?

A. The day before methotrexate administration
B. The same day as methotrexate administration (Correct Answer)
C. The day after methotrexate administration
D. Two days after methotrexate administration
E. Three days after methotrexate administration

Explanation: ***The same day as methotrexate administration*** - **Methotrexate** is a **dihydrofolate reductase inhibitor**; taking folic acid on the same day can theoretically provide a substrate that competes with the drug, potentially reducing its **therapeutic efficacy**. - The **BNF** and clinical guidelines recommend omitting folic acid on the day of methotrexate to ensure maximal suppression of the **folate metabolic pathway** in target cells. *The day before methotrexate administration* - Taking folic acid 24 hours prior to the dose does not interfere with the **pharmacokinetics** or the peak activity of methotrexate. - It helps maintain **tissue folate stores**, reducing the risk of side effects like **mucositis** and bone marrow suppression. *The day after methotrexate administration* - This is the most common clinical practice, known as a **"folate rescue,"** usually occurring at least **24 hours after** the methotrexate dose. - Taking it at this interval helps mitigate **gastrointestinal toxicity** and hepatotoxicity without compromising the drug's immunosuppressive action. *Two days after methotrexate administration* - Folic acid administration 48 hours post-dose is safe and keeps the supplement well outside the **peak concentration window** of methotrexate. - Clinical protocols vary (e.g., 5mg weekly vs. daily except on drug day), but this delay poses no risk to **drug efficacy**. *Three days after methotrexate administration* - Supplementing later in the week remains effective for preventing **folate deficiency** symptoms caused by chronic methotrexate use. - The primary concern is simply avoiding the **same-day co-administration**, so any day sufficiently distal to the dose is acceptable.

Question 148: A 77-year-old man with atrial fibrillation and chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²) is on apixaban 2.5mg twice daily. He weighs 73kg, is 178cm tall, and is 78 years old. His creatinine is 156 μmol/L. On medication review, you calculate his CHA₂DS₂-VASc score as 4 and HAS-BLED score as 3. His apixaban dose was reduced based on meeting dose reduction criteria. However, on careful review, what is the most appropriate action?

A. Continue apixaban 2.5mg twice daily as the dose reduction is appropriate
B. Increase apixaban to 5mg twice daily as he does not meet the criteria for dose reduction (Correct Answer)
C. Switch to rivaroxaban 15mg once daily as this is more appropriate for his renal function
D. Switch to warfarin as apixaban dosing is too complex in renal impairment
E. Continue current dose but add low-dose aspirin for additional thromboembolic protection

Explanation: ***Increase apixaban to 5mg twice daily as he does not meet the criteria for dose reduction***- Apixaban dose reduction (2.5mg BD) for atrial fibrillation requires meeting at least **two out of three** criteria: Age **≥80 years**, Weight **≤60kg**, or Serum Creatinine **≥133 μmol/L**.- This patient only meets **one criterion** (Creatinine 156 μmol/L); since he is **78 years old** and weighs **73kg**, the standard **5mg twice daily** dose is required for effective stroke prevention.*Continue apixaban 2.5mg twice daily as the dose reduction is appropriate*- This is incorrect because providing a reduced dose when not indicated leads to **suboptimal anticoagulation** and an increased risk of **ischemic stroke**.- A common clinical error is reducing the dose based on **renal impairment alone**, but apixaban specifically requires the "two-out-of-three" rule for dose reduction.*Switch to rivaroxaban 15mg once daily as this is more appropriate for his renal function*- While **Rivaroxaban 15mg** once daily is an alternative for patients with a CrCl of 15-49 ml/min, there is no clinical indication to switch if **Apixaban** can be correctly dosed and is tolerated.- **Apixaban** is often preferred in renal impairment (CKD stage 3) due to a potentially lower rate of **major bleeding** compared to other DOACs.*Switch to warfarin as apixaban dosing is too complex in renal impairment*- **DOACs** like apixaban are generally preferred over **Warfarin** in non-valvular AF due to a better safety profile, fewer drug-drug interactions, and no need for routine **INR monitoring**.- Apixaban is safely used in **CKD stage 3b** as long as the dosing criteria are followed correctly; its dosing is not overly complex for this patient.*Continue current dose but add low-dose aspirin for additional thromboembolic protection*- Adding **Aspirin** to an anticoagulant in the absence of a specific indication (e.g., recent acute coronary syndrome/stent) significantly increases **bleeding risk** without providing additional stroke prevention benefit in AF.- The priority is to optimize the **anticoagulant dose** (apixaban 5mg BD) to ensure adequate stroke prevention.

Question 149: A 54-year-old woman with type 1 diabetes for 28 years presents with recurrent severe hypoglycaemic episodes, including two requiring emergency services in the past 3 months. She has hypoglycaemia unawareness and takes insulin degludec 32 units once daily and insulin aspart before meals. Her HbA1c is 48 mmol/mol. Continuous glucose monitoring shows significant glycaemic variability with frequent hypoglycaemic episodes, particularly nocturnal. What is the most appropriate next step in her management?

A. Reduce insulin degludec to 24 units and accept higher HbA1c target of 58-64 mmol/mol
B. Switch to continuous subcutaneous insulin infusion (insulin pump) therapy
C. Refer urgently to specialist diabetes centre for assessment for islet cell or pancreas transplantation (Correct Answer)
D. Add a GLP-1 receptor agonist to reduce insulin requirements and hypoglycaemia risk
E. Switch from insulin degludec to NPH insulin to allow more dose flexibility

Explanation: ***Refer urgently to specialist diabetes centre for assessment for islet cell or pancreas transplantation*** - This patient, with long-standing Type 1 diabetes, **hypoglycaemia unawareness**, and recurrent **severe hypoglycaemic episodes** (requiring emergency services) despite optimal basal-bolus insulin and **continuous glucose monitoring (CGM)**, meets the criteria for transplantation assessment. - When life-threatening **glycaemic variability** and severe hypoglycaemia persist despite advanced medical management, **pancreas or islet cell transplantation** offers the best chance for cure or significant improvement in glycaemic control and resolution of hypoglycaemia unawareness.*Reduce insulin degludec to 24 units and accept higher HbA1c target of 58-64 mmol/mol* - While accepting a higher **HbA1c target** can reduce hypoglycaemia risk and help restore **hypoglycaemia awareness**, this standalone measure is insufficient for a patient experiencing such severe and recurrent life-threatening episodes. - This approach might only partially mitigate the risk and could lead to **hyperglycaemia** without addressing the underlying failure of **counterregulatory responses** to hypoglycaemia.*Switch to continuous subcutaneous insulin infusion (insulin pump) therapy* - **Insulin pump therapy (CSII)** offers more precise and flexible insulin delivery, but this patient is already using modern analogue insulins (degludec, aspart) and **CGM**, yet still experiences severe episodes. - Given the severity (emergency services required twice in 3 months) and the failure of current advanced management, a pump alone is unlikely to provide the necessary level of control, and the patient has likely progressed beyond this as the primary next step.*Add a GLP-1 receptor agonist to reduce insulin requirements and hypoglycaemia risk* - **GLP-1 receptor agonists** are primarily indicated for Type 2 diabetes and are not routinely licensed or recommended for Type 1 diabetes, nor are they effective in addressing the lack of **glucagon response** in hypoglycaemia unawareness. - Adding such an agent could potentially complicate glycaemic control by slowing gastric emptying and increasing the risk of **gastrointestinal side effects** without offering significant protection against severe hypoglycaemia.*Switch from insulin degludec to NPH insulin to allow more dose flexibility* - **Insulin degludec** is a modern **ultra-long-acting insulin analogue** known for its very flat profile and low **intra-individual variability**, which significantly reduces the risk of nocturnal hypoglycaemia. - Switching to **NPH insulin**, an intermediate-acting human insulin with a pronounced peak and higher variability, would likely *increase* the risk of **nocturnal hypoglycaemia** and further destabilize glycaemic control, making the patient's condition worse.

Question 150: A 69-year-old man on rivaroxaban 20mg once daily for atrial fibrillation (CHA₂DS₂-VASc score 4) undergoes routine blood tests. Results show: eGFR 28 ml/min/1.73m² (previously 45 ml/min/1.73m² six months ago), creatinine 198 μmol/L. He has no bleeding and is otherwise well. What is the most appropriate management of his anticoagulation?

A. Continue rivaroxaban 20mg once daily; dose reduction not required until eGFR <15 ml/min/1.73m²
B. Reduce rivaroxaban dose to 15mg once daily and monitor renal function closely (Correct Answer)
C. Switch to apixaban 2.5mg twice daily as it is safer in renal impairment
D. Switch to warfarin with target INR 2-3 as DOACs are contraindicated in CKD stage 4
E. Stop anticoagulation due to increased bleeding risk; start aspirin 75mg once daily

Explanation: ***Reduce rivaroxaban dose to 15mg once daily and monitor renal function closely***- For patients with atrial fibrillation and an **eGFR between 15-49 ml/min/1.73m²**, the licensed dose of **rivaroxaban** is reduced from 20mg to **15mg once daily** to prevent accumulation and bleeding.- This patient’s eGFR has declined to **28 ml/min/1.73m² (CKD stage 4)**, making the standard 20mg dose inappropriate and requiring closer monitoring of renal status.*Continue rivaroxaban 20mg once daily; dose reduction not required until eGFR <15 ml/min/1.73m²*- Maintaining the 20mg dose at an eGFR of 28 ml/min/1.73m² ignores established **renal dosing guidelines** and increases the patient's risk of **major hemorrhage**.- Dose reduction must occur when the **CrCl or eGFR falls below 50 ml/min**, not just when reaching end-stage renal disease.*Switch to apixaban 2.5mg twice daily as it is safer in renal impairment*- **Apixaban 2.5mg** twice daily is indicated only if the patient meets at least two criteria: **age ≥80**, **weight ≤60kg**, or **creatinine ≥133 μmol/L**; this patient only meets the creatinine criterion.- While apixaban has less renal clearance than rivaroxaban, a switch is not mandatory if the current agent can be correctly **dose-adjusted**.*Switch to warfarin with target INR 2-3 as DOACs are contraindicated in CKD stage 4*- DOACs like rivaroxaban and apixaban are **not contraindicated in CKD stage 4** (eGFR 15-29 ml/min); they are generally only contraindicated when **eGFR falls below 15 ml/min**.- Warfarin is an alternative for advanced CKD, but it requires frequent **monitoring** and is not the immediate required step given the license for dose-adjusted DOACs.*Stop anticoagulation due to increased bleeding risk; start aspirin 75mg once daily*- With a **CHA₂DS₂-VASc score of 4**, the patient is at high risk for **ischemic stroke**, and stopping anticoagulation would be hazardous.- **Aspirin monotherapy** is no longer recommended for stroke prevention in atrial fibrillation as it is significantly less effective than anticoagulants and still carries a bleeding risk.

Question 151: A 62-year-old woman with type 2 diabetes attends for review. She is on insulin detemir 28 units twice daily and insulin aspart with meals. Her home blood glucose monitoring shows fasting readings of 5-7 mmol/L, but her HbA1c has risen from 58 mmol/mol to 72 mmol/mol over 6 months. Her mealtime and evening glucose readings are 12-16 mmol/L. She reports taking her basal insulin reliably but admits often forgetting or deliberately missing mealtime insulin doses due to concerns about hypoglycaemia and weight gain. What is the most appropriate management strategy?

A. Increase insulin detemir to 36 units twice daily to improve overall control
B. Switch to premixed insulin twice daily to simplify the regimen
C. Address her concerns through education, consider adding GLP-1 receptor agonist, and optimize mealtime insulin dosing (Correct Answer)
D. Switch basal insulin to once-daily insulin glargine U300 and continue current mealtime insulin
E. Add SGLT2 inhibitor and reduce insulin detemir dose by 20%

Explanation: ***Address her concerns through education, consider adding GLP-1 receptor agonist, and optimize mealtime insulin dosing*** - The patient's elevated **HbA1c** and high **mealtime glucose readings** are primarily due to non-adherence to mealtime insulin, driven by her **fears of hypoglycemia and weight gain**; addressing these concerns through education is paramount. - A **GLP-1 receptor agonist** is an excellent addition as it promotes **weight loss**, improves **postprandial glucose control**, and carries a **low risk of hypoglycemia**, directly counteracting her primary concerns. *Increase insulin detemir to 36 units twice daily to improve overall control* - The patient's **fasting glucose readings** (5-7 mmol/L) are already within the target range, indicating that her current **basal insulin** dose is sufficient. - Increasing the basal insulin dose would primarily lower fasting glucose further, potentially causing **nocturnal or morning hypoglycemia**, and would not address the elevated postprandial glucose due to missed mealtime insulin. *Switch to premixed insulin twice daily to simplify the regimen* - While simplifying the regimen might improve adherence for some, **premixed insulin** still contains rapid-acting components that could cause **hypoglycemia** and contribute to **weight gain**, thus not addressing her core fears. - This approach offers less flexibility in managing fluctuating mealtime carbohydrate intake and may not resolve the underlying psychological barriers to insulin use. *Switch basal insulin to once-daily insulin glargine U300 and continue current mealtime insulin* - The patient's **basal insulin regimen** (insulin detemir) is effectively controlling her fasting glucose, so switching to another basal insulin provides no specific clinical advantage for her current problem. - This strategy fails to address the critical issue of her **non-adherence to mealtime insulin** due to her concerns about hypoglycemia and weight gain. *Add SGLT2 inhibitor and reduce insulin detemir dose by 20%* - While **SGLT2 inhibitors** can aid in weight loss and lower glucose, they are not primarily targeted at addressing **postprandial spikes** caused by missing mealtime insulin. - Reducing the **basal insulin dose** by 20% when fasting glucose is already well-controlled would likely lead to **fasting hyperglycemia** and would not resolve the issue of high postprandial readings.

Question 152: A 71-year-old man with atrial fibrillation is on warfarin with a target INR of 2-3. Over the past 8 weeks, his INR results have been: 2.1, 2.8, 1.6, 3.4, 1.9, 3.6, 2.2, and 3.8. His time in therapeutic range (TTR) is calculated at 52%. He is compliant with monitoring and takes no new medications. What is the most appropriate management approach?

A. Continue warfarin with more frequent INR monitoring until control improves
B. Switch to a direct oral anticoagulant (DOAC) such as apixaban (Correct Answer)
C. Refer to anticoagulation clinic for specialist review of warfarin dosing regimen
D. Add low-dose aspirin 75mg daily to improve thromboembolic protection
E. Increase warfarin dose by 20% and review INR weekly for 4 weeks

Explanation: ***Switch to a direct oral anticoagulant (DOAC) such as apixaban***- The patient's **Time in Therapeutic Range (TTR)** of 52% is significantly below the recommended target of **>65-70%** for effective and safe anticoagulation with **warfarin** in atrial fibrillation.- Given the patient's compliance and absence of other influencing factors, switching to a **DOAC** is the most appropriate management to achieve stable anticoagulation and reduce the risk of **stroke** and **bleeding** events.*Continue warfarin with more frequent INR monitoring until control improves*- Frequent **INR monitoring** is typically used for initial stabilization or when fluctuations are due to identifiable, correctable factors; it is unlikely to resolve persistent, poor **TTR** despite compliance.- This approach would prolong the period of **sub-therapeutic** and **supra-therapeutic** anticoagulation, increasing the risks of both **thromboembolism** and **hemorrhage**.*Refer to anticoagulation clinic for specialist review of warfarin dosing regimen*- While specialist review can optimize warfarin therapy, current guidelines favor switching to a **DOAC** for persistently poor **TTR** in non-valvular atrial fibrillation, especially when compliance is good and no clear reversible causes exist.- Specialist review is often reserved for patients with contraindications to **DOACs**, mechanical heart valves, or very complex comorbid conditions.*Add low-dose aspirin 75mg daily to improve thromboembolic protection*- Adding **aspirin** to anticoagulation in atrial fibrillation significantly increases the **risk of major bleeding** without providing substantial additional benefit for stroke prevention compared to anticoagulation alone.- This strategy does not address the fundamental issue of inadequate and unstable **warfarin** control.*Increase warfarin dose by 20% and review INR weekly for 4 weeks*- An increase in **warfarin** dose is inappropriate as the patient's INR values are fluctuating both above and below the target range, indicating instability rather than consistent under-anticoagulation.- This action would likely lead to dangerous **over-anticoagulation**, significantly elevating the risk of serious **bleeding complications**, such as intracranial or gastrointestinal hemorrhages.

Question 153: A 48-year-old man with newly diagnosed type 2 diabetes is started on basal-bolus insulin therapy following failure of oral agents. He is prescribed insulin glargine 18 units at bedtime and insulin lispro before meals. He asks how to adjust his mealtime insulin when eating different amounts of carbohydrate. What is the most appropriate advice regarding insulin lispro dosing?

A. Take a fixed dose of insulin lispro before each meal regardless of carbohydrate content
B. Use a carbohydrate counting system with insulin-to-carbohydrate ratios to calculate mealtime insulin doses (Correct Answer)
C. Double the insulin lispro dose for large meals and halve for small meals
D. Take insulin lispro only when blood glucose is above 10 mmol/L before meals
E. Adjust insulin lispro based on blood glucose level 2 hours after the previous meal

Explanation: ***Use a carbohydrate counting system with insulin-to-carbohydrate ratios to calculate mealtime insulin doses*** - **Carbohydrate counting** is the most physiological and flexible method for dosing **rapid-acting insulin** like **insulin lispro**, allowing for precise matching of insulin to glucose load. - This approach improves **glycemic control** and reduces the risk of **hypoglycemia** or postprandial hyperglycemia by utilizing a specific **insulin-to-carbohydrate ratio (ICR)**. *Take a fixed dose of insulin lispro before each meal regardless of carbohydrate content* - Using a **fixed dose** does not account for variations in carbohydrate intake, leading to poor control when meal sizes change. - This rigid approach increases the risk of **hypoglycemia** if a patient consumes fewer carbohydrates than the dose was intended for. *Double the insulin lispro dose for large meals and halve for small meals* - This method is far too imprecise and lacks the quantitative accuracy required for **safe insulin management**. - Arbitrary adjustments like doubling doses significantly increase the danger of **severe hypoglycemia** and unpredictable glucose fluctuations. *Take insulin lispro only when blood glucose is above 10 mmol/L before meals* - This is a reactive "sliding scale" approach that only treats existing **hyperglycemia** rather than preventing the rise caused by the meal. - Failing to cover mealtime carbohydrates with insulin results in significant **postprandial glucose spikes** and poor long-term HbA1c control. *Adjust insulin lispro based on blood glucose level 2 hours after the previous meal* - This approach is flawed because the glucose level 2 hours post-meal reflects the **previous dose's efficacy**, not the requirements for the upcoming meal. - Effective **basal-bolus therapy** requires dosing based on the **projected carbohydrate intake** of the meal about to be consumed.

Question 154: A 68-year-old woman on warfarin (target INR 2-3) for atrial fibrillation presents with an INR of 7.8. She has no active bleeding but reports noticing increased bruising over the past week. Her current warfarin dose is 5mg daily. According to current British Society for Haematology guidelines, what is the most appropriate immediate management?

A. Withhold warfarin for 1-2 days, restart when INR <5, check INR daily
B. Give oral vitamin K 1-5mg, withhold warfarin, check INR in 24 hours (Correct Answer)
C. Give intravenous vitamin K 10mg, withhold warfarin, check INR in 6 hours
D. Continue warfarin at reduced dose of 2.5mg, check INR in 3 days
E. Withhold warfarin for 1 dose only, give oral vitamin K 500 micrograms, check INR next day

Explanation: ***Give oral vitamin K 1-5mg, withhold warfarin, check INR in 24 hours***- For an **INR of 7.8** with minor bleeding symptoms like **bruising**, British Society for Haematology guidelines recommend withholding warfarin and administering **oral vitamin K 1-5mg**.- This approach provides a controlled and timely reversal of anticoagulation, aiming to bring the INR back into the therapeutic range within **24 hours** without overshooting or causing future warfarin resistance.*Withhold warfarin for 1-2 days, restart when INR <5, check INR daily*- This management is typically appropriate for an **INR between 5.0 and 8.0** with **no bleeding** or only mild, non-progressive bruising.- Given the patient's INR is near 8.0 with noticed increased bruising, actively administering **oral vitamin K** is preferred to expedite INR correction and reduce bleeding risk.*Give intravenous vitamin K 10mg, withhold warfarin, check INR in 6 hours*- **Intravenous vitamin K 10mg** is reserved for scenarios with **major or life-threatening bleeding** (e.g., GI bleed, intracranial hemorrhage) or extremely high INR values (e.g., >8.0 with high bleeding risk).- Such an aggressive approach is unnecessary for minor bruising and can lead to **warfarin resistance**, complicating future anticoagulation management for atrial fibrillation.*Continue warfarin at reduced dose of 2.5mg, check INR in 3 days*- Continuing warfarin when the **INR is 7.8** is contraindicated and significantly increases the risk of **severe hemorrhagic complications**.- The priority at this elevated INR is to **reduce its value** quickly and safely, not to maintain any level of anticoagulation.*Withhold warfarin for 1 dose only, give oral vitamin K 500 micrograms, check INR next day*- A dose of **500 micrograms (0.5mg) oral vitamin K** is generally considered insufficient for an INR of 7.8 with clinical signs of over-anticoagulation like bruising.- Guidelines recommend a higher dose of **1-5mg oral vitamin K** in this situation to ensure effective and predictable INR reduction within 24 hours.

Question 155: A 56-year-old man with type 2 diabetes is on metformin 1g twice daily and insulin glargine 40 units at bedtime. He is admitted for elective inguinal hernia repair under general anaesthetic, scheduled as the first case at 8:00 AM. His fasting blood glucose at 6:00 AM is 8.2 mmol/L. What is the most appropriate perioperative insulin management?

A. Omit morning insulin glargine, give usual dose in the evening after surgery
B. Give 80% of usual insulin glargine dose (32 units) the evening before surgery, omit morning of surgery
C. Start variable rate intravenous insulin infusion at 6:00 AM
D. Give usual insulin glargine dose (40 units) the evening before surgery, no insulin on morning of surgery (Correct Answer)
E. Give 50% of usual insulin glargine dose (20 units) on the morning of surgery

Explanation: ***Give usual insulin glargine dose (40 units) the evening before surgery, no insulin on morning of surgery*** - For a patient undergoing short, elective procedures as the first case on the morning list, the **usual dose of basal insulin** (like glargine) should be given the evening before to maintain stable glycaemic levels. - Since the patient is scheduled for 8:00 AM and is likely to return to a normal diet quickly, the previous evening's **basal coverage** is sufficient without additional morning doses. *Omit morning insulin glargine, give usual dose in the evening after surgery* - Basal insulin should not be omitted entirely as it is required to prevent **perioperative ketoacidosis** and basal hyperglycaemia in insulin-dependent patients. - Omitting the dose would cause a significant gap in **insulin coverage**, leading to poor metabolic control during the surgical stress response. *Give 80% of usual insulin glargine dose (32 units) the evening before surgery, omit morning of surgery* - While some guidelines suggest a minor reduction (20%) for certain patients, current UK perioperative guidance (JBDS) often recommends maintaining the **full dose of long-acting basal insulin** to ensure stable background levels. - Reducing the dose unnecessarily may lead to **perioperative hyperglycaemia** in a patient whose current control (fasting glucose 8.2 mmol/L) is already stable. *Start variable rate intravenous insulin infusion at 6:00 AM* - **Variable rate intravenous insulin infusion (VRIII)** is indicated for major surgery, prolonged fasting (skipping more than one meal), or poorly controlled diabetes (HbA1c > 69 mmol/mol). - For a short, elective **inguinal hernia repair** where the patient will eat shortly after, VRIII is overly invasive and unnecessary. *Give 50% of usual insulin glargine dose (20 units) on the morning of surgery* - If the basal insulin was normally taken in the morning, a **reduction (usually to 80%)** might be considered; however, this patient takes his glargine at **bedtime**. - Administering a half-dose on the morning of surgery when the patient is already fasting increases the risk of **hypoglycaemia** during the procedure and deviates from his established routine.

Question 156: A 72-year-old man with atrial fibrillation on apixaban 5mg twice daily is admitted with a suspected acute stroke. CT head shows a large ischaemic stroke with no haemorrhage. He last took apixaban 4 hours ago. Thrombolysis is being considered. What is the most appropriate management of his anticoagulation?

A. Proceed with thrombolysis immediately; apixaban does not contraindicate thrombolysis
B. Give idarucizumab to reverse anticoagulation, then proceed with thrombolysis
C. Wait 24 hours from last apixaban dose, then consider thrombolysis if still within time window
D. Thrombolysis is contraindicated; apixaban should be continued and patient managed with aspirin (Correct Answer)
E. Measure anti-Xa level; if normal, proceed with thrombolysis

Explanation: ***Thrombolysis is contraindicated; apixaban should be continued and patient managed with aspirin*** - **Direct Oral Anticoagulants (DOACs)** like **apixaban** taken within the last 48 hours are a **contraindication** for intravenous thrombolysis due to a significantly increased risk of **intracranial haemorrhage**. - With the last dose taken only **4 hours ago**, thrombolysis is explicitly contraindicated. Long-term management for **atrial fibrillation** involves continuing **apixaban**, and acute management of the stroke often includes **aspirin** for antiplatelet effect, typically initiated after a safe interval (e.g., 24 hours post-stroke without haemorrhage). *Proceed with thrombolysis immediately; apixaban does not contraindicate thrombolysis* - Therapeutic anticoagulation with a **DOAC** taken within the last 48 hours is a major **exclusion criterion** for intravenous alteplase due to the significant risk of **haemorrhagic transformation**. - Proceeding with thrombolysis in this context would lead to a dangerously high risk of **intracerebral haemorrhage**, which is life-threatening. *Give idarucizumab to reverse anticoagulation, then proceed with thrombolysis* - **Idarucizumab** is a specific reversal agent for **dabigatran** (a direct thrombin inhibitor), not for **Factor Xa inhibitors** like apixaban. - The appropriate reversal agent for apixaban is **andexanet alfa**, but its routine use before thrombolysis in acute stroke is not standard practice and comes with its own risks and limited evidence. *Wait 24 hours from last apixaban dose, then consider thrombolysis if still within time window* - The contraindication for thrombolysis with DOACs extends to **48 hours** (or longer depending on renal function/dose), not just 24 hours. - Waiting 24 hours is insufficient to clear apixaban to safe levels for thrombolysis, and thrombolysis itself is time-dependent, making such a delay often render the patient outside the treatment window. *Measure anti-Xa level; if normal, proceed with thrombolysis* - While **anti-Xa levels** can measure apixaban's anticoagulant effect, determining a "normal" or safe threshold for thrombolysis is complex and not routinely used to guide thrombolysis decisions in acute stroke guidelines. - Most guidelines recommend against thrombolysis if DOACs were taken within the last 48 hours, regardless of measured levels, due to the high risk, and turnaround time for such a test would delay critical treatment.

Question 157: A 43-year-old woman with type 1 diabetes presents to the emergency department with a 2-day history of vomiting and diarrhoea. Her capillary blood glucose is 16.2 mmol/L and urinalysis shows 3+ ketones. Her regular insulin regimen is insulin aspart 8 units three times daily with meals and insulin glargine 22 units at bedtime. What is the most appropriate immediate insulin management?

A. Omit all insulin until she is able to eat and drink normally
B. Continue insulin glargine at usual dose, give 50% of usual insulin aspart doses
C. Continue insulin glargine at usual dose, give additional correction doses of insulin aspart every 4-6 hours based on blood glucose (Correct Answer)
D. Switch to variable rate intravenous insulin infusion immediately
E. Increase insulin glargine to 30 units and omit insulin aspart doses

Explanation: ***Continue insulin glargine at usual dose, give additional correction doses of insulin aspart every 4-6 hours based on blood glucose***- During intercurrent illness, patients with **Type 1 Diabetes** must never stop their **basal insulin** (glargine) to prevent absolute insulin deficiency and rapid progression to **Diabetic Ketoacidosis (DKA)**.- Management involves following **sick day rules**, which include frequent monitoring and using **correction doses** of rapid-acting insulin (aspart) to manage hyperglycemia and ketonemia.*Omit all insulin until she is able to eat and drink normally*- Omitting insulin in Type 1 Diabetes is dangerous and significantly increases the risk of developing **life-threatening DKA**.- Even if oral intake is reduced, the body requires **basal insulin** to manage hepatic glucose production and prevent ketogenesis.*Continue insulin glargine at usual dose, give 50% of usual insulin aspart doses*- While the patient may not be eating full meals, simply reducing **bolus insulin** by half is insufficient when **ketonuria** and hyperglycemia (16.2 mmol/L) are present.- Fixed reductions do not account for the **increased insulin resistance** typically caused by the underlying illness and physiological stress.*Switch to variable rate intravenous insulin infusion immediately*- A **Variable Rate Intravenous Insulin Infusion (VRIII)** is primarily indicated if the patient is in **DKA**, is vomiting persistently, or is unable to manage subcutaneous doses.- In this stable presentation without confirmed acidosis, **subcutaneous management** and monitoring of sick day rules is the appropriate immediate step.*Increase insulin glargine to 30 units and omit insulin aspart doses*- Increasing **long-acting basal insulin** provides poor flexibility for managing the rapidly fluctuating glucose levels seen during acute illness.- Omitting **rapid-acting insulin** prevents necessary corrections of hyperglycemia and fails to address the metabolic demands caused by the current infection or illness.

Question 158: A 67-year-old woman with atrial fibrillation is established on warfarin. She is prescribed a 7-day course of ciprofloxacin for a urinary tract infection. Which of the following best describes the mechanism of interaction between warfarin and ciprofloxacin and the appropriate management?

A. Ciprofloxacin induces CYP2C9, decreasing warfarin levels; increase warfarin dose and check INR in 3-5 days
B. Ciprofloxacin inhibits CYP2C9, increasing warfarin effect; reduce warfarin dose and check INR in 3-5 days (Correct Answer)
C. Ciprofloxacin displaces warfarin from plasma proteins; no dose adjustment needed but check INR after completing antibiotics
D. Ciprofloxacin has no significant interaction with warfarin; continue both medications unchanged
E. Ciprofloxacin inhibits CYP3A4, increasing warfarin levels; withhold warfarin during antibiotic course

Explanation: ***Ciprofloxacin inhibits CYP2C9, increasing warfarin effect; reduce warfarin dose and check INR in 3-5 days***- Ciprofloxacin is a known **enzyme inhibitor** that specifically targets the **CYP2C9** isoenzyme, which metabolizes the potent **S-enantiomer** of warfarin.- This inhibition leads to decreased clearance and **increased serum levels** of warfarin, necessitating a proactive **dose reduction** and close monitoring of the **INR** to prevent bleeding complications.*Ciprofloxacin induces CYP2C9, decreasing warfarin levels; increase warfarin dose and check INR in 3-5 days*- This incorrectly identifies ciprofloxacin as an inducer; enzyme induction (by drugs like **rifampicin** or **carbamazepine**) would lead to **decreased** warfarin efficacy and subtherapeutic INR.- Inducers typically take 1-2 weeks to exert their full effect, whereas ciprofloxacin's inhibitory effect on warfarin is **rapid**.*Ciprofloxacin displaces warfarin from plasma proteins; no dose adjustment needed but check INR after completing antibiotics*- While some drugs interact via **protein displacement**, the clinically significant interaction for fluoroquinolones is through **CYP450 inhibition**.- Monitoring only after the course is finished is dangerous, as the **anticoagulant effect** and bleeding risk increase shortly after starting the antibiotic.*Ciprofloxacin has no significant interaction with warfarin; continue both medications unchanged*- Fluoroquinolones are notorious for interacting with warfarin, often raising the INR significantly and increasing the risk of **major hemorrhage**.- Additionally, antibiotics can enhance warfarin's effect by altering **gut flora** that produce vitamin K, making an interaction even more likely.*Ciprofloxacin inhibits CYP3A4, increasing warfarin levels; withhold warfarin during antibiotic course*- While metabolism via CYP3A4 occurs, **CYP2C9** is the primary pathway for the most active form of warfarin; withholding the drug entirely risks **thromboembolic events** unnecessarily.- The correct management involves **titrating the dose** downwards based on INR results rather than complete cessation of therapy.

Question 159: A 51-year-old man with psoriatic arthritis is being considered for methotrexate therapy. He drinks approximately 35 units of alcohol per week. What is the most appropriate action regarding methotrexate prescribing in this patient?

A. Prescribe methotrexate with increased frequency of liver function monitoring
B. Advise reduction of alcohol intake to within recommended limits before starting methotrexate (Correct Answer)
C. Start methotrexate at a reduced dose of 5mg weekly
D. Prescribe methotrexate only if the patient agrees to complete abstinence from alcohol
E. Methotrexate is contraindicated; select an alternative disease-modifying agent

Explanation: ***Advise reduction of alcohol intake to within recommended limits before starting methotrexate*** - **Methotrexate** is known to be **hepatotoxic**, and concurrent heavy alcohol consumption significantly increases the risk of liver fibrosis and cirrhosis. - Current guidelines recommend that alcohol intake should be within the safe limit of **14 units per week**; this patient consumes 35 units, necessitating a reduction before therapy begins. *Prescribe methotrexate with increased frequency of liver function monitoring* - While **Liver Function Test (LFT)** monitoring is essential for all patients on methotrexate, it does not mitigate the baseline risk caused by excessive alcohol intake. - Monitoring only identifies damage after it has occurred, whereas the goal is **prevention of hepatotoxicity** by addressing modifiable risk factors first. *Start methotrexate at a reduced dose of 5mg weekly* - Starting at a **sub-therapeutic dose** does not eliminate the synergistic risk of liver damage between alcohol and methotrexate. - Dosage should be based on **disease activity** and clinical response, while liver safety is primarily managed through lifestyle modification. *Prescribe methotrexate only if the patient agrees to complete abstinence from alcohol* - **Complete abstinence** is generally not required for patients on methotrexate unless there is pre-existing liver disease or high-risk factors. - Guidelines advise staying within **national recommended limits** (14 units/week) rather than enforcing total sobriety. *Methotrexate is contraindicated; select an alternative disease-modifying agent* - Excessive alcohol use is a **relative precaution** rather than an absolute contraindication for methotrexate use. - Methotrexate remains a **first-line DMARD** for psoriatic arthritis; therefore, resolving the alcohol issue is preferred over switching to potentially less effective or more expensive agents.

Question 160: A 64-year-old woman with newly diagnosed deep vein thrombosis is commenced on rivaroxaban. She has normal renal function (eGFR 82 ml/min/1.73m²) and weighs 70kg. What is the appropriate initial treatment regimen for rivaroxaban in acute DVT according to current UK licensing?

A. 15mg once daily for 21 days, then 20mg once daily
B. 20mg once daily from day 1
C. 15mg twice daily for 21 days, then 20mg once daily (Correct Answer)
D. 10mg twice daily for 21 days, then 10mg once daily
E. 15mg twice daily for 7 days, then 15mg once daily

Explanation: ***15mg twice daily for 21 days, then 20mg once daily*** - For the initial management of **acute DVT**, rivaroxaban requires a high-intensity loading phase of **15mg twice daily** (BID) for the first **3 weeks (21 days)**. - Following the loading phase, the dose transitions to a maintenance phase of **20mg once daily** (OD) for the remainder of the treatment duration. *15mg once daily for 21 days, then 20mg once daily* - The **once-daily** administration during the first 21 days is incorrect and would provide inadequate anticoagulation for an **acute thrombus**. - High-risk initial windows in DVT treatment require higher frequency dosing to ensure **steady-state therapeutic levels**. *20mg once daily from day 1* - Starting immediately with the **maintenance dose** of 20mg OD is inappropriate for acute DVT/PE as it bypasses the necessary **loading phase**. - This regimen is more common for **Atrial Fibrillation (AF)** stroke prevention, not for the treatment of an active venous thromboembolism. *10mg twice daily for 21 days, then 10mg once daily* - This dosing regimen does not correspond to standard **UK NICE** or licensing guidelines for rivaroxaban in acute DVT management. - A **10mg OD** dose is typically only considered for long-term **extended prophylaxis** after at least 6 months of initial treatment. *15mg twice daily for 7 days, then 15mg once daily* - This duration is incorrect; the **21-day loading period** is specific to rivaroxaban, whereas a 7-day loading period is seen with **Apixaban** (10mg BID). - Switching to **15mg OD** as maintenance is only indicated in specific populations with significant **renal impairment** (CrCl <50 ml/min).

Question 161: Which of the following insulin types has the longest duration of action and is classified as an ultra-long-acting basal insulin analogue?

A. Insulin glargine U100 (Lantus)
B. Insulin detemir (Levemir)
C. Insulin degludec (Tresiba) (Correct Answer)
D. Insulin glargine U300 (Toujeo)
E. NPH insulin (isophane insulin)

Explanation: ***Insulin degludec (Tresiba)*** - Classified as an **ultra-long-acting** basal insulin, it forms multi-hexamer strings in subcutaneous tissue, resulting in a **duration of action exceeding 42 hours**. - It provides a very stable, **peakless profile** which is associated with a lower risk of nocturnal **hypoglycaemia** and allows for greater dosing flexibility. *Insulin glargine U100 (Lantus)* - This is a standard **long-acting** insulin analogue typically providing a **24-hour** duration of action. - While it provides a relatively flat basal rate, it does not reach the ultra-long duration seen with **degludec**. *Insulin detemir (Levemir)* - A long-acting analogue that binds to **albumin**, its duration of action is **dose-dependent**, typically ranging from **12 to 24 hours**. - It often requires **twice-daily dosing** in patients with type 1 diabetes to maintain adequate basal coverage. *Insulin glargine U300 (Toujeo)* - A **concentrated** form of glargine that lasts longer than U100 (approximately **36 hours**), but is generally considered shorter-acting than degludec. - It has a **flatter and more prolonged** pharmacokinetic profile than U100 but remains categorized below the ultra-long duration of Tresiba. *NPH insulin (isophane insulin)* - Classified as an **intermediate-acting** insulin with a duration of only **12 to 18 hours**. - It has a distinct **peak of action** (4-12 hours), which increases the clinical risk of **hypoglycaemia** compared to basal analogues.

Question 162: A 59-year-old man with atrial fibrillation is prescribed warfarin. According to the British National Formulary, what is the standard loading dose regimen for initiating warfarin therapy in a patient without hepatic impairment or other risk factors?

A. 5mg daily for 2 days, then adjust dose according to INR
B. 10mg on day 1, 10mg on day 2, then adjust dose according to INR
C. 10mg on day 1, 5mg on day 2, then adjust dose according to INR (Correct Answer)
D. 2.5mg daily for 2 days, then adjust dose according to INR
E. 7.5mg daily for 2 days, then adjust dose according to INR

Explanation: ***10mg on day 1, 5mg on day 2, then adjust dose according to INR*** - The **British National Formulary (BNF)** recommends this regimen as the standard loading dose for **warfarin initiation** in adults without specific risk factors like advanced age or hepatic impairment. - This approach aims to achieve a therapeutic **International Normalized Ratio (INR)** quickly and safely, with subsequent doses adjusted based on the measured INR response, typically on day 3. *5mg daily for 2 days, then adjust dose according to INR* - A lower induction dose of **5mg daily** is usually reserved for patients with increased **bleeding risk**, such as those over 75 years old, with hepatic impairment, or on interacting medications. - For a healthy 59-year-old, this dose would likely prolong the time taken to reach the desired **therapeutic INR range**, delaying effective anticoagulation. *10mg on day 1, 10mg on day 2, then adjust dose according to INR* - Administering **10mg for two consecutive days** is generally considered an aggressive loading regimen and significantly increases the risk of **over-anticoagulation** and bleeding complications. - Such a high initial dose can lead to a rapid depletion of **Protein C**, potentially causing a transient **prothrombotic state** or skin necrosis before other vitamin K-dependent clotting factors are reduced. *2.5mg daily for 2 days, then adjust dose according to INR* - This dose is typically too low to serve as an effective **loading dose** for most adult patients initiating warfarin therapy. - It would lead to a considerably delayed achievement of the **therapeutic INR**, leaving the patient sub-optimally anticoagulated and at increased risk of thromboembolic events. *7.5mg daily for 2 days, then adjust dose according to INR* - This particular loading dose regimen is **not a standard recommendation** outlined by major drug formularies like the BNF for typical warfarin initiation. - Following non-standard protocols can lead to unpredictable **INR responses** and potential challenges in achieving and maintaining therapeutic anticoagulation.

Question 163: A 62-year-old man with type 2 diabetes is admitted with hyperosmolar hyperglycaemic state (HHS). His blood glucose is 48.6 mmol/L, serum osmolality 358 mOsm/kg, and he is significantly dehydrated. Intravenous fluid resuscitation is commenced. According to the Joint British Diabetes Societies guidelines for HHS management, at what rate should the blood glucose be lowered initially?

A. Aim for blood glucose reduction of 10 mmol/L/hour
B. Aim for blood glucose reduction of 5 mmol/L/hour
C. Aim for blood glucose reduction of 3-5 mmol/L/hour (Correct Answer)
D. Aim for blood glucose reduction of 1-3 mmol/L/hour
E. Aim to normalize blood glucose within 6 hours

Explanation: ***Aim for blood glucose reduction of 3-5 mmol/L/hour*** - According to the **Joint British Diabetes Societies (JBDS) guidelines** for HHS management, the target rate for initial blood glucose reduction is **3-5 mmol/L/hour**. - This gradual reduction helps prevent rapid osmotic shifts, which can lead to complications such as **cerebral oedema** due to the movement of water into brain cells.*Aim for blood glucose reduction of 10 mmol/L/hour* - This rate is **too rapid** and significantly increases the risk of **cerebral oedema** and dangerous osmotic shifts. - A fast drop in blood glucose can cause a steep decline in **serum osmolality**, potentially leading to severe neurological complications.*Aim for blood glucose reduction of 5 mmol/L/hour* - While 5 mmol/L/hour is at the higher end of the recommended range, the guideline specifies a **range of 3-5 mmol/L/hour**, not a single fixed rate. - Adhering to the specified range allows for appropriate clinical judgment and adjustment based on the patient's individual response to **fluid resuscitation**.*Aim for blood glucose reduction of 1-3 mmol/L/hour* - This rate is considered **too slow** for the initial management of HHS and may unnecessarily prolong the patient's **hyperosmolar state** and dehydration. - A slower reduction might delay the resolution of severe hyperglycemia and its associated metabolic derangements.*Aim to normalize blood glucose within 6 hours* - Normalizing blood glucose within 6 hours is **dangerously fast** and highly discouraged in HHS management, which typically takes **24-72 hours** for full resolution. - Such rapid correction significantly increases the risk of **cerebral oedema**, central pontine myelinolysis, and cardiovascular instability due to drastic fluid and electrolyte shifts.

Question 164: A 53-year-old woman with epilepsy has been taking phenytoin 300mg daily for 10 years with good seizure control. Her phenytoin level 6 months ago was 12 mg/L (therapeutic range 10-20 mg/L). She now reports episodes of ataxia, nystagmus, and slurred speech. A repeat phenytoin level is 28 mg/L. She has not changed her dose and denies taking any new medications. Which of the following best explains her phenytoin toxicity?

A. Phenytoin exhibits first-order kinetics so small dose increases cause proportional level increases
B. Phenytoin exhibits zero-order kinetics so saturation of metabolism causes disproportionate level increases (Correct Answer)
C. Phenytoin undergoes extensive first-pass metabolism which decreases with age
D. Phenytoin is highly protein-bound and total levels increase with age due to increased albumin
E. Phenytoin auto-induces its own metabolism leading to accumulation over time

Explanation: ***Phenytoin exhibits zero-order kinetics so saturation of metabolism causes disproportionate level increases*** - Phenytoin follows **Michaelis-Menten kinetics**, meaning its metabolism shifts from **first-order to zero-order (non-linear)** kinetics once the hepatic enzyme systems become saturated, typically at therapeutic concentrations. - Once these enzymes are saturated, the drug is eliminated at a fixed rate, so even minor changes in dose or metabolic capacity can cause a **disproportionate and rapid rise** in serum levels, leading to characteristic signs of toxicity such as **ataxia, nystagmus, and slurred speech**. *Phenytoin exhibits first-order kinetics so small dose increases cause proportional level increases* - In **first-order kinetics**, a constant **fraction** of the drug is eliminated per unit of time, which means plasma levels increase proportionally with dose increases. - This mechanism does not explain the sudden, sharp increase in phenytoin levels from 12 mg/L to 28 mg/L in this patient on a stable dose, indicating a shift away from proportional elimination. *Phenytoin undergoes extensive first-pass metabolism which decreases with age* - Phenytoin has good oral bioavailability and does not undergo significant **first-pass metabolism**; its elimination is primarily via hepatic metabolism. - While hepatic metabolism can be affected by age, the primary explanation for the toxicity here is the **saturation kinetics** of phenytoin, rather than changes in first-pass effect. *Phenytoin is highly protein-bound and total levels increase with age due to increased albumin* - Phenytoin is indeed **highly protein-bound**, mainly to albumin, but **albumin levels** typically **decrease** or remain stable with age or chronic illness, rather than increase. - A decrease in albumin would increase the **free (unbound) fraction** of phenytoin, potentially causing toxicity, but it would not explain such a significant increase in the **total serum level** itself. *Phenytoin auto-induces its own metabolism leading to accumulation over time* - Phenytoin is a known **inducer** of hepatic cytochrome P450 enzymes, which means it generally **increases** the metabolism of other drugs and, to some extent, its own. - Auto-induction would lead to **lower serum concentrations** over time due to faster clearance, not accumulation and toxicity as observed in this case.

Question 165: A 59-year-old man is being considered for dabigatran therapy for stroke prevention in atrial fibrillation. He has a CHA₂DS₂-VASc score of 3. His renal function shows eGFR of 42 ml/min/1.73m². According to current licensing and guidance, what is the appropriate dose of dabigatran for this patient?

A. Dabigatran 150mg twice daily
B. Dabigatran 110mg twice daily (Correct Answer)
C. Dabigatran 75mg twice daily
D. Dabigatran is contraindicated; use alternative anticoagulant
E. Dabigatran 150mg once daily

Explanation: ***Dabigatran 110mg twice daily***- Patients with **moderate renal impairment** (eGFR 30–49 ml/min) require a dose reduction to **110mg twice daily** to prevent drug accumulation and minimize bleeding risk.- Per guidelines (e.g., NICE and SMPC), this lower dose is indicated because **dabigatran** is approximately **80% renally excreted**.*Dabigatran 150mg twice daily*- This is the **standard dose** for patients with good renal function (eGFR ≥50 ml/min) who are under 80 years of age.- Administering this dose to a patient with an **eGFR of 42 ml/min** would significantly increase the **risk of major hemorrhage**.*Dabigatran 75mg twice daily*- The **75mg twice daily** dose is primarily used in the USA for **severe renal impairment** (CrCl 15–30 ml/min) but is not the licensed dose for AF in several other jurisdictions like the UK.- At an eGFR of 42 ml/min, this dose would be **sub-therapeutic** for stroke prevention in atrial fibrillation.*Dabigatran is contraindicated; use alternative anticoagulant*- Dabigatran is only **contraindicated** when the eGFR or CrCl falls **below 30 ml/min** (or 15 ml/min depending on specific local guidelines).- Since this patient’s renal function is **42 ml/min**, it is safe to use provided the **dose is adjusted** appropriately.*Dabigatran 150mg once daily*- Dabigatran is not licensed for **once-daily administration** for the prevention of stroke in patients with atrial fibrillation.- **Twice-daily dosing** is required due to the **pharmacokinetic profile** and half-life of the medication to maintain stable plasma concentrations.

Question 166: A 41-year-old man with type 1 diabetes presents to the emergency department with a 24-hour history of vomiting and abdominal pain. He has continued his usual insulin doses. Blood tests show: glucose 22.4 mmol/L, pH 7.28, bicarbonate 14 mmol/L, ketones 4.2 mmol/L. He is diagnosed with diabetic ketoacidosis. According to the Joint British Diabetes Societies guidelines, what is the recommended initial fixed-rate intravenous insulin infusion rate for this patient weighing 80 kg?

A. 0.05 units/kg/hour (4 units/hour)
B. 0.1 units/kg/hour (8 units/hour) (Correct Answer)
C. 0.15 units/kg/hour (12 units/hour)
D. 0.2 units/kg/hour (16 units/hour)
E. 10 units/hour regardless of weight

Explanation: ***0.1 units/kg/hour (8 units/hour)*** - According to the **Joint British Diabetes Societies (JBDS)** guidelines, the recommended initial **fixed-rate intravenous insulin infusion (FRIII)** for DKA is **0.1 units/kg/hour**. - For a patient weighing **80 kg**, this calculation (0.1 x 80) equals **8 units/hour**, which is the standardized rate to suppress ketogenesis and resolve acidosis. *0.05 units/kg/hour (4 units/hour)* - This dose is generally too low to effectively switch off **ketone production** in the initial stages of DKA management. - A lower rate like this might be considered only in specific scenarios where **insulin sensitivity** is extremely high to avoid rapid metabolic shifts, but it is not the standard starting dose. *0.15 units/kg/hour (12 units/hour)* - Using a rate higher than 0.1 units/kg/hour increases the risk of **hypokalaemia** and a too-rapid fall in blood glucose levels. - Rapid shifts in **osmolarity** caused by higher insulin rates can theoretically increase the risk of **cerebral oedema**, especially in younger patients. *0.2 units/kg/hour (16 units/hour)* - This dosage is double the recommended guideline and significantly increases the risk of **iatrogenic complications** like severe hypoglycaemia. - Guidelines moved away from such high doses because **0.1 units/kg/hour** is sufficient to saturate insulin receptors and achieve maximal metabolic effect. *10 units/hour regardless of weight* - Modern DKA management emphasizes a **weight-based approach** to tailor therapy to the individual's metabolic needs. - A fixed **non-weight-based** dose of 10 units/hour would be an overdose for a small person and an underdose for a very large person, leading to inconsistent clinical outcomes.

Question 167: A 75-year-old woman with atrial fibrillation has been on warfarin for 5 years with consistently stable INR values between 2.0-3.0, checked every 8 weeks. She is now diagnosed with recurrent urinary tract infections requiring frequent antibiotic courses. Over the past 3 months, she has required 3 courses of antibiotics (trimethoprim, nitrofurantoin, and cefalexin). What is the most appropriate modification to her anticoagulation management?

A. Continue warfarin with more frequent INR monitoring during antibiotic courses
B. Switch to a direct oral anticoagulant to avoid INR monitoring (Correct Answer)
C. Continue warfarin but increase target INR range to 2.5-3.5
D. Stop anticoagulation during antibiotic courses then restart
E. Switch to aspirin monotherapy to avoid drug interactions

Explanation: ***Switch to a direct oral anticoagulant to avoid INR monitoring*** - **Direct oral anticoagulants (DOACs)** like apixaban or rivaroxaban are preferred here because they provide stable anticoagulation without the need for frequent **INR monitoring** or risk of drug-drug interactions with most antibiotics. - Frequent antibiotic courses significantly destabilize **warfarin** levels by inhibiting **CYP450 enzymes** or altering **gut flora**, making DOACs a safer and more convenient alternative for this patient. *Continue warfarin with more frequent INR monitoring during antibiotic courses* - While technically possible, this approach is **burdensome** for the patient and increases the risk of **sub-therapeutic or supratherapeutic INR** levels between checks. - Frequent monitoring does not eliminate the inherent **instability** of warfarin therapy caused by repeated antibiotic exposure. *Continue warfarin but increase target INR range to 2.5-3.5* - Raising the **target INR** is clinically inappropriate and significantly increases the **risk of major hemorrhage**, especially in an elderly patient. - A higher target range does not address the underlying issue of **pharmacokinetic interactions** between antibiotics and warfarin. *Stop anticoagulation during antibiotic courses then restart* - Suspending anticoagulation leaves the patient at high risk for **embolic stroke** or systemic embolism, even during short antibiotic courses. - The transient nature of the infection does not justify exposing the patient to the **pro-thrombotic risk** of stopping therapy. *Switch to aspirin monotherapy to avoid drug interactions* - **Aspirin monotherapy** is significantly less effective than anticoagulation for stroke prevention in **atrial fibrillation** and is no longer recommended for this purpose. - While aspirin has fewer interactions, it would provide **inadequate protection** (only ~20% risk reduction) compared to the ~64% reduction provided by anticoagulants.

Question 168: A 32-year-old woman with type 1 diabetes is 24 weeks pregnant. She is on insulin aspart before meals and insulin detemir at bedtime. Her HbA1c is 48 mmol/mol (6.5%). She reports frequent hypoglycaemic episodes (glucose <3.5 mmol/L) occurring 2-3 times weekly, particularly in the afternoon. She is concerned about the effect on her baby. According to current guidance, what is the most appropriate management approach?

A. Reassure that HbA1c is excellent and continue current regimen with glucose monitoring
B. Increase carbohydrate intake in the morning to prevent afternoon hypoglycaemia
C. Reduce morning insulin aspart dose and accept higher HbA1c to reduce hypoglycaemia risk (Correct Answer)
D. Consider continuous subcutaneous insulin infusion (insulin pump) therapy
E. Add metformin to reduce insulin requirements and hypoglycaemia risk

Explanation: ***Reduce morning insulin aspart dose and accept higher HbA1c to reduce hypoglycaemia risk*** - The frequent **afternoon hypoglycaemic episodes** suggest that the **morning (breakfast) insulin aspart dose** is too high for her current physiological needs, especially given the increased insulin sensitivity that can occur in the second trimester of pregnancy. - While maintaining a low HbA1c is important in pregnancy to reduce fetal risks, preventing **severe maternal hypoglycaemia** is paramount. It is appropriate to slightly relax the HbA1c target to ensure maternal safety and well-being. *Reassure that HbA1c is excellent and continue current regimen with glucose monitoring* - Although an **HbA1c of 48 mmol/mol (6.5%)** is within an acceptable range for pregnancy, it does not negate the significant risk posed by frequent and symptomatic **hypoglycaemia**. - Continuing an insulin regimen that causes frequent hypoglycemia is unsafe and could lead to severe adverse events for the mother, which must be prioritized. *Increase carbohydrate intake in the morning to prevent afternoon hypoglycaemia* - While increased carbohydrate intake might temporarily raise glucose, it is a reactive measure and does not address the underlying mismatch between **insulin dose** and need. - This approach can lead to **post-prandial hyperglycemia** and complicate overall glycemic control, making it harder to manage long-term. *Consider continuous subcutaneous insulin infusion (insulin pump) therapy* - While an **insulin pump** can offer more precise insulin delivery and potentially reduce hypoglycaemia, it is a more advanced intervention that is usually considered after optimizing a multiple daily injection regimen. - Simple dose adjustments, particularly reducing the specific insulin dose causing the hypoglycemia, should be the initial approach before escalating to pump therapy. *Add metformin to reduce insulin requirements and hypoglycaemia risk* - **Metformin** is generally not recommended as a primary treatment for **type 1 diabetes** in pregnancy, especially not to manage insulin-induced hypoglycaemia. - Its main role in diabetes management is to reduce **hepatic glucose production** and improve **insulin sensitivity**, which is not the direct solution for an over-dosed rapid-acting insulin causing hypoglycemia.

Question 169: A 68-year-old man with non-valvular atrial fibrillation has been taking apixaban 5mg twice daily for 2 years. He now presents with acute cholecystitis requiring emergency cholecystectomy. His last dose of apixaban was 8 hours ago. He has normal renal function (eGFR >80 ml/min/1.73m²). According to perioperative anticoagulation guidelines, what is the most appropriate management of his apixaban for surgery scheduled in 6 hours?

A. Proceed with surgery as planned; apixaban can be omitted for one dose (Correct Answer)
B. Delay surgery for 24 hours after last dose of apixaban
C. Give 2000 units of four-factor prothrombin complex concentrate and proceed
D. Delay surgery for 48 hours after last dose of apixaban
E. Give idarucizumab to reverse anticoagulation and proceed immediately

Explanation: ***Proceed with surgery as planned; apixaban can be omitted for one dose*** - For urgent surgeries like **cholecystectomy** in a patient with normal renal function, a direct oral anticoagulant (**DOAC**) like apixaban can often be safely managed by omitting doses and ensuring a sufficient time interval. - With the last dose 8 hours ago and surgery scheduled in 6 hours, there will be a **14-hour gap** since the last dose, which is generally considered safe for urgent procedures with low-moderate bleeding risk in patients with normal kidney function. *Delay surgery for 24 hours after last dose of apixaban* - While a 24-hour delay is often appropriate for **elective procedures** or those with a higher bleeding risk, it is too long for an **urgent cholecystectomy**. - Delaying surgery for acute cholecystitis increases the risk of complications such as **gallbladder perforation**, empyema, or sepsis. *Give 2000 units of four-factor prothrombin complex concentrate and proceed* - **Four-factor prothrombin complex concentrate (4F-PCC)** is primarily used for rapid reversal in **life-threatening bleeding** or for emergency major surgeries when a DOAC has been taken very recently. - Given the 14-hour interval between the last apixaban dose and scheduled surgery, the anticoagulant effect is already significantly reduced, making 4F-PCC unnecessary and potentially prothrombotic. *Delay surgery for 48 hours after last dose of apixaban* - A 48-hour delay is typically reserved for **high-bleeding-risk elective surgeries** or for patients with **renal impairment** where DOACs are cleared more slowly. - This duration is excessive and unsafe for an urgent procedure like cholecystectomy, which requires timely intervention to prevent further complications. *Give idarucizumab to reverse anticoagulation and proceed immediately* - **Idarucizumab** is a specific reversal agent for **dabigatran** (a direct thrombin inhibitor), not for apixaban, which is a Factor Xa inhibitor. - The specific reversal agent for apixaban is **andexanet alfa**, but its use is generally reserved for severe or life-threatening bleeding or very high-risk emergency surgeries where immediate complete reversal is critical.

Question 170: A 47-year-old woman with rheumatoid arthritis has been taking methotrexate 20mg weekly for 3 years with good disease control. She presents to her GP with a 4-day history of cough, fever, and shortness of breath. Chest examination reveals bilateral crepitations. Her oxygen saturation is 92% on room air. Blood tests show: white cell count 3.2 × 10⁹/L (neutrophils 1.8 × 10⁹/L), platelets 165 × 10⁹/L. Chest X-ray shows bilateral interstitial infiltrates. What is the most important immediate action regarding her methotrexate?

A. Continue methotrexate but add folic acid 5mg daily
B. Reduce methotrexate dose to 15mg weekly
C. Stop methotrexate immediately and consider differential diagnosis including methotrexate pneumonitis (Correct Answer)
D. Continue methotrexate but prescribe prophylactic co-trimoxazole
E. Switch from weekly methotrexate to daily low-dose methotrexate

Explanation: ***Stop methotrexate immediately and consider differential diagnosis including methotrexate pneumonitis*** - This patient presents with a triad of **fever, cough, and dyspnoea**, which alongside **bilateral interstitial infiltrates** and **hypoxia**, suggests either **methotrexate-induced pneumonitis** or an **opportunistic infection**. - Immediate **cessation of methotrexate** is the most critical step, as the drug is either the direct cause of the lung injury or a contributor to **immunosuppression** during a severe infection. *Continue methotrexate but add folic acid 5mg daily* - Adding **folic acid** is standard to reduce chronic GI side effects or macrocytosis, but it will not treat or stop the progression of acute **methotrexate pneumonitis**. - Continuing an **immunosuppressant** in a patient with active respiratory distress and **interstitial changes** is dangerous and medically inappropriate. *Reduce methotrexate dose to 15mg weekly* - **Dose reduction** is insufficient for managing severe adverse reactions; the drug must be stopped entirely to prevent further pulmonary damage or worsening of **bone marrow suppression**. - The current presentation indicates a life-threatening complication that requires **total withdrawal** of the offending agent. *Continue methotrexate but prescribe prophylactic co-trimoxazole* - While **co-trimoxazole** treats bacterial infections like **Pneumocystis jirovecii**, it does not address the potential direct toxicity of methotrexate on lung tissue. - **Methotrexate** and **co-trimoxazole** interact to increase the risk of severe **pancytopenia** through additive anti-folate effects, making this combination hazardous here. *Switch from weekly methotrexate to daily low-dose methotrexate* - Methotrexate for rheumatoid arthritis must **always be given weekly**; switching to daily dosing is a prescribing error that leads to fatal **toxicity**. - Daily dosing would worsen the patient's existing **neutropenia** and pulmonary inflammation by providing constant, rather than pulsed, folate antagonism.

Question 171: What is the recommended initial frequency for monitoring international normalised ratio (INR) when a patient is first started on warfarin therapy following a deep vein thrombosis?

A. Daily until INR is stable in therapeutic range for 2 consecutive days (Correct Answer)
B. Every 2-3 days until INR is stable in therapeutic range
C. Weekly for the first month then monthly
D. Daily for the first week then twice weekly
E. Every 2 days for the first week then weekly

Explanation: ***Daily until INR is stable in therapeutic range for 2 consecutive days*** - **Daily monitoring** is essential during the initiation phase because of **warfarin's delayed onset** and the high degree of inter-individual variability in response. - Stabilizing the **INR** within the therapeutic range (typically 2.0-3.0 for **DVT**) for two consecutive days ensures the patient is safely anticoagulated before extending monitoring intervals. *Every 2-3 days until INR is stable in therapeutic range* - Waiting 2-3 days initially is risky because **warfarin** inhibits **Protein C and S** first, potentially creating a **prothrombotic state** that requires close observation. - This frequency is more appropriate for the **maintenance phase** after initial stabilization has already been achieved. *Weekly for the first month then monthly* - **Weekly monitoring** at the start of therapy is inadequate and poses a high risk of **bleeding complications** or subtherapeutic dosing. - **Monthly monitoring** is only reserved for patients who have demonstrated long-term **INR stability** on a consistent dose. *Daily for the first week then twice weekly* - While it starts with daily checks, transitioning to twice weekly based on a fixed timeline rather than **therapeutic stability** increases the risk of dosage errors. - The decision to reduce frequency must be based on reaching the **target INR range** for two consecutive days, not just the passage of one week. *Every 2 days for the first week then weekly* - Monitoring every 2 days during the first week is insufficient to detect rapid fluctuations in **clotting factor levels** as different factors have different **half-lives**. - A **weekly** transition is premature for a patient who hasn't yet reached a proven **steady state** on their prescribed warfarin dose.

Question 172: A 56-year-old man with type 2 diabetes is established on insulin detemir 32 units subcutaneously at 22:00 hours and insulin aspart 8 units three times daily with meals. Over the past week, his pre-breakfast glucose readings have been consistently between 3.8-4.2 mmol/L, while his pre-lunch, pre-dinner, and bedtime readings are all 7-9 mmol/L. He denies any hypoglycaemic symptoms. What is the most appropriate adjustment to his insulin regimen?

A. Reduce insulin detemir by 4 units (to 28 units) (Correct Answer)
B. Reduce breakfast insulin aspart by 2 units (to 6 units)
C. Increase all insulin aspart doses by 2 units
D. Split insulin detemir to twice daily dosing
E. Reduce dinner insulin aspart by 2 units (to 6 units)

Explanation: ***Reduce insulin detemir by 4 units (to 28 units)***- The pre-breakfast glucose readings (3.8-4.2 mmol/L) are at the **lower limit of target**, indicating the **basal insulin** (detemir) given at 22:00 is too high and risks **nocturnal hypoglycaemia**.- A dose reduction of approximately **10-15%** (4 units is 12.5% of 32 units) is the standard safe adjustment to correct fasting levels.*Reduce breakfast insulin aspart by 2 units (to 6 units)*- Reducing **breakfast bolus** insulin would primarily affect the **pre-lunch** glucose levels, not the pre-breakfast levels.- Since his pre-lunch readings (7-9 mmol/L) are already at the upper end of the target, this change would likely lead to **hyperglycaemia**.*Increase all insulin aspart doses by 2 units*- Increasing the **bolus insulin** doses would lower daytime glucose but does not address the primary concern of near-hypoglycaemic **fasting glucose**.- This action increases the overall risk of **daytime hypoglycaemia** while leaving the excessive basal dose unchanged.*Split insulin detemir to twice daily dosing*- **Splitting the dose** is usually indicated if there is significant "wear-off" where the basal insulin does not last 24 hours, which is not evidenced here.- The current issue is the **total dose** of basal insulin being too high overnight, not its duration of action.*Reduce dinner insulin aspart by 2 units (to 6 units)*- **Dinner bolus** insulin affects the **bedtime glucose** reading rather than the fasting glucose reading the next morning.- This adjustment would increase his bedtime glucose (currently 7-9 mmol/L) without correcting the low morning readings caused by the **insulin detemir**.

Question 173: A 71-year-old man with atrial fibrillation is on warfarin with a target INR of 2.0-3.0. He is admitted with community-acquired pneumonia and started on clarithromycin 500mg twice daily. His INR on admission is 2.4. After 3 days of antibiotics, he develops haematuria and his INR is found to be 7.8. He is haemodynamically stable with no other bleeding. What is the most appropriate immediate management?

A. Give 5mg oral vitamin K, withhold warfarin, and recheck INR in 24 hours
B. Give 10mg intravenous vitamin K and 4-factor prothrombin complex concentrate
C. Withhold warfarin for 2 doses and recheck INR daily without vitamin K
D. Give 1-2mg intravenous vitamin K, withhold warfarin, and recheck INR in 24 hours (Correct Answer)
E. Stop warfarin permanently and switch to direct oral anticoagulant

Explanation: ***Give 1-2mg intravenous vitamin K, withhold warfarin, and recheck INR in 24 hours*** - An **INR of 7.8** with **minor bleeding** (haematuria) in a haemodynamically stable patient warrants rapid, but not aggressive, reversal of anticoagulation. - **Low-dose intravenous vitamin K** (1-2mg) is the recommended intervention, as it provides a predictable and timely reduction in INR, along with **withholding warfarin**. *Give 5mg oral vitamin K, withhold warfarin, and recheck INR in 24 hours* - While **oral vitamin K** is an option for elevated INR without bleeding, **intravenous administration** is preferred for active bleeding (like haematuria) due to its faster onset and more reliable effect. - A **5mg dose** of vitamin K may be excessive for minor bleeding, potentially causing **warfarin resistance** for several days, complicating subsequent anticoagulation management. *Give 10mg intravenous vitamin K and 4-factor prothrombin complex concentrate* - **Prothrombin complex concentrate (PCC)** and a high dose of **intravenous vitamin K (10mg)** are reserved for **major life-threatening bleeding** (e.g., intracranial hemorrhage) or urgent surgical needs. - This patient is **haemodynamically stable** with only minor bleeding, making such aggressive and costly reversal measures inappropriate and potentially harmful. *Withhold warfarin for 2 doses and recheck INR daily without vitamin K* - Simply **withholding warfarin** is insufficient to rapidly lower an **INR of 7.8** with active bleeding, as warfarin's anticoagulant effect takes several days to diminish. - Active reversal with **vitamin K** is crucial in this scenario to quickly reduce the INR and mitigate the risk of the minor bleeding progressing to a more serious event. *Stop warfarin permanently and switch to direct oral anticoagulant* - The elevated INR and haematuria are likely due to a **drug-drug interaction** between **warfarin** and **clarithromycin**, a known **CYP3A4 inhibitor**, increasing warfarin's effect. - Permanent cessation of warfarin is not indicated, as the issue is transient; once the INR is controlled and the antibiotic course is complete, warfarin can typically be safely resumed at an adjusted dose.

Question 174: A 39-year-old woman with type 1 diabetes on basal-bolus insulin therapy (insulin glargine 24 units at bedtime and insulin aspart with meals) is admitted with acute appendicitis requiring emergency surgery. She last ate 6 hours ago. Her current blood glucose is 8.2 mmol/L. The operation is scheduled in 2 hours. What is the most appropriate management of her insulin during the perioperative period?

A. Continue basal insulin, omit bolus insulin, and start variable rate intravenous insulin infusion with dextrose (Correct Answer)
B. Stop all subcutaneous insulin and start variable rate intravenous insulin infusion with dextrose
C. Continue both basal and bolus insulin at current doses with hourly glucose monitoring
D. Give 50% of basal insulin dose, omit bolus insulin, and monitor glucose 2-hourly
E. Stop basal insulin, give half dose of bolus insulin, and start intravenous insulin only if glucose >15 mmol/L

Explanation: ***Continue basal insulin, omit bolus insulin, and start variable rate intravenous insulin infusion with dextrose*** - For **Type 1 Diabetes** patients undergoing surgery, **basal insulin** must be continued to prevent the development of **diabetic ketoacidosis (DKA)**. - A **variable rate intravenous insulin infusion (VRIII)**, paired with a glucose substrate like **dextrose**, ensures tight glycemic control during fasting periods and surgical stress. *Stop all subcutaneous insulin and start variable rate intravenous insulin infusion with dextrose* - Discontinuing **long-acting basal insulin** in Type 1 Diabetes increases the risk of **DKA** if the IV infusion is interrupted or stopped prematurely. - Clinical guidelines recommend maintaining the **subcutaneous basal dose** as a safety net, even when using a VRIII. *Continue both basal and bolus insulin at current doses with hourly glucose monitoring* - Administering **bolus insulin** (insulin aspart) when the patient is **NPO** (nil per os) carries a very high risk of inducing severe **hypoglycemia**. - While frequent glucose monitoring is crucial, it does not mitigate the danger of giving short-acting insulin without an appropriate carbohydrate intake. *Give 50% of basal insulin dose, omit bolus insulin, and monitor glucose 2-hourly* - Reducing the **basal insulin** dose to 50% may be insufficient to counteract the **stress-induced hyperglycemia** during acute appendicitis and surgery in a Type 1 diabetic. - For emergency or major surgery, a **VRIII** provides more dynamic and precise glucose management compared to a fixed, reduced subcutaneous dose with less frequent monitoring. *Stop basal insulin, give half dose of bolus insulin, and start intravenous insulin only if glucose >15 mmol/L* - Completely stopping **basal insulin** in Type 1 Diabetes is highly dangerous and will rapidly precipitate **DKA** due to the lack of endogenous insulin production. - Waiting for blood glucose to exceed **15 mmol/L** before initiating intravenous insulin is unsafe, as perioperative targets should ideally be maintained between **6.0-10.0 mmol/L** to prevent complications.

Question 175: According to the National Patient Safety Agency guidance on high-risk medicines, which of the following monitoring parameters is specifically recommended for patients on long-term amiodarone therapy?

A. Monthly electrocardiogram and liver function tests
B. Six-monthly thyroid function tests and annual chest X-ray (Correct Answer)
C. Weekly international normalised ratio and renal function
D. Three-monthly full blood count and serum amiodarone levels
E. Annual echocardiogram and monthly ophthalmic examination

Explanation: ***Six-monthly thyroid function tests and annual chest X-ray*** - **Amiodarone** is a high-iodine compound that can cause **hypothyroidism** or **thyrotoxicosis**, requiring **thyroid function tests (TFTs)** every 6 months. - **Pulmonary toxicity** is a life-threatening complication, necessitating an **annual chest X-ray** to monitor for interstitial lung disease or fibrosis. *Monthly electrocardiogram and liver function tests* - While **Liver Function Tests (LFTs)** are required every 6 months, monthly testing is not the standard recommendation for stable patients. - **Electrocardiograms (ECGs)** are performed at baseline and periodically, but **monthly routine monitoring** is not mandate by NPSA guidelines. *Weekly international normalised ratio and renal function* - **International Normalised Ratio (INR)** monitoring is critical only if amiodarone is used concurrently with **warfarin**, due to a significant drug interaction. - Amiodarone does not typically require **renal function** monitoring, as it is primarily metabolized through the **liver** and excreted in bile. *Three-monthly full blood count and serum amiodarone levels* - **Full blood counts** are not standard monitoring requirements for amiodarone, as it does not commonly cause myelosuppression. - Routine monitoring of **serum amiodarone levels** is not clinically useful or recommended due to the drug's extremely long half-life and large volume of distribution. *Annual echocardiogram and monthly ophthalmic examination* - **Echocardiograms** are not part of routine amiodarone monitoring unless there is a clinical suspicion of worsening heart failure or specific arrhythmias. - **Ophthalmic examinations** are recommended at baseline and only if visual symptoms occur; **monthly examinations** are not required for asymptomatic patients.

Question 176: A 50-year-old man with bipolar disorder has been stable on lithium carbonate 800mg twice daily for 18 months. His most recent lithium level 3 months ago was 0.75 mmol/L (therapeutic range 0.6-1.0 mmol/L). He now presents to his GP with a 5-day history of diarrhoea and vomiting following a gastrointestinal infection. He appears clinically dehydrated with a coarse tremor. What is the most appropriate immediate management?

A. Continue lithium and arrange lithium level within 7 days
B. Reduce lithium dose by 50% and recheck level in 1 week
C. Stop lithium immediately and arrange urgent lithium level (Correct Answer)
D. Continue lithium and start domperidone for symptom control
E. Switch to sodium valproate and monitor lithium level

Explanation: ***Stop lithium immediately and arrange urgent lithium level*** - The patient presents with clear signs of **lithium toxicity**, including a **coarse tremor** and clinical **dehydration**, precipitated by a **gastrointestinal infection** causing fluid loss. - Dehydration significantly impairs renal lithium excretion, leading to rapid accumulation and potentially dangerous **elevated plasma levels** that require immediate cessation and urgent monitoring. *Continue lithium and arrange lithium level within 7 days* - Continuing lithium in a patient with active **signs of toxicity** and **volume depletion** is extremely dangerous and risks escalating to severe toxicity, including **seizures** or **renal damage**. - Waiting 7 days for a lithium level is an unacceptably slow response given the acute and potentially life-threatening nature of **lithium overdose** in a dehydrated state. *Reduce lithium dose by 50% and recheck level in 1 week* - A **dose reduction** is insufficient as the patient is already displaying signs of **acute lithium toxicity** due to increased reabsorption from dehydration, meaning even a reduced dose would likely remain toxic. - The immediate priority is to stop the accumulation and facilitate excretion of the already elevated lithium; merely reducing the dose does not address the **acute toxic state** or the physiological changes causing it. *Continue lithium and start domperidone for symptom control* - **Domperidone** would only address the vomiting symptom, while completely ignoring the critical issue of **lithium accumulation** and ongoing toxicity exacerbated by dehydration. - This approach risks masking worsening symptoms and allowing the patient to progress toward **severe lithium toxicity** without appropriate intervention. *Switch to sodium valproate and monitor lithium level* - Switching to an alternative mood stabilizer like **sodium valproate** does not address the immediate medical emergency of **acute lithium toxicity** and its existing high levels in the patient's system. - The primary concern is to manage and clear the currently elevated and **renally-excreted lithium**, not to initiate a new mood stabilizer in an acutely unwell patient.

Question 177: A 63-year-old woman with metastatic breast cancer is started on enoxaparin for prophylaxis of venous thromboembolism. She has a past medical history of hypertension and stage 3 chronic kidney disease with eGFR of 35 ml/min/1.73m². Her weight is 55 kg. According to current prescribing guidance, what adjustment should be made to the standard dose of enoxaparin?

A. No dose adjustment required
B. Reduce dose by 25% and monitor anti-Xa levels
C. Reduce dose by 50% and monitor anti-Xa levels (Correct Answer)
D. Switch to unfractionated heparin instead
E. Increase dosing interval from once to twice daily

Explanation: ***Reduce dose by 50% and monitor anti-Xa levels*** - **Enoxaparin**, a low molecular weight heparin, is primarily cleared by the **kidneys**. With an **eGFR of 35 ml/min/1.73m² (Stage 3 CKD)** and **low body weight (55 kg)**, there is a high risk of drug accumulation. - Current guidelines recommend a **50% dose reduction** for VTE prophylaxis in patients with an eGFR below 30 mL/min or those with an eGFR between 30-50 mL/min who also have additional risk factors like low body weight, along with monitoring **anti-Xa levels**. *No dose adjustment required* - This patient's **Stage 3 CKD (eGFR 35 ml/min/1.73m²)** significantly impairs enoxaparin clearance, and her **low body weight (55 kg)** further increases the risk of accumulation. - Standard dosing without adjustment would lead to **toxic accumulation** and a substantially elevated risk of **bleeding**, which is unacceptable for anticoagulation. *Reduce dose by 25% and monitor anti-Xa levels* - A **25% dose reduction** is generally considered insufficient to adequately mitigate the risk of **enoxaparin accumulation** in patients with significant renal impairment and low body weight. - Pharmacokinetic data and clinical experience indicate that a more substantial reduction, typically **50%**, is necessary to maintain safe and effective **anti-Xa levels** for prophylaxis in this high-risk group. *Switch to unfractionated heparin instead* - While **unfractionated heparin (UFH)** is often preferred in cases of **severe renal failure (eGFR <15 ml/min)** due to its non-renal clearance, it is not strictly necessary for Stage 3 CKD where LMWH can be adjusted. - **UFH** requires more frequent monitoring via **aPTT** and has a shorter half-life, making it less practical for VTE prophylaxis compared to appropriately dose-adjusted enoxaparin. *Increase dosing interval from once to twice daily* - Increasing the frequency of administration from once to **twice daily** without reducing the individual dose would inadvertently **increase the total daily drug exposure**. - This would exacerbate the problem of **drug accumulation** in a renally impaired patient, significantly increasing the risk of **hemorrhagic complications**, rather than providing a safer regimen.

Question 178: A 63-year-old man with type 2 diabetes is established on a complex insulin regimen comprising insulin glargine 38 units at 22:00, insulin aspart 12 units with breakfast, 10 units with lunch, and 14 units with evening meal. He is admitted with acute pancreatitis and made nil by mouth, and a variable rate intravenous insulin infusion (VRIII) is commenced at 09:00 on Monday. His last dose of insulin glargine was at 22:00 on Sunday night. He improves and is ready to resume eating at 18:00 on Wednesday. When is the most appropriate time to discontinue the VRIII?

A. Discontinue VRIII immediately at 18:00 Wednesday and give insulin aspart 14 units with the evening meal
B. Discontinue VRIII at 19:00 Wednesday, 1 hour after insulin aspart 14 units given with evening meal
C. Discontinue VRIII at 22:00 Wednesday when insulin glargine is administered
D. Discontinue VRIII at 23:00 Wednesday, 1 hour after insulin glargine is administered (Correct Answer)
E. Continue VRIII overnight and discontinue at 07:00 Thursday before breakfast insulin aspart

Explanation: ***Discontinue VRIII at 23:00 Wednesday, 1 hour after insulin glargine is administered*** - To safely transition from a **Variable Rate Intravenous Insulin Infusion (VRIII)**, there must be adequate **overlap** with **long-acting basal insulin** to prevent a gap in insulin coverage and subsequent **hyperglycemia** or **ketogenesis**. - **Insulin glargine** has a delayed onset of action, typically taking 1-2 hours to reach therapeutic levels; therefore, the VRIII should continue for at least **30-60 minutes after** the basal insulin is administered to ensure continuous insulinization. *Discontinue VRIII immediately at 18:00 Wednesday and give insulin aspart 14 units with the evening meal* - Stopping the **VRIII** immediately at 18:00 would leave the patient without effective insulin coverage, as **intravenous insulin** has a very short half-life. - **Insulin aspart** is a rapid-acting bolus insulin for meal coverage and does not provide the essential **basal insulin** required for continuous glycemic control. *Discontinue VRIII at 19:00 Wednesday, 1 hour after insulin aspart 14 units given with evening meal* - While providing a 1-hour overlap, this option fails to re-establish **basal insulin** coverage, as **insulin aspart** is a rapid-acting mealtime insulin. - The patient would be without crucial **basal insulin** from 19:00 until the glargine dose at 22:00, risking significant **hyperglycemia** and **ketosis** overnight. *Discontinue VRIII at 22:00 Wednesday when insulin glargine is administered* - **Insulin glargine** requires time to be absorbed and exert its therapeutic effect (onset of 1-2 hours after subcutaneous injection). - Discontinuing the **VRIII** at the exact moment of glargine administration would create a **therapeutic gap** where the patient has no active insulin, leading to potential metabolic instability. *Continue VRIII overnight and discontinue at 07:00 Thursday before breakfast insulin aspart* - This approach is overly cautious and prolongs the use of **intravenous insulin**, increasing the risk of **hypoglycemia** and complications related to IV access. - Once **basal insulin** is restarted with appropriate overlap, the **VRIII** is no longer needed, making continuation until Thursday morning unnecessary.

Question 179: A 77-year-old man with atrial fibrillation and a mechanical mitral valve replacement is on warfarin with target INR 3.0-4.0. He requires urgent colonoscopy for suspected lower gastrointestinal bleeding (haemoglobin dropped from 125 to 95 g/L over 48 hours with melaena). His current INR is 3.6. He is haemodynamically stable. What is the most appropriate anticoagulation management strategy prior to the procedure?

A. Give prothrombin complex concentrate and proceed with colonoscopy immediately
B. Give intravenous vitamin K 5-10mg and proceed when INR falls below 1.5
C. Omit warfarin doses and proceed with colonoscopy when INR falls to 1.5-2.0 (Correct Answer)
D. Continue warfarin and proceed with colonoscopy as INR is within therapeutic range
E. Give oral vitamin K 1-2mg and proceed when INR falls below 2.0

Explanation: ***Omit warfarin doses and proceed with colonoscopy when INR falls to 1.5-2.0***- In a **haemodynamically stable** patient with a high thromboembolic risk (**mechanical mitral valve**), omitting doses allows for a controlled drop in INR to a safer range for endoscopy.- An **INR of 1.5-2.0** provides a necessary balance, reducing the risk of procedural bleeding while minimizing the time the patient is unprotected from valve thrombosis.*Give prothrombin complex concentrate and proceed with colonoscopy immediately*- **Prothrombin complex concentrate (PCC)** is reserved for **life-threatening bleeding** or emergency surgery, which is not indicated here as the patient is stable.- Rapid reversal with PCC can be pro-thrombotic and is dangerous for patients with **mechanical heart valves** unless absolutely necessary.*Give intravenous vitamin K 5-10mg and proceed when INR falls below 1.5*- High-dose **intravenous Vitamin K** can cause **warfarin resistance** for several days, making it difficult to restart therapeutic anticoagulation after the procedure.- Aiming for an **INR below 1.5** unnecessarily increases the duration of subtherapeutic coverage in a patient with a high-risk **mitral prosthesis**.*Continue warfarin and proceed with colonoscopy as INR is within therapeutic range*- Performing a colonoscopy for **GI bleeding** with an **INR of 3.6** carries an unacceptably high risk of exacerbating the bleed or causing procedural complications.- Most endoscopic interventions require the INR to be significantly lower than the **therapeutic range** for a mechanical valve to ensure haemostasis.*Give oral vitamin K 1-2mg and proceed when INR falls below 2.0*- While lower doses of **oral Vitamin K** are safer than IV, they are still generally unnecessary in a **haemodynamically stable** patient when simple omission of doses is an option.- Managing the INR through **natural decay** (omission) allows for more predictable re-titration of warfarin once the bleeding source is identified and treated.

Question 180: A 42-year-old woman with newly diagnosed type 1 diabetes is being established on a basal-bolus insulin regimen. Over the past week, her pre-meal and bedtime capillary glucose readings have been: breakfast 6.2-7.8 mmol/L, lunch 11.5-14.2 mmol/L, evening meal 7.1-8.9 mmol/L, bedtime 9.8-12.4 mmol/L. She is currently on insulin detemir 18 units at bedtime and insulin lispro 6 units before each meal. Which insulin adjustment would most appropriately address her glucose pattern?

A. Increase insulin detemir to 22 units at bedtime
B. Increase breakfast insulin lispro to 8 units (Correct Answer)
C. Increase lunch insulin lispro to 8 units
D. Increase evening meal insulin lispro to 8 units
E. Split insulin detemir to 10 units in the morning and 10 units at bedtime

Explanation: ***Increase breakfast insulin lispro to 8 units*** - The patient's **pre-lunch glucose readings (11.5-14.2 mmol/L)** are significantly elevated, indicating that the current **breakfast bolus insulin (lispro)** is insufficient to cover the carbohydrate intake from breakfast. - In a basal-bolus regimen, the rapid-acting insulin given before a meal is primarily responsible for controlling the **postprandial glucose excursion** and ensuring an appropriate glucose level before the subsequent meal. *Increase insulin detemir to 22 units at bedtime* - Increasing the **basal insulin (detemir)** primarily impacts the **fasting glucose** (pre-breakfast readings), which are currently within an acceptable range (6.2-7.8 mmol/L). - Adjusting basal insulin when fasting levels are well-controlled risks **nocturnal hypoglycemia** without addressing the specific post-breakfast hyperglycemia. *Increase lunch insulin lispro to 8 units* - Increasing the **lunch bolus insulin** would primarily affect the glucose levels before the **evening meal**, which are already acceptable (7.1-8.9 mmol/L). - This adjustment would not target the elevated glucose readings observed **before lunch**, which is the main problem area. *Increase evening meal insulin lispro to 8 units* - While bedtime glucose is slightly high (9.8-12.4 mmol/L), the most pronounced and concerning hyperglycemia is seen **before lunch**, which should be prioritized for intervention. - Increasing the evening bolus without addressing the morning issue could lead to inadequate daytime control and potentially mask the primary problem. *Split insulin detemir to 10 units in the morning and 10 units at bedtime* - Splitting the **basal insulin dose** can improve overall 24-hour glucose stability by providing more even coverage, but it does not directly address **postprandial spikes** related to specific meals. - This adjustment would not specifically correct the **insulin-to-carbohydrate ratio mismatch** identified after breakfast.

Question 181: A 54-year-old woman attends anticoagulation clinic for routine INR monitoring. She has been on warfarin for 18 months following an unprovoked pulmonary embolism. Her INR today is 8.2. She has no signs of bleeding and is completely asymptomatic. Her previous INR results over the past 3 months have ranged between 2.3-3.1. She reports no change in medications or diet and takes no over-the-counter preparations. What is the most appropriate immediate management?

A. Omit warfarin for 2 days, give oral vitamin K 1-5mg, and repeat INR the following day (Correct Answer)
B. Admit for intravenous vitamin K 5mg and prothrombin complex concentrate
C. Omit warfarin today and tomorrow, then restart at reduced dose when INR <5.0
D. Continue warfarin at reduced dose and repeat INR in 3 days
E. Omit warfarin for 1 day, continue at 50% dose for 2 days, then resume normal dosing

Explanation: ***Omit warfarin for 2 days, give oral vitamin K 1-5mg, and repeat INR the following day***- For an **INR of 8.2** with **no signs of bleeding**, withholding warfarin and administering **oral vitamin K (1-5 mg)** is the recommended immediate management to safely lower the INR.- Repeating the **INR the following day** is crucial to assess the effectiveness of vitamin K and guide subsequent warfarin dosing. *Admit for intravenous vitamin K 5mg and prothrombin complex concentrate*- These aggressive interventions, including **intravenous vitamin K** and **prothrombin complex concentrate (PCC)**, are reserved for **major or life-threatening bleeding** or extremely high INR values with high bleeding risk, which is not present in this asymptomatic patient.- PCC provides rapid but temporary reversal and carries its own risks, making it inappropriate for stable, asymptomatic over-anticoagulation. *Omit warfarin today and tomorrow, then restart at reduced dose when INR <5.0*- While omitting warfarin is part of the management for elevated INR, simply withholding doses without **vitamin K** is typically reserved for **INR values between 5.0 and 8.0** without bleeding.- Given an **INR > 8.0**, active reversal with vitamin K is necessary to achieve a quicker and more predictable reduction of the INR, reducing the risk of spontaneous hemorrhage. *Continue warfarin at reduced dose and repeat INR in 3 days*- Continuing warfarin at any dose with an **INR of 8.2** is extremely dangerous and significantly increases the immediate risk of **major hemorrhagic events**, such as intracranial or gastrointestinal bleeding.- Waiting **3 days** to repeat the INR is an unacceptable delay for such a critically elevated INR; more immediate monitoring is required after intervention. *Omit warfarin for 1 day, continue at 50% dose for 2 days, then resume normal dosing*- This plan is insufficient for managing an **INR of 8.2** as it does not include **oral vitamin K**, which is essential for prompt and effective reversal of significant over-anticoagulation.- Resuming warfarin, even at a reduced dose, without confirming a significant decrease in INR through **re-testing** after an acute management step is unsafe and may lead to recurrent over-anticoagulation.

Question 182: A 66-year-old man with heart failure (LVEF 30%) and chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²) is on the following medications: ramipril 10mg once daily, bisoprolol 10mg once daily, spironolactone 25mg once daily, and furosemide 40mg once daily. His latest blood results show: Na+ 138 mmol/L, K+ 5.7 mmol/L, creatinine 185 micromol/L (baseline 165 micromol/L). He is asymptomatic. Which medication adjustment represents the most appropriate initial management?

A. Reduce spironolactone to 25mg on alternate days
B. Add calcium resonium 15g three times daily
C. Reduce ramipril to 5mg once daily and continue spironolactone
D. Stop spironolactone and repeat blood tests in 5-7 days (Correct Answer)
E. Stop ramipril and repeat blood tests in 1 week

Explanation: ***Stop spironolactone and repeat blood tests in 5-7 days*** - In a patient with **hyperkalemia (K+ 5.7 mmol/L)**, **heart failure**, and **CKD**, spironolactone, a **mineralocorticoid receptor antagonist**, is the most likely cause and should be immediately discontinued. - Stopping spironolactone is a direct and effective initial step to lower potassium, while the **ACE inhibitor (ramipril)**, which provides significant prognostic benefit, can often be maintained if hyperkalemia resolves. *Reduce spironolactone to 25mg on alternate days* - **Alternate-day dosing** is generally not recommended for managing established hyperkalemia due to insufficient control and lack of evidence for efficacy. - Complete **cessation** is a more decisive and safer initial step to prevent further rises in potassium in this clinical context. *Add calcium resonium 15g three times daily* - **Calcium resonium** is a potassium-binding resin usually reserved for more **severe hyperkalemia** (typically K+ > 6.0 mmol/L) or when other measures fail. - The initial management should focus on identifying and removing the offending drug, rather than adding another medication to excrete potassium. *Reduce ramipril to 5mg once daily and continue spironolactone* - **Ramipril (an ACE inhibitor)** is a cornerstone medication for **heart failure with reduced ejection fraction** and contributes significant mortality benefit. - Prioritizing reduction of ramipril over discontinuing spironolactone is inappropriate, as spironolactone is a more potent and direct contributor to hyperkalemia, especially in CKD. *Stop ramipril and repeat blood tests in 1 week* - Discontinuing the **ACE inhibitor** first is not recommended given its crucial role in **HFrEF management** and the relatively modest rise in creatinine (less than 25% from baseline). - **Spironolactone** is considered more "expendable" in the acute management of hyperkalemia compared to ACE inhibitors and beta-blockers, particularly when it's the primary driver of potassium elevation.

Question 183: A 59-year-old man with type 2 diabetes is admitted for emergency laparotomy for perforated diverticulitis. His regular medications include metformin 1g twice daily, sitagliptin 100mg once daily, and insulin detemir 40 units at bedtime. His HbA1c 3 months ago was 58 mmol/mol (7.5%). He will be nil by mouth and commenced on a variable rate intravenous insulin infusion (VRIII). Which of his diabetes medications should be continued during the perioperative period?

A. Continue all diabetes medications at normal doses
B. Continue insulin detemir only; stop metformin and sitagliptin (Correct Answer)
C. Continue metformin only; stop insulin detemir and sitagliptin
D. Stop all diabetes medications while on VRIII
E. Continue sitagliptin and insulin detemir; stop metformin

Explanation: ***Continue insulin detemir only; stop metformin and sitagliptin*** - **Insulin detemir**, a **long-acting basal insulin**, should be continued (often at a reduced dose) to provide background glycemic control, preventing **insulin deficiency**, hyperglycemia, and **diabetic ketoacidosis (DKA)** in **nil by mouth (NBM)** patients. - Continuing basal insulin alongside a **variable rate intravenous insulin infusion (VRIII)** helps stabilize blood glucose levels, reduces the total insulin requirement from the VRIII, and facilitates a smoother transition back to subcutaneous insulin post-surgery. *Continue all diabetes medications at normal doses* - **Metformin** must be withheld perioperatively due to the risk of **lactic acidosis**, especially in emergency surgery where **acute kidney injury (AKI)** and hypoperfusion are concerns. - Oral hypoglycemics like **sitagliptin** are inappropriate for **NBM** patients as their effect depends on food intake and they can increase the risk of **hypoglycemia**, while a VRIII is managing acute glucose. *Continue metformin only; stop insulin detemir and sitagliptin* - Continuing **metformin** is contraindicated in this perioperative setting due to the significant risk of **lactic acidosis**, exacerbated by surgical stress and potential organ dysfunction. - Stopping **basal insulin (detemir)** entirely for an insulin-requiring patient who is **NBM** significantly increases the risk of **DKA** and severe hyperglycemia, even with a VRIII running concurrently. *Stop all diabetes medications while on VRIII* - While the **VRIII** provides acute glycemic control, completely stopping **basal insulin** in patients who are normally on it can lead to **insulin deficiency**, rebound hyperglycemia, and **DKA** once the VRIII is weaned or discontinued. - Current guidelines recommend continuing a portion of the patient's usual **basal insulin dose** (e.g., 50-80%) to maintain physiological insulin levels and prevent metabolic decompensation. *Continue sitagliptin and insulin detemir; stop metformin* - **Sitagliptin** (a DPP-4 inhibitor) should be withheld because the patient is **NBM** and its mechanism of action relies on the **incretin effect** stimulated by food. It offers no benefit and carries a potential risk of **hypoglycemia**. - Although continuing **insulin detemir** is correct, the inclusion of **sitagliptin** makes this option incorrect, as oral hypoglycemic agents are generally stopped during the perioperative period with VRIII.

Question 184: A 73-year-old woman with atrial fibrillation has been stable on warfarin for 3 years with target INR 2-3. Her recent INR results have been: 2.4, 2.6, 2.3, 2.5. She is admitted with lobar pneumonia and started on clarithromycin 500mg twice daily. She has normal renal function. What is the most appropriate warfarin management during her antibiotic course?

A. Continue warfarin at the same dose and check INR after completing the antibiotic course
B. Temporarily switch to a prophylactic dose DOAC for the duration of antibiotic treatment
C. Continue warfarin at the same dose but check INR after 3-5 days of concurrent antibiotic use (Correct Answer)
D. Reduce warfarin dose by 50% for the duration of antibiotic treatment
E. Withhold warfarin until antibiotic course is completed then restart

Explanation: ***Continue warfarin at the same dose but check INR after 3-5 days of concurrent antibiotic use***- **Clarithromycin** is a potent inhibitor of the **CYP450 system** (specifically **CYP3A4**), which reduces the metabolism of **warfarin** and significantly increases the risk of **bleeding**.- Regular monitoring of the **INR** within **3-5 days** allows for precise dose adjustments based on individual patient response, preventing over-anticoagulation while maintaining therapeutic levels.*Continue warfarin at the same dose and check INR after completing the antibiotic course*- Waiting until the antibiotic course is finished is dangerous because the **INR** can rise rapidly within days of starting **clarithromycin**, significantly increasing the risk of **major hemorrhage**.- Drug interactions with **macrolides** typically manifest early due to their effect on **warfarin metabolism**, making delayed monitoring an unsafe clinical practice.*Temporarily switch to a prophylactic dose DOAC for the duration of antibiotic treatment*- Switching to a **DOAC** is not indicated for managing short-term drug interactions and complicates anticoagulation in a patient stable on **warfarin**.- Furthermore, **clarithromycin** also interacts with most **DOACs** (like rivaroxaban and apixaban) via **P-glycoprotein** and **CYP3A4** inhibition, potentially increasing their levels and bleeding risk as well.*Reduce warfarin dose by 50% for the duration of antibiotic treatment*- A preemptive, fixed dose reduction is not recommended because the degree of **enzyme inhibition** and individual patient response to the interaction varies significantly.- This approach risks making the patient **subtherapeutic**, thereby increasing the risk of **thromboembolic events** like stroke in the setting of atrial fibrillation.*Withhold warfarin until antibiotic course is completed then restart*- Completely withholding **warfarin** leaves the patient without **anticoagulation**, placing them at a high risk for an **ischemic stroke** due to atrial fibrillation.- Warfarin has a long **half-life**, and stopping it abruptly without a clear clinical indication (e.g., active bleeding, very high INR) is inappropriate for managing a drug interaction, as the risk of thrombosis outweighs the risk of managed interaction.

Question 185: A 47-year-old woman with type 1 diabetes on basal-bolus insulin therapy (insulin glargine 24 units at bedtime and insulin aspart 8 units with meals) is experiencing recurrent nocturnal hypoglycaemia at 3am, with morning fasting glucose readings of 12-14 mmol/L. This pattern has been consistent for 2 weeks. What is the most appropriate adjustment to her insulin regimen?

A. Increase insulin glargine to 28 units at bedtime
B. Reduce insulin glargine to 20 units at bedtime (Correct Answer)
C. Add a bedtime snack without adjusting insulin doses
D. Switch insulin glargine administration from bedtime to morning
E. Reduce the evening meal insulin aspart dose

Explanation: ***Reduce insulin glargine to 20 units at bedtime*** - The patient's pattern of **recurrent nocturnal hypoglycemia** at 3 am followed by **rebound hyperglycemia** in the morning (12-14 mmol/L) is classic for the **Somogyi effect**. - Reducing the bedtime **basal insulin (glargine)** dose will prevent the nocturnal hypoglycemia, thus eliminating the counter-regulatory hormone response that causes the high morning blood glucose. *Increase insulin glargine to 28 units at bedtime* - Increasing the **basal insulin** dose would exacerbate the already existing **nocturnal hypoglycemia**, making it more severe and potentially dangerous for the patient. - The high morning fasting glucose is a rebound phenomenon, not a sign of insufficient basal insulin; therefore, an increase would worsen the underlying problem. *Add a bedtime snack without adjusting insulin doses* - While a bedtime snack might temporarily prevent hypoglycemia, it does not address the fundamental issue of **excessive basal insulin** dose throughout the night. - This approach may lead to **unintended weight gain** and could still result in hypoglycemia later in the night if the insulin dose remains too high. *Switch insulin glargine administration from bedtime to morning* - Changing the administration time of **insulin glargine** (a long-acting basal insulin) may alter its peak action slightly, but it does not resolve the problem of an **overall high basal dose**. - The primary concern is the total amount of basal insulin, not just its timing, especially with documented recurrent nocturnal lows. *Reduce the evening meal insulin aspart dose* - **Insulin aspart** is a rapid-acting insulin with a duration of action typically 3-5 hours, meaning its effect would have worn off well before 3 am. - Reducing the evening meal bolus would primarily lead to **post-prandial hyperglycemia** after dinner, without addressing the specific issue of nocturnal hypoglycemia.

Question 186: A 68-year-old man with paroxysmal atrial fibrillation (CHA₂DS₂-VASc score 4) is established on edoxaban 60mg once daily. He now requires elective inguinal hernia repair. His renal function is normal (eGFR 72 ml/min/1.73m²) and weight is 78kg. What is the most appropriate perioperative anticoagulation management?

A. Stop edoxaban 24 hours before surgery and restart 6 hours post-operatively if haemostasis achieved (Correct Answer)
B. Stop edoxaban 48 hours before surgery and restart 48-72 hours post-operatively
C. Continue edoxaban throughout the perioperative period without interruption
D. Stop edoxaban 24 hours before surgery, bridge with low molecular weight heparin, restart edoxaban 24 hours post-operatively
E. Stop edoxaban 72 hours before surgery and restart 24 hours post-operatively

Explanation: ***Stop edoxaban 24 hours before surgery and restart 6 hours post-operatively if haemostasis achieved*** - For procedures with **standard bleeding risk** (like inguinal hernia repair) and normal renal function (eGFR >50 mL/min), omitting **edoxaban** for **24 hours** (one dose) is sufficient due to its 10-14 hour half-life, ensuring adequate drug clearance before surgery. - **Direct Oral Anticoagulants (DOACs)** have a rapid onset of action, allowing them to be restarted relatively quickly, typically **6-24 hours** post-operatively, once primary haemostasis is secured and the risk of bleeding is minimized. *Stop edoxaban 48 hours before surgery and restart 48-72 hours post-operatively* - A **48-hour interruption** for edoxaban is generally reserved for procedures with **high bleeding risk** or in patients with moderate renal impairment (eGFR 15-50 mL/min), neither of which applies to this patient. - Delaying the restart of anticoagulation for **48-72 hours** post-operatively significantly increases the patient's risk of **thromboembolic events** given his CHA₂DS₂-VASc score of 4, without providing additional safety benefits for a standard-risk procedure. *Continue edoxaban throughout the perioperative period without interruption* - While some very minor procedures (e.g., minor dental work, superficial skin procedures) might allow uninterrupted anticoagulation, an **inguinal hernia repair** carries a sufficient bleeding risk to warrant a temporary cessation of anticoagulation. - Continuing **edoxaban** without interruption for this type of surgery would significantly increase the risk of **perioperative bleeding** and associated complications. *Stop edoxaban 24 hours before surgery, bridge with low molecular weight heparin, restart edoxaban 24 hours post-operatively* - **Bridging anticoagulation** with low molecular weight heparin (LMWH) is generally **not recommended** for patients on DOACs because they have predictable pharmacokinetics with a rapid offset and onset of action, unlike warfarin. - Studies have shown that **LMWH bridging** in DOAC patients significantly increases the risk of **major bleeding** without providing additional protection against stroke or other thromboembolic events. *Stop edoxaban 72 hours before surgery and restart 24 hours post-operatively* - An interruption of **72 hours** is excessive for a patient with normal renal function and a standard bleeding risk procedure, leading to an unnecessarily prolonged period of vulnerability to **thromboembolic events**. - Guideline-directed management for **standard risk** elective surgery aims to minimize the "off-drug" window to the shortest safe duration, which for edoxaban with normal renal function is typically 24 hours pre-operatively.

Question 187: A 52-year-old woman with newly diagnosed epilepsy is started on levetiracetam 500mg twice daily. She also takes levothyroxine 100mcg daily for hypothyroidism and the combined oral contraceptive pill. What is the most important prescribing safety consideration regarding her current medications?

A. Levetiracetam reduces the effectiveness of the combined oral contraceptive pill
B. Levetiracetam may cause psychiatric adverse effects and requires monitoring for mood changes (Correct Answer)
C. The dose of levothyroxine should be increased due to enzyme induction by levetiracetam
D. Levetiracetam levels need regular therapeutic drug monitoring
E. Combined oral contraceptive increases seizure frequency and should be stopped

Explanation: ***Levetiracetam may cause psychiatric adverse effects and requires monitoring for mood changes*** - **Levetiracetam** is well-known for causing **behavioral side effects** such as irritability, aggression, anxiety, and depression, which can affect a significant proportion of patients. - Given these potential **psychiatric symptoms**, especially in the initial phase of treatment, close monitoring for **mood changes** and behavioral disturbances is crucial to ensure patient safety and well-being. *Levetiracetam reduces the effectiveness of the combined oral contraceptive pill* - **Levetiracetam** is not a **hepatic enzyme inducer**, unlike many older antiepileptic drugs (e.g., carbamazepine, phenytoin). - Therefore, it does not significantly interact with or reduce the effectiveness of the **combined oral contraceptive pill** (COCP), making it a safer option for women of childbearing potential requiring contraception. *The dose of levothyroxine should be increased due to enzyme induction by levetiracetam* - **Levetiracetam** has minimal hepatic metabolism and does not induce **cytochrome P450 enzymes**, which are primarily responsible for drug interactions. - Consequently, it does not typically affect the metabolism or require dose adjustments of **levothyroxine**; routine TSH monitoring would continue as per standard hypothyroidism management. *Levetiracetam levels need regular therapeutic drug monitoring* - Routine **therapeutic drug monitoring (TDM)** for **levetiracetam** is generally not recommended because there is no strong correlation between its plasma concentration and **clinical efficacy** or toxicity. - Dosing adjustments for **levetiracetam** are primarily based on the patient's clinical response (seizure control) and renal function, rather than measured drug levels. *Combined oral contraceptive increases seizure frequency and should be stopped* - The **combined oral contraceptive pill** does not commonly affect the **seizure threshold** or significantly increase seizure frequency in most individuals with epilepsy. - Therefore, there is no general recommendation to stop the **COCP** in patients with epilepsy, provided there are no other contraindications or specific drug interactions with the antiepileptic medication.

Question 188: A 70-year-old man with atrial fibrillation on apixaban 5mg twice daily is admitted with acute diverticulitis. He requires IV antibiotics and is made nil by mouth. His renal function shows eGFR 55 ml/min/1.73m², and he has no evidence of active bleeding. How should his anticoagulation be managed during this acute admission?

A. Continue apixaban at current dose as it has good bioavailability and can be given with small sips of water (Correct Answer)
B. Stop apixaban and switch to therapeutic dose low molecular weight heparin
C. Stop apixaban and switch to intravenous unfractionated heparin infusion
D. Reduce apixaban dose to 2.5mg twice daily until oral intake resumes
E. Stop apixaban temporarily until oral intake is re-established, then restart

Explanation: ***Continue apixaban at current dose as it has good bioavailability and can be given with small sips of water*** - **Apixaban** has high oral **bioavailability** and can be safely administered with small sips of water in patients who are **nil by mouth (NBM)** for non-surgical reasons. - The patient has no **active bleeding** and his **eGFR of 55** supports the maintenance of the standard **5mg twice daily** dose for stroke prophylaxis in **atrial fibrillation**. *Stop apixaban and switch to therapeutic dose low molecular weight heparin* - **Bridging therapy** with **LMWH** is unnecessary and increases the risk of **hematoma** or bleeding complications when oral administration is still feasible. - **LMWH** is generally reserved for patients who are strictly prohibited from swallowing or have **severe malabsorption** syndromes. *Stop apixaban and switch to intravenous unfractionated heparin infusion* - **Unfractionated heparin** is typically indicated for patients at very high risk of bleeding who may need **rapid reversal** for urgent surgery, which is not indicated here. - This approach is unnecessarily invasive and requires intensive **aPTT monitoring**, adding complexity to the management of simple **diverticulitis**. *Reduce apixaban dose to 2.5mg twice daily until oral intake resumes* - Dose reduction targets specific criteria: **age ">=80"**, **weight " - Under-dosing **DOACs** without clinical indication increases the risk of **thromboembolic events** like stroke. *Stop apixaban temporarily until oral intake is re-established, then restart* - Temporary cessation without a parenteral bridge leaves the patient unprotected against **atrial fibrillation-related stroke**. - Since **diverticulitis** management allows for medication with small sips of water, there is no clinical rationale to hold **anticoagulation**.

Question 189: A 56-year-old woman with rheumatoid arthritis has been taking methotrexate 20mg weekly for 2 years with good disease control. She develops a severe chest infection and is started on antibiotics. Which antibiotic poses the highest risk of methotrexate toxicity due to drug interaction and should prompt consideration of temporary methotrexate dose reduction or suspension?

A. Amoxicillin
B. Doxycycline
C. Trimethoprim (Correct Answer)
D. Clarithromycin
E. Azithromycin

Explanation: ***Trimethoprim*** - Both methotrexate and trimethoprim inhibit **dihydrofolate reductase**, leading to a synergistic antifolate effect that can result in life-threatening **bone marrow suppression**. - Clinical guidelines specifically advise avoiding this combination because it drastically increases the risk of **pancytopenia** and mucosal toxicity.*Amoxicillin* - Penicillins can potentially reduce the **renal clearance** of methotrexate by competing for secretion in the renal tubules, but this interaction is generally less clinically significant than with antifolates. - While monitoring is advised, it does not pose the same high-level risk of direct **metabolic synergy** seen with trimethoprim.*Doxycycline* - This tetracycline antibiotic has **minimal interaction** with methotrexate and is generally considered safe to use for respiratory infections in this context. - It does not significantly affect the **folate metabolic pathway** or the renal excretion of methotrexate.*Clarithromycin* - As a macrolide, it can potentially increase methotrexate levels, but this interaction is **infrequent** and rarely leads to severe toxicity in patients with normal renal function. - It is more commonly associated with interactions involving drugs metabolized by **CYP3A4**, which is not the primary metabolic pathway for methotrexate.*Azithromycin* - Similar to other macrolides, it lacks a significant mechanism for interfering with **methotrexate excretion** or its action on folate metabolism. - It is considered a **safer alternative** for chest infections when compared to the high-risk profiles of antifolate or highly nephrotoxic agents.

Question 190: A 64-year-old man with type 2 diabetes is brought to hospital by ambulance after his wife found him confused at home. His capillary blood glucose is 2.1 mmol/L. He is conscious but unable to swallow safely. His current medications include metformin 1g twice daily, gliclazide 160mg twice daily, and atorvastatin 20mg once daily. What is the most appropriate immediate management?

A. Administer 100ml of 20% glucose intravenously over 15 minutes
B. Administer 1mg glucagon intramuscularly
C. Give 200ml orange juice orally with supervision
D. Administer 200ml of 10% glucose intravenously over 15 minutes (Correct Answer)
E. Give glucose gel 1.5-2 tubes squeezed into buccal cavity

Explanation: ***Administer 200ml of 10% glucose intravenously over 15 minutes*** - This patient presents with **severe hypoglycaemia** (2.1 mmol/L) and an **unsafe swallow** due to confusion, necessitating rapid parenteral treatment. - **200ml of 10% glucose** is the standard and safest initial intravenous treatment, providing adequate carbohydrate replacement with a lower risk of **vein irritation** compared to higher concentrations. *Administer 100ml of 20% glucose intravenously over 15 minutes* - While this provides a similar amount of glucose, **20% glucose** is highly hypertonic and carries a significant risk of **thrombophlebitis** and tissue damage if extravasation occurs. - National guidelines typically recommend **10% glucose** for routine management unless there are specific concerns about fluid overload. *Administer 1mg glucagon intramuscularly* - **Glucagon** relies on sufficient **hepatic glycogen stores** and may be less effective in patients on **sulfonylureas** like gliclazide, which can deplete these stores. - Its onset of action is slower than intravenous glucose, making it less suitable for immediate management in this critically hypoglycemic patient who has intravenous access established. *Give 200ml orange juice orally with supervision* - This is **contraindicated** as the patient is confused and has an **unsafe swallow**, which significantly increases the risk of **aspiration pneumonia**. - Oral fluids should only be given to conscious patients who can swallow safely. *Give glucose gel 1.5-2 tubes squeezed into buccal cavity* - While buccal glucose can be used, **intravenous glucose** is the most rapid and definitive treatment for **severe hypoglycaemia** with altered consciousness, especially when IV access is available. - Buccal absorption can be inconsistent and may not provide as quick or reliable a response as direct intravenous administration in this acute setting.

Question 191: According to the British National Formulary guidance, what is the minimum interval that should be left between switching from warfarin to a direct oral anticoagulant (DOAC) to minimise the risk of bleeding or thrombosis?

A. Start DOAC when INR falls below 2.0 (Correct Answer)
B. Start DOAC when INR falls below 2.5
C. Start DOAC 24 hours after the last warfarin dose
D. Start DOAC 48 hours after the last warfarin dose regardless of INR
E. Start DOAC when INR falls below 3.0

Explanation: ***Start DOAC when INR falls below 2.0*** - According to **BNF guidance**, when transitioning from **warfarin** to a **direct oral anticoagulant (DOAC)**, the INR should be confirmed to be **below 2.0**. - This threshold ensures that the patient is not **over-anticoagulated**, thereby minimizing the **risk of bleeding** when the new anticoagulant is introduced. *Start DOAC when INR falls below 2.5* - An INR of **2.5** is still within the therapeutic range for many warfarin indications, meaning that adding a DOAC at this level would result in **excessive anticoagulation** and a significantly increased **risk of bleeding**. - The specific guideline for a safe transition from warfarin to a DOAC, as per the BNF, is a stricter **INR cutoff of <2.0**. *Start DOAC 24 hours after the last warfarin dose* - Warfarin has a **highly variable half-life** and its anticoagulant effects can persist for several days after discontinuation, depending on individual patient factors. - Starting a DOAC based solely on a **fixed time interval** rather than the **INR** is unsafe, as it ignores individual variability in warfarin clearance and potential for dangerous **drug interactions**. *Start DOAC 48 hours after the last warfarin dose regardless of INR* - Simply waiting 48 hours does not guarantee that the **INR** has fallen to a safe level, especially in patients with impaired liver function or slow metabolism of warfarin. - Clinical practice dictates **objective measurement of the INR** to ensure that warfarin's anticoagulant effect has sufficiently dissipated before initiating a DOAC, preventing a period of **excessive anticoagulation**. *Start DOAC when INR falls below 3.0* - An INR of **3.0** is well within the **therapeutic range** for many patients on warfarin, such as those with **atrial fibrillation** or **venous thromboembolism (VTE)**. - Initiating a **DOAC** with an INR this high would lead to a substantial overlap of anticoagulant effects, significantly increasing the patient's **risk of major hemorrhage**.

Question 192: A 58-year-old woman with severe psoriasis is started on ciclosporin therapy. According to UK prescribing guidelines, which of the following monitoring parameters should be checked before initiating treatment and every 2 weeks for the first 3 months?

A. Full blood count and liver function tests
B. Blood pressure and serum creatinine (Correct Answer)
C. Thyroid function tests and lipid profile
D. Serum electrolytes and blood glucose
E. Urinalysis and chest radiograph

Explanation: ***Blood pressure and serum creatinine*** - **Ciclosporin** is a calcineurin inhibitor with a significant risk of **nephrotoxicity** and potential to induce **hypertension**. - UK guidelines specifically require these parameters to be checked at baseline and every **2 weeks** for the initial 3 months to identify early adverse effects. *Full blood count and liver function tests* - While ciclosporin can rarely affect **liver function** or **blood counts**, these are not the primary parameters requiring bi-weekly monitoring according to UK guidelines. - More frequent monitoring of **FBC** and **LFTs** is typically associated with drugs like **methotrexate** or **azathioprine** due to risks of myelosuppression and hepatotoxicity. *Thyroid function tests and lipid profile* - **Hyperlipidaemia** can be a side effect of ciclosporin, necessitating **lipid profile** monitoring, but usually at baseline and then at 3-6 month intervals, not bi-weekly. - **Thyroid function tests** are generally not a standard or frequently monitored parameter for patients on ciclosporin therapy. *Serum electrolytes and blood glucose* - Ciclosporin can cause **hyperkalaemia**, **hypomagnesaemia**, and **hyperglycaemia**, so **electrolytes** and **blood glucose** are monitored, but not as frequently as **creatinine** and **blood pressure** in the initial phase. - **Serum creatinine** is the critical parameter for immediate detection of dose-limiting **renal toxicity**. *Urinalysis and chest radiograph* - **Urinalysis** is not a routine bi-weekly monitoring requirement for ciclosporin, unlike for drugs known to cause proteinuria or bladder toxicity. - A **chest radiograph** is not used for monitoring ciclosporin side effects; it may be used for baseline screening for conditions like tuberculosis before initiating some biologics.

Question 193: A 67-year-old man attends anticoagulation clinic. He has been on warfarin for 4 years following an unprovoked pulmonary embolism. His INR today is 8.2. He has no signs of bleeding and is clinically well. His INR two weeks ago was 2.6. He reports no changes to medications, diet, or alcohol intake. He has not missed any doses. His regular medications are warfarin 4mg daily (Mon/Wed/Fri/Sat) and 5mg daily (Tues/Thurs/Sun), ramipril 5mg, and atorvastatin 40mg. What is the most appropriate immediate management?

A. Give oral vitamin K 1-2mg, omit next dose of warfarin, recheck INR in 24 hours
B. Admit for IV vitamin K and prothrombin complex concentrate
C. Continue warfarin but reduce all doses by 1mg, recheck INR in 1 week
D. Give oral vitamin K 5mg, omit warfarin for 2 days, recheck INR in 48 hours
E. Omit warfarin for 2 doses, reduce weekly dose by 10-15%, recheck INR in 3-5 days (Correct Answer)

Explanation: ***Omit warfarin for 2 doses, reduce weekly dose by 10-15%, recheck INR in 3-5 days*** - For an **INR between 4.5 and 10.0** with **no significant bleeding**, the recommended management is to omit 1-2 doses of warfarin and then cautiously reduce the maintenance dose. - This approach allows the INR to gradually decrease back into the therapeutic range without causing overly rapid reversal, which could increase the risk of thrombosis in a patient with a history of **pulmonary embolism**. *Give oral vitamin K 1-2mg, omit next dose of warfarin, recheck INR in 24 hours* - While oral vitamin K can be considered, it is typically reserved for an **INR >10** with no bleeding, or an INR between 5.0-10.0 with a high risk of bleeding. - Administering **oral Vitamin K** to an asymptomatic patient with an INR of 8.2 can lead to a period of **warfarin resistance**, making it difficult to re-establish stable anticoagulation. *Admit for IV vitamin K and prothrombin complex concentrate* - **Intravenous Vitamin K** and **Prothrombin Complex Concentrate (PCC)** are reserved for patients with **serious or life-threatening bleeding** or an extremely high INR (e.g., >20) requiring urgent reversal. - This patient is clinically well with **no signs of bleeding**, making admission and aggressive reversal inappropriate and potentially increasing thrombotic risk. *Continue warfarin but reduce all doses by 1mg, recheck INR in 1 week* - Continuing warfarin with an **INR of 8.2** is unsafe as it significantly increases the **risk of spontaneous hemorrhage**; doses must be omitted. - Rechecking the INR in **one week** is too long for such a highly elevated INR; closer monitoring is required to ensure a safe return to the therapeutic range. *Give oral vitamin K 5mg, omit warfarin for 2 days, recheck INR in 48 hours* - A **5mg dose of oral Vitamin K** is considered high for an asymptomatic patient with an INR of 8.2 and could result in **overshoot** (INR dropping too low), leading to warfarin resistance for several days. - While omitting warfarin for 2 days is a correct step, the addition of such a high dose of Vitamin K is generally not the primary recommendation for an **asymptomatic INR of 8.2**.

Question 194: A 44-year-old woman with type 1 diabetes is being prepared for emergency laparotomy for perforated appendicitis. She is on a variable rate intravenous insulin infusion (VRIII) at 4 units/hour. Her current blood glucose is 11.2 mmol/L and ketones are 0.4 mmol/L. She is receiving 0.9% sodium chloride with 5% glucose and 0.15% potassium chloride at 125ml/hour. The surgical team requests transfer to theatre immediately. What is the most appropriate management of her insulin during anaesthesia and surgery?

A. Continue VRIII and IV fluid infusion throughout surgery with hourly capillary glucose monitoring (Correct Answer)
B. Discontinue VRIII during anaesthesia as she cannot have IV fluids running during surgery
C. Switch to subcutaneous rapid-acting insulin every 2 hours during surgery
D. Reduce VRIII to 1 unit/hour during surgery to minimize hypoglycaemia risk
E. Give stat dose of long-acting insulin subcutaneously and stop VRIII for duration of surgery

Explanation: ***Continue VRIII and IV fluid infusion throughout surgery with hourly capillary glucose monitoring*** - Patients with **Type 1 Diabetes** require a continuous source of insulin to prevent **Diabetic Ketoacidosis (DKA)**, especially during the physiological stress of surgery. - For emergency cases or when the patient is expected to miss more than one meal, a **Variable Rate Intravenous Insulin Infusion (VRIII)** must be maintained intraoperatively with **hourly glucose monitoring**. *Discontinue VRIII during anaesthesia as she cannot have IV fluids running during surgery* - Discontinuing insulin in a Type 1 diabetic will lead to **absolute insulin deficiency** and rapid development of **ketoacidosis**. - Intravenous fluids and infusions are routinely continued during anesthesia via dedicated **venous access** to maintain metabolic stability. *Switch to subcutaneous rapid-acting insulin every 2 hours during surgery* - **Subcutaneous absorption** of insulin is unpredictable during anesthesia due to changes in **peripheral perfusion** and temperature. - **VRIII** is the preferred method because it allows for rapid, titratable adjustments to blood glucose levels in real-time. *Reduce VRIII to 1 unit/hour during surgery to minimize hypoglycaemia risk* - Arbitrarily reducing the rate is dangerous; insulin doses should be adjusted based on **hourly blood glucose** readings and established **sliding scale protocols**. - Given her current glucose of **11.2 mmol/L**, a reduction could lead to worsening **hyperglycemia** during the surgical stress response. *Give stat dose of long-acting insulin subcutaneously and stop VRIII for duration of surgery* - A single dose of **long-acting insulin** lacks the flexibility required to manage the dynamic glycemic changes occurring during a major procedure like a **laparotomy**. - Perioperative management requires the fine-tuned control provided by **intravenous infusion** to keep glucose within the target range (typically 6–10 mmol/L).

Question 195: A 52-year-old woman is started on low molecular weight heparin (LMWH) for confirmed deep vein thrombosis. Her weight is 142 kg (BMI 48 kg/m²). She has normal renal function (eGFR 94 ml/min/1.73m²). Which statement regarding her LMWH dosing and monitoring is most accurate?

A. Dose LMWH using actual body weight up to a maximum of 120 kg
B. Dose LMWH according to ideal body weight to avoid overdosing
C. Dose LMWH according to actual body weight and check peak anti-Xa levels after 3-4 doses (Correct Answer)
D. Dose LMWH using adjusted body weight formula: IBW + 0.4(ABW - IBW)
E. Dose LMWH according to actual body weight and no anti-Xa monitoring is required

Explanation: ***Dose LMWH according to actual body weight and check peak anti-Xa levels after 3-4 doses*** - In patients with **morbid obesity** (BMI >40 kg/m²), LMWH dosing for confirmed DVT should be based on **actual body weight** to ensure adequate therapeutic anticoagulation. - **Peak anti-Xa monitoring** is recommended after the 3rd or 4th dose (when steady-state is achieved) in obese patients to confirm therapeutic levels and prevent clinical failure or toxicity due to altered pharmacokinetics. *Dose LMWH using actual body weight up to a maximum of 120 kg* - Capping the LMWH dose at an arbitrary limit like **120 kg** risks significant **underdosing** in very obese patients, leading to potential treatment failure and recurrent VTE. - Current guidelines generally advocate for initial dosing based on **total body weight** without an empirical cap, followed by laboratory monitoring for confirmation. *Dose LMWH according to ideal body weight to avoid overdosing* - **Ideal body weight** significantly underestimates the volume of distribution for LMWH in obese patients, which often results in **subtherapeutic anticoagulation** and a higher risk of recurrent venous thromboembolism. - This dosing strategy is generally not recommended for therapeutic LMWH in obese individuals. *Dose LMWH using adjusted body weight formula: IBW + 0.4(ABW - IBW)* - While adjusted body weight formulas are used for certain medications with altered pharmacokinetics in obesity, it is **not the standard or preferred method** for therapeutic LMWH dosing in DVT. - Evidence primarily supports using **actual body weight** for initial LMWH dosing for VTE treatment in obese patients, with subsequent anti-Xa monitoring. *Dose LMWH according to actual body weight and no anti-Xa monitoring is required* - Although anti-Xa monitoring is often omitted in normal-weight patients with normal renal function, it is **strongly indicated for extreme body weights** (BMI >40 kg/m² or weight <50 kg). - In a patient with a **BMI of 48 kg/m²**, anti-Xa monitoring is crucial to confirm adequate therapeutic levels, preventing both underdosing (risk of VTE recurrence) and potential excessive anticoagulation (risk of bleeding).

Question 196: A 75-year-old man with type 2 diabetes is admitted with hypoglycaemia. His glucose on admission was 2.1 mmol/L. He was given oral glucose solution and his glucose recovered to 6.8 mmol/L. His current medications include insulin detemir 18 units in the morning and 14 units at bedtime, metformin 1g twice daily, and sitagliptin 100mg once daily. His HbA1c three months ago was 52 mmol/mol. He has had three episodes of hypoglycaemia in the past two weeks. What is the most appropriate medication adjustment?

A. Reduce both insulin detemir doses by 10-20% and continue all oral medications
B. Stop sitagliptin but continue insulin and metformin at current doses
C. Stop insulin completely and manage with metformin and sitagliptin alone given the low HbA1c
D. Reduce bedtime insulin detemir by 20-30% and stop sitagliptin (Correct Answer)
E. Continue all medications but advise more frequent snacking between meals

Explanation: ***Reduce bedtime insulin detemir by 20-30% and stop sitagliptin*** - Recurrent **hypoglycaemia** in an elderly patient with an **HbA1c of 52 mmol/mol** suggests overtreatment, necessitating a significant reduction in the medication carrying the highest risk, such as **basal insulin**. - Stopping **sitagliptin** reduces polypharmacy and complexity while addressing the additive risk it poses when used alongside **insulin**. *Reduce both insulin detemir doses by 10-20% and continue all oral medications* - A minor reduction and continuing all oral medications may be insufficient to prevent further episodes in the context of recent **frequent hypoglycaemia**. - It fails to address the appropriateness of **sitagliptin**, which offers limited benefit in this regimen compared to the risk of **hypoglycaemic events**. *Stop sitagliptin but continue insulin and metformin at current doses* - While stopping sitagliptin is helpful, it does not directly address the likely culprit of the nocturnal or fasting hypoglycemia, which is the **insulin detemir**. - Failing to reduce the **insulin dose** leaves the patient at high risk for immediate recurrence of severe **hypoglycaemia**. *Stop insulin completely and manage with metformin and sitagliptin alone given the low HbA1c* - Abruptly stopping **insulin** in a patient who requires it for glycaemic control can lead to rapid **hyperglycaemia** or metabolic instability. - The HbA1c of 52 mmol/mol is well-controlled but not low enough to suggest that **insulin** is entirely unnecessary. *Continue all medications but advise more frequent snacking between meals* - This approach is medically unsafe as it treats the symptom rather than the underlying cause of **excessive medication**. - Snacking leads to unwanted **weight gain** and does not provide a sustainable or therapeutic solution for **iatrogenic hypoglycaemia**.

Question 197: A 61-year-old man is on long-term warfarin therapy for recurrent venous thromboembolism associated with Factor V Leiden deficiency. Over the past 6 months, his INR results have shown marked variability despite good reported adherence: INR readings of 1.8, 3.6, 2.1, 4.2, 2.4, 3.8, 2.2. He takes no other regular medications and denies alcohol excess or dietary changes. What is the most appropriate next step in management?

A. Switch to a direct oral anticoagulant (DOAC) to avoid the need for monitoring
B. Refer to anticoagulation clinic for review of dosing schedule and consideration of pharmacogenetic testing (Correct Answer)
C. Add low-dose aspirin to provide consistent antiplatelet effect while reducing warfarin dose
D. Continue current warfarin dose but increase monitoring frequency to weekly
E. Prescribe vitamin K 1mg oral supplement daily to stabilize INR

Explanation: ***Refer to anticoagulation clinic for review of dosing schedule and consideration of pharmacogenetic testing*** - Marked **INR variability** despite reported adherence, no other medications, alcohol excess, or dietary changes, strongly indicates a need for **specialist evaluation** to identify subtle factors or underlying causes. - **Pharmacogenetic testing** for **CYP2C9** and **VKORC1** polymorphisms is crucial in cases of unexplained warfarin instability, as these genetic variations significantly affect warfarin metabolism and sensitivity. *Switch to a direct oral anticoagulant (DOAC) to avoid the need for monitoring* - While **DOACs** are effective, the immediate priority is to understand the cause of the **unstable INR** with warfarin. Switching without investigation might lead to similar issues or mismanage a potentially identifiable problem. - This patient has **Factor V Leiden**, and although DOACs are generally suitable, directly switching does not address the physiological reason for the current **erratic anticoagulation control**. *Add low-dose aspirin to provide consistent antiplatelet effect while reducing warfarin dose* - Adding **aspirin** to an unstable warfarin regimen significantly increases the **risk of bleeding** due to additive antiplatelet effects, without addressing the underlying **INR instability**. - **Aspirin** provides antiplatelet activity, which is not a substitute for the **anticoagulant effect** of warfarin needed for recurrent VTE associated with Factor V Leiden. *Continue current warfarin dose but increase monitoring frequency to weekly* - Increasing **monitoring frequency** merely tracks the fluctuations more often but does not provide a **solution** or diagnosis for the inherent instability in warfarin response. - Frequent dose adjustments based on weekly monitoring in an unstable patient can lead to a

Question 198: A 37-year-old woman with type 1 diabetes presents to the emergency department with vomiting and abdominal pain. Her capillary blood glucose is 24.5 mmol/L and ketones are 4.2 mmol/L. Arterial blood gas shows pH 7.22, bicarbonate 11 mmol/L. She is diagnosed with diabetic ketoacidosis. Her usual insulin is insulin degludec 32 units once daily and insulin lispro with meals. What is the correct approach to her basal insulin during DKA management?

A. Stop insulin degludec and manage with fixed-rate intravenous insulin infusion (FRIII) alone
B. Continue insulin degludec at usual dose alongside fixed-rate intravenous insulin infusion (Correct Answer)
C. Reduce insulin degludec to 50% of usual dose alongside fixed-rate intravenous insulin infusion
D. Give insulin degludec only if FRIII is interrupted or discontinued
E. Switch from insulin degludec to insulin glargine at 80% of the dose alongside FRIII

Explanation: ***Continue insulin degludec at usual dose alongside fixed-rate intravenous insulin infusion***- Current clinical guidelines recommend continuing **long-acting basal insulin** (e.g., degludec, glargine, or detemir) at the patient's **usual dose and timing** during DKA management.- This practice ensures **basal insulin coverage** is maintained, which facilitates a smoother transition back to subcutaneous insulin and prevents **rebound ketosis** or hyperglycemia once the IV infusion is stopped.*Stop insulin degludec and manage with fixed-rate intravenous insulin infusion (FRIII) alone*- Stopping basal insulin is an outdated practice that increases the risk of **metabolic instability** during the transition off the insulin pump or IV line.- Without background basal insulin, there is a significant delay in achieving therapeutic levels once the **short-acting IV insulin** is discontinued.*Reduce insulin degludec to 50% of usual dose alongside fixed-rate intravenous insulin infusion*- Arbitrarily reducing the basal insulin dose can result in **sub-therapeutic levels**, complicating the resolution of ketosis and glycemic control.- The **fixed-rate intravenous insulin infusion (FRIII)** is titrated to treat the acute DKA, while the usual basal dose simply maintains the established **physiologic baseline**.*Give insulin degludec only if FRIII is interrupted or discontinued*- Insulin degludec has a **long half-life** (approximately 25 hours); waiting until the FRIII is stopped would lead to a period without adequate insulin coverage.- To be effective for the transition, the medication must be given continuously to maintain **steady-state concentrations** in the bloodstream.*Switch from insulin degludec to insulin glargine at 80% of the dose alongside FRIII*- There is no clinical indication to switch between **basal analogues** during acute DKA management if the patient is already established on a regimen.- Changing the insulin type and dose simultaneously introduces unnecessary **complexity and risk** of prescribing errors during an emergency stabilization.

Question 199: A 48-year-old woman with newly diagnosed atrial fibrillation is being considered for anticoagulation. She has hypertension and type 2 diabetes. Her renal function shows: creatinine 156 μmol/L, eGFR 34 ml/min/1.73m². She weighs 54 kg and is 162 cm tall. Which direct oral anticoagulant (DOAC) regimen requires dose reduction in this patient?

A. Apixaban 5mg twice daily should be reduced to 2.5mg twice daily
B. Rivaroxaban 20mg once daily should be reduced to 15mg once daily
C. Edoxaban 60mg once daily should be reduced to 30mg once daily
D. Dabigatran 150mg twice daily should be reduced to 110mg twice daily
E. All of the above DOACs require dose reduction in this patient (Correct Answer)

Explanation: ***All of the above DOACs require dose reduction in this patient*** - This patient warrants dose reduction for all listed options due to her **moderate renal impairment** (eGFR 34 ml/min/1.73m²) and **low body weight** (54 kg). - Dose adjustments are critical in AF management to balance **stroke prevention** against the high risk of **major bleeding** associated with drug accumulation. *Apixaban 5mg twice daily should be reduced to 2.5mg twice daily* - Dose reduction is required if a patient meets two of the following: **age ≥80**, **weight ≤60kg**, or **creatinine ≥133 μmol/L**; she meets both the weight and creatinine criteria. - Using the standard dose in this patient would significantly increase the risk of **dose-dependent hemorrhage** due to decreased renal clearance. *Rivaroxaban 20mg once daily should be reduced to 15mg once daily* - For patients with a **Creatinine Clearance (CrCl)** between **15-49 ml/min**, the dose must be reduced to 15mg to maintain safety. - Her **eGFR of 34** places her firmly within the range where the standard 20mg dose is contraindicated. *Edoxaban 60mg once daily should be reduced to 30mg once daily* - Edoxaban requires a 50% dose reduction if **CrCl is 15-50 ml/min** or if the patient's **body weight is ≤60kg**. - This patient satisfies both the **renal function** and **weight-based** criteria, making the 30mg dose the only appropriate choice. *Dabigatran 150mg twice daily should be reduced to 110mg twice daily* - Although often weight-independent, Dabigatran dose reduction is recommended when the **eGFR/CrCl is 30-50 ml/min** or if there is an **increased bleeding risk**. - Her renal function (eGFR 34) falls below the threshold for the standard 150mg dose, requiring a step down to **110mg twice daily**.

Question 200: According to current UK guidance, what is the appropriate target INR range for a patient with antiphospholipid syndrome who has had recurrent venous thromboembolism despite therapeutic anticoagulation?

A. 2.0-3.0
B. 2.5-3.5
C. 3.0-4.0 (Correct Answer)
D. 3.5-4.5
E. Target INR is not applicable; switch to DOAC therapy

Explanation: ***3.0-4.0*** - For patients with **antiphospholipid syndrome (APS)** who experience **recurrent venous thromboembolism (VTE)** despite therapeutic anticoagulation (typically INR 2.0-3.0), current UK guidelines recommend increasing the **target INR to 3.0-4.0**. - This higher intensity anticoagulation aims to prevent further thrombotic events, especially in cases of **arterial thrombosis** or persistent VTE on standard therapy. *2.0-3.0* - This range represents the **standard intensity** anticoagulation for initial VTE events or stable APS without a history of recurrent thrombosis. - It is deemed **insufficient** for patients who have already experienced breakthrough VTE while adequately anticoagulated within this range. *2.5-3.5* - While this target INR might be considered in specific circumstances, such as some **mechanical prosthetic heart valves**, it is not the primary recommended intensified target for recurrent APS-related VTE in current UK guidelines. - The specific recommendation for recurrent VTE in APS points towards a higher target range to ensure adequate antithrombotic protection. *3.5-4.5* - This very high INR range significantly increases the **risk of major bleeding** complications without clear evidence of superior efficacy over the 3.0-4.0 range for recurrent APS-related VTE. - Such aggressive anticoagulation is typically avoided due to the unfavourable **risk-benefit profile** in most clinical scenarios. *Target INR is not applicable; switch to DOAC therapy* - **Direct oral anticoagulants (DOACs)** are generally **not recommended** in patients with high-risk APS, particularly those who have experienced recurrent thrombosis or arterial events. - Evidence, including the **TRAPS trial**, suggests that DOACs may be associated with a **higher rate of recurrent thrombosis** compared to warfarin in certain APS populations, especially those with triple antibody positivity.

Question 201: A 55-year-old man is prescribed clozapine for treatment-resistant schizophrenia. He is currently on day 18 of titration, taking 200mg daily in divided doses. His full blood count today shows: Hb 142 g/L, WBC 2.8 × 10⁹/L, neutrophils 1.2 × 10⁹/L, platelets 245 × 10⁹/L. He is clinically well with no signs of infection. What is the most appropriate immediate action?

A. Continue clozapine at current dose and repeat FBC in one week
B. Stop clozapine immediately, admit for urgent haematology assessment, and never rechallenge
C. Reduce clozapine dose by 50%, repeat FBC in 48 hours, and increase dose cautiously if neutrophils rise
D. Stop clozapine immediately, repeat FBC in 24 hours, and do not rechallenge if neutropenia confirmed (Correct Answer)
E. Continue clozapine but increase monitoring frequency to twice weekly FBC until neutrophils normalise

Explanation: ***Stop clozapine immediately, repeat FBC in 24 hours, and do not rechallenge if neutropenia confirmed***- This patient's **absolute neutrophil count (ANC)** is 1.2 × 10⁹/L, which falls into the **Red Light** category (<1.5 × 10⁹/L) of the clozapine monitoring protocol.- The drug must be **ceased immediately** due to the risk of progressing to **agranulocytosis**; a repeat FBC within 24 hours is required to track recovery and confirm the finding.*Continue clozapine at current dose and repeat FBC in one week*- Continuing the drug with a **Red Light** result is unsafe and violates clozapine safety protocols designed to prevent **fatal sepsis**.- Weekly monitoring is part of the standard schedule for the first 18 weeks but is insufficient when **severe neutropenia** is detected.*Stop clozapine immediately, admit for urgent haematology assessment, and never rechallenge*- While the drug must stop, **urgent admission** is typically reserved for patients who are clinically unwell or have **agranulocytosis** (ANC <0.5 × 10⁹/L).- Rechallenge is generally prohibited after a **Red Light** event, but the immediate clinical priority in an asymptomatic patient is cessation and outpatient monitoring.*Reduce clozapine dose by 50%, repeat FBC in 48 hours, and increase dose cautiously if neutrophils rise*- Dose reduction is not an acceptable response to **Red Light neutropenia** because the reaction is often **idiosyncratic** rather than dose-dependent.- The protocol mandates **complete cessation** rather than dose manipulation to ensure patient safety and bone marrow recovery.*Continue clozapine but increase monitoring frequency to twice weekly FBC until neutrophils normalise*- This management strategy is appropriate for the **Amber Light** category (ANC 1.5–2.0 × 10⁹/L), where monitoring is increased but the drug is continued.- Since the patient’s ANC is **1.2 × 10⁹/L**, this lenient approach would expose the patient to a dangerous risk of further **marrow suppression**.

Question 202: A 69-year-old man with non-valvular atrial fibrillation has a CHA₂DS₂-VASc score of 4 and HAS-BLED score of 3. He experienced a fall resulting in a subdural haematoma requiring surgical evacuation three weeks ago. He has made a good neurological recovery. His past medical history includes hypertension, type 2 diabetes, previous ischaemic stroke (18 months ago), and chronic kidney disease stage 3a (eGFR 52 ml/min/1.73m²). What is the most appropriate management of his stroke prevention?

A. Prescribe aspirin 75mg once daily as anticoagulation is contraindicated following intracranial haemorrhage
B. Arrange left atrial appendage occlusion device and avoid all anticoagulation
C. Restart anticoagulation with apixaban at 4-6 weeks post-haemorrhage after MDT discussion and imaging confirmation of haematoma resolution (Correct Answer)
D. Defer anticoagulation indefinitely as HAS-BLED score of 3 indicates high bleeding risk
E. Start warfarin with target INR 2.0-2.5 (lower than standard) to balance stroke and bleeding risk

Explanation: ***Restart anticoagulation with apixaban at 4-6 weeks post-haemorrhage after MDT discussion and imaging confirmation of haematoma resolution*** - In patients with a high **CHA₂DS₂-VASc** score (4), the risk of ischemic stroke often outweighs the risk of recurrent **intracranial hemorrhage**, especially when the bleed was a traumatic **subdural haematoma** rather than spontaneous. - Current guidelines suggest restarting **DOACs** rather than warfarin between 4–8 weeks post-event, provided **MDT discussion** and repeat imaging confirm the resolution of the hematoma. *Prescribe aspirin 75mg once daily as anticoagulation is contraindicated following intracranial haemorrhage* - **Aspirin** provides significantly inferior stroke prevention compared to anticoagulants in patients with **atrial fibrillation**. - Antiplatelet therapy still carries a notable risk of bleeding and is not considered a safe or effective long-term alternative to anticoagulation in this high-risk patient. *Arrange left atrial appendage occlusion device and avoid all anticoagulation* - **Left atrial appendage occlusion (LAAO)** is typically reserved for patients with absolute, permanent contraindications to anticoagulation where the bleeding risk is prohibitive. - Recent evidence and the traumatic nature of this bleed suggest that **anticoagulation** can often be safely resumed, making LAAO a second-line consideration here. *Defer anticoagulation indefinitely as HAS-BLED score of 3 indicates high bleeding risk* - A **HAS-BLED** score of 3 or more indicates a higher risk of bleeding but is not an absolute contraindication; it serves as a tool to identify and mitigate **modifiable risk factors**. - Indefinite deferral leaves the patient at a high (>4% per year) risk of a potentially fatal or disabling **ischemic stroke**. *Start warfarin with target INR 2.0-2.5 (lower than standard) to balance stroke and bleeding risk* - **DOACs** like apixaban are generally preferred over **warfarin** in this scenario because they are associated with a significantly lower risk of secondary intracranial hemorrhage. - There is no clinical evidence to support a lower **target INR** for stroke prevention in AF, as it results in sub-therapeutic protection without guaranteed safety.

Question 203: A 41-year-old woman with type 1 diabetes is admitted to hospital for elective laparoscopic cholecystectomy. Her usual insulin regimen is insulin glargine 24 units at bedtime and insulin aspart 8 units before each meal. She is scheduled for surgery at 2 PM and is third on the afternoon theatre list. What is the most appropriate insulin management on the day of surgery?

A. Omit morning glargine and all aspart doses; start variable rate intravenous insulin infusion (VRIII) from 7 AM
B. Give 80% of usual glargine dose in the morning; omit all aspart doses; start VRIII at 11 AM
C. Give usual glargine dose the night before; omit breakfast and lunch aspart; start VRIII from 7 AM with glucose/saline infusion (Correct Answer)
D. Give usual glargine dose the night before; give breakfast aspart with light breakfast; start VRIII from 11 AM when fasting begins
E. Convert to VRIII at midnight the night before surgery and continue until eating and drinking postoperatively

Explanation: ***Give usual glargine dose the night before; omit breakfast and lunch aspart; start VRIII from 7 AM with glucose/saline infusion*** - Patients with **Type 1 Diabetes** require continuous **basal insulin** (like glargine) to prevent ketosis; this should be continued at the usual dose the night before surgery. - Since the patient is scheduled for an afternoon surgery and will be **nil by mouth (NBM)** after breakfast, a **Variable Rate Intravenous Insulin Infusion (VRIII)** must be started by 7–8 AM to manage glycemic control during the fasting period with a concomitant **glucose/saline infusion** to prevent hypoglycemia. *Omit morning glargine and all aspart doses; start variable rate intravenous insulin infusion (VRIII) from 7 AM* - Basal insulin (like glargine) should **never be completely omitted** in Type 1 Diabetes patients, as it provides the essential background insulin needed to prevent **diabetic ketoacidosis (DKA)**. - While starting VRIII at 7 AM is appropriate, omitting the long-acting insulin entirely risks significant **hyperglycemia** and DKA, especially if the VRIII is interrupted or not started promptly. *Give 80% of usual glargine dose in the morning; omit all aspart doses; start VRIII at 11 AM* - Glargine is a **long-acting insulin analogue** usually given at bedtime or once daily; arbitrarily reducing the dose or giving it in the morning on the day of surgery can disrupt basal glycemic control. - Starting **VRIII at 11 AM is too late** for a patient who is third on an afternoon list, as they would have been fasting for several hours without adequate glucose or insulin cover, increasing the risk of **hypoglycemia** or **hyperglycemia**. *Give usual glargine dose the night before; give breakfast aspart with light breakfast; start VRIII from 11 AM when fasting begins* - Administering short-acting **insulin aspart** with a light breakfast is risky for surgical patients as it may lead to **hypoglycemia** if the surgical schedule changes, is delayed, or if the patient cannot tolerate the food. - For a patient who is third on an afternoon list, they should generally be **nil by mouth (NBM)** from earlier in the morning, with **VRIII and dextrose** started to maintain glycemic stability. *Convert to VRIII at midnight the night before surgery and continue until eating and drinking postoperatively* - Starting **VRIII at midnight** the night before elective day-time surgery is generally **unnecessary** and overly aggressive, increasing the patient's discomfort, the monitoring burden, and the risk of **hypoglycemia** during the night. - The standard approach for Type 1 DM patients undergoing elective surgery is to maintain their **subcutaneous basal insulin** (often at usual or reduced dose) and only initiate the intravenous infusion (VRIII with dextrose) on the morning of the procedure when fasting begins.

Question 204: A 64-year-old woman with atrial fibrillation on dabigatran 150mg twice daily is admitted with an acute upper gastrointestinal bleed. Her haemoglobin has dropped from 125 g/L to 78 g/L. Endoscopy shows a bleeding duodenal ulcer. She is haemodynamically stable after fluid resuscitation. Her renal function shows eGFR 68 ml/min/1.73m². What is the most appropriate immediate management of her anticoagulation?

A. Omit next dose of dabigatran and restart at reduced dose of 110mg twice daily after 48 hours
B. Administer idarucizumab immediately and restart dabigatran at 110mg twice daily after haemostasis
C. Administer idarucizumab, achieve haemostasis, and restart anticoagulation with warfarin after 7-14 days
D. Withhold dabigatran, monitor closely, and consider restarting at same dose once haemostasis achieved and patient stable (Correct Answer)
E. Administer prothrombin complex concentrate and vitamin K to reverse the effect

Explanation: ***Withhold dabigatran, monitor closely, and consider restarting at same dose once haemostasis achieved and patient stable***- In a **haemodynamically stable** patient with non-life-threatening bleeding, the primary management for **DOACs** is to withhold the medication and rely on its relatively short **half-life** for clearance.- Since the patient has **normal-to-mildly impaired renal function** (eGFR 68), dabigatran will be cleared within roughly 24-48 hours without the need for aggressive reversal agents.*Omit next dose of dabigatran and restart at reduced dose of 110mg twice daily after 48 hours*- Dose reduction from 150mg to 110mg is typically indicated by **age over 80**, concomitant **verapamil** use, or high bleeding risk, rather than a single treatable GI event.- Restarting anticoagulation too early (within 48 hours) after a significant **haemoglobin drop** and a visible bleeding ulcer increases the risk of **re-bleeding**.*Administer idarucizumab immediately and restart dabigatran at 110mg twice daily after haemostasis*- **Idarucizumab** is a specific reversal agent reserved for **life-threatening bleeding**, uncontrolled haemorrhage, or patients requiring **emergency surgery**.- This patient is **haemodynamically stable** after fluids, making the use of an expensive, specific reversal agent inappropriate in this clinical context.*Administer idarucizumab, achieve haemostasis, and restart anticoagulation with warfarin after 7-14 days*- Switching to **warfarin** is not indicated here, as **DOACs** are generally preferred for stroke prevention in **atrial fibrillation** due to a better safety profile regarding intracranial haemorrhage.- As noted previously, **idarucizumab** is not indicated in stable patients where supportive care and withholding the drug are sufficient.*Administer prothrombin complex concentrate and vitamin K to reverse the effect*- **Vitamin K** and **Prothrombin Complex Concentrate (PCC)** are used to reverse **warfarin**, but they do not specifically reverse the direct thrombin inhibition of **dabigatran**.- While PCC may be considered in severe DOAC bleeding if a specific agent is unavailable, it is not the first-line treatment for **dabigatran** reversal nor necessary in a stable patient.

Question 205: What is the recommended maximum duration for which a patient should remain on a treatment dose of low molecular weight heparin (LMWH) before reviewing the need for anti-Xa level monitoring in the context of renal impairment?

A. 24 hours
B. 48 hours
C. 72 hours (Correct Answer)
D. 5-7 days
E. Anti-Xa monitoring is not required in renal impairment

Explanation: ***72 hours*** - In patients with **renal impairment**, LMWH is not cleared efficiently, necessitating a review and **anti-Xa monitoring** typically after 3-4 doses or approximately **72 hours**. - This timeframe allows the drug to reach a **steady state**, ensuring the peak level measured reflects the actual clinical accumulation risk. *24 hours* - Monitoring at **24 hours** is generally too early as the drug has likely not reached a **steady state concentration** in the blood. - Clinical guidelines prioritize safety by allowing enough time for **bioaccumulation** to become detectable via laboratory testing. *48 hours* - While some accumulation occurs, **48 hours** is usually insufficient to represent the maximum level reached before a dosage adjustment is considered. - Standard protocols specifically identify the **third or fourth dose** (reaching the 72-hour mark) as the optimal window for **anti-Xa level** sampling. *5-7 days* - Waiting **5-7 days** poses a significant danger of **over-anticoagulation** and life-threatening bleeding in patients with a low **Creatinine Clearance**. - Routine monitoring for high-risk medications must occur sooner than a week to mitigate the risk of **dose-dependent toxicity**. *Anti-Xa monitoring is not required in renal impairment* - This statement is incorrect because LMWH is **renally excreted** and failure to monitor leads to a high risk of **hemorrhagic complications**. - In cases of severe renal failure (eGFR <30), **unfractionated heparin** is often preferred, but if LMWH is used, **anti-Xa monitoring** is mandatory.

Question 206: A 72-year-old man with type 2 diabetes is admitted with sepsis secondary to a urinary tract infection. His regular medications include metformin 1g twice daily, gliclazide 80mg twice daily, and ramipril 10mg once daily. His admission blood results show: sodium 138 mmol/L, potassium 4.2 mmol/L, creatinine 185 μmol/L (baseline 95 μmol/L), glucose 18.2 mmol/L. Which medication should be stopped immediately?

A. Both metformin and ramipril (Correct Answer)
B. Gliclazide only
C. Metformin only
D. Ramipril only
E. All three medications should be stopped

Explanation: ***Both metformin and ramipril*** - **Metformin** must be stopped during **sepsis** and **acute kidney injury (AKI)** because it is renally excreted, and its accumulation carries a high risk of life-threatening **lactic acidosis**. - **Ramipril** (an ACE inhibitor) should be withheld as it can worsen renal perfusion and increase the risk of **hyperkalemia** in patients with a rising **creatinine** (indicating AKI). *Gliclazide only* - While **sulfonylureas** like gliclazide require close monitoring for hypoglycemia during illness, they are not the primary concern regarding **nephrotoxicity** or metabolic acidosis in this patient. - Stopping only this medication would fail to address the serious risks posed by the current use of **metformin** and **ramipril** in the context of AKI and sepsis. *Metformin only* - Stopping **metformin** is essential due to the side effect of **lactic acidosis**, but it is insufficient management on its own for this patient's acute kidney injury. - **Ramipril** must also be discontinued because it interferes with autoregulation of the **glomerular filtration rate (GFR)** during acute illness and dehydration, potentially worsening AKI. *Ramipril only* - While **ramipril** must be stopped to avoid further deterioration of **renal function**, this choice ignores the severe risk of **lactic acidosis** from continuing metformin. - Guidelines for **"sick day rules"** strictly dictate that both ACE inhibitors and metformin should be paused in the context of significant **sepsis** and AKI. *All three medications should be stopped* - **Gliclazide** is often continued under close supervision to manage hyperglycemia in acute illness, though doses may be adjusted; it does not carry the same systemic danger as the other two in AKI. - Total cessation of all diabetes medications may lead to **severe hyperglycemia**, whereas the priority is removing **nephrotoxic** and acidotic-triggering agents.

Question 207: A 58-year-old woman is started on treatment for tuberculosis. Her regimen includes rifampicin, isoniazid, pyrazinamide, and ethambutol. She has been taking warfarin for five years following a pulmonary embolism. What is the most appropriate management of her anticoagulation?

A. Switch to low molecular weight heparin for the duration of tuberculosis treatment
B. Continue warfarin and monitor INR weekly for the first month, then monthly
C. Switch to a direct oral anticoagulant (DOAC) such as apixaban
D. Continue warfarin and monitor INR 3-4 times in the first week, then frequently until stable (Correct Answer)
E. Discontinue anticoagulation as the tuberculosis treatment takes priority

Explanation: ***Continue warfarin and monitor INR 3-4 times in the first week, then frequently until stable*** - **Rifampicin** is a potent **cytochrome P450 enzyme inducer**, which significantly increases the metabolism of **warfarin**, leading to a drop in **INR** and increased thrombotic risk. - Frequent monitoring is essential because the dose of **warfarin** may need to be increased by **50-100%** to maintain a therapeutic range during co-administration. *Switch to low molecular weight heparin for the duration of tuberculosis treatment* - While **LMWH** avoids the P450 interaction, prescribing it for the full 6-month course of **TB treatment** is unnecessary and burdensome for the patient. - **Warfarin** can be maintained safely provided that **INR monitoring** and dose adjustments are performed diligently. *Continue warfarin and monitor INR weekly for the first month, then monthly* - Monitoring **weekly** is insufficient because the inducing effect of **rifampicin** begins within days and can cause a rapid decline in **anticoagulation levels**. - Sub-therapeutic **INR** levels in a patient with a history of **pulmonary embolism** pose an immediate risk of recurrent thrombosis. *Switch to a direct oral anticoagulant (DOAC) such as apixaban* - **Rifampicin** also induces **P-glycoprotein (P-gp)** and **CYP3A4**, which are the same pathways used to metabolize **DOACs** like **apixaban**. - Using **DOACs** with rifampicin is generally contraindicated as it leads to significantly reduced plasma concentrations and potential **treatment failure**. *Discontinue anticoagulation as the tuberculosis treatment takes priority* - **Tuberculosis treatment** does not necessitate the cessation of **anticoagulation**, especially in a patient with a high-risk history of **pulmonary embolism**. - Both conditions must be managed simultaneously; stopping **warfarin** would expose the patient to life-threatening **thromboembolic events**.

Question 208: Understanding the principles of insulin prescribing for surgical patients, which statement regarding the management of long-acting insulin analogues during the perioperative period is correct?

A. Long-acting insulin analogues should always be stopped when a variable rate intravenous insulin infusion is commenced
B. Long-acting insulin analogues should be continued at the usual dose throughout the perioperative period in patients with type 1 diabetes (Correct Answer)
C. Long-acting insulin analogues should be reduced by 50% on the day of surgery in all patients
D. Long-acting insulin analogues should be replaced with short-acting insulin when patients are fasted
E. Long-acting insulin analogues can be omitted for up to 24 hours without significant metabolic consequences

Explanation: ***Long-acting insulin analogues should be continued at the usual dose throughout the perioperative period in patients with type 1 diabetes***- Patients with **Type 1 Diabetes** have an absolute insulin deficiency and require continuous **basal insulin** to prevent the development of **diabetic ketoacidosis (DKA)**.- Continuing the long-acting analogue provide a **safety net** if the intravenous infusion is interrupted, ensuring the patient is never without circulating insulin.*Long-acting insulin analogues should always be stopped when a variable rate intravenous insulin infusion is commenced*- Stopping basal insulin during a **Variable Rate Intravenous Insulin Infusion (VRIII)** is dangerous as it significantly increases the risk of **rebound hyperglycemia** and DKA when the drip is discontinued.- Current **JBDS guidelines** recommend maintaining background insulin to facilitate a smoother transition back to subcutaneous regimens after surgery.*Long-acting insulin analogues should be reduced by 50% on the day of surgery in all patients*- Routine reduction by 50% for **Type 1 diabetics** is not typically recommended as it may lead to inadequate **basal coverage** during the stress of surgery.- While doses might be slightly adjusted (e.g., a 20% reduction) in some **Type 2 diabetics** or specific high-risk scenarios, it is not a universal rule for "all patients."*Long-acting insulin analogues should be replaced with short-acting insulin when patients are fasted*- Short-acting insulin has a brief duration of action and cannot provide the steady **basal metabolic rate** coverage required over 24 hours.- Relying solely on short-acting insulin during fasting increases the risk of **glycemic instability** and requires more frequent monitoring than a stable long-acting dose.*Long-acting insulin analogues can be omitted for up to 24 hours without significant metabolic consequences*- Omitting insulin in a Type 1 diabetic for 24 hours is life-threatening and can lead to severe **metabolic acidosis** and ketoacidosis within hours.- The **half-life** of intravenous insulin is only minutes; without long-acting subcutaneous insulin, the patient has no protection if the IV line fails.

Question 209: A 57-year-old woman is taking warfarin following a mechanical mitral valve replacement. Her target INR is 2.5-3.5. She has been stable on warfarin 4mg daily for 6 months with INR consistently 2.8-3.2. She now requires treatment for newly diagnosed hypothyroidism and is started on levothyroxine. How should her warfarin therapy be managed?

A. No change to warfarin dose; levothyroxine does not interact with warfarin
B. Reduce warfarin dose by 10-20% immediately and check INR in 3-5 days
C. Increase warfarin dose by 10-20% immediately and check INR in 3-5 days
D. Continue current warfarin dose and check INR more frequently (weekly) for the first 4-6 weeks of levothyroxine treatment (Correct Answer)
E. Switch from warfarin to a direct oral anticoagulant to avoid the interaction

Explanation: ***Continue current warfarin dose and check INR more frequently (weekly) for the first 4-6 weeks of levothyroxine treatment***- **Thyroid hormones** increase the catabolism of vitamin K-dependent **clotting factors**, meaning that as the patient reaches a euthyroid state, the anticoagulant effect of warfarin may be **potentiated**, increasing the INR.- Because this metabolic shift occurs gradually as **levothyroxine** levels stabilize, the safest management is **frequent monitoring** rather than an immediate empirical dose adjustment.*No change to warfarin dose; levothyroxine does not interact with warfarin*- This is incorrect because thyroid status directly influences the **metabolic clearance** of clotting factors and changes the body's sensitivity to warfarin.- Failing to monitor the **INR** during thyroid replacement therapy puts the patient at an increased risk of **hemorrhagic complications**.*Reduce warfarin dose by 10-20% immediately and check INR in 3-5 days*- An immediate dose reduction is **premature** as the metabolic effects of levothyroxine take time to manifest and the exact dose requirement change is unpredictable.- Pre-emptive adjustments may lead to a **subtherapeutic INR**, which is dangerous for a patient with a **mechanical mitral valve** requiring a high target range.*Increase warfarin dose by 10-20% immediately and check INR in 3-5 days*- This action is contraindicated because corrected hypothyroidism typically **increases** the effect of warfarin (higher INR), not decreases it.- Increasing the dose would significantly raise the risk of **major bleeding** as the patient transition from a hypothyroid to a euthyroid state.*Switch from warfarin to a direct oral anticoagulant to avoid the interaction*- **Direct oral anticoagulants (DOACs)** are strictly **contraindicated** in patients with **mechanical heart valves** due to a higher risk of thromboembolic events and bleeding compared to warfarin.- Warfarin remains the **gold standard** and only indicated long-term anticoagulant for patients with mechanical mitral valve replacements.

Question 210: A 66-year-old man with type 2 diabetes is reviewed in clinic. His diabetes is managed with insulin detemir 34 units in the morning and 28 units at bedtime, plus metformin 1g twice daily. His HbA1c is 76 mmol/mol (9.1%) and he reports frequent missed insulin doses because he 'forgets which dose to take when'. His BMI is 34 kg/m². He has no complications. What is the most appropriate modification to improve adherence and glycaemic control?

A. Switch to once-daily insulin glargine U300 and continue metformin
B. Add a GLP-1 receptor agonist and reduce insulin doses
C. Switch to premixed insulin (biphasic insulin aspart) twice daily and continue metformin (Correct Answer)
D. Arrange for district nurses to supervise insulin administration
E. Continue current regimen but provide a dosette box system for insulin pens

Explanation: ***Switch to premixed insulin (biphasic insulin aspart) twice daily and continue metformin*** - Switching to **premixed (biphasic) insulin** simplifies the regimen by using the same dose or product twice daily with meals, directly addressing the patient's confusion and **missed doses**. - This approach combines **basal and prandial insulin** into a single injection, which is highly effective for patients with type 2 diabetes who struggle with the complexity of multiple insulin titration schedules. *Switch to once-daily insulin glargine U300 and continue metformin* - While **once-daily glargine** simplifies the basal component, it may not provide sufficient **glycaemic control** for a patient with an HbA1c of 9.1% without additional mealtime coverage. - This modification does not solve the need for prandial support, which might eventually lead to an even more complex **basal-bolus** regimen that the patient already struggles with. *Add a GLP-1 receptor agonist and reduce insulin doses* - Adding a **GLP-1 receptor agonist** is beneficial for weight loss and glycaemic control, but it introduces a **new medication class** and potential side effects rather than simplifying the current confusion. - The primary issue is **adherence** due to regimen complexity; adding more varied treatments may further complicate the patient's routine. *Arrange for district nurses to supervise insulin administration* - **District nurse supervision** is a resource-intensive intervention usually reserved for patients with physical or cognitive disabilities who cannot self-administer. - It does not promote **patient autonomy** or address the underlying issue of an unnecessarily complex insulin schedule for a capable patient. *Continue current regimen but provide a dosette box system for insulin pens* - **Dosette boxes** (multi-compartment compliance aids) are designed for oral tablets and cannot be used to organize or store **insulin pens** or injections. - Continuing the current regimen ignores the patient's explicit feedback that the **different dosing schedule** is the cause of his non-adherence.

Question 211: A 79-year-old woman with atrial fibrillation on edoxaban 60mg once daily is admitted with a fractured neck of femur requiring surgical repair. Her eGFR is 48 ml/min/1.73m². She had her last dose of edoxaban 8 hours ago. Surgery is planned for 10:00 tomorrow (26 hours after last dose). What is the most appropriate perioperative anticoagulation management?

A. Proceed with surgery at 10:00 tomorrow and restart edoxaban 6 hours post-operatively
B. Delay surgery for a further 24 hours, proceed at 50 hours after last edoxaban dose
C. Bridge with therapeutic low molecular weight heparin until 12 hours before surgery
D. Give prothrombin complex concentrate pre-operatively to reverse edoxaban
E. Proceed with surgery at 10:00 tomorrow and restart edoxaban 48-72 hours post-operatively depending on haemostasis (Correct Answer)

Explanation: ***Proceed with surgery at 10:00 tomorrow and restart edoxaban 48-72 hours post-operatively depending on haemostasis*** - The 26-hour hold before surgery allows for sufficient **edoxaban** clearance, as approximately two half-lives (average 10-14 hours) would have passed, significantly reducing drug levels, which is appropriate for **urgent femur fracture repair** given an **eGFR of 48 ml/min**. - Restarting **edoxaban** should be delayed for **48–72 hours** after major orthopaedic surgery like a **femur fracture repair** to ensure reliable **haemostasis** and minimize the risk of serious post-operative bleeding or hematoma formation. *Proceed with surgery at 10:00 tomorrow and restart edoxaban 6 hours post-operatively* - Restarting a full-dose **DOAC** only **6 hours** after major orthopaedic surgery carries a very high risk of **post-operative bleeding** due to the rapid onset of its anticoagulant effect. - Guidelines for high-bleeding-risk surgery typically recommend delaying DOAC restart for at least **48-72 hours** to allow for initial surgical site healing and stable **haemostasis**. *Delay surgery for a further 24 hours, proceed at 50 hours after last edoxaban dose* - Undue delay of **hip fracture surgery** beyond 36-48 hours is associated with increased **mortality** and a higher incidence of complications like **pneumonia**, **pressure ulcers**, and functional decline in elderly patients. - A 26-hour hold is generally considered adequate for this type of urgent surgery in a patient with moderate renal impairment, making further delay medically unnecessary and potentially harmful. *Bridge with therapeutic low molecular weight heparin until 12 hours before surgery* - **Bridging anticoagulation** with LMWH is generally **not recommended** for patients on **DOACs** undergoing surgery, as it increases the risk of **perioperative bleeding** without offering superior antithrombotic protection. - The predictable offset and rapid onset of **DOACs** mean a simple withholding strategy is preferred, avoiding the added complexity and bleeding risk of LMWH. *Give prothrombin complex concentrate pre-operatively to reverse edoxaban* - **Prothrombin complex concentrate (PCC)** or specific reversal agents are reserved for situations of **life-threatening bleeding** or highly emergent surgery where delay is not possible. - This **femur fracture repair** is urgent but allows for a planned delay of 26 hours, making a waiting strategy safer and more appropriate than immediate pharmacological **anticoagulation reversal**, which has its own risks and high costs.

Question 212: A 44-year-old man with type 1 diabetes is admitted with severe gastroenteritis, vomiting, and diarrhoea. He is unable to eat. His capillary blood glucose is 14.2 mmol/L and ketones are 3.8 mmol/L. He normally takes insulin degludec 30 units once daily and insulin aspart with meals. What is the most appropriate management of his insulin therapy?

A. Stop all insulin until he is able to eat and drink normally
B. Continue insulin degludec at usual dose, stop insulin aspart, and start variable rate intravenous insulin infusion (Correct Answer)
C. Stop insulin degludec, stop insulin aspart, and start variable rate intravenous insulin infusion
D. Reduce insulin degludec to 50% of normal dose and stop insulin aspart
E. Continue insulin degludec at usual dose, give reduced dose insulin aspart with any food intake, and monitor closely

Explanation: ***Continue insulin degludec at usual dose, stop insulin aspart, and start variable rate intravenous insulin infusion*** - This patient is in **Diabetic Ketoacidosis (DKA)**, evidenced by significant ketonemia (3.8 mmol/L) and hyperglycemia (14.2 mmol/L); management requires a **Variable Rate Intravenous Insulin Infusion (VRIII)** to precisely control glucose and ketones. - In **Type 1 diabetes**, **basal insulin** (Degludec) should generally be continued alongside VRIII to prevent **rebound ketosis** and facilitate a smooth transition off IV insulin once DKA resolves. Mealtime insulin (Aspart) is stopped as he cannot eat. *Stop all insulin until he is able to eat and drink normally* - Stopping all insulin in a **Type 1 diabetic** with ketosis is dangerous, as it leads to absolute insulin deficiency and rapid worsening of **metabolic acidosis** and DKA. - **Sick day rules** for Type 1 diabetes strongly advise against discontinuing all insulin, even during illness or inability to eat, to prevent severe ketosis. *Stop insulin degludec, stop insulin aspart, and start variable rate intravenous insulin infusion* - Discontinuing **long-acting basal insulin** (Degludec) while on VRIII increases the risk of **rebound hyperglycemia** and ketosis, especially when transitioning back to subcutaneous insulin. - Maintaining basal insulin provides essential background coverage, crucial for suppressing **ketogenesis** and stabilizing blood glucose throughout the DKA resolution process. *Reduce insulin degludec to 50% of normal dose and stop insulin aspart* - In the context of **DKA** and acute illness, the body's stress response typically *increases* insulin requirements, making a 50% reduction in basal insulin insufficient and potentially harmful. - This approach does not address the acute need for **intravenous insulin therapy** to rapidly reverse the established DKA and metabolic acidosis. *Continue insulin degludec at usual dose, give reduced dose insulin aspart with any food intake, and monitor closely* - This strategy is inadequate for a patient with established **DKA** who is unable to eat or drink; it lacks the necessary rapid and precise glucose and ketone control offered by IV insulin. - Giving **insulin aspart** with "any food intake" is impractical given the patient's severe vomiting and inability to tolerate oral intake, making bolus insulin ineffective and potentially risky.

Question 213: A 52-year-old woman with epilepsy controlled on carbamazepine 400mg twice daily is started on apixaban 5mg twice daily for newly diagnosed pulmonary embolism. After 2 weeks, she develops worsening leg swelling and breathlessness. A repeat CT pulmonary angiogram shows extension of her pulmonary embolism. What is the most likely explanation?

A. Apixaban underdosing due to her weight exceeding 120kg
B. Apixaban resistance due to factor V Leiden mutation
C. Reduced apixaban levels due to enzyme induction by carbamazepine (Correct Answer)
D. Inadequate treatment duration with only 2 weeks of anticoagulation
E. Development of heparin-induced thrombocytopenia from bridging therapy

Explanation: ***Reduced apixaban levels due to enzyme induction by carbamazepine***- **Carbamazepine** is a potent inducer of **CYP3A4** and **P-glycoprotein (P-gp)**, significantly increasing the metabolism and clearance of **apixaban**.- This **drug-drug interaction** leads to sub-therapeutic plasma concentrations of apixaban, resulting in **treatment failure** and extension of the pulmonary embolism.*Apixaban underdosing due to her weight exceeding 120kg*- Although extreme body weight can influence **DOAC** pharmacokinetics, the patient's weight is not provided, making this speculative.- The direct and significant interaction of **carbamazepine** as an enzyme inducer is a more probable and medically established explanation for therapeutic failure.*Apixaban resistance due to factor V Leiden mutation*- **Factor V Leiden** is a thrombophilia causing resistance to **activated protein C**, not direct oral anticoagulants like **apixaban**, which targets **Factor Xa**.- Genetic thrombophilias are underlying risk factors for clotting, not mechanisms of 'resistance' to the direct action of a specific anticoagulant.*Inadequate treatment duration with only 2 weeks of anticoagulation*- Two weeks is generally sufficient time for **apixaban** to achieve steady-state therapeutic levels and prevent clot extension.- The **extension** of the pulmonary embolism while on treatment indicates a failure of drug efficacy rather than an insufficient duration of therapy.*Development of heparin-induced thrombocytopenia from bridging therapy*- **Heparin-induced thrombocytopenia (HIT)** requires prior exposure to **heparin**, which is not mentioned in the patient's history.- **Apixaban** is a direct Factor Xa inhibitor and does not cause HIT; it is often used as an alternative anticoagulant in HIT.

Question 214: A 71-year-old man is admitted with an acute ST-elevation myocardial infarction and undergoes primary percutaneous coronary intervention with drug-eluting stent insertion. He has atrial fibrillation with a CHA₂DS₂-VASc score of 5. His eGFR is 55 ml/min/1.73m². What is the most appropriate antithrombotic regimen on discharge?

A. Aspirin 75mg, clopidogrel 75mg, and apixaban 5mg twice daily (triple therapy) (Correct Answer)
B. Aspirin 75mg and rivaroxaban 20mg once daily (dual therapy)
C. Aspirin 75mg, clopidogrel 75mg, and warfarin with target INR 2-3 (triple therapy)
D. Clopidogrel 75mg and apixaban 5mg twice daily (dual therapy) after 1 week of triple therapy
E. Aspirin 75mg, ticagrelor 90mg twice daily, and apixaban 2.5mg twice daily (triple therapy)

Explanation: ***Aspirin 75mg, clopidogrel 75mg, and apixaban 5mg twice daily (triple therapy)***- Patients with **atrial fibrillation** (CHA₂DS₂-VASc score 5) undergoing PCI for **STEMI** with DES insertion require **triple therapy** (aspirin, clopidogrel, and a DOAC) for an initial duration (typically 1 week to 1 month) to prevent both stent thrombosis and embolic stroke.- **Apixaban 5mg twice daily** is the standard dose as this patient (71 years old, eGFR 55 ml/min/1.73m²) does not meet two or more dose-reduction criteria (age ≥80, weight ≤60kg, or creatinine ≥1.5 mg/dL). *Aspirin 75mg and rivaroxaban 20mg once daily (dual therapy)*- This regimen lacks a **P2Y12 inhibitor**, which is mandatory immediately following **acute coronary syndrome (ACS)** and stent insertion to prevent acute stent thrombosis.- **Triple therapy** is the preferred initial discharge strategy for a patient with a high-risk event like STEMI and AF before transitioning to dual therapy. *Aspirin 75mg, clopidogrel 75mg, and warfarin with target INR 2-3 (triple therapy)*- Current guidelines prefer **DOACs** over **warfarin** in triple therapy regimens due to a significantly lower risk of **intracranial hemorrhage** and major bleeding.- Warfarin should generally only be used for triple therapy if there is a specific contraindication to DOACs, such as a **mechanical heart valve**. *Clopidogrel 75mg and apixaban 5mg twice daily (dual therapy) after 1 week of triple therapy*- While transitioning to **dual therapy** (DOAC + single antiplatelet) is a valid long-term strategy, the standard discharge instruction for an acute STEMI with high ischemic risk usually involves a defined period of **triple therapy**.- This option describes a step-down approach; however, for the immediate **discharge** after STEMI-related PCI, triple therapy remains the primary recommendation for the initial phase. *Aspirin 75mg, ticagrelor 90mg twice daily, and apixaban 2.5mg twice daily (triple therapy)*- **Ticagrelor** is generally avoided in triple therapy due to a significantly increased **bleeding risk**; **clopidogrel** is the P2Y12 inhibitor of choice when combined with anticoagulants.- **Apixaban 2.5mg twice daily** is an under-dose for this patient as he does not meet the specified clinical or biochemical criteria for dose reduction.

Question 215: A 58-year-old man with newly diagnosed type 2 diabetes is started on a basal-bolus insulin regimen. He injects insulin glargine 20 units at 22:00 and insulin lispro 6 units before each meal. He works shifts including night shifts. On a night shift week, he sleeps from 08:00 to 16:00 and has his main meal at 17:00 and 02:00. How should he adjust his basal insulin timing?

A. Continue glargine at 22:00 regardless of sleep pattern to maintain consistency (Correct Answer)
B. Take glargine at 08:00 (bedtime during night shifts) and 22:00 (bedtime during day shifts)
C. Take glargine at the same time each day (e.g., 22:00) but reduce dose by 20% on night shifts
D. Take glargine upon waking regardless of the time to maintain consistent post-sleep timing
E. Switch to twice-daily intermediate-acting insulin to provide more flexibility

Explanation: ***Continue glargine at 22:00 regardless of sleep pattern to maintain consistency*** - **Insulin glargine** is a **long-acting basal insulin** with a **24-hour duration** and no significant peak, meaning it should be administered at the same **clock time** every day to maintain a consistent background insulin level. - For shift workers, keeping the basal timing constant prevents **insulin stacking** (causing hypoglycemia) or **gaps** in coverage (causing hyperglycemia) that would occur if the timing shifted with sleep cycles, which helps maintain stable glycemic control. *Take glargine at 08:00 (bedtime during night shifts) and 22:00 (bedtime during day shifts)* - Shifting administration times by a large interval (e.g., 14 hours) based on sleep patterns would disrupt the **pharmacokinetic steady state** of long-acting insulin. - This approach would lead to unpredictable periods of either **excessive insulin levels** (if doses are too close) or **insulin deficiency** (if doses are too far apart), both detrimental to glucose management. *Take glargine at the same time each day (e.g., 22:00) but reduce dose by 20% on night shifts* - There is no general clinical indication that **metabolic basal insulin requirements** significantly decrease during night shifts compared to day shifts. - Arbitrarily reducing the dose can lead to **hyperglycemia** and poor glycemic control; any dose adjustments should be based on **blood glucose monitoring trends** and physician guidance. *Take glargine upon waking regardless of the time to maintain consistent post-sleep timing* - Administering **long-acting basal insulin** at variable times each day based on waking disrupts its consistent 24-hour action, making it difficult to predict its effect. - Only **bolus insulin (lispro)** should be adjusted based on meal timing and activity, while basal insulin provides a steady background. *Switch to twice-daily intermediate-acting insulin to provide more flexibility* - **Intermediate-acting insulins (like NPH)** have more pronounced **peaks** and shorter durations, making them **less flexible** and more prone to causing **hypoglycemia** during shift changes. - The current **basal-bolus regimen** using glargine is generally preferred for shift workers due to its stable, peakless profile and the ability to adjust mealtime boluses independently.

Question 216: A 63-year-old woman with rheumatoid arthritis is started on methotrexate 15mg once weekly. Which of the following monitoring schedules is recommended for the first 6 months of treatment?

A. Full blood count and liver function tests weekly for 6 weeks, then monthly
B. Full blood count and liver function tests every 2 weeks until stable for 6 weeks, then every 2-3 months
C. Full blood count, liver function tests and renal function every 2 weeks until stable for 6 weeks, then monthly for 3 months, then every 3 months (Correct Answer)
D. Full blood count and liver function tests monthly for 3 months, then every 3 months
E. Full blood count, liver function tests and renal function at baseline, 1 month, 3 months, and 6 months

Explanation: ***Full blood count, liver function tests and renal function every 2 weeks until stable for 6 weeks, then monthly for 3 months, then every 3 months***- This schedule aligns with **NICE** and **BSR guidelines** for **methotrexate monitoring**, effectively checking for **myelosuppression**, **hepatotoxicity**, and **renal impairment** during the critical initiation phase.- Including **renal function (U&Es)** is paramount because methotrexate is primarily **renally excreted**, and impaired kidney function significantly elevates the risk of drug toxicity.*Full blood count and liver function tests weekly for 6 weeks, then monthly*- While rigorous, **weekly monitoring** for 6 weeks is generally considered **overly frequent** and not standard practice, making it less practical for routine outpatient management.- This option critically **omits regular renal function monitoring**, which is an essential part of safe methotrexate prescribing due to its renal excretion.*Full blood count and liver function tests every 2 weeks until stable for 6 weeks, then every 2-3 months*- This monitoring schedule lacks the crucial **intermediate monthly monitoring phase** (typically for 3 months) that bridges initial stabilization and long-term maintenance.- Similar to other incorrect options, it fails to include **renal function (U&Es)** assessment, focusing only on blood counts and liver enzymes.*Full blood count and liver function tests monthly for 3 months, then every 3 months*- Starting with **monthly monitoring** is **insufficiently frequent** for newly initiated methotrexate, as rapid toxicities like **pancytopenia** can develop within the first few weeks.- This option also completely misses the requirement for **renal function** evaluation, which is vital for monitoring methotrexate clearance and preventing accumulation.*Full blood count, liver function tests and renal function at baseline, 1 month, 3 months, and 6 months*- This frequency of monitoring is **too sparse** to detect early adverse effects or idiosyncratic reactions, which often manifest shortly after starting methotrexate or adjusting its dose.- Guidelines mandate more frequent initial checks (e.g., bi-weekly) to ensure **patient safety** and allow for timely intervention or adjustment of the methotrexate regimen.

Question 217: A 76-year-old man on warfarin for atrial fibrillation (target INR 2-3) presents with INR of 6.8. He has no evidence of bleeding but reports taking antibiotics from his dentist 3 days ago for a tooth infection. His regular warfarin dose is 5mg daily. What is the most appropriate immediate management?

A. Give oral vitamin K 1-5mg and withhold 1-2 doses of warfarin, recheck INR in 24 hours (Correct Answer)
B. Give intravenous vitamin K 10mg and admit for observation
C. Withhold warfarin for 2 days and recheck INR without giving vitamin K
D. Give prothrombin complex concentrate and vitamin K 5mg IV
E. Continue warfarin at reduced dose of 2.5mg and recheck INR in 3 days

Explanation: ***Give oral vitamin K 1-5mg and withhold 1-2 doses of warfarin, recheck INR in 24 hours*** - For an **INR between 5.0 and 8.0** in a patient with **no bleeding** but additional risk factors (such as **age >70**), consensus guidelines recommend withholding warfarin and administering **low-dose oral Vitamin K**. - This approach ensures a controlled reduction of the INR within 24 hours without causing **warfarin resistance** upon re-initiation. *Give intravenous vitamin K 10mg and admit for observation* - High-dose **intravenous Vitamin K** is reserved for patients with **major bleeding** or extremely high INR levels to achieve rapid reversal. - Over-correction with 10mg IV can lead to **prolonged resistance** to warfarin therapy, complicating subsequent management of his atrial fibrillation. *Withhold warfarin for 2 days and recheck INR without giving vitamin K* - Simply **withholding doses** is typically reserved for an INR <5.0; at 6.8 with the patient's **advanced age**, more active management is needed to prevent hemorrhage. - Without Vitamin K, the INR may take too long to return to the **therapeutic range**, increasing the window of risk for a spontaneous bleed. *Give prothrombin complex concentrate and vitamin K 5mg IV* - **Prothrombin complex concentrate (PCC)** is the gold standard for **emergency reversal** of warfarin in the setting of life-threatening or **major bleeding**. - This patient is **hemodynamically stable** with no clinical bleeding, making the use of blood products unnecessary and clinically inappropriate. *Continue warfarin at reduced dose of 2.5mg and recheck INR in 3 days* - Continuing warfarin when the INR is significantly **above the therapeutic threshold (6.8)** poses a dangerous risk of intracranial or gastrointestinal hemorrhage. - Direct **drug-drug interactions** with the dentist's antibiotics (likely **metronidazole or erythromycin**) necessitate immediate cessation until the INR stabilizes.

Question 218: What is the recommended frequency for monitoring lithium levels in a patient who has been on a stable dose of lithium carbonate for 2 years with consistently therapeutic levels and no intercurrent illness?

A. Every month
B. Every 3 months (Correct Answer)
C. Every 6 months
D. Every 12 months
E. Only when clinically indicated

Explanation: ***Every 3 months*** - According to **NICE guidelines** and the **BNF**, lithium levels should be monitored every 3 months for patients on a stable dose of lithium for more than one year. - This frequency is necessary due to lithium's **narrow therapeutic index** (0.4–1.0 mmol/L) and the risk of toxicity from changes in **renal function** or fluid balance. *Every month* - Monthly monitoring is typically reserved for the **initiation phase** of treatment or during **dose titration** until therapeutic levels are stabilized. - It is not required for a patient who has been clinically stable and compliant on the same dose for **two years**. *Every 6 months* - While some stable patients under 65 may have monitoring extended under specific specialist guidance, the **standard protocol** remains every 3 months for long-term safety. - Waiting 6 months may delay the detection of a decline in **eGFR** or changes in serum levels, risking **lithium toxicity**. *Every 12 months* - An annual check is insufficient for monitoring serum levels because lithium concentrations can fluctuate significantly with **dietary salt**, hydration, or **NSAID use**. - Yearly monitoring applies to other parameters like **serum calcium**, but not to the serum lithium concentration itself. *Only when clinically indicated* - This approach is dangerous because lithium toxicity can develop **insidiously** without obvious external triggers. - Routine **proactive monitoring** is mandatory to prevent irreversible **nephrotoxicity** and thyroid dysfunction associated with long-term use.

Question 219: A 33-year-old woman with type 1 diabetes on basal-bolus insulin therapy is planning conception. Her current HbA1c is 58 mmol/mol (7.5%). She is on insulin detemir 22 units at bedtime and insulin aspart before meals. She also takes atorvastatin 20mg daily and ramipril 5mg daily for microalbuminuria. What is the most important prescribing change before conception?

A. Switch to insulin pump therapy to optimise glucose control
B. Stop ramipril and switch to labetalol or nifedipine (Correct Answer)
C. Increase insulin doses by 25% in preparation for pregnancy
D. Switch atorvastatin to a fibrate for lipid management
E. Add high-dose folic acid 5mg daily

Explanation: ***Stop ramipril and switch to labetalol or nifedipine*** - **ACE inhibitors** like ramipril are strictly **teratogenic**, especially in the second and third trimesters, causing **fetal renal dysgenesis**, skull hypoplasia, and **oligohydramnios**. - Transitioning to pregnancy-safe alternatives like **labetalol** or **nifedipine** is the most critical step to prevent major congenital malformations once conception occurs.*Switch to insulin pump therapy to optimise glucose control* - While an **insulin pump (CSII)** can improve glycemic control, it is not a mandatory requirement if the patient can achieve targets with **basal-bolus therapy**. - Optimization of the **HbA1c** (target <48 mmol/mol) is important, but discontinuing known **teratogens** takes immediate priority over changing the delivery method.*Increase insulin doses by 25% in preparation for pregnancy* - Insulin resistance typically increases during the **second and third trimesters**, not necessarily during the pre-conception phase. - Doses should be titrated based on **self-monitoring of blood glucose** rather than a preemptive fixed percentage increase, which could risk **hypoglycemia**.*Switch atorvastatin to a fibrate for lipid management* - Both **statins** and **fibrates** are generally avoided in pregnancy; statins are contraindicated due to potential interference with **fetal cholesterol synthesis**. - Standard practice is to **discontinue lipid-lowering therapy** entirely before conception as the risk of short-term hyperlipidemia is outweighed by fetal safety.*Add high-dose folic acid 5mg daily* - Women with diabetes are indeed recommended to take **5mg folic acid** to reduce the risk of **neural tube defects**. - While essential, the active cessation of a known **fetotoxic drug** like an ACE inhibitor is considered the most urgent safety intervention in pre-pregnancy counseling.

Question 220: A 69-year-old woman with chronic kidney disease stage 4 (eGFR 22 ml/min/1.73m²) requires anticoagulation for newly diagnosed atrial fibrillation. Her CHA₂DS₂-VASc score is 4 and HAS-BLED score is 2. She weighs 58 kg. Which anticoagulant and dose is most appropriate?

A. Apixaban 5mg twice daily
B. Apixaban 2.5mg twice daily (Correct Answer)
C. Rivaroxaban 20mg once daily
D. Dabigatran 110mg twice daily
E. Warfarin with target INR 2-3

Explanation: ***Apixaban 2.5mg twice daily*** - Dose reduction of **Apixaban** to 2.5mg twice daily is required if two of three criteria are met: **age ≥80**, **body weight ≤60 kg**, or **serum creatinine ≥133 μmol/L** (this patient meets weight and creatinine criteria). - **Apixaban** is generally preferred over other NOACs in **Severe Chronic Kidney Disease (Stage 4)** due to its lower renal clearance profile and reduced risk of major bleeding. *Apixaban 5mg twice daily* - This is the standard dose and would be considered **overdosing** in this patient given she meets the criteria for dose reduction (weight <60kg and low eGFR). - Using the full dose in this clinical scenario significantly increases the **hemorrhagic risk** without providing additional stroke protection. *Rivaroxaban 20mg once daily* - The standard 20mg dose is contraindicated in patients with an **eGFR <50 ml/min**, as it would lead to drug accumulation. - Even at a reduced dose of 15mg, **Rivaroxaban** is less established than apixaban in managing patients with severe renal impairment nearing **ESRD**. *Dabigatran 110mg twice daily* - **Dabigatran** is contra-indicated when the **eGFR is <30 ml/min** because it is primarily excreted (80%) by the kidneys. - Use in this patient would lead to a high risk of **toxicity** and life-threatening bleeding complications due to profound drug accumulation. *Warfarin with target INR 2-3* - While **Warfarin** can be used in renal failure, it is associated with a higher risk of **intracranial hemorrhage** and vascular calcification compared to apixaban. - Monitoring is more difficult in **CKD** patients, and recent evidence favors dose-adjusted **Apixaban** for its superior safety profile in Stage 4 disease.

Question 221: A 47-year-old man with type 2 diabetes is established on insulin glargine 28 units at bedtime and insulin lispro 8 units before each meal. He reports three episodes of nocturnal hypoglycaemia in the past week, with blood glucose readings of 2.8-3.2 mmol/L at 3 AM. His pre-dinner glucose averages 8.5 mmol/L and morning fasting glucose 11.2 mmol/L. What is the most appropriate adjustment to his insulin regimen?

A. Reduce bedtime insulin glargine dose by 10-20% (Correct Answer)
B. Increase bedtime insulin glargine dose by 2-4 units
C. Reduce pre-dinner insulin lispro dose by 2 units
D. Split insulin glargine into twice-daily dosing
E. Add metformin 500mg at bedtime to reduce insulin requirements

Explanation: ***Reduce bedtime insulin glargine dose by 10-20%*** - The patient is experiencing the **Somogyi effect**, where nocturnal hypoglycaemia leads to a counter-regulatory hormone surge, causing **rebound fasting hyperglycaemia**. - Reducing the **basal insulin** dose is the primary safety intervention to prevent **nocturnal hypoglycaemia** and address the unsafe 3 AM glucose levels. *Increase bedtime insulin glargine dose by 2-4 units* - This would dangerously worsen the **nocturnal hypoglycaemia** levels (currently 2.8-3.2 mmol/L), leading to potential seizures or coma. - Clinicians must prioritize solving **hypoglycaemia** before attempting to lower fasting glucose levels that are caused by rebound mechanisms. *Reduce pre-dinner insulin lispro dose by 2 units* - **Insulin lispro** is rapid-acting with a peak effect at 1-2 hours and a total duration of 3-5 hours, making it unlikely to cause **3 AM hypoglycaemia**. - Reducing the pre-dinner dose would further elevate the **pre-dinner glucose** levels (currently 8.5 mmol/L) without addressing the basal insulin excess. *Split insulin glargine into twice-daily dosing* - While splitting **glargine** can stabilize glucose profiles in some, the immediate clinical priority is a **total dose reduction** to stop the hypoglycaemic episodes. - Splitting the same high total dose usually does not resolve severe **nocturnal dips** as effectively as a simple dose reduction. *Add metformin 500mg at bedtime to reduce insulin requirements* - Adding **metformin** would increase insulin sensitivity and could potentially worsen the existing **hypoglycaemic episodes** if doses are not adjusted. - Pharmacological additions are inappropriate during an **acute safety issue** involving insulin titration and hypoglycaemia risk.

Question 222: A 54-year-old woman with deep vein thrombosis is started on low molecular weight heparin (LMWH) and warfarin. Her baseline INR is 1.1. After 3 days of overlapping therapy, her INR is 2.3. Her platelet count has dropped from 245 × 10⁹/L at baseline to 95 × 10⁹/L. She has no bleeding and feels well. What is the most appropriate immediate management?

A. Continue both LMWH and warfarin and recheck INR in 2 days
B. Stop LMWH immediately, continue warfarin and check for heparin-induced thrombocytopenia (Correct Answer)
C. Stop warfarin, continue LMWH and arrange haematology review
D. Stop both medications and start a direct oral anticoagulant
E. Continue current management and recheck platelet count in 1 week

Explanation: ***Stop LMWH immediately, continue warfarin and check for heparin-induced thrombocytopenia*** - The patient's **platelet count drop** by over 60% from baseline in 3 days while on LMWH is highly indicative of **Heparin-Induced Thrombocytopenia (HIT)**. - Immediate **cessation of all heparin products** is mandatory to prevent potentially fatal **thrombotic complications** associated with HIT. *Continue both LMWH and warfarin and recheck INR in 2 days* - Continuing LMWH in the presence of suspected **HIT** is dangerous as it can lead to paradoxical **arterial or venous thrombosis**. - A platelet drop of this magnitude requires **urgent intervention** rather than simple observation of the INR. *Stop warfarin, continue LMWH and arrange haematology review* - Continuing LMWH when **HIT** is suspected is contraindicated due to the high risk of **thromboembolism**. - While warfarin might need adjustment in HIT, the immediate priority is stopping the **heparin product**, which is the direct cause of the immune reaction. *Stop both medications and start a direct oral anticoagulant* - While DOACs are used in many DVT cases, the immediate priority is specifically identifying and managing **HIT** pathology. - Starting a DOAC may be an eventual management strategy, but the first clinical step involves the specific withdrawal of the **offending heparin agent** and formal testing. *Continue current management and recheck platelet count in 1 week* - Delaying the investigation and management of a significant **platelet drop** in suspected **HIT** could lead to rapid and catastrophic **thromboembolic events**. - Standard safety protocols require prompt diagnosis and intervention for **HIT**, making a 1-week delay unacceptable.

Question 223: A 35-year-old pregnant woman at 14 weeks gestation with newly diagnosed venous thromboembolism requires anticoagulation. She has normal renal function. Which anticoagulation strategy is most appropriate for the duration of her pregnancy?

A. Therapeutic dose low molecular weight heparin throughout pregnancy (Correct Answer)
B. Warfarin with target INR 2-3 after the first trimester
C. Rivaroxaban at standard VTE treatment dose
D. Fondaparinux at weight-adjusted dose
E. Unfractionated heparin via continuous intravenous infusion

Explanation: ***Therapeutic dose low molecular weight heparin throughout pregnancy*** - **Low molecular weight heparin (LMWH)** is the preferred anticoagulant in pregnancy as it does not cross the **placenta** and has no known teratogenic effects. - It is preferred over other options due to its predictable pharmacokinetics and reduced risk of **heparin-induced thrombocytopenia (HIT)** and osteoporosis. *Warfarin with target INR 2-3 after the first trimester* - **Warfarin** is generally avoided because it crosses the placenta and can cause **warfarin embryopathy** (nasal hypoplasia, epiphyseal stippling) and fetal hemorrhage. - While sometimes used for mechanical heart valves in the second trimester, it is not the standard of care for **VTE** management when LMWH is available. *Rivaroxaban at standard VTE treatment dose* - **Direct oral anticoagulants (DOACs)** like rivaroxaban are **contraindicated** in pregnancy due to lack of safety data and potential placental transfer. - Current guidelines recommend against their use during pregnancy and during **breastfeeding**. *Fondaparinux at weight-adjusted dose* - **Fondaparinux** has limited safety data regarding **fetal outcomes** and is not considered a first-line treatment in pregnancy. - Its use is typically reserved for women who cannot tolerate LMWH, such as those with a history of **heparin-induced thrombocytopenia**. *Unfractionated heparin via continuous intravenous infusion* - **Unfractionated heparin (UFH)** is impractical for long-term use throughout pregnancy and requires frequent **aPTT monitoring**. - Chronic UFH use is associated with a higher risk of **osteoporosis** and heparin-induced thrombocytopenia compared to LMWH.

Question 224: A 61-year-old man is prescribed phenytoin for seizure control following neurosurgery. His phenytoin level is reported as 45 μmol/L (therapeutic range 40-80 μmol/L). However, he develops ataxia, nystagmus, and confusion. What pharmacological principle best explains this clinical scenario?

A. Phenytoin exhibits first-order kinetics and the level will decrease predictably with dose reduction
B. Phenytoin exhibits zero-order kinetics and small dose increases can cause disproportionate level rises
C. The patient has developed acute phenytoin toxicity from a drug interaction reducing protein binding (Correct Answer)
D. Laboratory error has occurred as symptoms are inconsistent with therapeutic level
E. Phenytoin metabolites are causing toxicity despite therapeutic parent drug level

Explanation: ***The patient has developed acute phenytoin toxicity from a drug interaction reducing protein binding*** - Phenytoin is highly **protein-bound** (approx. 90%), but standard assays measure **total phenytoin**; toxicity occurs due to an increase in the **unbound (free) fraction**, which is the pharmacologically active form. - Displacement from albumin (e.g., by **valproate**, **sulfonamides**, or in **renal failure**) can cause classic signs of toxicity like **ataxia, nystagmus, and confusion** despite a **total level** appearing within the therapeutic range. *Phenytoin exhibits first-order kinetics and the level will decrease predictably with dose reduction* - Phenytoin elimination follows **Michaelis-Menten kinetics**, meaning it exhibits **dose-dependent (non-linear) kinetics**, rather than purely first-order. - At therapeutic concentrations, its metabolic enzymes become saturated, leading to a shift towards **zero-order kinetics**, where elimination rate is constant regardless of drug concentration. *Phenytoin exhibits zero-order kinetics and small dose increases can cause disproportionate level rises* - While phenytoin does exhibit **zero-order kinetics** at higher therapeutic concentrations due to enzyme saturation, this option doesn't fully explain the current scenario where the *total level is therapeutic* but toxicity is present. - The scenario points to an increase in the **free drug concentration** due to altered protein binding, rather than a disproportionate rise from a dose adjustment, which is a different aspect of its non-linear kinetics. *Laboratory error has occurred as symptoms are inconsistent with therapeutic level* - While lab errors are possible, it's less likely to be the *best explanation* when a clear pharmacological principle, like **altered protein binding** leading to increased free drug, can explain the discrepancy. - The symptoms of **ataxia, nystagmus, and confusion** are classic signs of **phenytoin toxicity**, strongly suggesting an exaggerated drug effect rather than a simple measurement error. *Phenytoin metabolites are causing toxicity despite therapeutic parent drug level* - Phenytoin is primarily metabolized to **inactive hydroxylated metabolites** (e.g., by CYP2C9 and CYP2C19), which generally do not contribute to the observed neurotoxicity. - The neurotoxic symptoms of **ataxia, nystagmus, and confusion** are directly attributable to high concentrations of the **unbound parent drug**, not its metabolites.

Question 225: A 69-year-old man with pulmonary embolism is being treated with rivaroxaban 15mg twice daily for the first 21 days. He weighs 58kg and has eGFR 28 ml/min/1.73m². On reviewing his prescription, what is the most appropriate action?

A. Continue current dose as prescribed for acute VTE treatment phase
B. Reduce dose to rivaroxaban 15mg once daily immediately
C. Stop rivaroxaban and switch to warfarin with LMWH bridging (Correct Answer)
D. Continue current dose but reduce to 15mg once daily after 21 days
E. Stop rivaroxaban and switch to apixaban at standard VTE dose

Explanation: ***Stop rivaroxaban and switch to warfarin with LMWH bridging***- **Rivaroxaban** is **contraindicated** in patients with an **eGFR < 30 ml/min/1.73m²** due to its significant renal excretion (approximately two-thirds), which leads to drug accumulation and an elevated **bleeding risk**.- **Warfarin** is a safer alternative in severe renal impairment as it is primarily **hepatically metabolized** and does not rely on renal clearance, though it necessitates **LMWH bridging** until a therapeutic **INR** is achieved.*Continue current dose as prescribed for acute VTE treatment phase*- Maintaining the high initial dose of **rivaroxaban 15mg twice daily** in a patient with an **eGFR of 28 ml/min/1.73m²** dramatically increases the risk of **hemorrhage** due to drug accumulation.- The standard acute VTE treatment regimen for rivaroxaban is predicated on adequate renal function; this patient's **compromised renal function** overrides standard dosing protocols.*Reduce dose to rivaroxaban 15mg once daily immediately*- A dose reduction to **15mg once daily** is still inappropriate and unsafe for a patient with an **eGFR of 28 ml/min/1.73m²**, as it remains above the recommended **contraindication threshold**.- Clinical guidelines for **rivaroxaban** specify **discontinuation** rather than dose reduction when the **eGFR falls below 30 ml/min**, highlighting the severe risk of renal impairment.*Continue current dose but reduce to 15mg once daily after 21 days*- This approach fails to address the immediate and severe risk of **rivaroxaban accumulation** during the initial 21-day high-dose phase, which is already contraindicated with the patient's **eGFR**.- Delaying action for 21 days with a contraindicated drug could lead to **life-threatening bleeding complications** before any dose adjustment is considered.*Stop rivaroxaban and switch to apixaban at standard VTE dose*- While **apixaban** has a lower renal clearance component compared to rivaroxaban, it also requires **dose adjustment** or caution in patients with both **low body weight (≤60kg)** and **renal impairment**, which this patient has.- For severe renal impairment (**eGFR < 30 ml/min**), **warfarin** remains the generally preferred and most evidence-supported oral anticoagulant due to its non-renal metabolism.

Question 226: A 66-year-old woman on warfarin for mechanical aortic valve replacement (target INR 2.5-3.5) requires urgent colonoscopy for suspected lower gastrointestinal bleeding. Her INR is 3.2. She has no active bleeding currently. What is the most appropriate anticoagulation management strategy?

A. Proceed with colonoscopy without adjusting warfarin, as investigation is for bleeding
B. Stop warfarin 5 days pre-procedure, start therapeutic low molecular weight heparin, stop heparin 24 hours pre-procedure (Correct Answer)
C. Give 5mg oral vitamin K, proceed with colonoscopy when INR <1.5, restart warfarin immediately post-procedure
D. Stop warfarin 3 days pre-procedure, give 2mg oral vitamin K, proceed when INR <1.5
E. Stop warfarin, proceed with colonoscopy within 48 hours without bridging anticoagulation

Explanation: ***Stop warfarin 5 days pre-procedure, start therapeutic low molecular weight heparin, stop heparin 24 hours pre-procedure*** - Patients with **mechanical heart valves** are at high risk for **thromboembolism** and require **bridging anticoagulation** with therapeutic LMWH when warfarin is interrupted for high-bleeding-risk procedures. - **Colonoscopy** is a high-bleeding-risk procedure requiring an **INR <1.5**. Warfarin needs to be stopped 5 days prior for its effect to wear off, and LMWH (given its shorter half-life) is stopped 24 hours before to allow for coagulation to normalize for the procedure. *Proceed with colonoscopy without adjusting warfarin, as investigation is for bleeding* - Performing a colonoscopy with a therapeutic **INR of 3.2** carries a very high risk of **major hemorrhage**, especially if biopsies or polypectomy are performed during the procedure. - While the investigation is for bleeding, the priority is to ensure the procedure itself does not exacerbate the bleeding or cause new, severe bleeding complications. *Give 5mg oral vitamin K, proceed with colonoscopy when INR <1.5, restart warfarin immediately post-procedure* - Giving 5mg oral **vitamin K** is too much and will significantly reverse warfarin's effect, making re-initiation and achieving a stable therapeutic INR very difficult and unpredictable for days, without an urgent need. - Restarting warfarin immediately post-procedure without bridging leaves the patient at high risk of **thromboembolism** as warfarin takes several days to achieve a therapeutic effect. *Stop warfarin 3 days pre-procedure, give 2mg oral vitamin K, proceed when INR <1.5* - Stopping warfarin only **3 days** prior is often insufficient for the INR to drop below 1.5, particularly if the patient has a stable, therapeutic INR. - This strategy completely lacks **bridging anticoagulation** with LMWH, which is critical for a patient with a **mechanical aortic valve** due to the high risk of **thromboembolism**. *Stop warfarin, proceed with colonoscopy within 48 hours without bridging anticoagulation* - Stopping warfarin and proceeding without **bridging anticoagulation** is contraindicated for high-risk patients like those with **mechanical heart valves**. - This approach leaves the patient vulnerable to **valve thrombosis** and potentially fatal **embolic events** for the duration of warfarin's offset and prior to any restart.

Question 227: A 43-year-old man with type 2 diabetes attends the emergency department having inadvertently injected 80 units of insulin glargine instead of his usual 8 units two hours ago. His current blood glucose is 6.5 mmol/L and he is asymptomatic. What is the most appropriate management?

A. Discharge home with advice to eat regular meals and check blood glucose 4-hourly
B. Admit for 24-hour monitoring with intravenous 10% glucose infusion (Correct Answer)
C. Observe for 4 hours, give oral carbohydrates, and discharge if blood glucose stable
D. Start variable rate intravenous insulin infusion to control any rebound hyperglycaemia
E. Admit for 12-hour observation with regular blood glucose monitoring and oral carbohydrates

Explanation: ***Admit for 24-hour monitoring with intravenous 10% glucose infusion*** - **Insulin glargine** is a **long-acting** basal insulin with a duration of action of approximately 24 hours, meaning a massive 10-fold overdose creates a prolonged risk of **severe hypoglycemia**. - Admission for **intravenous glucose** allows for precise, continuous glycemic support and the ability to adjust rates based on **hourly monitoring**, which is safer than relying on oral intake alone. *Discharge home with advice to eat regular meals and check blood glucose 4-hourly* - Discharging the patient is unsafe because the peak effect of the **overdose** may not occur for several hours, leading to potentially fatal **nocturnal hypoglycemia**. - Home monitoring every 4 hours is insufficient to detect the rapid drops in blood glucose associated with such a high dose of **exogenous insulin**. *Observe for 4 hours, give oral carbohydrates, and discharge if blood glucose stable* - A **4-hour observation** period is inadequate because it does not cover the full **pharmacodynamic profile** of long-acting glargine, which lasts up to a day. - Stability at 4 hours provides a false sense of security, as the patient remains at high risk for **delayed hypoglycemia** once the insulin reaches steady absorption. *Start variable rate intravenous insulin infusion to control any rebound hyperglycaemia* - A **variable rate intravenous insulin infusion (VRIII)** is contraindicated here because the clinical priority is treating **insulin toxicity**, not hyperglycemia. - Adding more insulin would exacerbate the existing **overdose** and significantly increase the risk of life-threatening **hypoglycemic coma**. *Admit for 12-hour observation with regular blood glucose monitoring and oral carbohydrates* - A **12-hour observation** is insufficient as it only covers half the expected duration of action of **glargine**, leaving the patient vulnerable after discharge. - Relying solely on **oral carbohydrates** is risky in the context of a 10-fold overdose, as the patient may be unable to maintain adequate intake if they become **drowsy** or symptomatic.

Question 228: A 78-year-old man with atrial fibrillation and CHA₂DS₂-VASc score of 5 is on dabigatran 150mg twice daily. He develops acute kidney injury with eGFR falling from 55 to 25 ml/min/1.73m². He presents with haematuria and dizziness. Blood pressure is 95/60 mmHg. What is the most appropriate immediate management?

A. Stop dabigatran and give idarucizumab 5g intravenously (Correct Answer)
B. Reduce dabigatran dose to 110mg twice daily and monitor
C. Stop dabigatran, give tranexamic acid, and observe
D. Switch from dabigatran to apixaban at reduced dose
E. Continue dabigatran but increase monitoring frequency

Explanation: ***Stop dabigatran and give idarucizumab 5g intravenously*** - The patient presents with **life-threatening bleeding** (haematuria, dizziness, hypotension) exacerbated by **dabigatran accumulation** due to acute kidney injury (eGFR 25 ml/min/1.73m²), where dabigatran is contraindicated. - **Idarucizumab** is the specific and immediate reversal agent for dabigatran, rapidly neutralizing its anticoagulant effect, which is critical in an emergency with **hemodynamic instability**. *Reduce dabigatran dose to 110mg twice daily and monitor* - Reducing the dose is insufficient and dangerous in the context of **active, significant bleeding** with **hemodynamic compromise**. - Dabigatran is largely renally cleared, and its use is **contraindicated** with an eGFR below 30 ml/min/1.73m², making a dose reduction inappropriate and ineffective for managing the current crisis. *Stop dabigatran, give tranexamic acid, and observe* - While stopping dabigatran is correct, **tranexamic acid** is an antifibrinolytic and does not directly reverse the **thrombin inhibition** caused by dabigatran. - **Observation** is unsafe given the patient's **hypotension** and potential for ongoing severe bleeding due to the accumulated dabigatran, which requires immediate and specific reversal. *Switch from dabigatran to apixaban at reduced dose* - Switching to another anticoagulant, even at a reduced dose, is absolutely **contraindicated** during an episode of **active bleeding** with hemodynamic instability. - The immediate priority is to stop the bleeding and reverse the existing anticoagulation, not to introduce a different anticoagulant. *Continue dabigatran but increase monitoring frequency* - Continuing dabigatran is medically **negligent** as the patient is actively bleeding, hypotensive, and has severe renal impairment leading to drug accumulation. - Increasing monitoring frequency does not address the **active bleeding** or the **toxic accumulation** of the drug and would delay critical intervention.

Question 229: A 52-year-old woman is started on amiodarone for recurrent atrial fibrillation. According to safe prescribing principles, which baseline investigation is most critical before initiating this medication?

A. Echocardiography to assess left ventricular function
B. Thyroid function tests, liver function tests, and chest radiograph (Correct Answer)
C. 24-hour Holter monitor to assess arrhythmia burden
D. Serum electrolytes including calcium and magnesium
E. Full blood count and coagulation screen

Explanation: ***Thyroid function tests, liver function tests, and chest radiograph*** - **Amiodarone** is known for its wide range of **extra-cardiac toxicities**, notably affecting the **thyroid** (due to high iodine content), **liver** (hepatotoxicity), and **lungs** (pulmonary fibrosis). - Baseline **thyroid function tests (TFTs)**, **liver function tests (LFTs)**, and a **chest radiograph (CXR)** are crucial to establish a baseline for monitoring these potential adverse effects throughout treatment. *Echocardiography to assess left ventricular function* - While an **echocardiogram** is valuable for diagnosing and assessing the underlying **cardiac pathology** contributing to atrial fibrillation, it is not primarily a *safety monitoring* test for amiodarone's *side effects*. - Amiodarone is considered a relatively **cardiac-safe antiarrhythmic**, especially in patients with **structural heart disease** or **heart failure**, making baseline LV function assessment less critical for drug safety *monitoring* compared to other organ systems. *24-hour Holter monitor to assess arrhythmia burden* - A **24-hour Holter monitor** is used to quantify the frequency and type of **arrhythmia**, which helps in assessing treatment efficacy, not for pre-treatment safety screening for amiodarone's known **toxicities**. - This investigation evaluates the *disease state* rather than the *patient's physiological readiness* for the drug's specific side effect profile. *Serum electrolytes including calcium and magnesium* - **Electrolyte imbalances** like **hypokalemia** and **hypomagnesemia** are important to correct before initiating *any* antiarrhythmic, as they can predispose to **proarrhythmia**, particularly **Torsades de Pointes**. - However, amiodarone's primary and most critical baseline monitoring targets its unique **multi-organ toxicity** (thyroid, liver, lung), making TFTs, LFTs, and CXR more specifically critical as *baseline safety investigations* for *this particular drug*. *Full blood count and coagulation screen* - **Amiodarone** does not typically cause **bone marrow suppression** or have direct, significant effects on the **coagulation cascade** that would necessitate a baseline **full blood count (FBC)** or **coagulation screen** as a primary safety measure. - While amiodarone can **potentiate oral anticoagulants** like **warfarin**, requiring closer **INR monitoring**, a baseline coagulation screen is not a specific safety requirement for amiodarone *itself* but rather for the **drug interaction** with other medications.

Question 230: A 67-year-old man taking warfarin for atrial fibrillation requires urgent dental extraction. His INR is 2.8 (target range 2-3). The dentist requests advice on anticoagulation management. What is the most appropriate recommendation?

A. Stop warfarin 5 days before procedure and restart immediately after
B. Continue warfarin and proceed with dental extraction (Correct Answer)
C. Stop warfarin 2 days before procedure and use bridging low molecular weight heparin
D. Reduce warfarin dose by 50% for 3 days before procedure
E. Stop warfarin and give 2mg oral vitamin K the day before procedure

Explanation: ***Continue warfarin and proceed with dental extraction*** - For minor surgical procedures with low bleeding risk, such as **dental extractions**, current guidelines recommend continuing **warfarin** if the **INR is < 4.0**. - The risk of **thromboembolic events** (e.g., stroke) from stopping anticoagulation outweighs the risk of local bleeding, which can be managed with **tranexamic acid mouthwash** or sutures. *Stop warfarin 5 days before procedure and restart immediately after* - Stopping warfarin for 5 days is unnecessary for **minor dentistry** and significantly increases the risk of **thromboembolism** in a patient with atrial fibrillation. - This approach is typically reserved for major surgeries with **high bleeding risk** where the INR must be < 1.5. *Stop warfarin 2 days before procedure and use bridging low molecular weight heparin* - **Bridging therapy** is not indicated for minor dental procedures and unnecessarily increases the cost and patient discomfort. - Bridging is usually reserved for patients with a very high **thromboembolic risk** (e.g., mechanical heart valves) undergoing major elective surgery. *Reduce warfarin dose by 50% for 3 days before procedure* - Reducing the dose is unpredictable and may lead to a **sub-therapeutic INR**, leaving the patient unprotected against **embolic stroke**. - There is no clinical evidence to support simple dose reduction for managing perioperative bleeding risk in **simple extractions**. *Stop warfarin and give 2mg oral vitamin K the day before procedure* - **Vitamin K** is used for reversing over-anticoagulation in cases of **excessive INR** or major bleeding, not for routine preoperative management. - Administering Vitamin K makes it difficult to re-establish a **therapeutic INR** postoperatively, extending the period of stroke risk.

Question 231: A 29-year-old woman with type 1 diabetes is found unconscious at home by her partner. Paramedics measure her blood glucose at 1.8 mmol/L. She has no intravenous access available. What is the most appropriate immediate treatment?

A. Administer 1mg intramuscular glucagon (Correct Answer)
B. Administer 15g oral glucose gel into buccal cavity
C. Administer 75ml of 20% glucose via intraosseous route
D. Establish intravenous access and give 100ml 10% glucose
E. Administer 10 units intramuscular rapid-acting insulin

Explanation: ***Administer 1mg intramuscular glucagon*** - In an **unconscious patient** with severe hypoglycaemia (1.8 mmol/L) and **no intravenous access**, IM glucagon is the first-line treatment to stimulate **hepatic glycogenolysis**. - It is effective, can be administered quickly by paramedics, and typically raises blood glucose levels within **10-15 minutes**. *Administer 15g oral glucose gel into buccal cavity* - Oral treatments, including glucose gels, are strictly **contraindicated** in unconscious patients due to the high risk of **aspiration**. - Absorption through the buccal mucosa is **unreliable and slow** compared to parenteral routes in an emergency setting. *Administer 75ml of 20% glucose via intraosseous route* - The **intraosseous (IO) route** is technically demanding and requires specialist equipment, making it a secondary option when **IM glucagon** can be given more easily. - IO access is generally reserved for **resuscitation** scenarios after both IV and IM options have been considered or failed. *Establish intravenous access and give 100ml 10% glucose* - While **IV glucose** is the preferred treatment for severe hypoglycaemia, attempting to establish access in a collapsed patient can cause **dangerous delays**. - The priority is to provide immediate glucose-raising therapy via the **intramuscular route** since the patient currently lacks access. *Administer 10 units intramuscular rapid-acting insulin* - Insulin lowers blood glucose; administering it to a patient with a level of 1.8 mmol/L would be **fatal**. - This intervention would worsen the **neuroglycopenia** and potentially lead to irreversible brain damage or death.

Question 232: A 71-year-old woman with atrial fibrillation on warfarin (target INR 2-3) presents with epistaxis. Her INR is 7.2. She has no other bleeding and is haemodynamically stable. According to current guidelines, what is the most appropriate immediate management?

A. Give 5mg intravenous vitamin K and 4-factor prothrombin complex concentrate
B. Give 5mg oral vitamin K and withhold warfarin until INR in target range
C. Withhold 1-2 doses of warfarin and recheck INR daily
D. Give 1-2mg intravenous vitamin K and withhold warfarin (Correct Answer)
E. Give fresh frozen plasma and withhold warfarin

Explanation: ***Give 1-2mg intravenous vitamin K and withhold warfarin***- For a patient with an **elevated INR (5.0-9.0)** and **minor bleeding** like epistaxis, guidelines recommend **1-2mg intravenous Vitamin K** to achieve rapid partial reversal. - This dose helps reduce the bleeding risk without causing **prolonged warfarin resistance**, facilitating easier re-warfarinisation when appropriate. Warfarin must also be withheld.*Give 5mg intravenous vitamin K and 4-factor prothrombin complex concentrate*- **Prothrombin complex concentrate (PCC)** and high-dose Vitamin K are reserved for **major or life-threatening bleeding** (e.g., intracranial hemorrhage, hemodynamic instability). - Administering PCC in a hemodynamically stable patient with minor epistaxis carries an unnecessary risk of **thromboembolic events**.*Give 5mg oral vitamin K and withhold warfarin until INR in target range*- While **oral Vitamin K** is suitable for high INR without bleeding, the **intravenous route** is preferred for active bleeding due to its faster onset of action. - A **5mg dose** of Vitamin K is often higher than needed for minor bleeding and may lead to **prolonged warfarin resistance**, complicating future anticoagulation.*Withhold 1-2 doses of warfarin and recheck INR daily*- This strategy is appropriate for patients with an **INR between 4.5 and 8.0** who have **no bleeding**. - Since the patient is actively bleeding (epistaxis), merely withholding warfarin is insufficient; active reversal with **Vitamin K** is indicated to promptly reduce the bleeding risk.*Give fresh frozen plasma and withhold warfarin*- **Fresh frozen plasma (FFP)** is less effective than **PCC** for rapid warfarin reversal, requiring larger volumes and posing risks of **volume overload**. - FFP is generally considered only if PCC is unavailable or contraindicated, and primarily for **major, life-threatening hemorrhage**, not minor epistaxis in a stable patient.

Question 233: A 56-year-old man with type 2 diabetes is admitted with pneumonia. His regular medications include metformin 1g twice daily and gliclazide 80mg twice daily. On admission, his blood glucose is 18.2 mmol/L, serum creatinine 156 μmol/L (baseline 95 μmol/L), lactate 3.2 mmol/L, and he is haemodynamically stable. What is the most appropriate management of his diabetic medications?

A. Continue both metformin and gliclazide at current doses
B. Stop metformin, continue gliclazide, and start variable rate intravenous insulin infusion
C. Stop metformin and gliclazide, start fixed dose subcutaneous insulin
D. Continue gliclazide, stop metformin temporarily, and add basal-bolus insulin regime (Correct Answer)
E. Reduce metformin dose by 50%, continue gliclazide, and monitor closely

Explanation: ***Continue gliclazide, stop metformin temporarily, and add basal-bolus insulin regime*** - **Metformin** must be withheld due to the presence of **acute kidney injury (AKI)** evidenced by a rising creatinine (156 μmol/L) and a raised **lactate** (3.2 mmol/L), which increases the risk of **lactic acidosis**. - A **basal-bolus insulin** regimen is the preferred method for managing **hyperglycemia** (18.2 mmol/L) in a non-critically ill, hemodynamically stable patient who is eating and drinking during an acute infection. *Continue both metformin and gliclazide at current doses* - Continuing metformin in the setting of **AKI** and **sepsis** is contraindicated because it can lead to toxic accumulation and **metformin-associated lactic acidosis (MALA)**. - This approach ignores the significant hyperglycemia, which requires more intensive titration than oral agents can provide during acute illness. *Stop metformin, continue gliclazide, and start variable rate intravenous insulin infusion* - **Variable rate intravenous insulin infusion (VRIII)** is usually reserved for patients who are **NBM (nil by mouth)**, hemodynamically unstable, or in **DKA/HHS**. - Since the patient is stable and likely consuming meals, **subcutaneous insulin** is safer and more appropriate for glycemic control. *Stop metformin and gliclazide, start fixed dose subcutaneous insulin* - While stopping metformin is correct, discontinuing all oral agents can lead to poor control if the **fixed-dose insulin** is not carefully calculated to cover basal and nutritional needs. - **Basal-bolus** regimens are superior to simple fixed-dose regimens as they offer better flexibility for glucose monitoring and meal-related adjustments. *Reduce metformin dose by 50%, continue gliclazide, and monitor closely* - Dose reduction is inappropriate in the context of an **acute rise** in creatinine and **elevated lactate**; complete temporary cessation is the standard safety protocol. - Simple monitoring without adding **insulin therapy** will not sufficiently address the severe hyperglycemia (18.2 mmol/L) caused by the **stress response** to pneumonia.

Question 234: A 45-year-old woman is prescribed azathioprine for Crohn's disease. Before starting treatment, thiopurine methyltransferase (TPMT) enzyme activity testing shows she has intermediate TPMT activity. What is the most appropriate prescribing action?

A. Start standard dose azathioprine with weekly full blood count monitoring
B. Start azathioprine at 50% of standard dose with increased monitoring (Correct Answer)
C. Avoid azathioprine completely and select an alternative agent
D. Start standard dose azathioprine with monthly full blood count monitoring
E. Start azathioprine at 75% of standard dose with standard monitoring

Explanation: ***Start azathioprine at 50% of standard dose with increased monitoring*** - Patients with **intermediate TPMT activity** (heterozygous) have a reduced capacity to metabolize azathioprine, leading to higher levels of active 6-TGN metabolites and increased risk of **myelosuppression**. - A **50% dose reduction** combined with frequent **full blood count (FBC)** monitoring allows for safe treatment while mitigating the risk of toxic side effects. *Start standard dose azathioprine with weekly full blood count monitoring* - Initiating a **standard dose** in a patient with reduced TPMT activity significantly increases the danger of rapid and severe **bone marrow suppression**. - Monitoring alone is insufficient to prevent toxicity if the initial dose exceeds the patient's metabolic capacity to clear the drug. *Avoid azathioprine completely and select an alternative agent* - **Complete avoidance** is typically reserved for patients with **absent TPMT activity** (homozygous deficiency), which occurs in roughly 0.3% of the population. - Patients with intermediate activity can still derive clinical benefit from **thiopurines** provided the dosage is carefully titrated downwards. *Start standard dose azathioprine with monthly full blood count monitoring* - **Monthly monitoring** is inadequate even for patients with normal TPMT activity during the initiation phase; it is dangerously infrequent for those at high risk. - A **standard dose** is contraindicated here as it would likely lead to toxic accumulations of active metabolites. *Start azathioprine at 75% of standard dose with standard monitoring* - A **75% dose** is often still too high for intermediate metabolizers and does not align with the safety margin provided by a **50% reduction**. - **Standard monitoring** is insufficient; these patients require **increased surveillance** to detect early signs of leucopenia or thrombocytopenia.

Question 235: A 74-year-old man with heart failure is taking spironolactone 25mg daily. His recent blood tests show potassium 5.8 mmol/L (normal range 3.5-5.0 mmol/L) and eGFR 42 ml/min/1.73m². Which medication from his regular list is most likely to be contributing to the hyperkalaemia alongside spironolactone?

A. Furosemide 40mg twice daily
B. Bisoprolol 5mg once daily
C. Ramipril 5mg once daily (Correct Answer)
D. Digoxin 125mcg once daily
E. Atorvastatin 40mg once daily

Explanation: ***Ramipril 5mg once daily*** - **ACE inhibitors** like ramipril block the conversion of angiotensin I to angiotensin II, leading to decreased **aldosterone** secretion and reduced renal **potassium excretion**. - Using an ACE inhibitor concurrently with **spironolactone** (a potassium-sparing diuretic) significantly increases the risk of **hyperkalaemia**, especially in patients with **renal impairment** (eGFR < 60 ml/min/1.73m²). *Furosemide 40mg twice daily* - Furosemide is a **loop diuretic** that typically promotes the excretion of potassium in the urine, leading to **hypokalaemia** rather than hyperkalaemia. - It is often used to counteract the potassium-retaining effects of drugs like spironolactone, making it an unlikely cause of elevated potassium. *Bisoprolol 5mg once daily* - Bisoprolol is a **beta-blocker** used in heart failure management that generally has a **minimal effect** on serum potassium levels at therapeutic doses. - While beta-blockers can theoretically interfere with potassium shift into cells, they are not a primary driver of clinically significant **hyperkalaemia** compared to mineralocorticoid antagonists. *Digoxin 125mcg once daily* - Digoxin inhibits the **Na+/K+-ATPase pump**, but significant hyperkalaemia is usually only seen in cases of **acute toxicity** or severe overdose. - In therapeutic doses, it does not typically contribute to the chronic elevation of potassium levels observed in this patient. *Atorvastatin 40mg once daily* - Atorvastatin is an **HMG-CoA reductase inhibitor** used for lipid lowering and has **no direct mechanism** or clinical association with serum potassium elevation. - Its primary monitoring requirements involve **liver enzymes** and **creatine kinase**, not electrolyte balances.

Question 236: A 62-year-old woman with hypertension and chronic kidney disease (eGFR 35 ml/min/1.73m²) is prescribed an angiotensin-converting enzyme (ACE) inhibitor. According to national prescribing guidelines, what is the most appropriate timeframe for checking her renal function after initiating therapy?

A. After 3 months of starting treatment
B. Within 24 hours of starting treatment
C. After 1-2 weeks of starting treatment (Correct Answer)
D. After 4 weeks of starting treatment
E. Only if symptoms of renal impairment develop

Explanation: ***After 1-2 weeks of starting treatment***- National guidelines recommend monitoring **renal function (U&Es)** and **potassium levels** within 1 to 2 weeks of initiating an **ACE inhibitor** or increasing the dose.- This timeframe is critical for identifying potential **acute kidney injury** or significant **hyperkalemia**, especially in high-risk patients with pre-existing **Chronic Kidney Disease (CKD)**.*Within 24 hours of starting treatment*- Monitoring within 24 hours is unnecessarily frequent and usually too early to see the full physiologic impact of **efferent arteriolar vasodilation** on serum creatinine.- This level of urgency is typically reserved for patients with **acute clinical instability** rather than routine outpatient management of hypertension or CKD.*After 4 weeks of starting treatment*- Waiting 4 weeks is considered too long for a patient with an **eGFR of 35 ml/min**, as significant renal deterioration could occur undetected.- Early detection is required to manage a rise in **creatinine** (acceptable up to 30%) or a dangerous rise in **potassium** early in the course of therapy.*After 3 months of starting treatment*- This timeframe is appropriate for **routine maintenance monitoring** once a patient is on a stable, long-term dose of an ACE inhibitor.- It is unsafe for the initial **titration phase**, where the risk of **renal dysfunction** and electrolyte imbalance is at its highest.*Only if symptoms of renal impairment develop*- **Renal impairment** and **hyperkalemia** are often asymptomatic until they become severe or life-threatening.- Relying on symptoms rather than **biochemical monitoring** is dangerous and contradicts standard safety protocols for drugs affecting the **Renin-Angiotensin-Aldosterone System (RAAS)**.

Question 237: A 68-year-old man with venous thromboembolism is established on apixaban. He develops acute kidney injury with his eGFR dropping from 65ml/min/1.73m² to 22ml/min/1.73m² secondary to sepsis. His weight is 80kg. What is the most appropriate modification to his anticoagulation?

A. Continue apixaban at current dose as it is minimally renally excreted
B. Reduce apixaban dose from 5mg twice daily to 2.5mg twice daily
C. Switch to warfarin with target INR 2-3 (Correct Answer)
D. Stop apixaban and give prophylactic dose LMWH
E. Stop apixaban and start intravenous unfractionated heparin infusion

Explanation: ***Switch to warfarin with target INR 2-3*** - Apixaban is **contraindicated** or should be used with extreme caution when the **creatinine clearance** falls below 15-30 ml/min due to the risk of drug accumulation and major hemorrhage. - **Warfarin** is the preferred long-term anticoagulant in severe renal impairment (CKD stage 4/5) because it is metabolized by the **liver** and its effect is easily monitored via **INR**. *Continue apixaban at current dose as it is minimally renally excreted* - Approximately **27% of apixaban** is renally excreted, making it the least renally cleared DOAC, but still unsafe at an **eGFR of 22 ml/min**. - Continuing the full dose during **acute kidney injury** significantly increases the patient's risk of life-threatening bleeding. *Reduce apixaban dose from 5mg twice daily to 2.5mg twice daily* - Dose reduction criteria for apixaban (age ">=80, weight ">=60kg, or creatinine ">=133 mol/L) applies primarily to **atrial fibrillation**, not necessarily therapeutic VTE treatment in acute failure. - Even at a reduced dose, the safety profile of apixaban is not well-established for patients with an **eGFR <30 ml/min** in the context of active VTE treatment. *Stop apixaban and give prophylactic dose LMWH* - **Low Molecular Weight Heparin (LMWH)** is renally excreted and will accumulate in a patient with an **eGFR of 22 ml/min**, increasing bleeding risk. - A **prophylactic dose** is insufficient for a patient who has established **venous thromboembolism (VTE)** and requires therapeutic-grade anticoagulation. *Stop apixaban and start intravenous unfractionated heparin infusion* - While **Unfractionated Heparin (UFH)** is safe in renal failure, it requires **continuous intravenous access** and intensive APTT monitoring, making it impractical for stable long-term management outside of an acute hospital setting. - UFH is typically reserved for the **initial stabilization** of unstable VTE or perioperative bridging, rather than a long-term alternative for stable outpatients.

Question 238: A 38-year-old woman with newly diagnosed type 1 diabetes is being initiated on insulin therapy. She weighs 70kg. Following best practice guidelines for initial insulin dosing in type 1 diabetes, what would be the most appropriate total daily insulin dose to start?

A. 20 units (0.3 units/kg/day) split as 50% basal and 50% bolus
B. 35 units (0.5 units/kg/day) split as 50% basal and 50% bolus (Correct Answer)
C. 70 units (1.0 units/kg/day) split as 40% basal and 60% bolus
D. 14 units (0.2 units/kg/day) as basal insulin only
E. 105 units (1.5 units/kg/day) split as 50% basal and 50% bolus

Explanation: ***35 units (0.5 units/kg/day) split as 50% basal and 50% bolus*** - For a newly diagnosed adult with **Type 1 Diabetes**, the standard initial **Total Daily Dose (TDD)** is typically **0.4 to 0.6 units/kg/day**. For a 70kg patient, 0.5 units/kg/day equals 35 units. - This dose is ideally split into **50% basal insulin** to suppress hepatic glucose production between meals and **50% bolus (prandial) insulin** to cover carbohydrate intake. *20 units (0.3 units/kg/day) split as 50% basal and 50% bolus* - An initial dose of **0.3 units/kg/day** is often considered too low for an adult with T1DM and may result in persistent **hyperglycemia** during the initiation phase. - While safer for patients with high insulin sensitivity or those in a **'honeymoon phase'**, it is not the standard starting recommendation for a typical 70kg adult. *70 units (1.0 units/kg/day) split as 40% basal and 60% bolus* - Starting at **1.0 units/kg/day** is excessively high for a fresh diagnosis and carries a significant risk of severe **iatrogenic hypoglycemia**. - Such high doses are generally reserved for patients with significant **insulin resistance**, such as those with obesity or during acute **illness/sepsis**. *14 units (0.2 units/kg/day) as basal insulin only* - **Basal-only regimens** are inappropriate for Type 1 Diabetes because these patients have an **absolute insulin deficiency** and require prandial coverage to manage post-meal glucose spikes. - Using only basal insulin at such a low dose would likely lead to inadequate glycemic control and a potential risk of **diabetic ketoacidosis (DKA)**. *105 units (1.5 units/kg/day) split as 50% basal and 50% bolus* - A dose of **1.5 units/kg/day** is extremely aggressive and dangerous for an initial prescription in a non-obese patient. - This level of dosing is far beyond the physiological requirement for a newly diagnosed patient and would almost certainly cause **hypoglycemic emergencies**.

Question 239: A 55-year-old man with rheumatoid arthritis has been on methotrexate 20mg weekly for 3 years with good disease control. He attends for routine monitoring bloods. Results show: Hb 142g/L, WCC 3.2×10⁹/L, neutrophils 1.6×10⁹/L, platelets 178×10⁹/L, ALT 68 U/L (normal 10-40), AST 58 U/L (normal 10-40), ALP 82 U/L (normal 30-130), bilirubin 14 μmol/L (normal 3-17). He is asymptomatic. What is the most appropriate management?

A. Stop methotrexate permanently due to hepatotoxicity
B. Continue methotrexate and recheck liver function in 2 weeks
C. Reduce methotrexate dose to 15mg weekly and recheck bloods in 1 week
D. Temporarily withhold methotrexate and recheck liver function in 1-2 weeks; consider restarting at reduced dose if improving (Correct Answer)
E. Continue methotrexate but add ursodeoxycholic acid for hepatoprotection

Explanation: ***Temporarily withhold methotrexate and recheck liver function in 1-2 weeks; consider restarting at reduced dose if improving*** - The patient's **ALT** and **AST** are elevated (ALT 1.7x ULN, AST 1.45x ULN), along with mild **neutropenia**, indicating **methotrexate toxicity**. - Temporarily withholding the drug allows the liver and bone marrow to recover, and subsequent **dose reduction** upon improvement helps prevent recurrence while maintaining disease control. *Stop methotrexate permanently due to hepatotoxicity* - Permanent discontinuation is typically reserved for more severe adverse effects, such as persistent **ALT/AST** elevation >3 times the **ULN** despite temporary withdrawal, or signs of significant **liver damage** like fibrosis. - In this case, the **transaminase** elevation is moderate, and the patient is asymptomatic, suggesting that the toxicity is likely reversible with appropriate management. *Continue methotrexate and recheck liver function in 2 weeks* - Continuing **methotrexate** at the current dose with elevated **liver enzymes** and **neutropenia** risks exacerbating **hepatotoxicity** and **myelosuppression**. - Monitoring guidelines mandate intervention, such as dose adjustment or temporary cessation, when **transaminase levels** exceed 1.5-2 times the **ULN**. *Reduce methotrexate dose to 15mg weekly and recheck bloods in 1 week* - While **dose reduction** might be part of the long-term management, the initial step for elevated **liver enzymes** and **myelosuppression** is usually a temporary cessation to allow for recovery. - A direct dose reduction without a brief drug holiday may not be sufficient to adequately reverse the observed **toxicity** and ensure patient safety. *Continue methotrexate but add ursodeoxycholic acid for hepatoprotection* - **Ursodeoxycholic acid** is primarily used to dissolve gallstones or treat **cholestatic liver diseases** like **Primary Biliary Cholangitis** by altering bile acid composition. - It has no established role or evidence in preventing or treating **methotrexate-induced hepatotoxicity**, which is a direct cytotoxic effect on hepatocytes.

Question 240: A 70-year-old man with atrial fibrillation is on rivaroxaban 20mg once daily. He undergoes emergency surgery for a ruptured appendix. His last dose of rivaroxaban was 8 hours ago. He is bleeding significantly during surgery. What is the most appropriate management for rivaroxaban reversal?

A. Administer vitamin K 10mg intravenously
B. Administer prothrombin complex concentrate (PCC) 50 units/kg
C. Administer andexanet alfa if available, or PCC if not (Correct Answer)
D. Administer fresh frozen plasma 15-20ml/kg
E. Administer tranexamic acid 1g intravenously

Explanation: ***Administer andexanet alfa if available, or PCC if not*** - **Andexanet alfa** is the specific, licensed reversal agent for **Factor Xa inhibitors** like rivaroxaban; it acts as a **decoy receptor** to neutralize the drug's effect. - In life-threatening or uncontrolled bleeding where the last dose was recent (~8 hours), **prothrombin complex concentrate (PCC)** is the secondary recommendation if andexanet is unavailable. *Administer vitamin K 10mg intravenously* - **Vitamin K** is only effective for reversing **Vitamin K Antagonists** (e.g., Warfarin) by assisting the synthesis of factors II, VII, IX, and X. - It has no role in reversing **Direct Oral Anticoagulants (DOACs)** like rivaroxaban, which inhibit clotting factors directly. *Administer prothrombin complex concentrate (PCC) 50 units/kg* - While 4-factor **PCC** is used when specific agents are unavailable, it is not the primary choice if **andexanet alfa** is on hand. - PCC works by providing a high concentration of **clotting factors** to overwhelm the inhibitor, but it does not directly neutralize the rivaroxaban molecule. *Administer fresh frozen plasma 15-20ml/kg* - **Fresh Frozen Plasma (FFP)** is generally ineffective for DOAC reversal because it requires **excessive volumes** to achieve the necessary concentration of factors. - Using FFP carries a significant risk of **transfusion-associated circulatory overload (TACO)** and is not recommended over PCC or specific antidotes. *Administer tranexamic acid 1g intravenously* - **Tranexamic acid** is an **antifibrinolytic** that prevents the breakdown of clots; it is a supportive measure rather than a direct reversal agent. - While often used in major trauma or surgical bleeding, it cannot reverse the **Factor Xa inhibition** caused by rivaroxaban.

Question 241: A 42-year-old woman with type 2 diabetes on insulin presents to the emergency department following accidental administration of 50 units of rapid-acting insulin (insulin aspart) instead of her usual 10 units. This was given 30 minutes ago. Her current blood glucose is 8.2mmol/L and she is asymptomatic. What is the most appropriate immediate management strategy?

A. Administer 50ml of 50% glucose intravenously immediately
B. Observe for 2 hours with blood glucose monitoring every 15 minutes and treat hypoglycemia if it develops
C. Give 100ml of 20% glucose intravenously followed by 10% glucose infusion with close monitoring for at least 12 hours (Correct Answer)
D. Administer intramuscular glucagon 1mg and discharge with advice
E. Give oral glucose 20g and recheck blood glucose in 15 minutes

Explanation: ***Give 100ml of 20% glucose intravenously followed by 10% glucose infusion with close monitoring for at least 12 hours*** - This represents a significant **insulin overdose**; since rapid-acting insulin peaks within 1-3 hours, proactive **intravenous glucose** is required to prevent severe, life-threatening hypoglycemia. - A 10% or 20% dextrose infusion provides a steady supply of glucose, and monitoring for **at least 12 hours** is necessary to ensure the pharmacological effect of the large insulin dose has fully dissipated. *Administer 50ml of 50% glucose intravenously immediately* - **50% dextrose** is highly hypertonic, irritating to veins (thrombophlebitis risk), and is generally reserved for patients in an actual **hypoglycemic coma**. - Administering it while the patient is currently **normoglycemic** (8.2 mmol/L) could cause unnecessary **rebound hyperglycemia** and does not provide the sustained coverage needed for an overdose. *Observe for 2 hours with blood glucose monitoring every 15 minutes and treat hypoglycemia if it develops* - A **2-hour observation** is insufficient because the metabolic effects and potential hypoglycemia from a 50-unit insulin aspart overdose can persist beyond this window. - Waiting for **neuroglycopenia** or symptomatic hypoglycemia to develop before acting is unsafe in the context of a known massive **medication error**. *Administer intramuscular glucagon 1mg and discharge with advice* - **Glucagon** has a very short duration of action and is often less effective in **Type 2 Diabetes** patients who may have depleted glycogen stores. - Discharge is contraindicated; significant insulin overdoses require **inpatient admission** due to the high risk of delayed, severe hypoglycemia. *Give oral glucose 20g and recheck blood glucose in 15 minutes* - While **oral glucose** is used for mild, symptomatic hypoglycemia, it is insufficient to counteract the potent, sustained glucose-lowering effect of a **5-fold insulin overdose**. - Relying solely on oral intake risks a sudden drop in consciousness, which would then necessitate **unprotected airway** management and emergency IV access.

Question 242: A 65-year-old woman with mechanical mitral valve replacement is on warfarin with target INR 2.5-3.5. She is scheduled for dental extraction in 2 weeks. Her current INR is 3.0. What is the most appropriate peri-procedural anticoagulation management?

A. Continue warfarin without interruption as dental procedures are low-bleeding risk (Correct Answer)
B. Stop warfarin 5 days before procedure, bridge with therapeutic LMWH, restart warfarin post-procedure
C. Stop warfarin 3 days before procedure, no bridging required, restart warfarin evening of procedure
D. Switch to DOAC 2 weeks before procedure for easier management
E. Stop warfarin 5 days before, start IV heparin infusion, stop 4 hours before procedure

Explanation: ***Continue warfarin without interruption as dental procedures are low-bleeding risk***- Dental extractions are considered **low-bleeding risk** procedures, and the risk of **thromboembolism** from stopping anticoagulation in a patient with a mechanical mitral valve outweighs the risk of minor local hemorrhage.- Guidelines recommend continuing **warfarin** if the **INR is within the therapeutic range** (typically <3.5 or 4.0), and using local hemostatic measures like **tranexamic acid** mouthwash or suturing to manage any minor bleeding. *Stop warfarin 5 days before procedure, bridge with therapeutic LMWH, restart warfarin post-procedure* - **Bridging anticoagulation** with low molecular weight heparin (LMWH) is not required for **minor dental procedures** and significantly increases the risk of **post-operative bleeding** without providing additional thrombotic protection. - While the patient has a **mechanical mitral valve** (high thrombotic risk), the low-bleeding-risk nature of the procedure means routine interruption and bridging are unnecessary and potentially harmful. *Stop warfarin 3 days before procedure, no bridging required, restart warfarin evening of procedure* - Stopping **warfarin** for 3 days without any bridging in a patient with a **mechanical mitral valve** exposes them to a high risk of **valve thrombosis** and systemic **embolism** due to an extended period of subtherapeutic anticoagulation. - This approach is inappropriate as it creates a significant **anticoagulation gap** for a patient at high thrombotic risk, without sufficient justification given the procedure's low bleeding risk. *Switch to DOAC 2 weeks before procedure for easier management* - **Direct Oral Anticoagulants (DOACs)** are **contraindicated** in patients with **mechanical prosthetic heart valves** due to an increased risk of thromboembolic events and valve thrombosis. - Patients with mechanical valves must remain on **Vitamin K Antagonists** like warfarin for life-long anticoagulation. *Stop warfarin 5 days before, start IV heparin infusion, stop 4 hours before procedure* - **IV heparin bridging** is reserved for high-thrombotic-risk patients undergoing **major surgical procedures** with high bleeding risk, not for low-bleeding-risk minor dental work. - This strategy is excessively invasive, carries its own risks (e.g., heparin-induced thrombocytopenia), and increases the complexity and **cost of care** unnecessarily for a simple dental extraction.

Question 243: A 28-year-old man with newly diagnosed epilepsy is started on sodium valproate. What is the single most important baseline investigation that must be performed before starting sodium valproate?

A. Serum ammonia levels
B. Genetic testing for mitochondrial disorders
C. Electroencephalogram (EEG)
D. Full blood count and liver function tests (Correct Answer)
E. Pregnancy test if female of childbearing potential

Explanation: ***Full blood count and liver function tests*** - **Sodium valproate** is associated with rare but severe **hepatotoxicity**, making baseline **liver function tests (LFTs)** mandatory to identify pre-existing hepatic disease. - It can also cause **thrombocytopenia** and other blood dyscrasias, necessitating a baseline **Full Blood Count (FBC)** for subsequent monitoring. *Serum ammonia levels* - **Hyperammonemia** is a known side effect of valproate, but levels are typically only measured if the patient develops signs of **encephalopathy**. - It is not a standard baseline investigation as it does not reliably predict the development of future **valproate-induced toxicity**. *Electroencephalogram (EEG)* - An **EEG** is vital for the **diagnosis and classification** of epilepsy syndromes, but it is not a safety-related prerequisite for starting medication. - The decision to treat is based on clinical diagnosis; the EEG helps guide drug choice but does not monitor for **drug adverse effects**. *Pregnancy test if female of childbearing potential* - While the **Valproate Pregnancy Prevention Programme** makes this crucial for females due to **teratogenicity**, the patient in this scenario is a **28-year-old man**. - For a male patient, this investigation is irrelevant and does not form part of his mandatory **pre-treatment safety screening**. *Genetic testing for mitochondrial disorders* - This is indicated primarily in children with suspected **Alpers-Huttenlocher syndrome** due to the high risk of **acute liver failure** with valproate. - It is not a routine baseline requirement for an **adult male** unless there is a specific family history or clinical suspicion of a **mitochondrial disorder**.

Question 244: A 82-year-old woman with atrial fibrillation is on warfarin with stable INR of 2.5. She develops a urinary tract infection and the GP prescribes a 7-day course of antibiotics. Which antibiotic would be most likely to significantly increase her INR?

A. Nitrofurantoin 100mg twice daily
B. Trimethoprim 200mg twice daily (Correct Answer)
C. Cefalexin 500mg three times daily
D. Amoxicillin 500mg three times daily
E. Fosfomycin 3g single dose

Explanation: ***Trimethoprim 200mg twice daily*** - **Trimethoprim** is a potent inhibitor of the **CYP2C9** enzyme, which is primarily responsible for the metabolism of **S-warfarin**, the more active isomer. - This inhibition significantly reduces **warfarin clearance**, leading to a rapid and substantial increase in **INR** and a high risk of bleeding. *Nitrofurantoin 100mg twice daily* - **Nitrofurantoin** has minimal interaction with the cytochrome P450 system and is not known to inhibit warfarin metabolism. - It is generally considered a **safer antibiotic** choice for patients on warfarin, with a low risk of significant INR fluctuations. *Cefalexin 500mg three times daily* - **Cefalexin**, a **cephalosporin**, does not inhibit the enzymes responsible for warfarin metabolism and usually has a **negligible effect** on INR. - Significant clinical interactions are rare unless a patient has a severe pre-existing **vitamin K deficiency**. *Amoxicillin 500mg three times daily* - **Amoxicillin** is not a known enzyme inhibitor and does not significantly interfere with the **pharmacokinetics** of warfarin. - It is frequently used for infections in warfarinized patients with **stable INR** profiles and typically requires no dose adjustments. *Fosfomycin 3g single dose* - A single dose of **fosfomycin** has a very short duration of action and no known interaction with the **cytochrome P450 system**. - Its lack of systemic metabolic interference makes it an **excellent alternative** for treating uncomplicated UTIs in patients on therapeutic anticoagulation.

Question 245: A 76-year-old man is prescribed lithium carbonate for bipolar affective disorder. Which of the following is the most appropriate monitoring schedule for lithium therapy?

A. Lithium levels weekly for first month, then monthly thereafter
B. Lithium levels at 12 hours post-dose weekly until stable, then every 3 months with 6-monthly renal and thyroid function (Correct Answer)
C. Lithium levels and full blood count monthly for first year
D. Lithium levels daily for first week, then weekly for 3 months
E. Lithium levels every 6 months with annual renal function tests

Explanation: ***Lithium levels at 12 hours post-dose weekly until stable, then every 3 months with 6-monthly renal and thyroid function***- Serum **lithium levels** should be measured **12 hours post-dose** to ensure they fall within the narrow therapeutic range of **0.4 to 1.0 mmol/L**, with weekly checks initially until stability.- Routine monitoring requires **renal function (eGFR)** and **thyroid function tests (TFTs)** every **6 months** due to risks of nephrotoxicity and hypothyroidism.*Lithium levels weekly for first month, then monthly thereafter*- Weekly checks are appropriate until the dose is **stabilized**, but monthly thereafter is too frequent for stable maintenance and omits vital organ function tests.- For stable patients, monitoring intervals extend to every **3 months**, not monthly, and must include **renal and thyroid** function.*Lithium levels and full blood count monthly for first year*- A **full blood count (FBC)** is not a routine requirement for lithium monitoring; this test is generally associated with other psychotropic medications.- Monthly lithium levels are more frequent than required for a stable patient, and this option critically misses essential **renal and thyroid** function checks.*Lithium levels daily for first week, then weekly for 3 months*- **Daily lithium monitoring** is typically reserved for managing acute **lithium toxicity** or complex inpatient titration, not routine initiation.- Weekly monitoring for 3 months is excessive if a **stable serum level** is achieved earlier, and this schedule omits critical **renal and thyroid** monitoring.*Lithium levels every 6 months with annual renal function tests*- Monitoring lithium levels every **6 months** is only considered for very stable patients after the **first year** of treatment.- **Annual renal function** tests are inadequate, as lithium can cause **nephrogenic diabetes insipidus** and progressive renal decline, requiring at least **bi-annual** checks.

Question 246: A 34-year-old woman with type 1 diabetes is 10 weeks pregnant. She is currently on a basal-bolus insulin regimen with insulin glargine 20 units at night and insulin aspart with meals. Her HbA1c is 7.8% (62mmol/mol). What is the most appropriate modification to her diabetes management?

A. Switch to oral hypoglycemic agents as insulin crosses the placenta
B. Increase insulin doses to aim for pre-meal glucose 3.5-5.9mmol/L and 1-hour post-meal <7.8mmol/L (Correct Answer)
C. Reduce insulin doses by 50% to minimize risk of hypoglycemia
D. Switch to twice-daily mixed insulin for simplicity
E. Continue current regimen as HbA1c is acceptable in pregnancy

Explanation: ***Increase insulin doses to aim for pre-meal glucose 3.5-5.9mmol/L and 1-hour post-meal <7.8mmol/L*** - In pregnancy, **glycemic targets** are very strict to reduce the risk of **macrosomia**, congenital anomalies, and neonatal complications; an HbA1c of 7.8% is above the recommended target of **<6.5% (48 mmol/mol)**. - According to **NICE guidelines**, patients should aim for fasting/pre-meal levels between **3.5–5.3 mmol/L** and 1-hour post-meal levels **<7.8 mmol/L** to ensure optimal fetal outcomes. *Switch to oral hypoglycemic agents as insulin crosses the placenta* - **Type 1 diabetes** specifically requires **insulin therapy** because of absolute insulin deficiency; oral agents cannot replace insulin in these patients. - Most insulin formulations do **not cross the placenta** in significant amounts and are the safe, preferred treatment during pregnancy. *Reduce insulin doses by 50% to minimize risk of hypoglycemia* - Reducing doses would lead to **hyperglycemia**, which significantly increases the risk of **fetal malformations** and obstetric complications. - While the risk of **hypoglycemia** is higher in the first trimester, management involves frequent monitoring rather than prophylactic large-scale dose reductions. *Switch to twice-daily mixed insulin for simplicity* - **Mixed insulin** regimens are less flexible and make it difficult to achieve the precise **tight glycemic control** required in pregnancy. - A **basal-bolus regimen** is preferred as it allows for specific adjustments of mealtime (aspart) and background (glargine) insulin to meet changing metabolic demands. *Continue current regimen as HbA1c is acceptable in pregnancy* - An HbA1c of **7.8% (62 mmol/mol)** is considered high for pregnancy and is associated with increased risks of **preeclampsia** and adverse neonatal outcomes. - Treatment must be **intensified** immediately to bring the glucose levels into the target range as the pregnancy progresses into the second trimester.

Question 247: A 58-year-old man is started on direct oral anticoagulant (DOAC) therapy following a diagnosis of atrial fibrillation. His CHA₂DS₂-VASc score is 3. He has normal renal function (eGFR 78ml/min/1.73m²) and normal liver function. Which of the following statements about DOAC monitoring is correct?

A. INR monitoring is required monthly while on apixaban
B. Renal function should be checked at least annually (Correct Answer)
C. Full blood count monitoring is required every 3 months
D. Liver function tests are only needed if symptoms develop
E. Anti-Xa levels should be checked before each dose adjustment

Explanation: ***Renal function should be checked at least annually*** - For patients on **Direct Oral Anticoagulants (DOACs)** with a stable **eGFR >60 ml/min**, clinical guidelines recommend monitoring renal function at least **once every 12 months**. - More frequent monitoring is necessary if renal function declines, as DOAC clearance is heavily dependent on **renal excretion**, increasing the risk of toxicity. *INR monitoring is required monthly while on apixaban* - Unlike warfarin, DOACs like **apixaban** have a predictable effect and do not require **INR monitoring** or regular titration. - Using **INR** to monitor DOACs is clinically inappropriate as these drugs do not affect the **International Normalized Ratio** in a consistent or reliable way. *Full blood count monitoring is required every 3 months* - While a baseline **Full Blood Count (FBC)** is essential to screen for anemia, routine **three-monthly monitoring** is not a standard requirement for stable patients. - FBC is typically repeated **annually** or if clinical signs of **occult bleeding** or procedural needs arise. *Liver function tests are only needed if symptoms develop* - Guidelines state that **Liver Function Tests (LFTs)** should be checked at **baseline** and then at least **annually** for patients on chronic DOAC therapy. - Many DOACs, particularly **rivaroxaban** and **apixaban**, undergo significant **hepatic metabolism**, making regular assessment of liver health necessary for safe prescribing. *Anti-Xa levels should be checked before each dose adjustment* - **Anti-Xa assays** are not used for routine dose adjustments; dosing for DOACs is strictly based on clinical criteria like **age, weight, and creatinine clearance**. - Measurement of drug levels is reserved for **emergency situations**, such as major bleeding, suspected overdose, or before **urgent surgery**.

Question 248: A 55-year-old woman with rheumatoid arthritis on methotrexate 15mg weekly presents to the emergency department with a 3-day history of mouth ulcers, sore throat, and fever. Her full blood count shows: Hb 118g/L, WCC 1.2×10⁹/L, neutrophils 0.3×10⁹/L, platelets 245×10⁹/L. What is the most critical immediate action?

A. Prescribe oral folinic acid 15mg daily for 3 days
B. Stop methotrexate permanently and avoid restarting
C. Stop methotrexate and start broad-spectrum antibiotics immediately (Correct Answer)
D. Reduce methotrexate dose to 10mg weekly and continue monitoring
E. Continue methotrexate but add prophylactic co-trimoxazole

Explanation: ***Stop methotrexate and start broad-spectrum antibiotics immediately***- The patient presents with **febrile neutropenia**, characterized by a **neutrophil count of 0.3×10⁹/L** and fever, a critical and life-threatening complication of **methotrexate-induced myelosuppression**.- The most urgent immediate action is to stop the causative drug and initiate **empiric intravenous broad-spectrum antibiotics** promptly to manage the severe infection risk and prevent rapid clinical deterioration.*Prescribe oral folinic acid 15mg daily for 3 days*- **Folinic acid** is used as a rescue therapy to mitigate methotrexate toxicity by replenishing folate stores, but it does not address the immediate life-threatening **risk of sepsis**.- While important as an adjunctive measure, administering **broad-spectrum antibiotics** to treat the underlying infection takes precedence in the acute management of **febrile neutropenia**.*Stop methotrexate permanently and avoid restarting*- While methotrexate must be stopped immediately due to severe toxicity, **permanent discontinuation** is not always necessary and depends on the resolution of toxicity and assessment of precipitating factors.- A specialist may consider re-challenging with a lower dose or switching to another DMARD after full **bone marrow recovery** and careful risk assessment.*Reduce methotrexate dose to 10mg weekly and continue monitoring*- Continuing methotrexate, even at a reduced dose, is dangerously inappropriate in the presence of **severe myelosuppression** and active infection like **febrile neutropenia**.- Any evidence of **significant neutropenia** requires immediate cessation of the drug until the **full blood count** normalizes and the patient's condition stabilizes.*Continue methotrexate but add prophylactic co-trimoxazole*- Continuing methotrexate is contraindicated given the patient's severe myelosuppression and signs of infection.- **Co-trimoxazole** is known to increase methotrexate toxicity by displacing it from protein binding and decreasing its renal excretion, which would severely worsen the current **myelosuppression** rather than help.

Question 249: A 72-year-old man is started on digoxin for rate control in atrial fibrillation. Which of the following factors would require a dose reduction of digoxin?

A. Body weight of 95kg
B. eGFR of 35ml/min/1.73m² (Correct Answer)
C. Concurrent use of bisoprolol
D. History of hypertension
E. Age over 70 years alone

Explanation: ***eGFR of 35ml/min/1.73m²*** - **Digoxin** is primarily excreted by the **kidneys**; therefore, patients with **renal impairment** (eGFR < 50ml/min) require a dose reduction to avoid accumulation and toxicity. - An eGFR of 35ml/min/1.73m² (CKD stage 3b) significantly increases the risk of **digitalis toxicity**, which can result in life-threatening **arrhythmias**, nausea, and visual changes. *Body weight of 95kg* - Digoxin has a large **volume of distribution** and primarily distributes to **lean muscle mass**, so a higher total body weight does not typically necessitate a dose reduction. - Dose adjustments are usually only considered for patients with a very **low body mass** (e.g., <50kg) to avoid high serum concentrations. *Concurrent use of bisoprolol* - While both drugs have **negative chronotropic** effects and offer additive **rate control**, bisoprolol does not alter the **pharmacokinetics** (metabolism or excretion) of digoxin. - **Drug-drug interactions** that would require dose reduction include those with **amiodarone**, verapamil, or quinidine, which increase digoxin plasma levels. *History of hypertension* - Hypertension is a common comorbidity in patients with **atrial fibrillation** but does not independently affect the **clearance** or mechanism of action of digoxin. - Dosing is primarily driven by **renal function** and serum electrolyte levels (e.g., potassium) rather than blood pressure status. *Age over 70 years alone* - While **elderly patients** often have lower renal reserves, age alone is not a definitive indication for dose reduction if the **renal function** is otherwise normal. - Dosing should be based on a calculated **creatinine clearance** or eGFR rather than age as a stand-alone factor.

Question 250: A 45-year-old woman with type 1 diabetes mellitus is admitted with diabetic ketoacidosis. After initial resuscitation with intravenous fluids and insulin infusion, her blood glucose drops from 28mmol/L to 14mmol/L within 2 hours. Her pH is 7.18 and ketones remain elevated at 4.2mmol/L. What is the most appropriate next step in insulin management?

A. Stop the insulin infusion until ketones normalize
B. Reduce the insulin infusion rate by half and continue monitoring
C. Continue the insulin infusion at the same rate and add 10% glucose (Correct Answer)
D. Switch from intravenous to subcutaneous insulin immediately
E. Increase the insulin infusion rate to clear ketones more rapidly

Explanation: ***Continue the insulin infusion at the same rate and add 10% glucose***- In **Diabetic Ketoacidosis (DKA)**, the primary goal is the suppression of ketogenesis and correction of acidosis; insulin must be maintained to achieve **ketone clearance** even if glucose levels drop.- When blood glucose falls below **14 mmol/L**, 10% glucose should be started to prevent **hypoglycemia** while the fixed-rate insulin continues to treat the underlying ketosis.*Stop the insulin infusion until ketones normalize*- Stopping insulin represents a critical error as it allows **ketogenesis** to resume, worsening the metabolic acidosis.- High **ketone levels (4.2 mmol/L)** and low **pH (7.18)** indicate the DKA is not yet resolved, necessitating continuous insulin therapy.*Reduce the insulin infusion rate by half and continue monitoring*- Fixed-rate intravenous insulin infusion (FRIII) should generally be maintained at **0.1 units/kg/hour** to ensure adequate suppression of ketone production.- Reducing the rate prematurely can delay the resolution of **acidosis** and lead to a rebound in ketone levels.*Switch from intravenous to subcutaneous insulin immediately*- The criteria for switching to **subcutaneous insulin** include a pH >7.3, bicarbonate >15 mmol/L, and ketones <0.6 mmol/L, none of which are met here.- Switching before **DKA resolution** can lead to a rapid relapse into ketoacidosis due to the short half-life of IV insulin.*Increase the insulin infusion rate to clear ketones more rapidly*- The insulin rate is typically fixed based on weight; increasing it beyond the standard protocol increases the risk of **cerebral edema** and severe **hypokalemia**.- Rapid shifts in **osmolarity** should be avoided; adding glucose is the standard method to allow continued insulin action safely.

Question 251: A 68-year-old man with atrial fibrillation is admitted with acute confusion and headache. His INR is 8.2. He has no signs of bleeding. His regular medications include warfarin 5mg daily. What is the most appropriate immediate management?

A. Administer oral vitamin K 1-3mg and withhold warfarin (Correct Answer)
B. Administer intravenous vitamin K 10mg and withhold warfarin
C. Administer prothrombin complex concentrate and vitamin K 5mg intravenously
D. Withhold warfarin and recheck INR in 24 hours
E. Give fresh frozen plasma 15ml/kg and withhold warfarin

Explanation: ***Administer oral vitamin K 1-3mg and withhold warfarin*** - For a patient with an **INR > 8.0** and **no evidence of bleeding**, international guidelines recommend withholding **warfarin** and administering **oral Vitamin K** to safely reduce the INR. - **Oral administration** is preferred in non-bleeding patients as it effectively lowers INR within 24 hours without the **anaphylaxis risk** associated with IV forms. *Administer intravenous vitamin K 10mg and withhold warfarin* - **Intravenous Vitamin K** at this dose (10mg) is reserved for **major or life-threatening hemorrhage** where rapid reversal is critical. - This patient has **no signs of bleeding**, and such a high IV dose may cause prolonged **warfarin resistance** if anticoagulation needs to be restarted. *Administer prothrombin complex concentrate and vitamin K 5mg intravenously* - **Prothrombin complex concentrate (PCC)** is indicated only for **emergency reversal** of warfarin in the presence of severe, **life-threatening bleeding**. - Since this patient has **no clinical signs of bleeding**, using clotting factor concentrates is unnecessary and carries a risk of **thrombosis**. *Withhold warfarin and recheck INR in 24 hours* - Simply **withholding warfarin** is only appropriate if the INR is between 5.0 and 8.0 with no bleeding. - Because the INR is **exceeding 8.0**, the risk of spontaneous hemorrhage is significantly elevated, necessitating the addition of **Vitamin K** to accelerate INR reduction. *Give fresh frozen plasma 15ml/kg and withhold warfarin* - **Fresh frozen plasma (FFP)** is not recommended for routine warfarin reversal due to suboptimal factor replacement and the risk of **fluid overload** and **allergic reactions**. - It is generally only considered if **PCC is unavailable** and there is active, **major bleeding** occurring, which is not the case here.

Practice by Chapter

Anticoagulant safety

Practice Questions

High-risk medicines

Practice Questions

Insulin safety

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Safe Prescribing — MCQs

Safe Prescribing — MCQs

On this page